WorldWideScience

Sample records for aripiprazole improves depressive

  1. Aripiprazole Improves Depressive Symptoms and Immunological Response to Antiretroviral Therapy in an HIV-Infected Subject with Resistant Depression

    Directory of Open Access Journals (Sweden)

    Chiara Cecchelli

    2010-01-01

    Full Text Available Aripiprazole is the first medication approved by the FDA as an add-on treatment for MDD. The impact of aripiprazole on the response to HIV is unknown. The patient we report on was diagnosed HIV-positive in 1997 and has been treated with antiretroviral therapy since then. In 2008, we diagnosed resistant major depression, hypochondria, and panic disorder. On that occasion, blood tests showed a significantly reduced CD4 count and a positive viral load. We treated this patient with aripiprazole and citalopram. Mood, somatic symptoms, and occupational functioning progressively improved. The last blood examination showed an increase in the CD4 count and a negative viral load. On the basis of the present case study and the review of the literature concerning the effects of psychotropic agents on viral replication, we suggest that the use of aripiprazole in HIV-infected subjects warrants further research.

  2. Aripiprazole Improves Depressive Symptoms and Immunological Response to Antiretroviral Therapy in an HIV-Infected Subject with Resistant Depression

    OpenAIRE

    Chiara Cecchelli; Giacomo Grassi; Stefano Pallanti

    2010-01-01

    Aripiprazole is the first medication approved by the FDA as an add-on treatment for MDD. The impact of aripiprazole on the response to HIV is unknown. The patient we report on was diagnosed HIV-positive in 1997 and has been treated with antiretroviral therapy since then. In 2008, we diagnosed resistant major depression, hypochondria, and panic disorder. On that occasion, blood tests showed a significantly reduced CD4 count and a positive viral load. We treated this patient with aripiprazole...

  3. Aripiprazole

    Science.gov (United States)

    ... bipolar disorder (manic-depressive disorder; a disease that causes episodes of depression, episodes of mania, and other abnormal moods). Aripiprazole is also used with an antidepressant to treat depression when symptoms cannot ... difficulty communicating and interacting with others). Aripiprazole may ...

  4. A retrospective study of predictive factors for effective aripiprazole augmentation of antidepressant therapy in treatment-resistant depression

    Directory of Open Access Journals (Sweden)

    Sugawara H

    2016-05-01

    Full Text Available Hiroko Sugawara,1,2 Kaoru Sakamoto,1 Tsuyoto Harada,3 Satoru Shimizu,4 Jun Ishigooka1 1Department of Psychiatry, Tokyo Women’s Medical University, 2Support Center for Women Health Care Professionals and Researchers, Tokyo Women’s Medical University, Shinjuku-ku, 3Department of Psychiatry, Tokyo Women’s Medical University Medical Center East, Arakawa-ku, 4Department of Research, Medical Research Institute, Tokyo Women’s Medical University, Shinjuku-ku, Tokyo, Japan Background: Several studies have evaluated the efficacy and tolerability of aripiprazole for augmentation of antidepressant therapy for treatment-resistant depression (TRD. Here, we investigated the efficacy of aripiprazole augmentation for TRD including both major depressive disorder and bipolar disorder and the clinical predictors of treatment efficacy in a Japanese population.  Methods: Eighty-five depressed Japanese patients who underwent aripiprazole augmentation therapy after failing to respond satisfactorily to antidepressant monotherapy were included in the study. Treatment responses were evaluated based on Clinical Global Impression Improvement scores assessed 8 weeks after initiation of aripiprazole administration. We compared demographic and diagnostic variables, psychiatric medication variables, and clinical variables between remission and nonremission groups.  Results: The aripiprazole augmentation remission rate was 36.5%. Multiple logistic regression analysis indicated that aripiprazole augmentation was significantly more effective for bipolar depression than for major depressive disorder, and both absence of comorbid anxiety disorders and current episode duration >3 months were significantly associated with the efficacy of aripiprazole augmentation.  Conclusion: Polarity of depression, comorbidity of anxiety disorders, and current episode duration may predict the efficacy of aripiprazole augmentation for TRD including both major depressive disorder and

  5. Determining Whether a Definitive Causal Relationship Exists Between Aripiprazole and Tardive Dyskinesia and/or Dystonia in Patients With Major Depressive Disorder, Part 3: Clinical Trial Data.

    Science.gov (United States)

    Preskorn, Sheldon H; Macaluso, Matthew

    2016-03-01

    This series of columns has 3 main goals: (1) to explain class warnings as used by the United States Food and Drug Administration, (2) to increase awareness of movement disorders that may occur in patients treated with antipsychotic medications, and (3) to understand why clinicians should refrain from immediately assuming a diagnosis of tardive dyskinesia/dystonia (TD) in patients who develop abnormal movements during treatment with antipsychotics. The first column in the series presented a patient who developed abnormal movements while being treated with aripiprazole as an augmentation strategy for major depressive disorder (MDD) and reviewed data concerning the historical background, incidence, prevalence, and risk factors for tardive and spontaneous dyskinesias, the clinical presentations of which closely resemble each other. The second column in the series reviewed the unique mechanism of action of aripiprazole and preclinical studies and an early-phase human translational study that suggest a low, if not absent, risk of TD with aripiprazole. This column reviews clinical trial data to assess whether those data support the conclusion that aripiprazole has a low to absent risk of causing TD when used as an augmentation strategy to treat MDD. To date, no randomized, placebo-controlled trials have established a definitive link between exposure to aripiprazole and TD in patients with MDD. One long-term, open-label, safety trial examined aripiprazole as an augmentation strategy in individuals with MDD and found a rare occurrence (4/987, 0.4%, the confidence interval of which overlaps with zero) of an adverse event termed TD. In all 4 cases, the observed movements resolved within weeks of aripiprazole discontinuation, suggesting that they were either amenable to treatment or represented an acute syndrome rather than TD. No cases of TD were reported in the registration trials for the MDD indication for aripiprazole. These data were presented in a pooled analysis of

  6. Determining Whether a Definitive Causal Relationship Exists Between Aripiprazole and Tardive Dyskinesia and/or Dystonia in Patients With Major Depressive Disorder, Part 4: Case Report Data.

    Science.gov (United States)

    Macaluso, Matthew; Flynn, Alexandra; Preskorn, Sheldon

    2016-05-01

    This series of columns has 3 main goals: (1) to explain class warnings as used by the United States Food and Drug Administration, (2) to increase awareness of movement disorders that may occur in patients treated with antipsychotic medications, and (3) to understand why clinicians should refrain from immediately assuming a diagnosis of tardive dyskinesia/dystonia (TD) in patients who develop abnormal movements during treatment with antipsychotics. The first column in the series presented a patient who developed abnormal movements while being treated with aripiprazole as an augmentation strategy for major depressive disorder and reviewed data concerning the historical background, incidence, prevalence, and risk factors for tardive and spontaneous dyskinesias, the clinical presentations of which closely resemble each other. The second column in the series reviewed the unique mechanism of action of aripiprazole and reviewed preclinical studies and an early-phase human translational study that suggest a low, if not absent, risk of TD with aripiprazole. The third column in this series reviewed the registration trial data for aripiprazole across all of its indications and found a raw incidence of TD ranging from 0.004 (4 out of 987) in long-term studies of the drug as an augmentation strategy for major depressive disorder to 0.0016 (19 out of 11,897) based on all short-term (ie, weeks to <6 mo) and long-term (6 mo to 1 y) studies combined. This fourth column in the series reviews the "real-world" data on aripiprazole and assesses whether these data also support the conclusion that aripiprazole has a low to absent risk of causing TD. The "real-world" data consist of case reports from the medical literature and the United States Food and Drug Administration Adverse Event Reporting System (FAERS). We found 37 cases in the medical literature reporting what was termed TD in association with aripiprazole treatment as well as 27 case reports suggesting improvement in

  7. Aripiprazole Improved Obsessive Compulsive Symptoms in Asperger's Disorder.

    Science.gov (United States)

    Celik, Gonca; Tahiroglu, Aysegul Yolga; Firat, Sunay; Avci, Ayşe

    2011-12-01

    There are many comorbid disorders associated with autism spectrum disorders in child and adolescent population. Although obsessive compulsive disorder and autism spectrum disorders (ASD) comorbidity has common in clinical practice, there are few reports about psychopharmacological treatment for obsessive compulsive symptoms in children with ASD in the literacy. We report a successful treatment case with aripiprazole in Asperger's Disorder with obsessive compulsive symptoms. The Yale Brown Obsessive Compulsive Scale was performed to assess symptom variety. This case report supports the effectiveness of aripiprazole in treatment of obsessive compulsive symptoms in Asperger's Disorder or ASDs. Aripiprazole may be beneficial to obsessive compulsive disorder comorbid autism spectrum disorders in child and adolescent age group. PMID:23429759

  8. Aripiprazole Improved Obsessive Compulsive Symptoms in Asperger's Disorder

    OpenAIRE

    Celik, Gonca; Tahiroglu, Aysegul Yolga; Firat, Sunay; AVCI, Ayşe

    2011-01-01

    There are many comorbid disorders associated with autism spectrum disorders in child and adolescent population. Although obsessive compulsive disorder and autism spectrum disorders (ASD) comorbidity has common in clinical practice, there are few reports about psychopharmacological treatment for obsessive compulsive symptoms in children with ASD in the literacy. We report a successful treatment case with aripiprazole in Asperger's Disorder with obsessive compulsive symptoms. The Yale Brown Obs...

  9. Aripiprazole Injection

    Science.gov (United States)

    ... of interest in life, and strong or inappropriate emotions). Aripiprazole injection (Abilify) is used to treat episodes ... street drugs or have overused prescription medication or alcohol or has or has ever had diabetes, obsessive ...

  10. Determining Whether a Definitive Causal Relationship Exists Between Aripiprazole and Tardive Dyskinesia and/or Dystonia in Patients With Major Depressive Disorder, Part 2: Preclinical and Early Phase Human Proof of Concept Studies.

    Science.gov (United States)

    Macaluso, Matthew; Flynn, Alexandra; Preskorn, Sheldon

    2016-01-01

    This series of columns has 3 main goals: (1) to explain class warnings as used by the United States Food and Drug Administration, (2) to increase awareness of movement disorders that may occur in patients treated with antipsychotic medications, and (3) to understand why clinicians should refrain from immediately assuming a diagnosis of tardive dyskinesia/dystonia (TD) in patients treated with antipsychotics. The first column in this series began with the case of a 76-year-old man with major depressive disorder who developed orofacial dyskinesias while being treated with aripiprazole as an antidepressant augmentation strategy. It was alleged that a higher than intended dose of aripiprazole (ie, 20 mg/d for 2 wk followed by 10 mg/d for 4 wk instead of the intended dose of 2 mg/d) was the cause of the dyskinetic movements in this man, and the authors were asked to review the case and give their opinion. The principal basis for this theory of causation was the class warning about TD in the package insert for aripiprazole. The rationale for concluding aripiprazole caused TD in the 76-year-old man led to this series of columns about aripiprazole, its potential--if any--to cause TD, and the presence of a class warning about TD in its package insert. The central point is to illustrate why class warnings exist and their implications for practice. The first column in this series focused on the historical background, incidence, prevalence, risk factors, and clinical presentations of tardive and spontaneous dyskinesias and concluded with a discussion of diagnostic considerations explaining why clinicians should avoid making a diagnosis of TD until a thorough differential diagnosis has been considered. This second column in the series reviews the pharmacology of aripiprazole and the preclinical and phase I translational human studies that suggest aripiprazole should have a low to nonexistent risk of causing TD compared with other antipsychotics. The third column in the series

  11. Aripiprazole-Induced Parkinsonism: Report of Two Cases

    OpenAIRE

    Çetin Kürşad Akpınar; Dursun Aygün; Hakan Doğru

    2015-01-01

    Aripiprazole is one of the recently introduced atypical antipsychotics used in the treatment of psychosis related to schizophrenia, depression, bipolar disorder, and Parkinson’s disease. Well-documented side effects associated with the use of aripiprazole include insomnia, anxiety, headache, nausea, vomiting, and somnolence. Aripiprazole is associated with infrequent extrapyramidal side effects. Parkinsonism is caused by some drugs that block dopamine receptors. The sign of dru...

  12. Low dosage of aripiprazole induced neuroleptic malignant syndrome after interaction with other neuroleptic drugs

    Directory of Open Access Journals (Sweden)

    Albino Petrone

    2013-09-01

    Full Text Available Aripiprazole is a 2nd generation antipsychotic medication, atypical neuroleptic used for treatment of schizophrenia improving symptoms such as hallucinations, delusions, and disorganized thinking. A potentially fatal symptom complex sometimes referred to as neuroleptic malignant syndrome (NMS has been reported in association with administration of antipsychotic drugs, including aripiprazole. Rare cases of NMS occurred during aripiprazole treatment in the worldwide clinical database. The disease is characterized by a distinctive clinical syndrome of mental status change, rigidity, fever, and dysautonomia. We report on a 63-year old woman with depression syndrome who developed neuroleptic malignant syndrome after twelve days of aripripazole 5 mg per day. Our case is added to the small number already described and suggests the need for caution when aripripazole is added to increase the effect of other antipsychotics.

  13. 阿立哌唑合并抗抑郁药治疗抑郁症的临床疗效及安全性研究%Study on the clinical effect and safety of aripiprazole combined with antidepressants in the treatment of depression

    Institute of Scientific and Technical Information of China (English)

    姜美俊

    2014-01-01

    目的:探讨阿立哌唑合并抗抑郁药(三环类抗抑郁剂阿米替林)治疗抑郁症的临床疗效及安全性。方法选择120例抑郁症患者随机分为研究组和对照组。对照组给予常规抗抑郁药物治疗,研究组在常规抗抑郁治疗基础上给予阿立哌唑。采用汉密尔顿抑郁量表和副反应量表对两组患者治疗前和治疗后进行评定。结果研究组治疗后的第1、2、4、6周汉密尔顿抑郁量表评分分别与对照组同期比较,差异有统计学意义(P0.05)。结论阿立哌唑能够提高抗抑郁药(三环类抗抑郁剂阿米替林)治疗抑郁症的临床治疗效果,可作为临床抗抑郁治疗的一种增效手段。%Objective To study clinical effect and safety of aripiprazole combined with antidepressants(tricyclic antidepressants amitriptyline) in the treatment of depression. Methods From January 2010 to December 2013, 120 patients with depression patients were selected and randomly divided into study group and control group , control group was given regular treatment of antidepressant drugs, study group was given aripiprazole combined with antidepressants(tricyclic antidepressants amitriptyline). The Hamilton Depression Scale (HAMD) and Treatment Emergent Symptom Scale (TESS) were used in the two group s of patients before and after treatment. Results Hamilton Depression Scale scores in the study group after treatment of the first week, second week, fourth week and sixth week of study group was compared with those in control group , the difference was statistically significant(P0.05). Conclusion Aripiprazole can improve the clinical efficacy of antidepressants (tricyclic antidepressants amitriptyline) in the treatment of depression, which can be one of the augmentations in the treatment of depression.

  14. Aripiprazole (Otsuka Pharmaceutical Co).

    Science.gov (United States)

    Ozdemir, Vural; Fourie, Jeanne; Ozdener, Fatih

    2002-01-01

    Otsuka Pharmaceuticals in collaboration with Bristol-Myers Squibb is developing aripiprazole, a dual dopamine autoreceptor agonist and postsynaptic D2 receptor antagonist, for the potential treatment of psychoses including schizophrenia [281327], [340364]. A regulatory filing for schizophrenia in the US was submitted at the end of 2001 [340364]. The compound entered phase III trials in Japan in 1995 [192966]. Although presynaptic dopamine autoreceptor agonists may be efficacious in the treatment of schizophrenia, they may also potentially increase the risk for exacerbation of psychosis through stimulation of postsynaptic dopaminergic receptors [245791], [350478], [350479]. However, earlier neuropharmacology studies have shown that aripiprazole can act as a presynaptic D2 agonist while displaying an antagonistic effect at the postsynaptic D2 receptors [281327], [337126], [350479], [424587], [424588]. In animal models, aripiprazole inhibits the apomorphine-induced stereotypy, without causing catalepsy [281327], [337126]. Moreover, in contrast to classical antipsychotics that produce disabling movement disorders, aripiprazole does not cause an upregulation of D2 receptors or an increase in expression of the c-fos mRNA in the striatum, in agreement with the low risk for extrapyramidal side effects (EPS) during aripiprazole treatment [245781], [262096], [350481], [350483]. Collectively, aripiprazole is an important atypical antipsychotic candidate with a favorable safety profile. Moreover, the mechanism of action of aripiprazole differentiates it from both typical and atypical antipsychotics and hence, may provide important leads for pharmacotherapy of schizophrenia and other psychotic disorders. In January 2000, Lehman Brothers predicted peak sales of aripiprazole could reach US $500 million [357788]. In February 2001, Credit Suisse First Boston predicted sales of US $403 million in 2005 [399484]. PMID:12054061

  15. Effects of switching to aripiprazole from current atypical antipsychotics on subsyndromal symptoms and tolerability in patients with bipolar disorder.

    Science.gov (United States)

    Woo, Young Sup; Bahk, Won-Myong; Park, Young-Min; Chung, Sangkeun; Yoon, Bo-Hyun; Won, Seunghee; Lee, Jeong Goo; Lee, Hwang-Bin; Kim, Won; Jeong, Jong-Hyun; Lee, Kwanghun; Kim, Moon-Doo

    2016-09-01

    We evaluated the effectiveness of aripiprazole among bipolar patients who had switched to this medication as a result of difficulty maintaining on their prestudy atypical antipsychotics (AAPs) because of subsyndromal mood symptoms or intolerance. This study included 77 bipolar patients who were in syndromal remission with an AAP as monotherapy or with an AAP combined with a mood stabilizer(s) who needed to switch from their present AAP because of subsyndromal symptoms or intolerance. At 24 weeks after switching to aripiprazole, the remission rates on the Montgomery-Åsberg Depression Rating Scale (MADRS) and on both the MADRS and the Young Mania Rating Scale were increased significantly in the full sample and in the inefficacy subgroup. In the inefficacy subgroup, the MADRS score change was significant during the 24 weeks of study. Total cholesterol and prolactin decreased significantly after switching to aripiprazole. The proportion of patients who had abnormal values for central obesity and hypercholesterolemia decreased significantly from baseline to week 24. These findings suggest that a change from the current AAP to aripiprazole was associated with improvement in subsyndromal mood symptoms and several lipid/metabolic or safety profile parameters in patients with bipolar disorder with tolerability concerns or subsyndromal mood symptoms. PMID:27487259

  16. Use of Aripiprazole in Clozapine Induced Enuresis: Report of Two Cases

    OpenAIRE

    Lee, Myung-Ji; Kim, Chul-Eung

    2010-01-01

    This report describes the efficacy of combined use of aripiprazole in the treatment of a patient with clozapine induced enuresis. Aripiprazole acts as a potential dopamine partial agonist and the dopamine blockade in the basal ganglia might be one of the causes of urinary incontinence and enuresis. We speculate that aripiprazole functioned as a D2 agonist in hypodopaminergic state of basal ganglia caused by clozapine and maintained dopamine level that would improve enuresis ultimately.

  17. Aripiprazole-induced hyperprolactinemia in a young female with delusional disorder

    OpenAIRE

    Sam Padamadan Joseph

    2016-01-01

    Hyperprolactinemia is a common adverse effect of antipsychotic medication. Switching over to aripiprazole or adjunctive aripiprazole has been advocated for optimal management of antipsychotic-induced hyperprolactinemia. Adjunctive treatment with aripiprazole has been shown to normalize prolactin levels without affecting already achieved improvements in psychotic symptoms. However, here, we present the case of a 36 year old female with delusional disorder who developed symptomatic hyperprolact...

  18. Retrospective Study of Japanese Patients with Schizophrenia Treated with Aripiprazole

    Science.gov (United States)

    Tanioka, Tetsuya; Fuji, Syoko; Kataoka, Mika; King, Beth; Tomotake, Masahito; Yasuhara, Yuko; Locsin, Rozzano; Sekido, Keiko; Mifune, Kazushi

    2012-01-01

    Aim. The purpose of this retrospective study was to evaluate changes in clinical indicators which influence the quality of life (QOL) of patients with schizophrenia treated by antipsychotic therapy before and after switching to aripiprazole. Methods. A retrospective chart review of 27 patients diagnosed with schizophrenia and who were switched from one antipsychotic to aripiprazole was performed. Clinical indicators about the daily dosage of antipsychotics and antiparkinsonian drugs, psychiatric condition, and glucose/lipid metabolism, clinical evaluation by nursing observation were used to measure the responsiveness of subjects to aripiprazole. Results. Of the 27 subjects, 14 responded to the switch to aripiprazole with significant improvement of the Brief Psychiatric Rating Scale (BPRS) score (P = 0.04), significant decrease in dosage of antipsychotics in 71% of patients (P = 0.03), and tendency toward reduction in dosage of antiparkinsonian drugs (P = 0.07) and body mass index (BMI) (P = 0.06). However, 8 of 27 subjects had a significant increase in lipid levels after switching to aripiprazole (P = 0.01). Conclusion. QOL for subjects who responded to the switch to aripiprazole improved as indicated by lower doses of antipsychotic and antiparkinson medications, improvement in BPRS score, and a decrease in BMI. Results indicate little influence on patient's QOL. PMID:22970386

  19. An open-label pilot study of aripiprazole for male and female veterans with chronic post-traumatic stress disorder who respond suboptimally to antidepressants.

    Science.gov (United States)

    Youssef, Nagy A; Marx, Christine E; Bradford, Daniel W; Zinn, Sandra; Hertzberg, Michael A; Kilts, Jason D; Naylor, Jennifer C; Butterfield, Marian I; Strauss, Jennifer L

    2012-07-01

    Emerging data suggest that second-generation antipsychotics such as aripiprazole may be effective in the treatment of post-traumatic stress disorder (PTSD). However, few clinical trials have used aripiprazole in PTSD, and data are limited on its use in Veterans with PTSD. The objective of this pilot trial was to investigate the safety and efficacy of aripiprazole in Veterans with PTSD. Ten individuals (five men and five women) meeting the Diagnostic and statistical manual of mental disorders, 4th ed., PTSD criteria participated in this 12-week, open-label, flexibly dosed monotherapy trial. The dose range of aripiprazole was 5-30 mg/day, titrated to tolerability and clinical response. The primary outcome measure was the Clinician-Administered PTSD Scale. Additional outcomes included the Short PTSD Rating Interview, the Treatment Outcome PTSD Scale (Top-8), the Davidson Trauma Scale, the Positive and Negative Syndrome Scale, the Beck Depression Inventory-Fast Screen, and Clinical Global Impressions-Improvement. Eight participants completed the study, and aripiprazole was generally well tolerated and associated with a significant improvement in PTSD symptoms, as measured by the Clinician-Administered PTSD Scale (primary outcome measure) and by the Short PTSD Rating Interview, the Treatment Outcome PTSD Scale, and the Davidson Trauma Scale. An improvement was also observed on all three Positive and Negative Syndrome Scale subscales and the Beck Depression Inventory-Fast Screen, and the average Clinical Global Impressions-Improvement ratings indicated that patients were 'much improved'. These promising initial results merit further investigation in a larger, randomized-controlled trial. PMID:22475888

  20. Aripiprazole-induced hyperprolactinemia in a young female with delusional disorder

    Directory of Open Access Journals (Sweden)

    Sam Padamadan Joseph

    2016-01-01

    Full Text Available Hyperprolactinemia is a common adverse effect of antipsychotic medication. Switching over to aripiprazole or adjunctive aripiprazole has been advocated for optimal management of antipsychotic-induced hyperprolactinemia. Adjunctive treatment with aripiprazole has been shown to normalize prolactin levels without affecting already achieved improvements in psychotic symptoms. However, here, we present the case of a 36 year old female with delusional disorder who developed symptomatic hyperprolactinemia while on aripiprazole treatment. Dopamine acts as a tonic inhibitor of prolactin secretion through the tubero-infundibular dopaminergic system. Aripiprazole being a partial agonist has a lower intrinsic activity at the D2 receptor than dopamine, allowing it to act as both, a functional agonist and antagonist, depending on the surrounding levels of dopamine. Hence, in the absence of a competing D2 antagonist and the presence of dopamine (the natural agonist, aripiprazole could act as a functional antagonist and thus elevate prolactin levels.

  1. Aripiprazole-induced Hyperprolactinemia in a Young Female with Delusional Disorder.

    Science.gov (United States)

    Joseph, Sam Padamadan

    2016-01-01

    Hyperprolactinemia is a common adverse effect of antipsychotic medication. Switching over to aripiprazole or adjunctive aripiprazole has been advocated for optimal management of antipsychotic-induced hyperprolactinemia. Adjunctive treatment with aripiprazole has been shown to normalize prolactin levels without affecting already achieved improvements in psychotic symptoms. However, here, we present the case of a 36 year old female with delusional disorder who developed symptomatic hyperprolactinemia while on aripiprazole treatment. Dopamine acts as a tonic inhibitor of prolactin secretion through the tubero-infundibular dopaminergic system. Aripiprazole being a partial agonist has a lower intrinsic activity at the D2 receptor than dopamine, allowing it to act as both, a functional agonist and antagonist, depending on the surrounding levels of dopamine. Hence, in the absence of a competing D2 antagonist and the presence of dopamine (the natural agonist), aripiprazole could act as a functional antagonist and thus elevate prolactin levels. PMID:27335526

  2. Determining Whether a Definitive Causal Relationship Exists Between Aripiprazole and Tardive Dyskinesia and/or Dystonia in Patients With Major Depressive Disorder: Part 1.

    Science.gov (United States)

    Preskorn, Sheldon; Flynn, Alexandra; Macaluso, Matthew

    2015-09-01

    This series of columns has 2 main goals: (1) to explain the use of class warnings by the US Food and Drug Administration and (2) to increase clinicians' awareness of movement disorders that may occur in patients being treated with antipsychotic medications and why it is appropriate and good practice to refrain from immediately assuming the diagnosis is tardive dyskinesia/dystonia (TD). This first column in the series will focus on the second goal, which will then serve as a case example for the first goal. Clinicians should refrain from jumping to a diagnosis of TD because a host of other causes need to be ruled out first before inferring iatrogenic causation. The causal relationship between chronic treatment with dopamine antagonists and TD is based on pharmacoepidemiology (ie, the prevalence of such movement disorders is higher in individuals receiving chronic treatment with such agents than in a control group). There is nothing pathognomonic about movement disorders, nor is there any test that can currently prove a drug caused a movement disorder in a specific individual. Another goal of this series is to describe the types of research that would be needed to establish whether a specific agent has a meaningful risk of causing TD. In this first column of the series, we present the case of a patient who developed orofacial dyskinesia while being treated with aripiprazole. In this case, the movement disorder was prematurely called TD, which led to a malpractice lawsuit. This case highlights a number of key questions clinicians are likely to encounter in day-to-day practice. We then review data concerning the historical background, incidence, prevalence, and risk factors for 2 movement disorders, TD and spontaneous dyskinesia. Subsequent columns in this series will review: (1) unique aspects of the psychopharmacology of aripiprazole, (2) the limited and inconsistent data in the literature concerning the causal relationship between aripiprazole and TD, (3) the use of

  3. Adjunctive aripiprazole versus placebo for antipsychotic-induced hyperprolactinemia: meta-analysis of randomized controlled trials.

    Directory of Open Access Journals (Sweden)

    Xianbin Li

    Full Text Available OBJECTIVE: To compare the safety and efficacy of adjunctive aripiprazole versus placebo for antipsychotic-induced hyperprolactinemia. METHODS: POPULATION: adult patients presenting with antipsychotic-induced hyperprolactinemia diagnosed by prolactin level with or without prolactin-related symptoms. INTERVENTIONS: adjunctive aripiprazole vs. adjunctive placebo. OUTCOME MEASURES: adverse events and efficacy of treatment. STUDIES: randomized controlled trials. RESULTS: Five randomized controlled trials with a total of 639 patients (326 adjunctive aripiprazole, 313 adjunctive placebo met the inclusion criteria. Adjunctive aripiprazole was associated with a 79.11% (125/158 prolactin level normalization rate. Meta-analysis of insomnia, headache, sedation, psychiatric disorder, extrapyramidal symptom, dry mouth, and fatigue showed no significant differences in the adjunctive aripiprazole treatment group compared with the placebo group (risk difference (Mantel-Haenszel, random or fixed -0.05 to 0.04 (95% confidence interval -0.13 to 0.16; I(2 =0% to 68%, P=0.20 to 0.70. However, sedation, insomnia, and headache were more frequent when the adjunctive aripiprazole dose was higher than 15 mg/day. Meta-analysis of the prolactin level normalization indicated adjunctive aripiprazole was superior to placebo (risk difference (Mantel-Haenszel, random 0.76 (95% confidence interval 0.67 to 0.85; I(2 =43%, P<0.00001. The subgroup analysis confirmed that the subjects who received adjunctive aripiprazole 5 mg/day showed a degree of prolactin normalization similar to that of all participants. No significant differences between groups in discontinuation and improvements of psychiatric symptoms. CONCLUSION: Adjunctive aripiprazole is both safe and effective as a reasonable choice treatment for patients with antipsychotic-induced hyperprolactinemia. The appropriate dose of adjunctive aripiprazole may be 5 mg/day.

  4. Aripiprazole alone or in combination for acute mania

    OpenAIRE

    Brown, Rachel; Taylor, Matthew; Geddes, John

    2013-01-01

    BackgroundBipolar disorder is a mental disorder characterised by episodes of elevated or irritable mood (manic or hypomanic episodes) and episodes of low mood and loss of energy (depressive episodes). Drug treatment is the first-line treatment for acute mania with the initial aim of rapid control of agitation, aggression and dangerous behaviour. Aripiprazole, an atypical antipsychotic, is used in the treatment of mania both as monotherapy and combined with other medicines. The British Associa...

  5. Antipsychotic treatments for the elderly: efficacy and safety of aripiprazole

    Directory of Open Access Journals (Sweden)

    Izchak Kohen

    2010-03-01

    Full Text Available Izchak Kohen1, Paula E Lester2, Sum Lam31Division of Geriatric Psychiatry, Zucker-Hillside Hospital, Glen Oaks, NY, USA; 2Division of Geriatric Medicine, Winthrop University Hospital, Mineola, NY, USA; 3Division of Pharmacy and Geriatrics, St. John’s University College of Pharmacy and Allied Health Professions, Queens, NY, USAAbstract: Delusions, hallucinations and other psychotic symptoms can accompany a number of conditions in late life. As such, elderly patients are commonly prescribed antipsychotic medications for the treatment of psychosis in both acute and chronic conditions. Those conditions include schizophrenia, bipolar disorder, depression and dementia. Elderly patients are at an increased risk of adverse events from antipsychotic medications because of age-related pharmacodynamic and pharmacokinetic changes as well as polypharmacy. Drug selection should be individualized to the patient’s previous history of antipsychotic use, current medical conditions, potential drug interactions, and potential side effects of the antipsychotic. Specifically, metabolic side effects should be closely monitored in this population. This paper provides a review of aripiprazole, a newer second generation antipsychotic agent, for its use in a variety of psychiatric disorders in the elderly including schizophrenia, bipolar disorder, dementia, Parkinson’s disease and depression. We will review the pharmacokinetics and pharmacodynamics of aripiprazole as well as dosing, diagnostic indications, efficacy studies, and tolerability including its metabolic profile. We will also detail patient focused perspectives including quality of life, patient satisfaction and adherence.Keywords: aripiprazole, antipsychotics, elderly, adverse drug reaction

  6. Adjunctive treatment with aripiprazole for risperidone-induced hyperprolactinemia

    Directory of Open Access Journals (Sweden)

    Ranjbar F

    2015-03-01

    and 110. The median time to recovery based on normalization of prolactin was 84 days. Psychotic symptoms were present in 26 subjects at baseline, but in only two by the end of the study. Conclusion: The results of this study confirm the effects of aripiprazole in reducing risperidone-induced hyperprolactinemia and its sequelae. Aripiprazole also led to significant improvements in psychotic symptoms when compared with those present prior to treatment with aripiprazole. Keywords: hyperprolactinemia, aripiprazole, risperidone, psychotic disorder

  7. Effect of aripiprazole on mismatch negativity (MMN in schizophrenia.

    Directory of Open Access Journals (Sweden)

    Zhenhe Zhou

    Full Text Available BACKGROUND: Cognitive deficits are considered core symptoms of the schizophrenia. Cognitive function has been found to be a better predictor of functional outcome than symptom levels. Changed mismatch negativity (MMN reflects abnormalities of early auditory processing in schizophrenia. Up to now, no studies for the effects of aripiprazole on MMN in schizophrenia have been reported. METHODOLOGY/PRINCIPAL FINDINGS: Subjects included 26 patients with schizophrenia, and 26 controls. Psychopathology was rated in patients with the Positive and Negative Syndrome Scale (PANSS at baseline, after 4- and 8-week treatments with aripiprazole. Auditory stimuli for ERP consisted of 100 millisecond/1000 Hz standards, intermixed with 100 millisecond/1500 Hz frequency deviants and 250 millisecond/1000 Hz duration deviants. EEG was recorded at Fz. BESA 5.1.8 was used to perform data analysis. MMN waveforms were obtained by subtracting waveforms elicited by standards from waveforms elicited by frequency- or duration-deviant stimuli. Aripiprazole decreased all PANSS. Patients showed smaller mean amplitudes of frequency and duration MMN at baseline than did controls. A repeated measure ANOVA with sessions (i.e., baseline, 4- and 8-week treatments and MMN type (frequency vs. duration as within-subject factors revealed no significant MMN type or MMN type × session main effect for MMN amplitudes. Session main effect was significant. LSD tests demonstrated significant differences between MMN amplitudes at 8 weeks and those at both baseline and 4 weeks. There was significant negative correlation between changes in amplitudes of frequency and duration MMN and changes in PANSS total scores at baseline and follow-up periods. CONCLUSIONS: Aripiprazole improved the amplitudes of MMN. MMN offers objective evidence that treatment with the aripiprazole may ameliorate preattentive deficits in schizophrenia.

  8. Aripiprazole Augmentation in Treatment of Resistant Obsessive Compulsive Disorder

    Directory of Open Access Journals (Sweden)

    Karim Abdel Aziz

    2016-02-01

    Full Text Available Background: Aripiprazole is a novel antipsychotic medication that has been tried in the treatment of several psychiatric disorders. In an open clinical study, we evaluated the safety and efficacy of aripiprazole in patients with obsessive compulsive disorder resistant to normal regimen of treatment. Method: A total of nine hundred and sixty one patients were admitted over three year period of time (January 2012- December 2014 to the psychiatric department of Al Ain hospital, United Arab Emirates. All patients whose been fulfilled DSM-IV diagnosis of obsessive compulsive disorder (OCD (36 patients screened for further assessment. Patients with a diagnosis of schizophrenia (22 patients and one patient with eating disorder were excluded. Thirteen patients were contacted to be involved in the study. Participants were unstable although they were adherent to their medications (SSRIs when seen in the outpatient clinic two weeks after their discharge. One patient refused to participate in the study. A final number of 12 agreed to participate in the study. twelve patients aged 22 to 65 years who had DSM-IV diagnosis of OCD were treated with aripiprazole besides their normal treatment for a period of three months with daily doses ranging from ten to 20 mg daily. Results: a positive clinical response was noted in eight of the 12 patients within three months of study recruitment according to the Clinical Global Impression-Improvement scale. Aripiprazole was well tolerated by most of the patients. The most commonly reported side effect was headache. Conclusion: our findings suggest that aripiprazole may be an effective adjuvant and safe treatment for resistant OCD.

  9. Clinical efficacy and safety of lithium carbonate combined with aripiprazole in treatment of bipolar depression%碳酸锂联合阿立哌唑治疗双相障碍抑郁发作的疗效和安全性

    Institute of Scientific and Technical Information of China (English)

    粟幼嵩; 陈俊; 李则挚; 王勇; 黄佳; 方贻儒; 王祖承

    2011-01-01

    目的 探讨碳酸锂联合阿立哌唑治疗双相障碍抑郁发作的疗效和安全性.方法 81例双相障碍抑郁发作患者随机分为联合用药组(n=42)和锂盐组(n=39),分别给予碳酸锂联合阿立哌唑治疗或单用碳酸锂治疗,持续8周.在基线期及治疗第1、2、4、8周末,采用17项汉密顿抑郁量表(HAMD-17)和Young躁狂评定量表(YMRS)评定疗效,计算治疗有效率,采用治疗时出现的症状量表(TESS)评定不良反应.结果 基线期两组HAMD-17评分差异无统计学意义(P>0.05),治疗第1、2、4周末联合用药组HAMD-17评分显著低于锂盐组(P<0.05或P<0.01);治疗第8周末联合用药组HAMD-17评分低于锂盐组,但差异无统计学意义(P>0.05).两组基线期及治疗各阶段的YMRS评分均<7.两组治疗有效率和不良反应发生率比较差异均无统计学意义(P>0.05).结论 与单用碳酸锂比较,碳酸锂联合阿立哌唑治疗双相障碍抑郁发作起效快,疗效相似,不良反应无明显增加.%Objective To investigate the clinical efficacy and safety of lithium carbonate combined with aripiprazole in treatment of bipolar depression. Methods Eighty-one patients with bipolar depression were randomly divided into lithium carbonate combined with aripiprazole group (re = 42) or lithium carbonate group ( n = 39), and were treated with lithium carbonate combined with aripiprazole and lithium carbonate for 8 weeks respectively. At the baseline and the end of fthe irst, second, fourth and eighth week of treatment, Hamilton Depression Scale-17 ( HAMD-17) and Young Mania Rating Scale (YMRS) were employed to evaluate the clinical efficacy, the effective rates were calculated, and Treatment Emergent Symptom Scale (TESS) was adopted to assess the side effects. Results There was no significant difference in HAMD-17 score between two group at the baseline (P>0.05), while HAMD-17 scores at the end of first, second and fourth week of treatment in lithium

  10. Acanthosis nigricans during treatment with aripiprazole.

    Science.gov (United States)

    Manu, Peter; Al-Dhaher, Zainab; Dargani, Navin; Correll, Christoph U

    2014-01-01

    Aripiprazole is typically regarded as a metabolically sparing agent, in contrast to other second-generation antipsychotics, which are widely known to lead to weight gain and increase the cardiometabolic risk. We report for the first time the emergence of Acanthosis nigricans, a dermatological correlate of insulin resistance, during treatment with aripiprazole in an adolescent with a family history of diabetes mellitus. PMID:23011171

  11. 阿立哌唑治疗精神分裂症老年患者临床疗效观察%OBSERVATION ON THE CLINIC EFFICACY OF ARIPIPRAZOLE IN THE TREATMENT OF THE ELDERLY PATIENTS WITH SCHIZOPHRENIA

    Institute of Scientific and Technical Information of China (English)

    阿怀红

    2011-01-01

    [目的] 研究阿立哌唑治疗精神分裂症老年患者的临床疗效和不良反应,为临床提供依据.[方法] 选择符合CCMD-3精神分裂症诊断标准、简明精神疾病评定量表(BPRS)>35分、年龄≥65岁的病例共60例.随机分为阿立哌唑组与奋乃静组各30例.治疗前及治疗8周后分别用简明精神病评定量表(BPRS)及阳性和阴性综合征量表(PANSS)评定疗效,用副反应量表(TESS)评定不良反应.[结果] 阿立哌唑在治疗精神分裂症老年患者总疗效和对情感障碍、意志障碍的改善明显优于奋乃静.阿立哌唑在行为毒性、神经系和植物神经系的副作用明显低于奋乃静.阿立哌唑副反应轻且相对安全、依从性高.[结论] 阿立哌唑治疗精神分裂症老年患者效果确切、安全性强、依从性高,能全面提高患者生活质量.%[Objective] To study the efficacy and side effect of aripiprazole in the treatment of the elderly patients with schizophrenia, and to provide the basis for the clinical. [Methodsl According to CCMD-3, 65 patients with BPRS score over 35 and aged above 60 years old were selected and randomly divided into two groups: 30 patients had heen given aripiprazole for 8 weeks, and 30 patients had been given perphenazine for 8 weeks, then all patients were assessed by BPRS, PANSS and TESS. [ Results) Both aripiprazole and perphenazine had same effect on Psychiatric symptams. Aripiprazole were much better than perphenazine in these respects: anxiety, depression and exceasive activity. Aripiprazole has less side effecta than perphenazine. Aripiprazole was Side-Light and relatively safe and high compliance. [Conclusion] Aripiprazole is an effective trealment of the elderly patients with schizophrenia, strong security and , high compliance, we can improve the overall quality of life of patients.

  12. Successful treatment of a prolactinoma with the antipsychotic drug aripiprazole

    Directory of Open Access Journals (Sweden)

    Ilse C A Bakker

    2016-06-01

    Full Text Available In this report, we describe a female patient with both prolactinoma and psychotic disorder who was successfully treated with aripiprazole, a partial dopamine 2 receptor agonist. During the follow-up of more than 10 years, her psychotic symptoms improved considerably, prolactin levels normalised and the size of the prolactinoma decreased. This observation may be of clinical relevance in similar patients who often are difficult to treat with the regular dopaminergic drugs.

  13. Successful treatment of a prolactinoma with the antipsychotic drug aripiprazole

    OpenAIRE

    Bakker, Ilse C A; Schubart, Chris D.; Zelissen, Pierre M J

    2016-01-01

    Summary In this report, we describe a female patient with both prolactinoma and psychotic disorder who was successfully treated with aripiprazole, a partial dopamine 2 receptor agonist. During the follow-up of more than 10 years, her psychotic symptoms improved considerably, prolactin levels normalised and the size of the prolactinoma decreased. This observation may be of clinical relevance in similar patients who often are difficult to treat with the regular dopaminergic drugs. Learning poin...

  14. The effect of brexpiprazole (OPC-34712) and aripiprazole in adult patients with acute schizophrenia: results from a randomized, exploratory study.

    Science.gov (United States)

    Citrome, Leslie; Ota, Ai; Nagamizu, Kazuhiro; Perry, Pamela; Weiller, Emmanuelle; Baker, Ross A

    2016-07-01

    The aim of this study was to explore the effects of brexpiprazole and aripiprazole on efficacy, cognitive functioning, and safety in patients with acute schizophrenia. Patients who would benefit from hospitalization/continued hospitalization for acute relapse of schizophrenia were enrolled and randomized (2 : 1) to target doses of open-label brexpiprazole 3 mg/day or aripiprazole 15 mg/day for 6 weeks. Outcomes included change from baseline to week 6 in the Positive and Negative Syndrome Scale total score, Barratt Impulsiveness Scale 11-item score, and Cogstate computerized cognitive test battery scores. Patients treated with brexpiprazole (n=64) or aripiprazole (n=33) showed reductions in symptoms of schizophrenia as assessed by Positive and Negative Syndrome Scale total score (-22.9 and -19.4, respectively). A modest reduction in impulsivity was observed with brexpiprazole, but not aripiprazole (mean change in the Barratt Impulsiveness Scale 11-item total score: -2.7 and 0.1, respectively). No change in Cogstate scores was observed for either treatment. Brexpiprazole was well tolerated and the incidence of akathisia was lower in patients treated with brexpiprazole (9.4%) than aripiprazole (21.2%). Clinically relevant improvements in psychopathology were observed in patients with acute schizophrenia treated with brexpiprazole or aripiprazole. Brexpiprazole was well tolerated, with a lower incidence of akathisia than aripiprazole. PMID:26963842

  15. Quality improvement in depression care in the Netherlands: the Depression Breakthrough Collaborative. A quality improvement report.

    OpenAIRE

    2009-01-01

    Background: Improving the healthcare for patients with depression is a priority health policy across the world. Roughly, two major problems can be identified in daily practice: (1) the content of care is often not completely consistent with recommendations in guidelines and (2) the organization of care is not always integrated and delivered by multidisciplinary teams. Aim: To describe the content and preliminary results of a quality improvement project in primary care, aiming at improving th...

  16. Neurobehavioral and genotoxic parameters of antipsychotic agent aripiprazole in mice

    Institute of Scientific and Technical Information of China (English)

    Jaqueline Nascimento PICADA; Viviane Minuzzo PONTES; Patrícia PEREIRA; Bruna de Jesus Neto DOS SANTOS; Franciele CELSO; Jéssica Dias MONTEIRO; Kelly Morais DA ROSA; Leandro Rosa CAMACHO; Luciana Rodrigues VIEIRA; Taís Madelon FREITAS; Tatiana Grasiela DASILVA

    2011-01-01

    Aim:Aripiprazole is an antipsychotic agent to treat schizophrenia,which acts through dopamine D2 partial agonism,serotonin 5-HT1A partial agonism and 5-HT2A antagonism.This study was designed to evaluate the neurobehavioral effects and genotoxic/mutagenic activities of the agent,as well as its effects on lipoperoxidation.Methods:Open field and inhibitory avoidance tasks were used.Thirty min before performing the behavioral tasks,adult male CF-1 mice were administered aripiprazole (1,3 or 10 mg/kg,ip) once for the acute treatment,or the same doses for 5 d for the subchronic treatment.Genotoxic effects were assessed using comet assay in the blood and brain tissues.Mutagenic effects were evaluated using bone marrow micronucleus test.Lipoperoxidation was assessed with thiobarbituric acid reactive substances (TBARS).Results:Acute and subchronic treatments significantly decreased the number of crossing and rearing in the open field task.Acute treatment significantly increased the step-down latency for both the short- and long-term memory in the inhibitory avoidance task.Subchronic treatments with aripiprazole (3 and 10 mg/kg) caused significant DNA strain-break damage in peripheral blood but not in the brain.Mutagenic effect was not detected in the acute and subchronic treatments.Nor TBARS levels in the liver were affected.Conclusion:Aripiprazole improved memory,but could impair motor activities in mice.The drug increased DNA damage in blood,but did not show mutagenic effects,suggesting that it might affect long-term genomic stability.

  17. Aripiprazole for acute mania in an elderly person

    Directory of Open Access Journals (Sweden)

    Balaji Bharadwaj

    2011-01-01

    Full Text Available New-onset bipolar disorder is rare in the elderly. Symptom profile is similar to that in young adults but the elderly are more likely to have neurological co-morbidities. There are no case reports of elderly mania being treated with aripiprazole, an atypical antipsychotic. A 78-year-old gentleman presented to us with symptoms suggestive of mania of 1 month′s duration. He had similar history 3 years ago and a family history of postpartum psychosis in his mother. There were no neurological signs on examination and work-up for an organic etiology was negative except for age-related cerebral atrophy. He improved with aripiprazole and tolerated the medications well. The use of psychotropic medications in the elderly is associated with side-effects of sedation, increased cardiovascular risk, and greater risk of extra-pyramidal side-effects. The use of partial dopaminergic antagonists like aripiprazole may be useful in the balancing of effects and side-effects.

  18. The Treatment of Adult Bipolar Disorder with Aripiprazole: A Systematic Review.

    Science.gov (United States)

    Muneer, Ather

    2016-01-01

    Bipolar disorder is characterized by exacerbations of opposite mood polarity, ranging from manic to major depressive episodes. In the current nosological system of the Diagnostic and Statistical Manual - 5(th) edition (DSM-5), it is conceptualized as a spectrum disorder consisting of bipolar disorder type I, bipolar disorder type II, cyclothymic disorder, and bipolar disorder not otherwise specified. Treatment of all phases of this disorder is primarily with mood stabilizers, but many patients either show resistance to the conventional mood stabilizing medications or are intolerant to their side-effects. In this setting, second-generation antipsychotics have gained prominence as many bipolar subjects who are otherwise treatment refractory show response to these agents. Aripiprazole is a novel antipsychotic initially approved for the treatment of schizophrenia but soon found to be effective in bipolar disorder. This drug is well studied, as randomized controlled trials have been conducted in various phases of bipolar disorders. Aripiprazole exhibits the pharmacodynamic properties of partial agonism, functional selectivity, and serotonin-dopamine activity modulation - the new exemplars in the treatment of major psychiatric disorders. It is the first among a new series of psychotropic medications, which now also include brexpiprazole and cariprazine. The current review summarizes the data from controlled trials regarding the efficacy and safety of aripiprazole in adult bipolar patients. On the basis of this evidence, aripiprazole is found to be efficacious in the treatment and prophylaxis of manic and mixed episodes but has no effectiveness in acute and recurrent bipolar depression. PMID:27190727

  19. The Treatment of Adult Bipolar Disorder with Aripiprazole: A Systematic Review

    Science.gov (United States)

    2016-01-01

    Bipolar disorder is characterized by exacerbations of opposite mood polarity, ranging from manic to major depressive episodes. In the current nosological system of the Diagnostic and Statistical Manual – 5th edition (DSM-5), it is conceptualized as a spectrum disorder consisting of bipolar disorder type I, bipolar disorder type II, cyclothymic disorder, and bipolar disorder not otherwise specified. Treatment of all phases of this disorder is primarily with mood stabilizers, but many patients either show resistance to the conventional mood stabilizing medications or are intolerant to their side-effects. In this setting, second-generation antipsychotics have gained prominence as many bipolar subjects who are otherwise treatment refractory show response to these agents. Aripiprazole is a novel antipsychotic initially approved for the treatment of schizophrenia but soon found to be effective in bipolar disorder. This drug is well studied, as randomized controlled trials have been conducted in various phases of bipolar disorders. Aripiprazole exhibits the pharmacodynamic properties of partial agonism, functional selectivity, and serotonin-dopamine activity modulation – the new exemplars in the treatment of major psychiatric disorders. It is the first among a new series of psychotropic medications, which now also include brexpiprazole and cariprazine. The current review summarizes the data from controlled trials regarding the efficacy and safety of aripiprazole in adult bipolar patients. On the basis of this evidence, aripiprazole is found to be efficacious in the treatment and prophylaxis of manic and mixed episodes but has no effectiveness in acute and recurrent bipolar depression.

  20. Aripiprazole for the Treatment of Tourette's Disorder

    OpenAIRE

    Padala, Prasad R.; Qadri, S. Faiz; Madaan, Vishal

    2005-01-01

    Objective: Tourette's disorder is a neuropsychiatric syndrome that manifests with motor and vocal tics, including coprolalia. This article presents a report of successful treatment of these tics with aripiprazole in 2 consecutive patients with Tourette's disorder.

  1. Comparison the effectiveness of aripiprazole and risperidone for the treatment of acute bipolar mania

    Directory of Open Access Journals (Sweden)

    Amir Akhavan Rezayat

    2014-01-01

    Full Text Available Background: Second-generation antipsychotics, approved for the treatment of mania, are associated with adverse effects such as weight gain and metabolic disorders. Aripiprazole, a recently introduced second-generation antipsychotic, are thought to account for its low propensity for weight gain, metabolic disturbances and sedation. The purpose of this study was to investigate the effect of risperidone versus aripiprazole in the treatment of acute mania. Materials and Methods: Fifty patients with acute episodes of mania were enrolled in this study, and they were randomly assigned into a risperidone group of 24 cases and an aripiprazole group of 26 cases. In group A, aripiprazole with a dose of 5-30 mg/day and in group B, risperidone with a dose of 2-8 mg/day was given to patients. The average dose of aripiprazole was 27 mg/day, and the average dose of risperidone was 6 mg/day. The effects of each drug for the treatment of acute mania were assessed on the 1 st day of admission and on days 2, 4, 6, 8 and at weeks 2, 4 and 6 after therapy using the young mania rating scale (YMRS and at the baseline and on weeks 3 and 6 after admission using the clinical global impression (CGI scale. Results: The mean age of the group of risperidone was 34 ± 8.6 years and in a group of aripiprazole it was 34 ± 9.1 years (P = 0.83. Comparison of YMRS scores over the period of 6 weeks revealed a statistically significant difference in both groups (P < 0.0001.There was also a statistically significant difference in YMRS scores between risperidone and aripiprazole at day 8 (P = 0.026 and weeks 2 (P = 0.035 and 4 (P = 0.042. There was also a statistically significant difference in CGI-Severity scale score at weeks 3 (P = 0.003 and 6 (P = 0.000 and in CGI-Improvement scale score at weeks 3 (P = 0.005 and 6 (P = 0.002. The most common side-effect observed in both groups was headache (0%15/4 in aripiprazole vs. %16/7 in risperidone Conclusion: Aripiprazole that is readily

  2. Aripiprazole

    Science.gov (United States)

    ... of interest in life, and strong or inappropriate emotions) in adults and teenagers 13 years of age ... street drugs or have overused prescription medication or alcohol or has or has ever had diabetes, obsessive ...

  3. Change in Child Psychopathology with Improvement in Parental Depression

    Science.gov (United States)

    Gunlicks, Meredith L.; Weissman, Myrna M.

    2008-01-01

    The article identifies and evaluates the current research evidence of associations between improvement in parents' depression and their children's psychopathology. Findings indicate some evidence of associations between successful treatment of parents' depression and improvement in children's symptoms and functioning but further studies on these…

  4. Adjunctive Aripiprazole Treatment for Risperidone-Induced Hyperprolactinemia: An 8-Week Randomized, Open-Label, Comparative Clinical Trial.

    Directory of Open Access Journals (Sweden)

    Jingyuan Zhao

    Full Text Available The present study aimed to evaluate the efficacy and safety of adjunctive aripiprazole treatment in schizophrenia patients with risperidone-induced hyperprolactinemia.One hundred and thirteen patients who were receiving a stable dose of risperidone were randomly assigned to either adjunctive aripiprazole treatment (10 mg/day (aripiprazole group or no additional treatment (control group at a 1:1 ratio for 8 weeks. Schizophrenia symptoms were measured using the Positive and Negative Syndrome Scale (PANSS. Rating scales and safety assessments (RSESE, BARS, UKU were performed at baseline and at weeks 4 and 8. Serum levels of prolactin were determined at baseline and at weeks 2, 4, 6 and 8. Metabolic parameters were determined at baseline and again at weeks 4 and 8.One hundred and thirteen patients were enrolled in this study, and 107 patients completed the study (54 in the aripiprazole group, and 53 in the control group. PANSS-total scores in the aripiprazole group decreased significantly at week 4 (P = 0.003 and week 8 (P = 0.007 compared with the control group. PANSS-negative scores in the aripiprazole group also decreased significantly at week 4 (P = 0.005 and week 8 (P< 0.001 compared with the control group. Serum levels of prolactin in the aripiprazole group decreased significantly at week 2 (P< 0.001, week 4 (P< 0.001, week 6 (P< 0.001 and week 8 (P< 0.001 compared with the control group. There were no significant differences in changes of Fasting Plasma Glucose, Total cholesterol, Triglycerides and High Density Lipoprotein within each group at week 4 and 8 execpt low density lipoproteins. There was no significant difference in the incidence of adverse reactions between the two groups.Adjunctive aripiprazole treatment may be beneficial in reducing serum levels of prolactin and improving negative symptoms in schizophrenia patients with risperidone-induced hyperprolactinemia.chictr.org ChiCTR-IOR-15006278.

  5. Improving Depression Care Through an Online Learning Collaborative.

    Science.gov (United States)

    Starkey, Melissa; Wiest, Dawn; Qaseem, Amir

    2016-01-01

    Depression is a leading cause of disability worldwide, and many internists diagnose and treat depression. This study aimed to examine the impact of a practice improvement intervention on screening and managing patients with depression in primary care. This pre-post study design included a physician practice survey designed to capture what the physicians believed they were doing in practice, a chart audit tool to capture what physicians were actually doing in practice, and an intervention that included an evidence-based educational program, online toolkit, and practice improvement coaching conference calls that promoted group learning. Following completion of the intervention, participants increasingly used the Patient Health Questionnaire-9 to detect, diagnose, and gauge treatment success for depression and reported increased use of guidelines and team-based care. Although barriers to improving depression care exist, this study suggests that evidence-based quality improvement programs can positively affect practice. PMID:25351473

  6. Two Cases of Hypersexuality Probably Associated with Aripiprazole

    OpenAIRE

    Cheon, EunJin; Koo, Bon-Hoon; Seo, Sang Soo; Lee, Jun-Yeob

    2013-01-01

    Sexual dysfunction is a common side effect in patients treated with antipsychotics but significant differences exist across different compounds. We report hypersexuality symptoms in two female patients with schizophrenia who were receiving treatment with aripiprazole. The patients experienced more frequent sexual desire and greater sexual preoccupation after taking aripiprazole. We discuss the potential neuro-chemical mechanisms for this and argue that aripiprazole's unique pharmacological pr...

  7. Development of fixed dose combination tablets of aripiprazole plus divalproex sodium and their simultaneous determination using HPLC-UV.

    Science.gov (United States)

    Ahmed, Zia; Subhan, Fazal; Ahmed, Saba; Abdur Rasheed, Qazi; Ahmed, Sagheer; Shahid, Muhammad; Farooq, Saeed

    2016-09-01

    A vast majority of psychiatric patients are effectively treated with combination of drugs to improve efficacy and adherence, but due to limited research and development in fixed dose combination (FDC) in psychiatry, these products are not commonly available. The aim of this study is to prepare cost effective FDC tablets containing aripiprazole and divalproex sodium. Two batches of fixed dose combination tablets, FDC1 and FDC2, were successfully prepared using wet granulation technique. Furthermore, aripiprazole tablets A1 and A2 and divalproex tablets D1 were also formulated as reference to compare the in vitro availability profile. An accurate and simple isocratic HPLC method was established and validated for the simultaneous quantification of aripiprazole and valproic acid in the FDC tablets. A reversed-phase C18 (250 × 4.6 mm) column in isocratic mode was used. The mobile phase consisted of acetonitrile and 0.32% KH2PO4 (60:40, v/v), flow rate was set at 1.0 mL/min and the detection was performed at 210 nm. Average percent recoveries of aripiprazole and valproic acid were 96.0 and 95.5%, respectively, meeting the official requirements. The newly developed FDC product may be used for the better therapeutic outcomes of combined use of aripiprazole and valproic acid, which may improve patient adherence. PMID:26727505

  8. Orthognathic surgery improves quality of life and depression, but not anxiety, and patients with higher preoperative depression scores improve less.

    Science.gov (United States)

    Brunault, P; Battini, J; Potard, C; Jonas, C; Zagala-Bouquillon, B; Chabut, A; Mercier, J-M; Bedhet, N; Réveillère, C; Goga, D; Courtois, R

    2016-01-01

    This study assessed quality of life (QoL), depression, and anxiety before and after orthognathic surgery and identified risk factors for poorer postoperative outcome. This multicentre prospective study included 140 patients from five French medical centres. We assessed patients before surgery (T1), 3 months after surgery (T2), and 12 months after surgery (T3). We assessed the severity of the orofacial deformity, physical, psychological, social, and environmental QoL (WHOQOL-BREF), and depression and anxiety (GHQ-28). Risk factors for poorer outcome were identified using linear mixed models. Between baseline and 12 months, there was significant improvement in psychological and social QoL and in depression (although below the norms reported in the general population), but not in anxiety. Physical QoL was poorer in patients who were younger, who had a mild orofacial deformity, and who were depressed. Psychological QoL was poorer in younger patients and in depressed patients. Social QoL was poorer in patients who were single, who had a mild orofacial deformity, and who were depressed. Although orthognathic surgery provides a moderate improvement in psychological and social QoL, the systematic screening and treatment of depression could further improve QoL after surgery because it is a major predictor of poor QoL in this population. PMID:26359548

  9. The VA augmentation and switching treatments for improving depression outcomes (VAST-D) study: Rationale and design considerations.

    Science.gov (United States)

    Mohamed, Somaia; Johnson, Gary R; Vertrees, Julia E; Guarino, Peter D; Weingart, Kimberly; Young, Ilanit Tal; Yoon, Jean; Gleason, Theresa C; Kirkwood, Katherine A; Kilbourne, Amy M; Gerrity, Martha; Marder, Stephen; Biswas, Kousick; Hicks, Paul; Davis, Lori L; Chen, Peijun; Kelada, AlexandraMary; Huang, Grant D; Lawrence, David D; LeGwin, Mary; Zisook, Sidney

    2015-10-30

    Because two-thirds of patients with Major Depressive Disorder do not achieve remission with their first antidepressant, we designed a trial of three "next-step" strategies: switching to another antidepressant (bupropion-SR) or augmenting the current antidepressant with either another antidepressant (bupropion-SR) or with an atypical antipsychotic (aripiprazole). The study will compare 12-week remission rates and, among those who have at least a partial response, relapse rates for up to 6 months of additional treatment. We review seven key efficacy/effectiveness design decisions in this mixed "efficacy-effectiveness" trial. PMID:26279130

  10. Low-dose aripiprazole for refractory burning mouth syndrome.

    Science.gov (United States)

    Umezaki, Yojiro; Takenoshita, Miho; Toyofuku, Akira

    2016-01-01

    We report a case of refractory burning mouth syndrome (BMS) ameliorated with low dose of aripiprazole. The patient was a 66-year-old female who had suffered from chronic burning pain in her tongue for 13 months. No abnormality associated with the burning sensation was detected in the laboratory tests and the oral findings. Considering the clinical feature and the history together, we diagnosed the burning sensation as BMS. The BMS pain was decreased by aripiprazole (powder) 1.0 mg/d, though no other antidepressants had satisfying pain relief. It could be supposed that the efficacy of aripiprazole is caused by dopamine stabilization in this case, and BMS might have a subtype that is reactive to aripiprazole. Further studies are needed to confirm the efficacy of aripiprazole for BMS. PMID:27279742

  11. Training primary care physicians improves the management of depression

    NARCIS (Netherlands)

    van Os, TWDP; Ormel, J; van den Brink, RHS; Jenner, JA; Van der Meer, K; Tiemens, BG; van der Doorn, W; Smit, A; van den Brink, W

    1999-01-01

    The purpose of this pretest-posttest study was to evaluate effects of a training program designed to improve primary care physicians' (PCPs) ability to recognize mental health problems (MHP) and Co diagnose and manage depression according to clinical guidelines. The primary care settings were in the

  12. Innovative ICT solutions to improve treatment outcomes for depression: the ICT4Depression project.

    Science.gov (United States)

    Warmerdam, Lisanne; Riper, Heleen; Klein, Michel; van den Ven, Pepijn; Rocha, Artur; Ricardo Henriques, Mario; Tousset, Eric; Silva, Hugo; Andersson, Gerhard; Cuijpers, Pim

    2012-01-01

    Depression is expected to be the disorder with the highest disease burden in high-income countries by the year 2030. ICT4Depression (ICT4D) is a European FP7 project, which aims to contribute to the alleviation of this burden by making use of depression treatment and ICT innovations. In this project we developed an ICT-based system for use in primary care that aims to improve access as well as actual care delivery for depressed adults. Innovative technologies within the ICT4D system include 1) flexible self-help treatments for depression, 2) automatic assessment of the patient using mobile phone and web-based communication 3) wearable biomedical sensor devices for monitoring activities and electrophysiological indicators, 4) computational methods for reasoning about the state of a patient and the risk of relapse (reasoning engine) and 5) a flexible system architecture for monitoring and supporting people using continuous observations and feedback via mobile phone and the web. The general objective of the ICT4D project is to test the feasibility and acceptability of the ICT4D system within a pilot study in the Netherlands and in Sweden during 2012 and 2013. PMID:22954884

  13. Adjunctive Aripiprazole Treatment for Risperidone-Induced Hyperprolactinemia: An 8-Week Randomized, Open-Label, Comparative Clinical Trial

    Science.gov (United States)

    Zhao, Jingyuan; Song, Xueqin; Ai, Xiaoqing; Gu, Xiaojing; Huang, Guangbiao; Li, Xue; Pang, Lijuan; Ding, Minli; Ding, Shuang; Lv, Luxian

    2015-01-01

    Objective The present study aimed to evaluate the efficacy and safety of adjunctive aripiprazole treatment in schizophrenia patients with risperidone-induced hyperprolactinemia. Methods One hundred and thirteen patients who were receiving a stable dose of risperidone were randomly assigned to either adjunctive aripiprazole treatment (10 mg/day) (aripiprazole group) or no additional treatment (control group) at a 1:1 ratio for 8 weeks. Schizophrenia symptoms were measured using the Positive and Negative Syndrome Scale (PANSS). Rating scales and safety assessments (RSESE, BARS, UKU) were performed at baseline and at weeks 4 and 8. Serum levels of prolactin were determined at baseline and at weeks 2, 4, 6 and 8. Metabolic parameters were determined at baseline and again at weeks 4 and 8. Results One hundred and thirteen patients were enrolled in this study, and 107 patients completed the study (54 in the aripiprazole group, and 53 in the control group). PANSS-total scores in the aripiprazole group decreased significantly at week 4 (P = 0.003) and week 8 (P = 0.007) compared with the control group. PANSS-negative scores in the aripiprazole group also decreased significantly at week 4 (P = 0.005) and week 8 (P< 0.001) compared with the control group. Serum levels of prolactin in the aripiprazole group decreased significantly at week 2 (P< 0.001), week 4 (P< 0.001), week 6 (P< 0.001) and week 8 (P< 0.001) compared with the control group. There were no significant differences in changes of Fasting Plasma Glucose, Total cholesterol, Triglycerides and High Density Lipoprotein within each group at week 4 and 8 execpt low density lipoproteins. There was no significant difference in the incidence of adverse reactions between the two groups. Conclusions Adjunctive aripiprazole treatment may be beneficial in reducing serum levels of prolactin and improving negative symptoms in schizophrenia patients with risperidone-induced hyperprolactinemia. Trial Registration chictr.org Chi

  14. Behandling af Tourettes syndrom med aripiprazol

    DEFF Research Database (Denmark)

    Stenstrøm, Anne Dorte; Sindø, Ingrid

    2008-01-01

    Tourette's syndrome (TS) is a motoric disorder characterised by multiple motor and vocal tics. The treatment for patients with moderate to severe TS includes antipsychotic medication. A case report is described in which a 20 year-old male had taken antipsychotic medication since the age of five......, due to TS. The initial treatment consisted of pimozide and risperidone, both of which had an unsatisfactorily efficacy on tics and side effects in the form of weight gain and sedation. The patient is now treated with aripiprazole and there is a marked reduction of tics and no side effects...

  15. Dilemma of prescribing aripiprazole under the Taiwan health insurance program: a descriptive study

    Directory of Open Access Journals (Sweden)

    Hsu YC

    2015-01-01

    Full Text Available Yi-Chien Hsu,1,2 Yu-Ching Chou,3 Hsin-An Chang,1,2,4 Yu-Chen Kao,1,2,5 San-Yuan Huang,1,2 Nian-Sheng Tzeng1,2,4 1Department of Psychiatry, Tri-Service General Hospital, Taipei, Taiwan; 2School of Medicine, 3School of Public Health, 4Student Counseling Center, National Defense Medical Center, Taipei, Taiwan; 5Department of Psychiatry, Tri-Service General Hospital, Song-Shan Branch, Taipei, Taiwan Objectives: Refractory major depressive disorder (MDD is a serious problem leading to a heavy economic burden. Antipsychotic augmentation treatment with aripiprazole and quetiapine is approved for MDD patients and can achieve a high remission rate. This study aimed to examine how psychiatrists in Taiwan choose medications and how that choice is influenced by health insurance payments and administrative policy.Design: Descriptive study.Outcome measures: Eight questions about the choice of treatment strategy and atypical antipsychotics, and the reason to choose aripiprazole.Intervention: We designed an augmentation strategy questionnaire for psychiatrists whose patients had a poor response to antidepressants, and handed it out during the annual meeting of the Taiwanese Society of Psychiatry in October 2012. It included eight questions addressing the choice of treatment strategy and atypical antipsychotics, and the reason whether or not to choose aripiprazole as the augmentation antipsychotic.Results: Choosing antipsychotic augmentation therapy or switching to other antidepressant strategies for MDD patients with an inadequate response to antidepressants was common with a similar probability (76.1% vs 76.4%. The most frequently used antipsychotics were aripiprazole and quetiapine, however a substantial number of psychiatrists chose olanzapine, risperidone, and sulpiride. The major reason for not choosing aripiprazole was cost (52.1%, followed by insurance official policy audit and deletion in the claims review system (30.1%.Conclusion: The prescribing

  16. Add-on effects of a low-dose aripiprazole in resolving hyperprolactinemia induced by risperidone or paliperidone.

    Science.gov (United States)

    Qiao, Ying; Yang, Fuzhong; Li, Chunbo; Guo, Qian; Wen, Hui; Zhu, Suoyu; Ouyang, Qiong; Shen, Weidi; Sheng, Jianhua

    2016-03-30

    This study investigated the effects of a low-dose aripiprazole adjunctive treatment for risperidone- or paliperidone-induced hyperprolactinemia in Han Chinese women with schizophrenia. After 4 weeks of risperidone or paliperidone treatment, 60 out of 66 patients improved significantly and experienced hyperprolactinemia. They were randomly assigned to the treatment group (aripiprazole adjunctive treatment) (n=30) or control group (non-adjunctive treatment) (n=30). The dosage of risperidone and paliperidone were maintained; and aripiprazole was maintained at 5mg/day during the 8-week study period. The prolactin levels at the end of the 8th week were significantly lower in the treatment group than in the control group. The estradiol level correlated negatively with serum prolactin level both in the treatment group and the control group at the end of the 8th week and the 4th week respectively. The Positive and Negative Syndrome Scale score improved significantly during the 8-week study period in both groups. The incidence of treatment-emergent adverse event was similar in two groups. Low-dose aripiprazole adjunctive treatment is effective in relieving risperidone- and paliperidone-induced hyperprolactinemia in female schizophrenic patients without increasing adverse event. PMID:26921057

  17. The prescribing pattern of a new antipsychotic: A descriptive study of aripiprazole for psychiatric in-patients

    DEFF Research Database (Denmark)

    Johansson, M.; Manniche, C.; Andersen, Stig Ejdrup

    2008-01-01

    -naive. In 25% aripiprazole, monotherapy was commenced whereas aripiprazole-antipsychotic combinations were initially prescribed in 75%. Overall, 85% of the patients received periods of antipsychotic polypharmacy and aripiprazole was combined with 17 different antipsychotics. Each patient received median...... three (range 0-8) psychoactive drugs parallel with aripiprazole. This study demonstrates reality in psychopharmacology and quote aripiprazole as example. In day-to-day practice, aripiprazole is used as part of highly individualized regimens comprising polypharmacy and excessive dosing. Although...

  18. ARIPIPRAZOLE VERSUS HALOPERIDOL TREATMENT IN EARLY-STAGE SCHIZOPHRENIA

    OpenAIRE

    Girgis, Ragy R; Merrill, David B.; Vorel, Stanislav R.; Kim, Edward; Portland, Kimberly; You, Min; Pikalov, Andrei; Whitehead, Richard; Lieberman, Jeffrey A.

    2010-01-01

    We conducted a secondary analysis of a completed study of the differential efficacy and side effects of aripiprazole versus haloperidol in early-stage schizophrenia (ESS), a subpopulation of patients which does not include first episode or chronic patients. A subpopulation of 360 individuals with ESS were identified from a randomized, multi-center, double-blind study of 1294 individuals with schizophrenia at different stages of illness who were randomized to treatment with aripiprazole (ESS=2...

  19. Aripiprazole Augmentation in Treatment of Resistant Obsessive Compulsive Disorder

    OpenAIRE

    Karim Abdel Aziz; Nisrin M El-Saadouni; Mohammed Hashim E. Elamin; Dina Aly El-Gabry; Hamdy F Moselhy

    2016-01-01

    Background: Aripiprazole is a novel antipsychotic medication that has been tried in the treatment of several psychiatric disorders. In an open clinical study, we evaluated the safety and efficacy of aripiprazole in patients with obsessive compulsive disorder resistant to normal regimen of treatment. Method: A total of nine hundred and sixty one patients were admitted over three year period of time (January 2012- December 2014) to the psychiatric department of Al Ain hospital, United Arab Emir...

  20. Low-dose aripiprazole for refractory burning mouth syndrome

    Directory of Open Access Journals (Sweden)

    Umezaki Y

    2016-05-01

    Full Text Available Yojiro Umezaki,1 Miho Takenoshita,2 Akira Toyofuku2 1Psychosomatic Dentistry Clinic, Dental Hospital, 2Psychosomatic Dentistry, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan Abstract: We report a case of refractory burning mouth syndrome (BMS ameliorated with low dose of aripiprazole. The patient was a 66-year-old female who had suffered from chronic burning pain in her tongue for 13 months. No abnormality associated with the burning sensation was detected in the laboratory tests and the oral findings. Considering the clinical feature and the history together, we diagnosed the burning sensation as BMS. The BMS pain was decreased by aripiprazole (powder 1.0 mg/d, though no other antidepressants had satisfying pain relief. It could be supposed that the efficacy of aripiprazole is caused by dopamine stabilization in this case, and BMS might have a subtype that is reactive to aripiprazole. Further studies are needed to confirm the efficacy of aripiprazole for BMS. Keywords: burning mouth syndrome, low-dose aripiprazole, chronic pain

  1. The effect of antipsychotic medication on sexual function and serum prolactin levels in community-treated schizophrenic patients: results from the Schizophrenia Trial of Aripiprazole (STAR study (NCT00237913

    Directory of Open Access Journals (Sweden)

    Pans Miranda

    2008-12-01

    Full Text Available Abstract Background The aim of this paper is to evaluate the effect of antipsychotics for the treatment of schizophrenia in a community based study on sexual function and prolactin levels comparing the use of aripiprazole and standard of care (SOC, which was a limited choice of three widely used and available antipsychotics (olanzapine, quetiapine or risperidone (The Schizophrenia Trial of Aripiprazole [STAR] study [NCT00237913]. Method This open-label, 26-week, multi-centre, randomised study compared aripiprazole to SOC (olanzapine, quetiapine or risperidone in patients with schizophrenia (DSM-IV-TR criteria. The primary effectiveness variable was the mean total score of the Investigator Assessment Questionnaire (IAQ at Week 26. The outcome research variables included the Arizona Sexual Experience scale (ASEX. This along with the data collected on serum prolactin levels at week 4, 8, 12, 18 and 26 will be the focus of this paper. Results A total of 555 patients were randomised to receive aripiprazole (n = 284 or SOC (n = 271. Both treatment groups experienced improvements in sexual function from baseline ASEX assessments. However at 8 weeks the aripiprazole treatment group reported significantly greater improvement compared with the SOC group (p = 0.007; OC. Although baseline mean serum prolactin levels were similar in the two treatment groups (43.4 mg/dL in the aripiprazole group and 42.3 mg/dL in the SOC group, p = NS at Week 26 OC, mean decreases in serum prolactin were 34.2 mg/dL in the aripiprazole group, compared with 13.3 mg/dL in the SOC group (p Conclusion The study findings suggest that aripiprazole has the potential to reduce sexual dysfunction, which in turn might improve patient compliance.

  2. Depression remitted after subarachnoid haemorrhage

    DEFF Research Database (Denmark)

    Lauritsen, Lise; Vinberg, Maj

    2015-01-01

    A 65-year-old man was seen in a specialized ambulatory for mood disorders because of treatment-resistant depression. He was treated throughout a period of three years with selective serotonin reuptake inhibitor, dual action, lithium, nortriptyline, reboxetine, aripiprazole, benzodiazepines...

  3. [Hypersexuality associated with aripiprazole: a new case and review of the literature].

    Science.gov (United States)

    Vrignaud, Laura; Aouille, Jerémie; Mallaret, Michel; Durrieu, Geneviève; Jonville-Béra, Annie-Pierre

    2014-01-01

    We report the case of a patient with hypersexuality while he was treated with aripiprazole since 6 months. Clinical manifestations were an increased libido, unusual frequent masturbation and sexual instincts. All have resolved upon discontinuation of aripiprazole, and recurred after it was restarted. The partial dopaminergic agonist effect of aripiprazole could probably explain the occurrence of this compulsive behaviour. PMID:25293487

  4. Effect of combination of aripiprazole with carbamazepine and fluvoxamine on liver functions in experimental animals

    Directory of Open Access Journals (Sweden)

    Chakrakodi S Shastry

    2013-01-01

    Conclusions: There would be an accumulation of aripiprazole when coadministered with fluvoxamine, a known inhibitor of CYP3A4, leading to hepatic damage and reduction in aripiprazole when administered along with carbamazepine. Therefore, aripiprazole with fluvoxamine and carbamazepine should be coprescribed with caution. The patients should be monitored for signs of adverse effects like hepatic damage or decreased efficacy of these drugs.

  5. Depression

    Science.gov (United States)

    ... usually feel better with the right treatment. What Causes Depression? There is no one cause of depression. For ... changes in the brain can affect mood and cause depression. Sometimes, those under a lot of stress, like ...

  6. Diabetes education improves depressive state in newly diagnosed patients with type 2 diabetes

    OpenAIRE

    Chen, Bin; Zhang, Xiyao; XU, XIUPING; Lv, Xiaofeng; Yao, Lu; Huang, Xu; Guo, Xueying; Liu, Baozhu; Li, Qiang; Cui, Can

    2013-01-01

    Objectives: The prevalence of depression is relatively high in individuals with diabetes. However, screening and monitoring of depressive state in patients with diabetes is still neglected in developing countries and the treatment of diabetes-related depression is rarely performed in these countries. In this study, our aim was to study the role of diabetes education in the improvement of depressive state in newly diagnosed patients with type 2 diabetes. Methods: The Dutch version of the cente...

  7. Schizophrenia relapse and the clinical usefulness of once-monthly aripiprazole depot injection

    Directory of Open Access Journals (Sweden)

    Wang SM

    2014-08-01

    Full Text Available Sheng-Min Wang,1 Changsu Han,2 Soo-Jung Lee,5 Ashwin A Patkar,3 Prakash S Masand,4 Chi-Un Pae3,5 1International Health Care Center, Seoul St Mary’s Hospital, The Catholic University of Korea, College of Medicine, Seoul, Republic of Korea; 2Department of Psychiatry, College of Medicine, Korea University, Seoul, Republic of Korea; 3Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC, 4Global Medical Education, New York, NY, USA; 5Department of Psychiatry, Bucheon St Mary’s Hospital, The Catholic University of Korea, College of Medicine, Seoul, Republic of Korea Abstract: Improving medication adherence is critical to improving outcomes in patients with schizophrenia. A long-acting injectable (depot antipsychotic is one of the most effective methods for improving treatment adherence and decreasing rehospitalization rates in patients with schizophrenia. Until recently, only three second-generation antipsychotics were available in a long-acting injectable formulation (risperidone, paliperidone, and olanzapine. In this respect, the emergence of long-acting aripiprazole injection (ALAI, approved by the US Food and Drug Administration for the treatment of schizophrenia in 2013, is timely. ALAI is a lyophilized powder of aripiprazole, and the aripiprazole molecule is unmodified. The initial and target dosage of ALAI is 400 mg once monthly, but it could be reduced to 300 mg if adverse reactions occur with 400 mg. When first administering ALAI, it is recommended to continue treatment with oral aripiprazole (10–20 mg/day or another oral antipsychotic for 2 weeks in order to maintain therapeutic antipsychotic concentrations. The primary clearance route for ALAI is hepatic, ie, cytochrome P450 (CYP2D6 and CYP3A4, so dose adjustment is required in poor CYP2D6 metabolizers. The efficacy of ALAI was demonstrated in three studies. A randomized controlled trial that formed the basis for approval of ALAI in the

  8. Depression

    DEFF Research Database (Denmark)

    Kessing, Lars Veddel; Bukh, Jens Otto Drachmann

    2014-01-01

    these diagnostic criteria represent an oversimplification, which has blurred the concept of depression. We suggest a greater emphasis on the depressed mood as the core symptom of depression, which may increase the specificity of the diagnosis. Furthermore, basic principles for the treatment of......The prevalence of depression is not clearly established, but estimated to 3-4% in a Danish questionnaire study. Lifetime's prevalences of 12-17% are reported in other community samples. In the current diagnostic system depression is defined categorically and operationally. It has been argued, that...... depression are presented....

  9. Depression

    DEFF Research Database (Denmark)

    Kessing, Lars Veddel; Bukh, Jens Drachmann

    2014-01-01

    The prevalence of depression is not clearly established, but estimated to 3-4% in a Danish questionnaire study. Lifetime's prevalences of 12-17% are reported in other community samples. In the current diagnostic system depression is defined categorically and operationally. It has been argued, that...... these diagnostic criteria represent an oversimplification, which has blurred the concept of depression. We suggest a greater emphasis on the depressed mood as the core symptom of depression, which may increase the specificity of the diagnosis. Furthermore, basic principles for the treatment of...... depression are presented....

  10. Cognitive and psychomotor effects of adjunctive aripiprazole or paliperidone in patients of schizophrenia receiving olanzapine: a double blind placebo controlled clinical study

    Directory of Open Access Journals (Sweden)

    Mayur M. Mayabhate

    2014-02-01

    Conclusions: The best augmenting strategy with for olanzapine nonresponsive patients will be D2 receptor partial agonist like aripiprazole rather than D2 antagonist like paliperidone and other atypical antipsychotic agents for better improvement in cognition and psychomotor domains. [Int J Basic Clin Pharmacol 2014; 3(1.000: 130-138

  11. A Depression Training Session With Consumer Educators to Reduce Stigmatizing Views and Improve Pharmacists’ Depression Care Attitudes and Practices

    Science.gov (United States)

    Smits, Tim; Laekeman, Gert; Foulon, Veerle

    2013-01-01

    Objective. To measure the impact of a depression training day for pharmacists that included a 75-minute session with a consumer educator. Design. The training day included interactive lectures on depression; the effects and side effects of and indications for the use of antidepressants; adherence issues; non-drug treatment options for depression; and basic skills in communication. Pharmacists also participated in a session with a consumer educator and in counseling exercises that included role playing. Assessment. The study used a randomized, clustered, comparative design to measure pharmacists' stigma, attitudes, and current practice related to the provision of pharmaceutical care to people with depression. Mean scores for depression-care practice after the training session were significantly higher in the intervention group than in the control group. Analysis of the changes between baseline and postintervention measures in both the control and intervention groups confirmed a significant difference in the change in both social distance and practice but no significant difference in the change in attitude between the 2 groups of pharmacists. Conclusion. A continuing-education depression training day for pharmacists that involve consumer educators may improve the care delivered in the community pharmacy to people with depression. PMID:23966723

  12. Depression

    Science.gov (United States)

    ... or more of the following: Your genes. Sometimes depression is hereditary, meaning it runs in your family. If you have a parent or sibling who has depression, you may be more at risk for having ...

  13. Depression

    OpenAIRE

    Grace Sherry L; Gucciardi Enza; Stewart Donna E

    2004-01-01

    Abstract Health Issue Depression causes significant distress or impairment in physical, social, occupational and other key areas of functioning. Women are approximately twice as likely as men to experience depression. Psychosocial factors likely mediate the risks for depression incurred by biological influences. Key Findings Data from the 1999 National Population Health Survey show that depression is more common among Canadian women, with an annual self-reported incidence of 5.7% compared wit...

  14. Depression

    OpenAIRE

    Stewart, Donna E.; Gucciardi, Enza; Grace, Sherry L.

    2004-01-01

    Health Issue Depression causes significant distress or impairment in physical, social, occupational and other key areas of functioning. Women are approximately twice as likely as men to experience depression. Psychosocial factors likely mediate the risks for depression incurred by biological influences. Key Findings Data from the 1999 National Population Health Survey show that depression is more common among Canadian women, with an annual self-reported incidence of 5.7% compared with 2.9% in...

  15. The Teen Depression Awareness Project: Building an Evidence Base for Improving Teen Depression Care. Research Highlights

    Science.gov (United States)

    Adamson, David M.

    2010-01-01

    Depression's effects on adolescent functioning and family burden are not well understood; there is also limited understanding of teens' and parents' attitudes and knowledge about depression, how these and other factors influence readiness for treatment, and the barriers to care that teens and their parents encounter. To address these knowledge…

  16. Depression

    DEFF Research Database (Denmark)

    Cizza, G; Ravn, Pernille; Chrousos, G P;

    2001-01-01

    Existing studies of the relationship between depression and osteoporosis have been heterogeneous in their design and use of diagnostic instruments for depression, which might have contributed to the different results on the comorbidity of these two conditions. Nevertheless, these studies reveal a...... strong association between depression and osteoporosis. Endocrine factors such as depression-induced hypersecretion of corticotropin-releasing hormone and hypercortisolism, hypogonadism, growth hormone deficiency and increased concentration of circulating interleukin 6, might play a crucial role in the...... bone loss observed in subjects suffering from major depression....

  17. Studies of phase transitions in the aripiprazole solid dosage form.

    Science.gov (United States)

    Łaszcz, Marta; Witkowska, Anna

    2016-01-01

    Studies of the phase transitions in an active substance contained in a solid dosage form are very complicated but essential, especially if an active substance is classified as a BCS Class IV drug. The purpose of this work was the development of sensitive methods for the detection of the phase transitions in the aripiprazole tablets containing initially its form III. Aripiprazole exhibits polymorphism and pseudopolymorphism. Powder diffraction, Raman spectroscopy and differential scanning calorimetry methods were developed for the detection of the polymorphic transition between forms III and I as well as the phase transition of form III into aripiprazole monohydrate in tablets. The study involved the initial 10 mg and 30 mg tablets, as well as those stored in Al/Al blisters, a triplex blister pack and HDPE bottles (with and without desiccant) under accelerated and long term conditions. The polymorphic transition was not observed in the initial and stored tablets but it was visible on the DSC curve of the Abilify(®) 10 mg reference tablets. The formation of the monohydrate was observed in the diffractograms and Raman spectra in the tablets stored under accelerated conditions. The monohydrate phase was not detected in the tablets stored in the Al/Al blisters under long term conditions. The results showed that the Al/Al blisters can be recommended as the packaging of the aripiprazole tablets containing form III. PMID:26397209

  18. Salivary and serum biomarkers for the study of side effects of aripiprazole coprescribed with mirtazapine in rats.

    Science.gov (United States)

    Bogdan, Maria; Silosi, Isabela; Surlin, Petra; Tica, Andrei Adrian; Tica, Oana Sorina; Balseanu, Tudor-Adrian; Rauten, Anne-Marie; Camen, Adrian

    2015-01-01

    The aim of this study was to investigate whether the co-administration of aripiprazole and mirtazapine could determine weight gain and lipid metabolism disorders in Wistar rats, compared to the same side effects produced by mirtazapine alone, and the risk of hepatotoxicity due to the combination of the two substances. Tumor necrosis factor alpha (TNF-α), liver fatty acid binding protein (L-FABP/FABP1) and repulsive guidance molecule C/hemojuvelin (RGM-C/HJV) levels were determined in serum and in saliva. Also, serum levels for total cholesterol (TC), low and high-density lipoprotein (LDL, HDL), triglycerides (TG), aspartate aminotransferase (ASAT) and alanine amino transferase (ALAT) were assessed. We found positive and statistically significant correlations between serum and salivary levels of TNF-α, L-FABP/FABP1 and RGM-C/HJV. Mirtazapine determined significantly differences of TNF-α and L-FABP serum levels; final body weight; TC and LDL levels, leading to higher concentrations than its association with aripiprazole. Although not statistically significant, mirtazapine group experienced higher values for salivary levels of TNF-α, TG and ASAT, and lower values for HDL, compared to aripiprazole + mirtazapine group. The results suggest that aripiprazole might improve some of the disturbances caused by mirtazapine, and that the two drugs combination cause no additional alterations in liver function. Also, the findings indicate that TNF-α, L-FABP/FABP1 and RGM-C/HJV levels can be helpful as biomarkers for metabolic disturbances and impaired function of hepatocytes, and that their salivary determination can replace serum determination. PMID:26221370

  19. Additional intranasal oxytocin to escitalopram improves depressive symptoms in resistant depression: An open trial.

    OpenAIRE

    Scantamburlo, Gabrielle; Hansenne, Michel; Geenen, Vincent; Legros, Jean-Jacques; Ansseau, Marc

    2015-01-01

    The aim of this open trial was to assess the antidepressant/anxiolytic effects of oxytocin used as an adjunct to antidepressant in treatment-resistant depression. Fourteen patients, who have not responded to 40mg of escitalopram, received intranasal synthetic oxytocin during 4 weeks, in association with antidepressant. This is the first open trial study suggesting OT in association with escitalopram significantly reduced scores on Hamilton Depression Rating Scale. Peer reviewed

  20. Improvement of Depression after Treatment of Dural Arteriovenous Fistula: A Case Report and a Review

    OpenAIRE

    Minoru Nakagawa; Kenji Sugiu; Koji Tokunaga; Chihoko Sakamoto; Kenjiro Fujiwara

    2012-01-01

    Patients with dural arteriovenous fistulas (DAVFs) in the transverse-sigmoid sinus suffer from several symptoms: bruit, headache, visual impairment, and so on. But depression is rare in patients with DAVF. The authors reported a rare case presenting the improvement of depression after the treatment of a dural arteriovenous fistula in the left transverse-sigmoid sinus. A 46-year-old male had suffered from depression and was treated with antidepressants at a local hospital for four years. The p...

  1. Depression

    Science.gov (United States)

    ... cycle Depression and insomnia References American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders . 5th ed. Arlington, VA: American Psychiatric Publishing. 2013. ...

  2. Treatment and prevention of mania in bipolar I disorder: focus on aripiprazole

    OpenAIRE

    Muzina, David J.

    2009-01-01

    Aripiprazole is a second-generation antipsychotic with a unique pharmacologic receptor profile that has efficacy in the treatment and prevention of mania in bipolar I disorder. This article reviews the evidence supporting treatment of adults with bipolar I disorder using aripiprazole as monotherapy or adjunctively during acute mania and its utility as an intramuscular agent for agitation in manic patients. Results from one of the longest bipolar maintenance trials which support aripiprazole a...

  3. Aripiprazole Augmentation in Childhood Obsessive-Compulsive Disorder: Three Case Reports

    OpenAIRE

    Murat Yuce

    2013-01-01

    Aripiprazole is a third generation antipsychotic that has a partial dopamine agonistic activity. There is an increasing usage of aripiprazole in children and adolescents with schizophrenia, pervasive developmental disorders, and bipolar disorders. In these presentation, we aimed to present three pediatric obsessive%u2013compulsive disorder (OCD) cases who were resistant to two different selective serotonin reuptake inhibitor treatments and prescribed aripiprazole for augmentation therapy. Th...

  4. Increased Anxiety, Akathisia, and Suicidal Thoughts in Patients with Mood Disorder on Aripiprazole and Lamotrigine

    OpenAIRE

    Milena Pereira Pondé; Antonio Carlos Cruz Freire

    2015-01-01

    Introduction. Akathisia affects around 18% of patients with bipolar disorder treated with aripiprazole and may worsen when aripiprazole is combined with lamotrigine and antidepressants. Case. This paper reports on two clinical cases involving patients with a diagnosis of mood disorder who developed severe akathisia, anxiety, and suicidal ideation while using a combination of aripiprazole, antidepressants, and lamotrigine. Discussion. We recommend that patients with a mood disorder taking mult...

  5. Depression

    DEFF Research Database (Denmark)

    Johansen, Jon O. J.

    2013-01-01

    Nyhederne er fulde af historier om depression. Overskrifter som: ’Danskerne propper sig med lykkepiller’ eller ‘depression er stadigvæk tabu’ går tit igen i dagspressen. Men hvor er nuancerne, og hvorfor gider vi læse de samme historier igen og igen? Måske er det fordi, vores egne forestillinger er...

  6. Pediatric Depression: Is There Evidence to Improve Evidence-Based Treatments?

    Science.gov (United States)

    Brent, David A.; Maalouf, Fadi T.

    2009-01-01

    Although there have been advances in our ability to treat child and adolescent depression, use of evidence-based treatments still results in many patients with residual symptoms. Advances in our understanding of cognitive, emotional, and ecological aspects of early-onset depression have the potential to lead to improvements in the assessment and…

  7. A controlled study between Aripiprazole combined with low-Dose of Clozapine and single Aripiprazole in the Treatment of Female Chronic Schizophrenia%阿立哌唑合用小剂量氯氮平与阿立哌唑单用治疗女性慢性精神分裂症对照研究

    Institute of Scientific and Technical Information of China (English)

    陆德青; 肖刚

    2014-01-01

    Objective To investigate the clinical efficacy and adverse reaction of aripiprazole combined with low- dose of clozapine in the treatment of female patients with chronic schizophrenia.Methods The Study Group 20 cases were treated by aripiprazole combined with low-dose of clozapine treatment,20 cases in the control group only treated with aripiprazole,analyzed the assessment efficacy with the Brief Psychiatric Rating Scale(BPRS)and Scale for the Assessment of Negative Symptoms(SANS),applied the Treatment Emergent Symptom Scale(TESS)to analyze their adverse reactions.Results There was no significant difference between the BPRS scores of the two groups before treatment.After treatment,it showed Significant diference in depression and anxiety and thought disorder(P<0.05), in the activity and total scores,it showed a very significant difference(P<0.01);The same group before and after treatment,the difference is very significant(P<0.01).SANS scores of the two groups had no sign- ificant difference before treatment,After treatment,in lack of interest/social lack had significant differences(P<0.05); The same group before and after treatment,the difference is very significant(P<0.01).TESS statistics showed that two groups’Side reaction occurred with the same frequency.Conclusion Regardless of aripiprazole combined with smal dose of clozapine or single use of aripiprazole in female patients with chronic schizophrenia had a definite effect,aripiprazole combined with smal dose of clozapine has advantages in improvement activities,improve interest/social and so on ,and the adverse reactions were not increased.%目的:探讨阿立哌唑合用小剂量氯氮平与阿立哌唑单用治疗女性慢性精神分裂症患者的临床疗效和不良反应。方法研究组20例应用阿立哌唑合用小剂量氯氮平治疗,对照组20例仅应用阿立哌唑单独治疗,应用简明精神病评定量表(BPRS)和阴性症状量表(SANS)评定疗效,应用副反应

  8. Improvement in Fatigue during Natalizumab Treatment is Linked to Improvement in Depression and Day-Time Sleepiness

    DEFF Research Database (Denmark)

    Penner, Iris-Katharina; Sivertsdotter, Eva Catharina; Celius, Elisabeth G; Fuchs, Siegrid; Schreiber, Karen; Berkö, Sara; Svenningsson, Anders

    2015-01-01

    BACKGROUND: Fatigue is a frequent symptom in multiple sclerosis (MS) and often interrelated with depression and sleep disorders making symptomatic treatment decisions difficult. In the single-arm, observational phase IV TYNERGY study, relapsing-remitting MS patients showed a clinically meaningful...... decrease in fatigue over 1 year of treatment with natalizumab. OBJECTIVE: To evaluate whether fatigue improvement might be directly linked to improved depression and day-time sleepiness. METHODS: Patients were assessed regarding fatigue, depression, and day-time sleepiness. The relation between changes of...... the two latter symptoms and changes in fatigue was analyzed. RESULTS: After 1 year of natalizumab treatment, the majority of patients (>92%) remained stable or improved in total, motor, and cognitive fatigue. Proportion of patients without depression increased by 17% while proportions of mildly...

  9. Adjunctive aripiprazole in the treatment of risperidone-induced hyperprolactinemia: A randomized, double-blind, placebo-controlled, dose-response study.

    Science.gov (United States)

    Chen, Jing-Xu; Su, Yun-Ai; Bian, Qing-Tao; Wei, Li-He; Zhang, Rong-Zhen; Liu, Yan-Hong; Correll, Christoph; Soares, Jair C; Yang, Fu-De; Wang, Shao-Li; Zhang, Xiang-Yang

    2015-08-01

    Hyperprolactinemia is an unwanted adverse effect associated with several antipsychotics. The addition of partial dopamine receptor agonist aripiprazole may attenuate antipsychotic-induced hyperprolactinemia effectively. However, the ideal dosing regimen for this purpose is unknown. We aimed to evaluate the dose effects of adjunctive treatment with aripiprazole on prolactin levels and hyperprolactinemia in schizophrenia patients. Stable subjects 18-45 years old with schizophrenia and hyperprolactinemia (i.e., >24 ng/ml for females and >20 ng/ml for males) were randomly assigned to receive 8 weeks of placebo (n=30) or oral aripiprazole 5mg/day (n=30), 10mg/day (n=29), or 20mg/day (n=30) added on to fixed dose risperidone treatment. Serum prolactin levels were measured at baseline and after 2, 4 and 8 weeks; clinical symptoms and side effects were assessed at baseline and week 8 using the Positive and Negative Syndrome Scale, Clinical Global Impressions Severity scale, Barnes Akathisia Scale, Simpson-Angus Scale and UKU Side Effects Rating Scale. Of 119 randomized patients, 107 (89.9%) completed the 8-week study. At study end, all three aripiprazole doses resulted in significantly lower prolactin levels (beginning at week 2), higher response rates (≥30% prolactin reduction) and higher prolactin normalization rates than placebo. Effects were significantly greater in the 10 and 20mg/day groups than the 5mg/day group. No significant changes were observed in any treatment groups regarding psychopathology and adverse effect ratings. Adjunctive aripiprazole treatment was effective and safe for resolving risperidone-induced hyperprolactinemia, producing significant and almost maximal improvements by week 2 without significant effects on psychopathology and side effects. PMID:25981348

  10. Depression

    Science.gov (United States)

    ... of the brain. There are a variety of causes, including genetic, biological, environmental, and psychological factors. Depression can happen at any age, but it often begins in teens and young adults. It is much more common in women. Women ...

  11. Depressants

    Science.gov (United States)

    ... treatment of insomnia that share many of the properties of benzodiazepines. Other CNS depressants include meprobamate, methaqualone ( ... they are prescribed for to put you to sleep, relieve anxiety and muscle spasms, and prevent seizures. ...

  12. Depressants

    Science.gov (United States)

    ... Other long-term effects include: impaired sexual function insomnia and other sleep problems breathing problems convulsions (similar to seizures) depression and other mental health issues continue Other Possible Problems Taking too much ...

  13. Depression

    Science.gov (United States)

    ... caring for children and aging parents, abuse, and poverty may trigger depression in some people. Medical illness – ... and places that can help you get treatment. Family doctor Counselors or social workers Family service, social ...

  14. Hyperprolactinemia due to paliperidone palmitate and treatment with aripiprazole

    OpenAIRE

    gokay alpak; ahmet unal; feridun bulbul; ihsan aksoy; bahadir demir; haluk asuman savas

    2014-01-01

    For all typical antipsychotics, potent D2 receptor antagonism and prolonged connection to the receptor causes increased secretion of prolactin. Among second-generation antipsychotics, risperidone and amisulpride increase prolactin levels similar to typical antipsychotics whereas clozapine, olanzapine, quetiapine, aripiprazole and ziprasidone do not increase prolactin levels significantly. It has been claimed that the ongoing D2 receptor blockage by active metabolites of antipsychotic drugs mi...

  15. When to start aripiprazole therapy in patients with bipolar mania

    OpenAIRE

    Sayyaparaju KK; Grunze H; Fountoulakis KN

    2014-01-01

    Kiran Kumar Sayyaparaju,1 Heinz Grunze,1 Kostas N Fountoulakis2 1Newcastle University, Institute of Neuroscience, Academic Psychiatry, Newcastle upon Tyne, UK; 23rd Department of Psychiatry, Division of Neurosciences, School of Medicine, Aristotle University of Thessaloniki, Greece Abstract: Aripiprazole is a third generation atypical antipsychotic with compelling evidence as a highly effective treatment option in the management of acute manic and mixed episodes of bipolar I disorders. It ha...

  16. Assessing organizational readiness for depression care quality improvement: relative commitment and implementation capability

    OpenAIRE

    Rubenstein, Lisa V; Danz, Marjorie S; Crain, A. Lauren; Glasgow, Russell E.; Whitebird, Robin R.; Solberg, Leif I.

    2014-01-01

    Background Depression is a major cause of morbidity and cost in primary care patient populations. Successful depression improvement models, however, are complex. Based on organizational readiness theory, a practice’s commitment to change and its capability to carry out the change are both important predictors of initiating improvement. We empirically explored the links between relative commitment (i.e., the intention to move forward within the following year) and implementation capability. Me...

  17. Improving Confidence for Self Care in Patients with Depression and Chronic Illnesses

    OpenAIRE

    Ludman, Evette J; Peterson, Do; Katon, Wayne J; Lin, Elizabeth H. B.; Von Korff, Michael; Ciechanowski, Paul; Young, Bessie; Gensichen, Jochen

    2013-01-01

    The aim of this study was to examine whether patients who received a multi-condition collaborative care intervention for chronic illnesses and depression had greater improvement in self-care knowledge and efficacy, and whether greater knowledge and self-efficacy is positively associated with improved target outcomes. A randomized controlled trial with 214 patients with comorbid depression and poorly controlled diabetes and/or coronary heart disease tested a 12-month team-based intervention th...

  18. Short term synaptic depression improves information transfer in perceptual multistability

    OpenAIRE

    Zachary P Kilpatrick

    2013-01-01

    Competitive neural networks are often used to model the dynamics of perceptual bistability. Switching between percepts can occur through fluctuations and/or a slow adaptive process. Here, we analyze switching statistics in competitive networks with short term synaptic depression and noise. We start by analyzing a ring model that yields spatially structured solutions and complement this with a study of a space-free network whose populations are coupled with mutual inhibition. Dominance times a...

  19. The cardiac safety of aripiprazole treatment in patients at high risk for torsade

    DEFF Research Database (Denmark)

    Polcwiartek, Christoffer; Sneider, Benjamin; Graff, Claus;

    2015-01-01

    reviewed and cardiac safety data were extracted. Continuous and dichotomous QTc data were used in the meta-analysis. RESULTS: Preclinical studies suggested that aripiprazole has limited affinity for the delayed rectifier potassium current. TdP was reported in two case reports and SCD was reported in one...... case report and one case series. No clinical studies assessing aripiprazole's cardiac safety in patients at high risk for torsade were found. No thorough QT (TQT) study with aripiprazole was found. The meta-analysis revealed that the mean ΔQTc interval was decreased with aripiprazole and QTc...... factors. OBJECTIVES: Aripiprazole's cardiac safety has not been assessed in patients at high risk for torsade, where QTc prolongation risk is highly increased. METHODS: MEDLINE, Embase, and The Cochrane Library were searched for preclinical, clinical, and epidemiological studies. Eligible studies were...

  20. Depression improvement and parenting in low-income mothers in home visiting.

    Science.gov (United States)

    Ammerman, Robert T; Altaye, Mekibib; Putnam, Frank W; Teeters, Angelique R; Zou, Yuanshu; Van Ginkel, Judith B

    2015-06-01

    Research on older children and high-resource families demonstrates that maternal improvement in depression often leads to parallel changes in parenting and child adjustment. It is unclear if this association extends to younger children and low-income mothers. This study examined if In-Home Cognitive Behavioral Therapy (IH-CBT), a treatment for depressed mothers participating in home visiting programs, contributes to improvements in parenting and child adjustment. Ninety-three depressed mothers in home visiting between 2 and 10 months postpartum were randomly assigned to IH-CBT (n = 47) plus home visiting or standard home visiting (SHV; n = 46). Mothers were identified via screening and subsequent diagnosis of major depressive disorder (MDD). Measures of depression, parenting stress, nurturing parenting, and child adjustment were administered at pre-treatment, post-treatment, and 3 months follow-up. Results indicated that there were no differences between IH-CBT and controls on parenting and child adjustment. Low levels of depression were associated with decreased parenting stress and increased nurturing parenting. Improvement in depression was related to changes in parenting in low-income mothers participating in home visiting programs. IH-CBT was not independently associated with these improvements, although to the extent that treatment facilitated improvement; there were corresponding benefits to parenting. Child adjustment was not associated with maternal depression, a finding possibly attributed to the benefits of concurrent home visiting or measurement limitations. Future research should focus on longer-term follow-up, implications of relapse, and child adjustment in later years. PMID:25369906

  1. A Practice Improvement Education Program Using a Mentored Approach to Improve Nursing Facility Depression Care-Preliminary Data.

    Science.gov (United States)

    Chodosh, Joshua; Price, Rachel M; Cadogan, Mary P; Damron-Rodriguez, JoAnn; Osterweil, Dan; Czerwinski, Alfredo; Tan, Zaldy S; Merkin, Sharon S; Gans, Daphna; Frank, Janet C

    2015-11-01

    Depression is common in nursing facility residents. Depression data obtained using the Minimum Data Set (MDS) 3.0 offer opportunities for improving diagnostic accuracy and care quality. How best to integrate MDS 3.0 and other data into quality improvement (QI) activity is untested. The objective was to increase nursing home (NH) capability in using QI processes and to improve depression assessment and management through focused mentorship and team building. This was a 6-month intervention with five components: facilitated collection of MDS 3.0 nine-item Patient Health Questionnaire (PHQ-9) and medication data for diagnostic interpretation; education and modeling on QI approaches, team building, and nonpharmacological depression care; mentored team meetings; educational webinars; and technical assistance. PHQ-9 and medication data were collected at baseline and 6 and 9 months. Progress was measured using team participation measures, attitude and care process self-appraisal, mentor assessments, and resident depression outcomes. Five NHs established interprofessional teams that included nursing (44.1%), social work (20.6%), physicians (8.8%), and other disciplines (26.5%). Members participated in 61% of eight offered educational meetings (three onsite mentored team meetings and five webinars). Competency self-ratings improved on four depression care measures (P = .05 to data, depression scores did not change while medication use declined, from 37.2% of residents at baseline to 31.0% at 9 months (P < .001). This structured mentoring program improved care processes, achieved medication reductions, and was well received. Application to other NH-prevalent syndromes is possible. PMID:26503548

  2. Improvement of Glycemic Control in Insulin-Dependent Diabetics with Depression by Concomitant Treatment with Antidepressants.

    Science.gov (United States)

    Radojkovic, Jana; Sikanic, Natasa; Bukumiric, Zoran; Tadic, Marijana; Kostic, Nada; Babic, Rade

    2016-01-01

    BACKGROUND It is still disputable whether negative effects of comorbid depression in diabetics can be diminished by successful treatment of depression. The primary aim of this study was to assess whether addition of antidepressants to existing insulin treatment would further improve glycemic control in these patients. A secondary objective was to assess whether such treatment impairs their lipid and inflammatory status. MATERIAL AND METHODS Total of 192 patients with poorly controlled diabetes (defined as HbA1c ≥8%) in the absence of any uncontrolled medical condition entered the 6-month run-in phase with optimization of diabetic therapy. Depression status was screened at the end of this phase by BDI-II depression testing. Patients with BDI-II ≥14 and psychiatric confirmation of depression (58 patients) entered the 6-month interventional phase with SSRI class antidepressants. RESULTS Fifty patients completed the study. During the run-in phase, HbA1c dropped from 10.0±1.8% to 8.5±1.2% (pdepression scale and improvement in glycemic control was observed (R²=0.139, p=0.008). Lipid profile and inflammatory status did not change significantly during the interventional phase. CONCLUSIONS Patients with poorly controlled diabetes and comorbid depression might benefit from screening and treatment of depression with SSRI antidepressants by achieving an incremental effect on glycoregulation. This therapy did not have any adverse effects on lipid profile or inflammatory status. PMID:27329213

  3. Time to improve and recover from depressive symptoms and interpersonal problems in a clinical trial.

    Science.gov (United States)

    Lopes, Rodrigo T; Gonçalves, Miguel M; Fassnacht, Daniel; Machado, Paulo P P; Sousa, Inês

    2015-01-01

    Results from an earlier clinical trial comparing narrative therapy with cognitive-behavioural therapy (Lopes et al., 2013) suggested that narrative therapy is efficacious for depression. However, there were significant differences in symptom reduction on the Beck Depression Inventory-II, favouring cognitive-behavioural therapy, if dropouts were included in the analysis, suggesting that time to recovery or improvement would differ in both treatments. Contrarily, results showed that treatment assignment was not a predictor for differential effect. Using a survival analytic approach, it was found that four sessions were necessary for 50% improvement and 16 sessions for 50% recovery. Additionally, depressive symptoms changes occurred significantly faster than interpersonal changes, again regardless of treatment assignment. These results support previous findings of the dose-response literature and of the phase model of change, with the advantage of being specific to psychotherapy with depressive clients. PMID:24166937

  4. Depression

    Science.gov (United States)

    ... to get better. Not a Normal Part of Aging Click for more information Depression is a common problem among older adults, but it is NOT a ... Z | videos A-Z | training | about us | contact us | site map National Institute on Aging | U.S. National Library of Medicine | National Institutes of ...

  5. Everolimus improves memory and learning while worsening depressive- and anxiety-like behavior in an animal model of depression.

    Science.gov (United States)

    Russo, Emilio; Leo, Antonio; Crupi, Rosalia; Aiello, Rossana; Lippiello, Pellegrino; Spiga, Rosangela; Chimirri, Serafina; Citraro, Rita; Cuzzocrea, Salvatore; Constanti, Andrew; De Sarro, Giovambattista

    2016-07-01

    Everolimus (EVR) is an orally-administered rapamycin analog that selectively inhibits the mammalian target of rapamycin (mTOR) kinase (mainly mTORC1 and likely mTORC2) and the related signaling pathway. mTOR is a serine/threonine protein kinase regulating multiple important cellular functions; dysfunction of mTOR signaling has also been implicated in the pathophysiology of several neurological, neurodegenerative, developmental and cognitive disorders. EVR is widely used as an anti-neoplastic therapy and more recently in children with tuberous sclerosis complex (TSC). However, no clear correlation exists between EVR use and development of central side effects e.g. depression, anxiety or cognitive impairment. We studied the effects of a 3 weeks administration of EVR in mice chronically treated with betamethasone 21-phosphate disodium (BTM) as a model of depression and cognitive decline. EVR treatment had detrimental effects on depressive- and anxiety-like behavior while improving cognitive performance in both control (untreated) and BTM-treated mice. Such effects were accompanied by an increased hippocampal neurogenesis and synaptogenesis. Our results therefore might support the proposed pathological role of mTOR dysregulation in depressive disorders and confirm some previous data on the positive effects of mTOR inhibition in cognitive decline. We also show that EVR, possibly through mTOR inhibition, may be linked to the development of anxiety. The increased hippocampal neurogenesis by EVR might explain its ability to improve cognitive function or protect from cognitive decline. Our findings suggest some caution in the use of EVR, particularly in the developing brain; patients should be carefully monitored for their psychiatric/neurological profiles in any clinical situation where an mTOR inhibitor and in particular EVR is used e.g. cancer treatment, TSC or immunosuppression. PMID:27019134

  6. Physician attitude toward depression care interventions: Implications for implementation of quality improvement initiatives

    OpenAIRE

    Chanin Johann C; Chou Ann F; Henke Rachel; Zides Amanda B; Scholle Sarah

    2008-01-01

    Abstract Background Few individuals with depression treated in the primary care setting receive care consistent with clinical treatment guidelines. Interventions based on the chronic care model (CCM) have been promoted to address barriers and improve the quality of care. A current understanding of barriers to depression care and an awareness of whether physicians believe interventions effectively address those barriers is needed to enhance the success of future implementation. Methods We cond...

  7. Zn2+ chelation improves recovery by delaying spreading depression-like events

    OpenAIRE

    Carter, Russell E.; Weiss, John H; Shuttleworth, C. William

    2010-01-01

    We previously reported Zn2+ chelation improved recovery of synaptic potentials after transient oxygen and glucose deprivation in brain slices. Such an effect could be due to reduced accumulation of Zn2+ in postsynaptic neurons, or could also be due to prevention of the onset of spreading depression-like events. A combination of optical and electrical recording was used here to demonstrate that Zn2+ chelation is effective because it delays spreading depression-like events. If the duration of o...

  8. Lumbar microdiscectomy and lumbar decompression improve functional outcomes and depression scores

    OpenAIRE

    Tharin, Suzanne; Mayer, Eric; Krishnaney, Ajit

    2012-01-01

    Study design:  Retrospective review. Introduction:  Lumbar radiculopathy and claudicant leg pain are common degenerative spinal conditions often treated by elective microdiscectomy or decompression. Published outcome data for these procedures have focused on improvement in pain scores, and not on grounded functional outcome or depression scores.1,2,3 Moreover, depression is considered by many surgeons to be a red flag for poor outcome for surgical treatment. We asked what effect lumbar microd...

  9. A 64-week, multicenter, open-label study of aripiprazole effectiveness in the management of patients with schizophrenia or schizoaffective disorder in a general psychiatric outpatient setting

    Directory of Open Access Journals (Sweden)

    Chiu Nan-Ying

    2010-09-01

    Full Text Available Abstract Objective To evaluate the overall long-term effectiveness of aripiprazole in patients with schizophrenia in a general psychiatric practice setting in Taiwan. Methods This was a prospective, open-label, multicenter, post-market surveillance study in Taiwanese patients with a Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV diagnosis of schizophrenia or schizoaffective disorder requiring a switch in antipsychotic medication because current medication was not well tolerated and/or clinical symptoms were not well controlled. Eligible patients were titrated to aripiprazole (5-30 mg/day over a 12-week switching phase, during which their previous medication was discontinued. Patients could then enter a 52-week, long-term treatment phase. Aripiprazole was flexibly dosed (5-30 mg/day at the discretion of the treating physicians. Efficacy was assessed using the Clinical Global Impression scale Improvement (CGI-I score, the Clinical Global Impression scale Severity (CGI-S score, The Brief Psychiatry Rating Scale (BPRS, and the Quality of Life (QOL scale, as well as Preference of Medicine (POM ratings by patients and caregivers. Safety and tolerability were also assessed. Results A total of 245 patients were enrolled and switched from their prior antipsychotic medications, and 153 patients entered the 52-week extension phase. In all, 79 patients (32.2% completed the study. At week 64, the mean CGI-I score was 3.10 and 64.6% of patients who showed response. Compared to baseline, scores of CGI-S, QOL, and BPRS after 64 weeks of treatment also showed significant improvements. At week 12, 65.4% of subjects and 58.9% of caregivers rated aripiprazole as better than the prestudy medication on the POM. The most frequently reported adverse events (AEs were headache, auditory hallucinations and insomnia. A total of 13 patients (5.3% discontinued treatment due to AEs. No statistically significant changes were noted with respect to

  10. The Coronary Health Improvement Projects Impact on Lowering Eating, Sleep, Stress, and Depressive Disorders

    Science.gov (United States)

    Merrill, Ray M.; Aldana, Stephen G.; Greenlaw, Roger L.; Diehl, Hans A.

    2008-01-01

    Background: The Coronary Health Improvement Project (CHIP) is designed to lower cardiovascular risk factors among a group of generally healthy individuals through health education. Purpose: This study will evaluate the efficacy of the CHIP intervention at improving eating, sleep, stress, and depressive disorders. Methods: A health education…

  11. Reduction in delta activity predicted improved negative affect in Major Depressive Disorder.

    Science.gov (United States)

    Cheng, Philip; Goldschmied, Jennifer; Casement, Melynda; Kim, Hyang Sook; Hoffmann, Robert; Armitage, Roseanne; Deldin, Patricia

    2015-08-30

    While prior research has demonstrated a paradoxical antidepressant effect of slow-wave disruption (SWD), the specific dimensions of depression affected is still unclear. The current study aimed to extend this research by utilizing a dimensional approach in examining the antidepressant effects of SWD. Of particular interest is the affective dimension, as negative affect in depression is arguably the most salient characteristic of depression. This sample included 16 individuals with depression (10 female) recruited from the community. Participants slept in the lab for three nights (adaptation, baseline night, and SWD) with polysomnography, and completed measures of negative affect and depression severity the following morning. Results show that reduction in delta power was linearly associated with improved negative affect. Comparison of individual change scores revealed that half of the individuals showed improved negative affect, which is comparable to the reported 40-60% antidepressant response rate to sleep deprivation. Results suggest that vulnerability in the sleep homeostatic system may be a contributing individual differences factor in response to slow-wave disruption in depression. PMID:26123231

  12. Depression remitterede efter subaraknoidal hæmoragi

    DEFF Research Database (Denmark)

    Lauritsen, Lise; Vinberg, Maj

    2015-01-01

    A 65-year-old man was seen in a specialized ambulatory for mood disorders because of treatment-resistant depression. He was treated throughout a period of three years with selective serotonin reuptake inhibitor, dual action, lithium, nortriptyline, reboxetine, aripiprazole, benzodiazepines...

  13. Improving confidence for self care in patients with depression and chronic illnesses.

    Science.gov (United States)

    Ludman, Evette J; Peterson, Do; Katon, Wayne J; Lin, Elizabeth H B; Von Korff, Michael; Ciechanowski, Paul; Young, Bessie; Gensichen, Jochen

    2013-01-01

    The aim of this study was to examine whether patients who received a multicondition collaborative care intervention for chronic illnesses and depression had greater improvement in self-care knowledge and efficacy, and whether greater knowledge and self-efficacy was positively associated with improved target outcomes. A randomized controlled trial with 214 patients with comorbid depression and poorly controlled diabetes and/or coronary heart disease tested a 12-month team-based intervention that combined self-management support and collaborative care management. At 6 and 12 month outcomes the intervention group showed significant improvements over the usual care group in confidence in ability to follow through with medical regimens important to managing their conditions and to maintain lifestyle changes even during times of stress. Improvements in self care-efficacy were significantly related to improvements in depression, and early improvements in confidence to maintain lifestyle changes even during times of stress explained part of the observed subsequent improvements in depression. PMID:23398269

  14. Improved Sleep in Military Personnel is Associated with Changes in the Expression of Inflammatory Genes and Improvement in Depression Symptoms

    OpenAIRE

    Livingston, Whitney S.; Rusch, Heather L.; Nersesian, Paula V.; Baxter, Tristin; Mysliwiec, Vincent; Gill, Jessica M.

    2015-01-01

    Study objectives Sleep disturbances are common in military personnel and are associated with increased risk for psychiatric morbidity, including posttraumatic stress disorder (PTSD) and depression, as well as inflammation. Improved sleep quality is linked to reductions in inflammatory bio-markers; however, the underlying mechanisms remain elusive. Methods In this study, we examine whole genome expression changes related to improved sleep in 68 military personnel diagnosed with inso...

  15. Improved Sleep in Military Personnel is Associated with Changes in the Expression of Inflammatory Genes and Improvement in Depression Symptoms

    Directory of Open Access Journals (Sweden)

    Whitney S. Livingston

    2015-04-01

    Full Text Available Study Objectives: Sleep disturbances are common in military personnel and are associated with increased risk for psychiatric morbidity, including posttraumatic stress disorder and depression, as well as inflammation. Improved sleep quality is linked to reductions in inflammatory bio-markers; however, the underlying mechanisms remain elusive. Methods: In this study we examine whole genome expression changes related to improved sleep in 68 military personnel diagnosed with insomnia. Subjects were classified into the following groups and then compared: improved sleep (n=46, or non-improved sleep (n=22 following three months of standard of care treatment for insomnia. Within subject differential expression was determined from microarray data using the Partek Genomics Suite analysis program and the interactive pathway analysis was used to determine key regulators of observed expression changes. Changes in symptoms of depression and posttraumatic stress disorder were also compared. Results: At baseline both groups were similar in demographics, clinical characteristics, and gene-expression profiles. The microarray data revealed that 217 coding genes were differentially expressed at the follow-up-period compared to baseline in the participants with improved sleep. Expression of inflammatory cytokines were reduced including IL-1β, IL-6, IL-8 and IL-13, with fold changes ranging from -3.19 to -2.1, and there were increases in the expression of inflammatory regulatory genes including toll-like receptors 1, 4, 7, and 8 in the improved sleep group. Interactive pathway analysis revealed 6 gene networks, including ubiquitin which was a major regulator in these gene-expression changes. The improved sleep group also had a significant reduction in the severity of depressive symptoms.Conclusions: Interventions that restore sleep likely reduce the expression of inflammatory genes, which relate to ubiquitin genes and relate to reductions in depressive symptoms.

  16. Training primary-care physicians to recognize, diagnose and manage depression: does it improve patient outcomes?

    NARCIS (Netherlands)

    Tiemens, B.G.; Ormel, J.; Jenner, J.A; Van Der Meer, K.; van Os, T.W.D.P.; van den Brink, R.H.S.; Smit, A.; Van den Brink, W.

    1999-01-01

    Background, We developed a comprehensive, 20-hour training programme for primary-care physicians, that sought to improve their ability to detect, diagnose and manage depression. We evaluated the effects of physician training on patient outcomes, using a pre-post design. Methods. In the pre-training

  17. Treatment and prevention of mania in bipolar I disorder: focus on aripiprazole

    Directory of Open Access Journals (Sweden)

    David J Muzina

    2009-05-01

    Full Text Available David J MuzinaCenter for Mood Disorders Treatment and Research, Cleveland Clinic Neurological Institute, Cleveland, Ohio, USAAbstract: Aripiprazole is a second-generation antipsychotic with a unique pharmacologic receptor profile that has efficacy in the treatment and prevention of mania in bipolar I disorder. This article reviews the evidence supporting treatment of adults with bipolar I disorder using aripiprazole as monotherapy or adjunctively during acute mania and its utility as an intramuscular agent for agitation in manic patients. Results from one of the longest bipolar maintenance trials which support aripiprazole as a prophylactic mood stabilizer, specifically against manic relapses, will be discussed as well as a post-hoc analysis that suggests efficacy for rapid cycling bipolar disorder. Safety and tolerability issues, patient-focused perspectives and aripiprazole’s place in therapy for bipolar mania will be covered.Keywords: bipolar disorder, mania, prevention, aripiprazole, rapid cycling

  18. Neurological, Metabolic, and Psychiatric Adverse Events in Children and Adolescents Treated With Aripiprazole

    DEFF Research Database (Denmark)

    Jakobsen, Klaus Damgaard; Bruhn, Christina Hedegaard; Pagsberg, Anne-Katrine;

    2016-01-01

    insomnia, Parkinsonism, behavioral changes psychoses, and weight gain, whereas the adverse effects in the PS group was predominantly anxiety, convulsions, and neuroleptic malignant syndrome. Although aripiprazole is considered safe and well tolerated in children and adolescents, severe adverse events as...... neuroleptic malignant syndrome, extreme insomnia, and suicidal behavior has been reported to health authorities. Clinicians should pay attention to these possible hazards when prescribing aripiprazole to this vulnerable group of patients....

  19. Treatment and prevention of mania in bipolar I disorder: focus on aripiprazole

    OpenAIRE

    Muzina, David J.

    2009-01-01

    David J MuzinaCenter for Mood Disorders Treatment and Research, Cleveland Clinic Neurological Institute, Cleveland, Ohio, USAAbstract: Aripiprazole is a second-generation antipsychotic with a unique pharmacologic receptor profile that has efficacy in the treatment and prevention of mania in bipolar I disorder. This article reviews the evidence supporting treatment of adults with bipolar I disorder using aripiprazole as monotherapy or adjunctively during acute mania and its utility as an intra...

  20. Comparison the effectiveness of aripiprazole and risperidone for the treatment of acute bipolar mania

    OpenAIRE

    Amir Akhavan Rezayat; Paria Hebrani; Fatemeh Behdani; Mohamad Salaran; Majid Nabizadeh Marvast

    2014-01-01

    Background: Second-generation antipsychotics, approved for the treatment of mania, are associated with adverse effects such as weight gain and metabolic disorders. Aripiprazole, a recently introduced second-generation antipsychotic, are thought to account for its low propensity for weight gain, metabolic disturbances and sedation. The purpose of this study was to investigate the effect of risperidone versus aripiprazole in the treatment of acute mania. Materials and Methods: Fifty patients wi...

  1. Effects of switching from olanzapine to aripiprazole on the metabolic profiles of patients with schizophrenia and metabolic syndrome: a double-blind, randomized, open-label study

    Directory of Open Access Journals (Sweden)

    Wani RA

    2015-03-01

    Full Text Available Rayees Ahmad Wani, Mansoor Ahmad Dar, Rajesh Kumar Chandel, Yasir Hassan Rather, Inaamul Haq, Arshad Hussain, Altaf Ahmad MallaDepartment of Psychiatry, Government Medical College, Srinagar, Jammu and Kashmir, IndiaBackground: Patients with schizophrenia suffer high rates of metabolic derangements on some antipsychotic medications that predispose them to cardiovascular diseases. Keeping this fact in mind, we planned this open-label study to see the effect on various metabolic parameters after switching stable schizophrenia subjects, who had developed metabolic syndrome on olanzapine, to aripiprazole.Methods: Sixty-two patients with schizophrenia who were stable on olanzapine and were fulfilling modified National Cholesterol Education Program (NCEP Adult Treatment Panel III (ATP-III criteria for the presence of metabolic syndrome were enrolled on the study. Patients were randomly assigned either to switch to aripiprazole or to stay on olanzapine, on a 1:1 basis. Cross-tapering over a period of 1 month was done while switching patients to aripiprazole. Laboratory assessment for metabolic parameters was done at baseline, 8 weeks, and 24 weeks after enrollment; efficacy assessment was done using the Positive and Negative Syndrome Scale (PANSS at baseline and 24 weeks, the Clinical Global Impressions severity subscale (CGI-S at baseline, and the Clinical Global Impressions improvement subscale (CGI-I at 24 weeks.Results: All parameters of metabolic syndrome (waist circumference, blood pressure, triglyceride level, fasting blood glucose, and high-density lipoprotein cholesterol kept deteriorating in the stay group, compared with a continuous improvement in the switch group over time. At the end of the study, 26 patients (100% from the stay group and 15 patients (42.8% from switch group met the modified NCEP ATP-III criteria for presence of metabolic syndrome (P<0.001. There were no statistically significant differences between groups in

  2. Adjunctive Aripiprazole Treatment for Risperidone-Induced Hyperprolactinemia: An 8-Week Randomized, Open-Label, Comparative Clinical Trial

    OpenAIRE

    Jingyuan Zhao; Xueqin Song; Xiaoqing Ai; Xiaojing Gu; Guangbiao Huang; Xue Li; Lijuan Pang; Minli Ding; Shuang Ding; Luxian Lv

    2015-01-01

    Objective The present study aimed to evaluate the efficacy and safety of adjunctive aripiprazole treatment in schizophrenia patients with risperidone-induced hyperprolactinemia. Methods One hundred and thirteen patients who were receiving a stable dose of risperidone were randomly assigned to either adjunctive aripiprazole treatment (10 mg/day) (aripiprazole group) or no additional treatment (control group) at a 1:1 ratio for 8 weeks. Schizophrenia symptoms were measured using the Positive an...

  3. Act in case of depression: the evaluation of a care program to improve the detection and treatment of depression in nursing homes. Study protocol

    OpenAIRE

    Vernooij-Dassen Myrra JFJ; Adang Eddy M; Leontjevas Ruslan; Teerenstra Steven; Smalbrugge Martin; Gerritsen Debby L; Derksen Els; Koopmans Raymond TCM

    2011-01-01

    Abstract Background The aim of this study is evaluating the (cost-) effectiveness of a multidisciplinary, evidence based care program to improve the management of depression in nursing home residents of somatic and dementia special care units. The care program is an evidence based standardization of the management of depression, including standardized use of measurement instruments and diagnostical methods, and protocolized psychosocial, psychological and pharmacological treatment. Methods/De...

  4. 阿立哌唑合并康复训练改善精神分裂症患者生活质量的临床研究%Clinical Study of Aripiprazole Combined with Rehabilitation Training to Improve the Quality of Life in Patients with Schizophrenia

    Institute of Scientific and Technical Information of China (English)

    程闯; 张新风

    2013-01-01

    Objective:To explore the effect of aripiprazole combined with rehabilitation training in patients with schizophrenia quality of life of the spirit.Method:Met the Chinese classification and diagnostic criteria of mental disorders Third Edition(CCMD-3)criteria for the diagnosis of 90 patients with schizophrenia were randomly divided into two groups,aripiprazole and clozapine in the treatment of,a total of 8 weeks,two groups were psychiatric rehabilitation training. The positive and negative symptoms scale before and after treatment(PANSS)was introduced in June to assess the efficacy,the side effects scale(TESS)assessment of adverse reactions,the WHO quality of life scale(WHOQOL-100)assessment of quality of life.Result:Aripiprazole group and clozapine group markedly effective rate were 73.3%and 75.6%,with no significant difference between two groups(P>0.05);4,8 weeks after treatment,two groups of PANSS scale scores were decreased than that before treatment(P0.05);治疗后4、8周,两组PANSS量表各项因子分均较治疗前下降(P<0.05),但治疗后8周阿立哌唑组阴性症状及一般精神病理分较氯氮平组差异有统计学意义(P<0.05);阿立哌唑组不良反应发生率显著低于氯氮平组(P<0.05);治疗6个月后两组在(WHOQOL-100)量表各领域均较治疗前有统计学意义(P<0.05),但阿立哌唑组在生理领域、心理领域、社会关系领域、精神支柱、生活质量方面较氯氮平组差异有统计学意义(P<0.05)。结论:阿立哌唑治疗精神分裂症疗效与氯氮平相仿,不良反应少,合并精神康复治疗可显著改善精神分裂症患者的生活质量。

  5. Act In case of Depression: The evaluation of a care program to improve the detection and treatment of depression in nursing homes. Study Protocol

    Directory of Open Access Journals (Sweden)

    Vernooij-Dassen Myrra JFJ

    2011-05-01

    Full Text Available Abstract Background The aim of this study is evaluating the (cost- effectiveness of a multidisciplinary, evidence based care program to improve the management of depression in nursing home residents of somatic and dementia special care units. The care program is an evidence based standardization of the management of depression, including standardized use of measurement instruments and diagnostical methods, and protocolized psychosocial, psychological and pharmacological treatment. Methods/Design In a 19-month longitudinal controlled study using a stepped wedge design, 14 somatic and 14 dementia special care units will implement the care program. All residents who give informed consent on the participating units will be included. Primary outcomes are the frequency of depression on the units and quality of life of residents on the units. The effect of the care program will be estimated using multilevel regression analysis. Secondary outcomes include accuracy of depression-detection in usual care, prevalence of depression-diagnosis in the intervention group, and response to treatment of depressed residents. An economic evaluation from a health care perspective will also be carried out. Discussion The care program is expected to be effective in reducing the frequency of depression and in increasing the quality of life of residents. The study will further provide insight in the cost-effectiveness of the care program. Trial registration Netherlands Trial Register (NTR: NTR1477

  6. Improving Care for Depression & Suicide Risk in Adolescents: Innovative Strategies for Bringing Treatments to Community Settings

    OpenAIRE

    Asarnow, Joan Rosenbaum; Miranda, Jeanne

    2014-01-01

    This article reviews the literature on interventions and services for depression and suicide prevention among adolescents, with the goals of placing this science within the context of current changing health care environments and highlighting innovative models for improving health and mental health. We examine the: challenges and opportunities offered by new initiatives and legislation designed to transform the U.S. health and mental healthcare systems; summarize knowledge regarding the treat...

  7. Community Partners in Care: Leveraging Community Diversity to Improve Depression Care for Underserved Populations

    OpenAIRE

    Khodyakov, Dmitry; Mendel, Peter; Dixon, Elizabeth; Jones, Andrea; Masongsong, Zoe; Wells, Kenneth

    2009-01-01

    Research suggests that the quality and outcomes of depression treatment for adults can be substantially improved through “collaborative care” programs. However, there is a lack of resources required to implement such programs in vulnerable communities. Our paper examines the planning phase of the Community Partners in Care (CPIC) initiative, which addresses this problem through a unique approach in which academic institutions partner directly with a wide range of community-based and service o...

  8. The improved Clinical Global Impression Scale (iCGI: development and validation in depression

    Directory of Open Access Journals (Sweden)

    Kadouri Alane

    2007-02-01

    Full Text Available Abstract Background The Clinical Global Impression scale (CGI is frequently used in medical care and clinical research because of its face validity and practicability. This study proposes to improve the reliability of the Clinical Global Impression (CGI scale in depressive disorders by the use of a semi-standardized interview, a new response format, and a Delphi procedure. Methods Thirty patients hospitalised for a major depressive episode were filmed at T1 (first week in hospital and at T2 (2 weeks later during a 5' specific interview. The Hamilton Depressive Rating Scale and the Symptom Check List were also rated. Eleven psychiatrists rated these videos using either the usual CGI response format or an improved response format, with or without a Delphi procedure. Results The new response format slightly improved (but not significantly the interrater agreement, the Delphi procedure did not. The best results were obtained when ratings by 4 independent raters were averaged. In this situation, intraclass correlation coefficients were about 0.9. Conclusion The Clinical Global Impression is a useful approach in psychiatry since it apprehends patients in their entirety. This study shows that it is possible to quantify such impressions with a high level of interrater agreement.

  9. Acute exercise improves cognition in the depressed elderly: the effect of dual-tasks

    Directory of Open Access Journals (Sweden)

    Paulo Eduardo Vasques

    2011-01-01

    Full Text Available OBJECTIVE: The goal of this study was to assess the acute effect of physical exercise on the cognitive function of depressed elderly patients in a dual-task experiment. INTRODUCTION: Physical exercise has a positive effect on the brain and may even act as a treatment for major depressive disorder. However, the effects of acute cardiovascular exercise on cognitive function during and after one session of aerobic training in elderly depressive patients are not known. METHODS: Ten elderly subjects diagnosed with major depressive disorder performed neuropsychological tests during and after a moderate physical exercise session (65-75%HRmax. A Digit Span Test (Forward and Backward and a Stroop Color-Word Test were used to assess cognitive function. The elderly participants walked on an electric treadmill for 30 minutes and underwent the same cognitive testing before, during, immediately after, and 15 minutes after the exercise session. In the control session, the same cognitive testing was conducted, but without exercise training. RESULTS: The results of the Digit Span Test did not change between the control and the exercise sessions. The results of the Stroop Color-Word Test improved after physical exercise, indicating a positive effect of exercise on cognition. CONCLUSIONS: These data suggest that the cognitive functions of depressed elderly persons, especially attention and inhibitory control, are not impaired during and after an acute session of physical exercise. In contrast, the effect of dual-tasks showed beneficial results for these subjects, mainly after exercise. The dual-task may be a safe and useful tool for assessing cognitive function.

  10. Perinatal depression

    OpenAIRE

    Alhusen, Jeanne L.; Alvarez, Carmen

    2016-01-01

    Abstract: Perinatal depression is a common condition with significant adverse maternal, fetal, neonatal, and early childhood outcomes. The perinatal period is an opportune time to screen, diagnose, and treat depression. Improved recognition of perinatal depression, particularly among low-income women, can lead to improved perinatal health outcomes.

  11. [Application of HPLC-UV method for aripiprazole determination in serum].

    Science.gov (United States)

    Synowiec, Anna; Gomółka, Ewa; Zyss, Tomasz; Zieba, Andrzej; Florek, Ewa; Piekoszewski, Wojciech

    2012-01-01

    Aripiprazole is a new drug applied in schizophrenia treatment. There are not strict indications for aripiprazole therapeutic drug monitoring. Despite, serum aripiprazole measuring would help control the drug doses effectiveness. The drug monitoring can eliminate overdosing, adverse effects and let control proper drug ingestion. The aim of the paper was to develop a simple method for aripiprazole determination in serum for therapeutic drug monitoring. High performance liquid chromatography with spectrophotometric detection (HPLC-UV) was used. Resolution was performed on LC-8 column; moving phase was solution 0,025M trimethylammonium buffer: acetonitrile (62:38). Isocratic flow was 1,2 ml/min; internal standard (IS) was promazine; monitored wavelength was lambda=214 nm. The validation parameters were: limits of linearity (LOL) 100-800 ng/ml, limit of detection (LOD) 10 ng/ml, limit of quantity (LOQ) 100 ng/ml. Coefficient of variation (CV) describing accuracy and precision didn't cross 10%. The method was useful for therapeutic drug monitoring in serum of patients treated with aripiprazole. PMID:23421079

  12. Collaborative Depression Care in a Safety Net Medical Home: Facilitators and Barriers to Quality Improvement.

    Science.gov (United States)

    Price-Haywood, Eboni G; Dunn-Lombard, Donisha; Harden-Barrios, Jewel; Lefante, John J

    2016-02-01

    Little is known about how to integrate primary care with mental/behavioral services outside of clinical trials. The authors implemented a collaborative care model (CCM) for depression in a safety net patient-centered medical home. The model focused on universal screening for symptoms, risk stratification based on symptom severity, care management for intensive follow-up, and psychiatry consultation. CCM increased rates of primary care physician encounters, timely follow-up for monitoring symptoms of depression, and documentation of treatment response. Contextual factors that facilitated or hindered practice redesign included clinic leadership, quality improvement culture, staffing, technology infrastructure, and external incentives/disincentives for organizational change. (Population Health Management 2016;19:46-55). PMID:26087153

  13. Reward circuit DBS improves Parkinson's gait along with severe depression and OCD.

    Science.gov (United States)

    Williams, Nolan R; Hopkins, Thomas R; Short, E Baron; Sahlem, Gregory L; Snipes, Jonathan; Revuelta, Gonzalo J; George, Mark S; Takacs, Istvan

    2016-01-01

    A 59-year-old Caucasian man with a past history of Parkinson's disease (PD) status post-bilateral subthalamic nucleus (STN) deep brain stimulation (DBS), who also had treatment-resistant (TR) obsessive-compulsive disorder (OCD), and treatment-resistant depression (TRD), presented for further evaluation and management of his TR OCD. After an unsuccessful attempt to treat his OCD by reprogramming his existing STN DBS, he was offered bilateral ventral capsule/ventral striatum (VC/VS) DBS surgery. In addition to the expected improvement in OCD symptoms, he experienced significant improvement in both PD-related apathy and depression along with resolution of suicidal ideation. Furthermore, the patient's festinating gait dramatically improved. This case demonstrates that DBS of both the STN and VC/VS appears to have an initial signal of safety and tolerability. This is the first instance where both the STN and the VC/VS DBS targets have been implanted in an individual and the first case where a patient with PD has received additional DBS in mood-regulatory circuitry. PMID:26644268

  14. A review of aripiprazole in the treatment of patients with schizophrenia or bipolar I disorder

    OpenAIRE

    Citrome, Leslie

    2006-01-01

    Aripiprazole has been approved by regulatory agencies for the treatment of schizophrenia and bipolar I disorder. Although it is a dopamine partial agonist, it also has substantial binding affinity for the serotonin 5HT2A receptor. Several double-blind randomized clinical trials have established the efficacy and tolerability of aripiprazole within the dose range of 10–30 mg/day for schizophrenia, and 15–30 mg/day for manic or mixed states associated with bipolar I disorder. Relatively few comp...

  15. Acute Dystonia Following a Switch in Treatment from Atomoxetine to Low-dose Aripiprazole

    OpenAIRE

    Başay, Ömer; Basay, Burge Kabukcu; Öztürk, Önder; Yüncü, Zeki

    2016-01-01

    The present report describes the cases of a 17-year-old male patient and a 13-year-old female patient who developed acute dystonia following the administration of low-dose aripiprazole (5 mg/day) after the cessation of atomoxetine treatment. Although aripiprazole-induced dystonia has been previously reported in the literature, it is rare, and most of these cases were associated with doses higher than 5 mg/day. Furthermore, both of the patients in the present study discontinued atomoxetine pri...

  16. Aripiprazole as augmentation therapy in bipolar patients with current minor or subsyndromal mood symptoms

    OpenAIRE

    Schweitzer, Isaac; Sarris, Jerome; Tuckwell, Virginia; Maguire, Kay; Smith, Deidre; Ng, Chee

    2013-01-01

    Background This study aims to evaluate the effectiveness of aripiprazole augmentation of maintenance treatment for bipolar disorder in patients with minor or subsyndromal mood episodes while on a stable dose of a mood stabiliser and/or antidepressant. Methods All subjects had a diagnosis of bipolar I or II disorder (Diagnostic and Statistical Manual of Mental Disorders-4th Edition, Text Revision). Open-label aripiprazole was given over 8 weeks initially. The starting dose was 5 to 15 mg/day w...

  17. Assessment of an enhanced program for depression management in primary care: a cluster randomized controlled trial. The INDI project (Interventions for Depression Improvement

    Directory of Open Access Journals (Sweden)

    Hernández Josep M

    2007-09-01

    Full Text Available Abstract Background Most depressed patients are attended at primary care. However, there are significant shortcomings in the diagnosis, management and outcomes of these patients. The aim of this study is to determine whether the implementation of a structured programme for managing depression will provide better health outcomes than usual management. Methods/Design Design: A cluster-randomized controlled trial involving two groups, one of which is the control group consisting of patients who are treated for depression in the usual way and the other is the intervention group consisting of patients on a structured programme for treating depression. Setting: 20 primary care centres in the province of Tarragona (Spain Sample: 400 patients over 18 years of age who have experienced an episode of major depression (DSM-IV and who need to initiate antidepressant treatment Intervention: A multi-component programme with clinical, educational and organisational procedures that includes training for the health care provider and evidence-based clinical guidelines. It also includes primary care nurses working as care-managers who provide educational and emotional support for the patients and who are responsible for active and systematic clinical monitoring. The programme aims to improve the primary care/specialized level interface. Measurements: The patients will be monitored by telephone interviews. The interviewer will not know which group the patient belongs to (blind trial. These interviews will be given at 0, 3, 6 and 12 months. Main variables: Severity of the depressive symptoms, response rate and remission rate. Analysis: Outcomes will be analyzed on an intent-to-treat basis and the unit of analysis will be the individual patient. This analysis will take into account the effect of study design on potential lack of independence between observations within the same cluster. Discussion The effectiveness of caring for depression in primary care can be

  18. Improving Treatment of Depression Among Latinos With Diabetes Using Project Dulce and IMPACT

    OpenAIRE

    Gilmer, Todd P.; Walker, Chris; Johnson, Elizabeth D.; Philis-Tsimikas, Athena; Unützer, Jürgen

    2008-01-01

    OBJECTIVE—To assess the feasibility and cost of integrating diabetes and depression care management in three community clinics serving a low-income and predominately Spanish-speaking Latino population. RESEARCH DESIGN AND METHODS—We screened diabetes patients for depression, and for those with depressive symptoms, we provided depression care management. We assessed changes in depressive symptoms using the Patient Health Questionnaire-9 (PHQ-9), diabetes self-care activities (nutrition, exerci...

  19. Effectiveness of an educational strategy to improve family physicians' detection and management of depression: a randomized controlled trial

    OpenAIRE

    Worrall, G.; J. Angel; Chaulk, P; Clarke, C.; Robbins, M

    1999-01-01

    BACKGROUND: Depression, a common disorder often treated by family physicians, may be both underdiagnosed and undertreated. The objective of this study was to determine whether the diagnosis and treatment of depression by family physicians could be improved through an educational strategy. METHODS: In this study, conducted between July and December 1997, 42 family physicians in Newfoundland were randomly assigned to an intervention group (3-hour case-based educational session on clinical pract...

  20. Comparison of risperidone and aripiprazole in the treatment of preschool children with disruptive behavior disorder and attention deficit-hyperactivity disorder: A randomized clinical trial.

    Science.gov (United States)

    Safavi, Parvin; Hasanpour-Dehkordi, Ali; AmirAhmadi, Maryam

    2016-01-01

    Although pharmacotherapy with atypical antipsychotics is common in child psychiatry, there has been little research on this issue. To compare the efficacy and safety of risperidone and aripiprazole in the treatment of preschool children with disruptive behavior disorders comorbid with attention deficit-hyperactivity disorder (ADHD). Randomized clinical trial conducted in a university-affiliated child psychiatry clinic in southwest Iran. Forty 3-6-year-old children, diagnosed with oppositional defiant disorder comorbid with ADHD, were randomized to an 8-week trial of treatment with risperidone or aripiprazole (20 patients in each group). Assessment was performed by Conners' rating scale-revised and clinical global impressions scale, before treatment, and at weeks 2, 4, and 8 of treatment. The data were analyzed by SPSS version 16. Mean scores between the two groups were compared by analysis of variance and independent and paired t-test. Mean scores of Conners rating scales were not different between two groups in any steps of evaluation. Both groups had significantly reduced scores in week 2 of treatment (P = 0.00), with no significant change in subsequent measurements. Rates of improvement, mean increase in weight (P = 0.894), and mean change in fasting blood sugar (P = 0.671) were not significantly different between two groups. Mean serum prolactin showed a significant increase in risperidone group (P = 0.00). Both risperidone and aripiprazole were equally effective in reducing symptoms of ADHD and oppositional defiant disorder, and relatively safe, but high rates of side effects suggest the cautious use of these drugs in children. PMID:27144151

  1. Comparison of risperidone and aripiprazole in the treatment of preschool children with disruptive behavior disorder and attention deficit-hyperactivity disorder: A randomized clinical trial

    Directory of Open Access Journals (Sweden)

    Parvin Safavi

    2016-01-01

    Full Text Available Although pharmacotherapy with atypical antipsychotics is common in child psychiatry, there has been little research on this issue. To compare the efficacy and safety of risperidone and aripiprazole in the treatment of preschool children with disruptive behavior disorders comorbid with attention deficit-hyperactivity disorder (ADHD. Randomized clinical trial conducted in a university-affiliated child psychiatry clinic in southwest Iran. Forty 3-6-year-old children, diagnosed with oppositional defiant disorder comorbid with ADHD, were randomized to an 8-week trial of treatment with risperidone or aripiprazole (20 patients in each group. Assessment was performed by Conners′ rating scale-revised and clinical global impressions scale, before treatment, and at weeks 2, 4, and 8 of treatment. The data were analyzed by SPSS version 16. Mean scores between the two groups were compared by analysis of variance and independent and paired t-test. Mean scores of Conners rating scales were not different between two groups in any steps of evaluation. Both groups had significantly reduced scores in week 2 of treatment (P = 0.00, with no significant change in subsequent measurements. Rates of improvement, mean increase in weight (P = 0.894, and mean change in fasting blood sugar (P = 0.671 were not significantly different between two groups. Mean serum prolactin showed a significant increase in risperidone group (P = 0.00. Both risperidone and aripiprazole were equally effective in reducing symptoms of ADHD and oppositional defiant disorder, and relatively safe, but high rates of side effects suggest the cautious use of these drugs in children.

  2. Neurological, Metabolic, and Psychiatric Adverse Events in Children and Adolescents Treated With Aripiprazole.

    Science.gov (United States)

    Jakobsen, Klaus Damgaard; Bruhn, Christina Hedegaard; Pagsberg, Anne-Katrine; Fink-Jensen, Anders; Nielsen, Jimmi

    2016-10-01

    Aripiprazole is a partial dopamine agonist with only minor neurological and psychiatric adverse effects, making it a potential first-line drug for the treatment of psychiatric disorders. However, the evidence of its use in children and adolescents is rather sparse. The aim of this case study is to discuss adverse drug reaction (ADR) reports concerning aripiprazole-associated neurological and psychiatric events in children and adolescents. The ADR report database at Danish Medicines Agency was searched for all ADRs involving children and adolescents (disorders (PS group) and nonpsychotic disorders (non-PS group). The PS group consisted of 5 patients with schizophrenia and psychoses, not otherwise specified; and the non-PS group consisted of fourteen cases including autism spectrum disorders, attention deficit and hyperactivity disorder, obsessive-compulsive disorder, and Tourette syndrome. The main reported adverse effects in the non-PS group were chronic insomnia, Parkinsonism, behavioral changes psychoses, and weight gain, whereas the adverse effects in the PS group was predominantly anxiety, convulsions, and neuroleptic malignant syndrome. Although aripiprazole is considered safe and well tolerated in children and adolescents, severe adverse events as neuroleptic malignant syndrome, extreme insomnia, and suicidal behavior has been reported to health authorities. Clinicians should pay attention to these possible hazards when prescribing aripiprazole to this vulnerable group of patients. PMID:27504593

  3. Aripiprazole blocks acute self-administration of cocaine and is not self-administered in mice

    DEFF Research Database (Denmark)

    Sørensen, Gunnar; Sager, Thomas N; Petersen, Jørgen H;

    2008-01-01

    RATIONALE: The novel antipsychotic aripiprazole in use for treatment of schizophrenia is a partial agonist at dopamine D(2) receptors with actions at a variety of other receptors as well. Cocaine is believed to exert an important part of its rewarding effect by increasing extracellular levels of ...

  4. Aripiprazole and Risperidone for Treatment of Methamphetamine-Associated Psychosis in Chinese Patients.

    Science.gov (United States)

    Wang, Gang; Zhang, Yao; Zhang, Sheng; Chen, Huijing; Xu, Zaifeng; Schottenfeld, Richard S; Hao, Wei; Chawarski, Marek Cezary

    2016-03-01

    We evaluated tolerability and efficacy of aripiprazole and risperidone for treatment of methamphetamine (METH) associated psychotic symptoms in China. Patients with acute METH-associated psychotic symptoms (N=42) and with Positive and Negative Syndrome Scale (PANSS) total score between 60 and 120 were randomized to aripiprazole (initial dose 5-10mg per day followed by flexible doses 5-15 mg per day) or risperidone (initial dose 2-4 mg per day followed by flexible doses 4-6 mg per day) from day 3 to 25 of inpatient hospital stay. Outcome measures included PANSS and Clinical Global Impressions-Severity of Illness scale (CGI-S), METH craving Visual Analogue Scale (VAS), Simpson Angus Scale (SAS), Barnes Assessments Akathasia Rating Scale (BARS), and self-reported adverse effects evaluated during treatment. Retention was evaluated using Kaplan-Meier survival analysis and the MIXED models procedure was used to compare the groups on measures of psychotic and extra-pyramidal symptoms. Patients in both aripiprazole and risperidone groups showed statistically significant reductions in psychotic symptomatology from baseline during treatment (p<0.001) with no statistically significant differences between the treatment groups (p=0.73 and p=0.15, respectively). Risperidone-treated patients reported significantly greater METH craving reductions (p<0.001). Overall, 71% of patients completed the entire study, but the aripiprazole group had a significantly lower retention than the risperidone group (p=0.007), primarily due to medication related adverse effects. Aripiprazole-treated patients also had significantly more akathisia (p=0.03) and agitation (p=0.02) than risperidone-treated patients. Patients in both groups who tolerated their medications and completed the entire study achieved comparable reductions of psychotic symptoms. PMID:26733277

  5. Profile of aripiprazole in the treatment of bipolar disorder in children and adolescents

    Directory of Open Access Journals (Sweden)

    Kirino E

    2014-11-01

    Full Text Available Eiji Kirino1–3 1Department of Psychiatry, Juntendo University School of Medicine, 2Department of Psychiatry, Juntendo University Shizuoka Hospital, 3Juntendo Institute of Mental Health, Shizuoka, Japan Abstract: Bipolar disorder is a pernicious illness. Compared with the later-onset form, early onset bipolar disorder is associated with worse psychosocial outcomes, and is characterized by rapid cycling and increased risks of substance abuse and suicide attempts. Controlling mood episodes and preventing relapse in this group of pediatric patients requires careful treatment. Here, we review the effectiveness of aripiprazole for bipolar disorder in children and adolescents, with discussion of this drug's unique pharmacological profile and various clinical study outcomes. Aripiprazole acts as a serotonin 5-HT2A receptor antagonist, as well as a partial agonist of the serotonin 5-HT1A and dopamine D2 receptors. It can be safely used in children and adolescents, as it is highly tolerated and shows lower rates of the side effects typically observed with other antipsychotic drugs, including sedation, weight gain, hyperprolactinemia, and extrapyramidal syndrome. The presently reviewed randomized controlled trials (RCTs and non-RCTs generally reported aripiprazole to be effective and well-tolerated in children and adolescents with bipolar disorder. However, due to the limited number of RCTs, the present conclusions must be evaluated cautiously. Furthermore, aripiprazole cannot yet be considered a preferred treatment for children and adolescents with bipolar disorder, as there is not yet evidence that aripiprazole shows greater efficacy compared to other second-generation antipsychotics. Additional data are needed from future head-to-head comparison studies. Keywords: child, mania, mixed state

  6. Improving long-term outcome of depression in primary care: a review of RCTs with psychological and supportive interventions

    Directory of Open Access Journals (Sweden)

    Annet Smit

    2007-03-01

    Full Text Available Background and objectives: Depression is often a recurrent or persistent disorder. Since the majority of depressed patients are treated in primary care, it is clear that to improve long-term outcomes more effective treatments in this setting are needed. The goal of this study was to review the strategies used for improvement of routine treatment in terms of their effects on patient outcome. Methods: We conducted a systematic literature search to identify improvement strategies tested in randomized controlled trials in primary care, reporting at least six months effects on depression course and outcome. Results: Four strategies were identified: (1 training primary care physicians (PCPs - this appears ineffective (2 supporting PCPs by other professionals - this produces better short term outcomes but does not prevent recurrence (3 organisational quality improvement - this shows improved outcomes at 6 months, and there is some evidence of longer term effectiveness; and (4 recurrence - and chronicity prevention strategies - these have not been shown to be effective. Conclusion: Since effects of the reviewed strategies generally do not seem to persist over time and no clear superiority over usual care has been demonstrated, we conclude that for improving long-term outcome of depression in primary care new directions or even a novel paradigm is needed.

  7. Rapid improvement of depressive symptoms in suicide attempters following treatment with milnacipran and tricyclic antidepressants – a case series

    Directory of Open Access Journals (Sweden)

    Kirino E

    2011-12-01

    Full Text Available Eiji Kirino, Masao GitohDepartment of Psychiatry, Juntendo University, School of Medicine, Shizuoka, JapanAbstract: Suicide is a serious social problem in many countries, including Japan. The majority of people who commit suicide suffer from depression. Suicide attempt patients suffering from serious physical injuries are initially treated in hospital emergency departments. The present post hoc analysis examined data from patients admitted to an emergency hospital for treatment of physical injuries, resulting from a suicide attempt, and initial psychiatric treatment for depression and prevention of future suicide attempts. The effects on depressive symptoms were studied in two groups of patients using the 17-item Hamilton depression scale (HAMD. One group (n = 6 had received intravenous tricyclic antidepressants (TCA (amitriptyline or clomipramine while the other group (n = 7 had been treated orally with milnacipran, a serotonin and norepinephrine reuptake inhibitor antidepressant. Prior to treatment the four highest scoring items on the HAMD scale were the same in both groups namely, item 1 (depressed mood, item 3 (suicidality, item 7 (interest in work and activities, and item 10 (psychic anxiety. After 1 week of treatment, mean global HAMD scores were significantly reduced in both groups. Treatment resulted in a significant reduction of five HAMD items in the TCA group, whereas in the milnacipran group 12 HAMD items were significantly reduced. Suicidality (item 3 was significantly improved by 1 week treatment with milnacipran, but not by TCAs. Milnacipran rapidly improved a wide range of depressive symptoms, including suicidality within the first week. The improvement with milnacipran would appear to be, at least, equivalent to that achieved with TCAs, possibly affecting a wider range of symptoms. Since milnacipran has been shown in comparative studies to be better tolerated than TCAs, this antidepressant offers an interesting option for the

  8. No difference in frontal cortical activity during an executive functioning task after acute doses of aripiprazole and haloperidol

    Directory of Open Access Journals (Sweden)

    Ingeborg eBolstad

    2015-05-01

    Full Text Available Background: Aripiprazole is an atypical antipsychotic drug that is characterized by partial dopamine D2 receptor agonism. Its pharmacodynamic profile is proposed to be beneficial in the treatment of cognitive impairment, which is prevalent in psychotic disorders. This study compared brain activation characteristics produced by aripiprazole with that of haloperidol, a typical D2 receptor antagonist, during a task targeting executive functioning.Methods: Healthy participants received an acute oral dose of haloperidol, aripiprazole or placebo before performing an executive functioning task while blood-oxygen-level-dependent (BOLD functional magnetic resonance imaging (fMRI was carried out. Results: There was a tendency towards reduced performance in the aripiprazole group compared to the two other groups. The image analysis yielded a strong task-related BOLD-fMRI response within each group. An uncorrected between-group analysis showed that aripiprazole challenge resulted in stronger activation in the frontal and temporal gyri and the putamen compared with haloperidol challenge, but after correcting for multiple testing there was no significant group difference. Conclusion: No significant group differences between aripiprazole and haloperidol in frontal cortical activation were obtained when corrected for multiple comparisons.This study is registered in ClinicalTrials.gov (identifier: 2009-016222-14; https://clinicaltrials.gov/.

  9. Anxiety and depression in association with morbid obesity: changes with improved physical health after duodenal switch

    OpenAIRE

    Sletteskog Nils; Bergsholm Per; Aasprang Anny; Andersen John; Våge Villy; Natvig Gerd

    2010-01-01

    Background Patients with morbid obesity have an increased risk for anxiety and depression. The "duodenal switch" is perhaps the most effective obesity surgery procedure for inducing weight loss. However, to our knowledge, data on symptoms of anxiety and depression after the duodenal switch are lacking. Furthermore, it has been hypothesized that self-reported physical health is the major predictor of symptoms of depression in patients with morbid obesity. We therefore investigated the symptom...

  10. Acute exercise improves cognition in the depressed elderly: the effect of dual-tasks

    OpenAIRE

    Paulo Eduardo Vasques; Helena Moraes; Heitor Silveira; Andrea Camaz Deslandes; Jerson Laks

    2011-01-01

    OBJECTIVE: The goal of this study was to assess the acute effect of physical exercise on the cognitive function of depressed elderly patients in a dual-task experiment. INTRODUCTION: Physical exercise has a positive effect on the brain and may even act as a treatment for major depressive disorder. However, the effects of acute cardiovascular exercise on cognitive function during and after one session of aerobic training in elderly depressive patients are not known. METHODS: Ten elderly subjec...

  11. A Videotape-Based Training Method for Improving the Detection of Depression in Residents of Long-Term Care Facilities

    Science.gov (United States)

    Wood, Stacey; Cummings, Jeffrey L.; Schnelle, Betha; Stephens, Mary

    2002-01-01

    Purpose: This article reviews the effectiveness of a new training program for improving nursing staffs' detection of depression within long-term care facilities. The course was designed to increase recognition of the Minimal Data Set (MDS) Mood Trigger items, to be brief, and to rely on images rather than didactics. Design and Methods: This study…

  12. Major depression

    Science.gov (United States)

    Depression - major; Depression - clinical; Clinical depression; Unipolar depression; Major depressive disorder ... Doctors do not know the exact causes of depression. It is believed that chemical changes in the ...

  13. Improving the Recognition of Depression in Adolescence: Can We Teach the Teachers?

    Science.gov (United States)

    Moor, Stephanie; Maguire, Ann; McQueen, Hester; Wells, J. Elisabeth; Elton, Robert; Wrate, Robert; Blair, Caroline

    2007-01-01

    This study evaluated the effectiveness of a schools-based psychoeducational intervention designed to help teachers recognize the symptoms of clinical depression in their adolescent pupils. Around 151 teachers in eight high schools in Scotland, UK were randomly assigned to experimental and control groups and all received training on depression. The…

  14. Does Adding Medication to Psychotherapy for Depression Improve or Worsen Outcome?

    Science.gov (United States)

    Karon, Bertram P.

    2007-01-01

    That two-thirds of depressed adults are resistant to medication has led to the addition of psychotherapy to treatment, but is medication necessary? Results are at least as good with psychotherapy alone, and the relapse rate is less. Handling of suicidal danger, sleep disorders, and common depressing issues in college students are discussed along…

  15. Treatment Preference, Engagement, and Clinical Improvement in Pharmacotherapy versus Psychotherapy for Depression

    OpenAIRE

    Kwan, Bethany M.; Dimidjian, Sona; Rizvi, Shireen L.

    2010-01-01

    Pharmacotherapy and psychotherapy are generally effective treatments for major depressive disorder (MDD); however, research suggests that patient preferences may influence outcomes. We examined the effects of treatment preference on attrition, therapeutic alliance, and change in depressive severity in a longitudinal randomized clinical trial comparing pharmacotherapy and psychotherapy. Prior to randomization, 106 individuals with MDD reported whether they preferred psychotherapy, antidepressa...

  16. Aripiprazole augmentation in poor insight obsessive-compulsive disorder: a case report

    Directory of Open Access Journals (Sweden)

    Vinciguerra Valentina

    2008-12-01

    Full Text Available Abstract Background Obsessive-compulsive disorder is associated with a relevant impairment in social and interpersonal functioning and severe disability. This seems to be particularly true for the poor insight subtype, characterised by a lack of consciousness of illness and, consequently, compliance with treatment. Poor responsiveness to serotonergic drugs in poor insight obsessive-compulsive patients may also require an augmentation therapy with atypical antipsychotics. Methods We reviewed a case in which a patient with a long history of poor insight obsessive-compulsive disorder was treated with a high dosage of serotonin reuptake inhibitors. Results The treatment resulted in a poor outcome. This patient was therefore augmentated with aripiprazole. Conclusion Doctors should consider aripiprazole as a possible augmentation strategy for serotonergic poor responder obsessive-compulsive patients, but further research on these subjects is needed.

  17. Implementation outcomes of evidence-based quality improvement for depression in VA community based outpatient clinics

    Directory of Open Access Journals (Sweden)

    Fortney John

    2012-04-01

    Full Text Available Abstract Background Collaborative-care management is an evidence-based practice for improving depression outcomes in primary care. The Department of Veterans Affairs (VA has mandated the implementation of collaborative-care management in its satellite clinics, known as Community Based Outpatient Clinics (CBOCs. However, the organizational characteristics of CBOCs present added challenges to implementation. The objective of this study was to evaluate the effectiveness of evidence-based quality improvement (EBQI as a strategy to facilitate the adoption of collaborative-care management in CBOCs. Methods This nonrandomized, small-scale, multisite evaluation of EBQI was conducted at three VA Medical Centers and 11 of their affiliated CBOCs. The Plan phase of the EBQI process involved the localized tailoring of the collaborative-care management program to each CBOC. Researchers ensured that the adaptations were evidence based. Clinical and administrative staff were responsible for adapting the collaborative-care management program for local needs, priorities, preferences and resources. Plan-Do-Study-Act cycles were used to refine the program over time. The evaluation was based on the RE-AIM (Reach, Effectiveness, Adoption, Implementation, Maintenance Framework and used data from multiple sources: administrative records, web-based decision-support systems, surveys, and key-informant interviews. Results Adoption: 69.0% (58/84 of primary care providers referred patients to the program. Reach: 9.0% (298/3,296 of primary care patients diagnosed with depression who were not already receiving specialty care were enrolled in the program. Fidelity: During baseline care manager encounters, education/activation was provided to 100% (298/298 of patients, barriers were assessed and addressed for 100% (298/298 of patients, and depression severity was monitored for 100% (298/298 of patients. Less than half (42.5%, 681/1603 of follow-up encounters during the acute

  18. Normalization of Risperidone-Induced Hyperprolactinemia with the Addition of Aripiprazole

    OpenAIRE

    Shores, Larry E.

    2005-01-01

    The objective of this study was to monitor metabolic changes, including hyperprolactinemia, in adolescents medicated with atypical antipsychotics, especially when polypharmacy is involved. This study specifically followed risperidone-induced hyperprolactinemia in adolescents (14 male patients and 2 female patients) after aripiprazole was added to begin transitioning to another atypical antipsychotic. No other changes were made in the medication regimen. Risperidone was continued at the previo...

  19. Verbessert sich das Gedächtnis euthymer bipolarer Patienten durch die Behandlung mit Aripiprazol?

    OpenAIRE

    Bellmann, Katharina

    2016-01-01

    BACKGROUND: Medical treatment in bipolar disorder has been more focused on dealing with the acute phase of the illness and preventing future relapse rather than treating cognitive dysfunctions. Cognitive impairment in bipolar patients is related to the central vulnerability of the dopaminergic and serotonergic system. Aripiprazole as a partial agonist at D2/D3- and 5HT1A- receptors includes activity in the dopaminergic and serotonergic systems. Previous studies on animals and schizophrenic pa...

  20. Aripiprazole and Haloperidol Activate GSK3β-Dependent Signalling Pathway Differentially in Various Brain Regions of Rats

    Directory of Open Access Journals (Sweden)

    Bo Pan

    2016-03-01

    Full Text Available Aripiprazole, a dopamine D2 receptor (D2R partial agonist, possesses a unique clinical profile. Glycogen synthase kinase 3β (GSK3β-dependent signalling pathways have been implicated in the pathophysiology of schizophrenia and antipsychotic drug actions. The present study examined whether aripiprazole differentially affects the GSK3β-dependent signalling pathways in the prefrontal cortex (PFC, nucleus accumbens (NAc, and caudate putamen (CPu, in comparison with haloperidol (a D2R antagonist and bifeprunox (a D2R partial agonist. Rats were orally administrated aripiprazole (0.75 mg/kg, bifeprunox (0.8 mg/kg, haloperidol (0.1 mg/kg or vehicle three times per day for one week. The levels of protein kinase B (Akt, p-Akt, GSK3β, p-GSK3β, dishevelled (Dvl-3, and β-catenin were measured by Western Blots. Aripiprazole increased GSK3β phosphorylation in the PFC and NAc, respectively, while haloperidol elevated it in the NAc only. However, Akt activity was not changed by any of these drugs. Additionally, both aripiprazole and haloperidol, but not bifeprunox, increased the expression of Dvl-3 and β-catenin in the NAc. The present study suggests that activation of GSK3β phosphorylation in the PFC and NAc may be involved in the clinical profile of aripiprazole; additionally, aripiprazole can increase GSK3β phosphorylation via the Dvl-GSK3β-β-catenin signalling pathway in the NAc, probably due to its relatively low intrinsic activity at D2Rs.

  1. Aripiprazole and Haloperidol Activate GSK3β-Dependent Signalling Pathway Differentially in Various Brain Regions of Rats.

    Science.gov (United States)

    Pan, Bo; Huang, Xu-Feng; Deng, Chao

    2016-01-01

    Aripiprazole, a dopamine D₂ receptor (D₂R) partial agonist, possesses a unique clinical profile. Glycogen synthase kinase 3β (GSK3β)-dependent signalling pathways have been implicated in the pathophysiology of schizophrenia and antipsychotic drug actions. The present study examined whether aripiprazole differentially affects the GSK3β-dependent signalling pathways in the prefrontal cortex (PFC), nucleus accumbens (NAc), and caudate putamen (CPu), in comparison with haloperidol (a D₂R antagonist) and bifeprunox (a D₂R partial agonist). Rats were orally administrated aripiprazole (0.75 mg/kg), bifeprunox (0.8 mg/kg), haloperidol (0.1 mg/kg) or vehicle three times per day for one week. The levels of protein kinase B (Akt), p-Akt, GSK3β, p-GSK3β, dishevelled (Dvl)-3, and β-catenin were measured by Western Blots. Aripiprazole increased GSK3β phosphorylation in the PFC and NAc, respectively, while haloperidol elevated it in the NAc only. However, Akt activity was not changed by any of these drugs. Additionally, both aripiprazole and haloperidol, but not bifeprunox, increased the expression of Dvl-3 and β-catenin in the NAc. The present study suggests that activation of GSK3β phosphorylation in the PFC and NAc may be involved in the clinical profile of aripiprazole; additionally, aripiprazole can increase GSK3β phosphorylation via the Dvl-GSK3β-β-catenin signalling pathway in the NAc, probably due to its relatively low intrinsic activity at D₂Rs. PMID:27043526

  2. Successful treatment of catatonic syndrome in bipolar I disorder adding aripiprazole to ECT: A case report

    Directory of Open Access Journals (Sweden)

    Diego Hidalgo, MD

    2012-09-01

    Full Text Available Background and Objectives: Catatonic syndrome is a condition presenting in multiple ways, sharing many of them with the neuroleptic malignant syndrome and other diseases. This diagnostic challenge is the main cause of keep treating catatonic syndromes without neuroleptics. Methods: Review of the literature and a case report. Results: We present the case of a 19 years old bipolar I patient with a severe catatonic syndrome, with a torpid clinical evolution, partial response to benzodiazepines and ECT, which successfully resolved with intramuscular aripiprazole. We found through a systematic review (PubMed 2005-2010 that there are few but significant case reports of catatonic syndromes treated with new second generation antipsychotics for different reasons with good outcomes as ours. The pharmacological profile of aripiprazole and the low incidence of NMS reported make it a suitable option in treating this syndrome. Conclusions: We think that this case report could contribute to add more evidence for aripiprazole to be considered a good third-line option in the treatment of catatonic syndrome. However, this would require randomized controlled trials to confirm its effectiveness and safety.

  3. Improving the cost-effectiveness of a healthcare system for depressive disorders by implementing telemedicine: a health economic modeling study

    Science.gov (United States)

    Lokkerbol, Joran; Adema, Dirk; Cuijpers, Pim; Reynolds, Charles F.; Schulz, Richard; Weehuizen, Rifka; Smit, Filip

    2014-01-01

    Objective Depressive disorders are important causes of disease burden and are associated with substantial economic costs. Therefore, it is important to design a health care system that can effectively manage depression at sustainable costs. This paper computes the benefit-to-costs ratio of the current Dutch health care system for depression, and investigates whether offering more online preventive interventions improves the cost-effectiveness overall. Methods A health economic (Markov) model was used to synthesize clinical and economic evidence and to compute population-level costs and effects of interventions. The model compares a base-case scenario without preventive telemedicine and alternative scenarios with preventive telemedicine. The central outcome is the benefit-to-cost ratio, also known as return-on-investment (ROI). Results In terms of ROI, a health care system with preventive telemedicine for depressive disorders offers better value for money than a health care system without internet-based prevention. Overall, the ROI increases from €1.45 ($1.72) in the base-case scenario to €1.76 ($2.09) in the alternative scenario where preventive telemedicine is offered. In a scenario where the costs of offering preventive telemedicine are balanced by cutting back on the expenditure for curative interventions, ROI increases to €1.77 ($2.10), while keeping the health care budget constant. Conclusion In order for a health care system for depressive disorders to remain economically sustainable, its cost-benefit ratio needs to be improved. Offering preventive telemedicine at a large scale is likely to introduce such an improvement. PMID:23759290

  4. Rivastigmine improves hippocampal neurogenesis and depression-like behaviors via 5-HT1A receptor stimulation in olfactory bulbectomized mice.

    Science.gov (United States)

    Islam, M R; Moriguchi, S; Tagashira, H; Fukunaga, K

    2014-07-11

    Rivastigmine is a non-competitive inhibitor of both acetylcholinesterase (AChE) and butylcholinesterase (BuChE) used to treat mild to moderate dementia in Alzheimer's disease (AD) patients. Although rivastigmine reportedly ameliorates cognitive dysfunction in these patients, its ability to improve Behavioral and Psychological Symptoms of Dementia (BPSD) remains unclear. To determine whether rivastigmine treatment antagonizes depression-like behaviors, we chronically administered rivastigmine (0.1-1.0mg/kg) to olfactory bulbectomized (OBX) mice once a day for 2weeks, starting 2weeks after bulbectomy. Chronic treatment at 0.3 or 1.0mg/kg dose dependently and significantly improved depression-like behaviors, as assessed by tail suspension (TST), forced swim (FST), locomotion and novelty-suppressed feeding (NSFT) tests. Importantly, co-administration with WAY-100635 (1.0mg/kg), a 5-HT1A receptor antagonist, but not ketanserin (1.0mg/kg,), a 5-HT2A receptor antagonist, completely blocked rivastigmine-induced anti-depressive effects, suggesting that 5-HT1A receptor stimulation mediates this activity. Consistent with this observation, rivastigmine treatment significantly rescued impaired neurogenesis observed in OBX mice in a 5-HT1A receptor-dependent manner. Furthermore, enhanced protein kinase B (Akt) and extracellular signal-regulated kinase (ERK) phosphorylation seen following rivastigmine treatment was closely associated with improved neurogenesis. These effects were blocked by WAY-100635 but not ketanserin treatment. Finally, we confirmed that 5-HT1A but not 5-HT2A receptor stimulation by specific agonists mimicked rivastigmine-induced anti-depression activity and promoted hippocampal neurogenesis. We conclude that, in addition to enhancing the cholinergic system, rivastigmine treatment restores normal function of the hippocampal serotonergic system, an activity that likely ameliorates depressive behaviors in AD patients. PMID:24797332

  5. The impact a first episode of major depression has on marital dissatisfaction: Is remission associated with improvement in dissatisfaction?

    Directory of Open Access Journals (Sweden)

    Jaime Moyá

    2010-03-01

    Full Text Available Background and Objectives: Prior research suggests that marital dissatisfaction is associated with Major Depression (MD. The purpose of this study was to investigate whether remission from a first episode of MD is associated with improvement in marital dissatisfaction and whether the degree of marital dissatisfaction at the time of diagnosis has an influence on the outcome of MD. Methods: The Hamilton Rating Scale for Depression, the Dyadic Adjustment Scale and the Areas of Change Questionnaire were administered to 59 married couples in which one member fulfilled DSM-IV criteria for a first Episode of MD, but her husband (or his wife did not suffer any mental disorder, and to 53 control couples at 6 outpatient clinics, at baseline and after a 6-months follow-up. Results: The level of marital dissatisfaction in couples with a persistent depressed participant decreased in comparison to couples without a depressed subject (p < 0.05 CI: -10.6 and -0.2, but there were no significant differences between couples in which the depressed spouse recovered from MD and comparison couples. Regardless of MD´s severity, high levels of satisfaction were associated with a higher probability to recover. Limitations: The follow-up period was short and we assessed the level of marital dissatisfaction using self-report measures. Conclusion: This study shows that MD has an influence on Marital Satisfaction even at a very early stage of the Depressive Disorder. What is more, changes in any of the two factors (MD or marital dissatisfaction influenced the other factor´s course; thus an effective intervention on MD may have a positive impact on marital dissatisfaction as well.

  6. Acute working memory improvement after tDCS in antidepressant-free patients with major depressive disorder.

    Science.gov (United States)

    Oliveira, Janaina F; Zanão, Tamires A; Valiengo, Leandro; Lotufo, Paulo A; Benseñor, Isabela M; Fregni, Felipe; Brunoni, André R

    2013-03-14

    Based on previous studies showing that transcranial direct current stimulation (tDCS), a non-invasive brain stimulation technique that employs weak, direct currents to induce cortical-excitability changes, might be useful for working memory (WM) enhancement in healthy subjects and also in treating depressive symptoms, our aim was to evaluate whether tDCS could acutely enhance WM in depressed patients. Twenty-eight age- and gender-matched, antidepressant-free depressed subjects received a single-session of active/sham tDCS in a randomized, double-blind, parallel design. The anode was positioned over the left and the cathode over the right dorsolateral prefrontal cortex. The n-back task was used for assessing WM and it was performed immediately before and 15min after tDCS onset. We found that active vs. sham tDCS led to an increase in the rate of correct responses. We also used signal detection theory analyses to show that active tDCS increased both discriminability, i.e., the ability to discriminate signal (correct responses) from noise (false alarms), and response criterion, indicating a lower threshold to yield responses. All effect sizes were large. In other words, one session of tDCS acutely enhanced WM in depressed subjects, suggesting that tDCS can improve "cold" (non affective-loaded) working memory processes in MDD. Based on these findings, we discuss the effects of tDCS on WM enhancement in depression. We also suggest that the n-back task could be used as a biomarker in future tDCS studies investigating prefrontal activity in healthy and depressed samples. PMID:23370288

  7. Towards an improvement of the differentiation of depressive disorders. A multidimensional approach

    OpenAIRE

    Winter, Remco Frank Peter de

    2009-01-01

    Background: It is assumed that the endogenous subtype of depression is a form of depression with various biological abnormalities and a genetic predisposition. The clinical picture rarely shows prior stress and/or an abnormal personality. According to the DSM-IV, this subtype is reproduced as the melancholic subtype, but this subtype has insufficient external validity. This is mainly due to the specific operational method used in the categorical DSM system. Question: Reformulating the melanch...

  8. Ondansetron attenuates co-morbid depression and anxiety associated with obesity by inhibiting the biochemical alterations and improving serotonergic neurotransmission.

    Science.gov (United States)

    Kurhe, Yeshwant; Mahesh, Radhakrishnan

    2015-09-01

    In our earlier study we reported the antidepressant activity of ondansetron in obese mice. The present study investigates the effect of ondansetron on depression and anxiety associated with obesity in experimental mice with biochemical evidences. Male Swiss albino mice were fed with high fat diet (HFD) for 14weeks to induce obesity. Then the subsequent treatment with ondansetron (0.5 and 1mg/kg, p.o.), classical antidepressant escitalopram (ESC) (10mg/kg, p.o.) and vehicle (distilled water 10ml/kg, p.o.) was given once daily for 28days. Behavioral assay for depression including sucrose preference test, forced swim test (FST) and anxiety such as light dark test (LDT) and hole board test (HBT) were performed in obese mice. Furthermore, in biochemical estimations oral glucose tolerance test (OGTT), plasma leptin, insulin, corticosterone, brain oxidative stress marker malonaldehyde (MDA), antioxidant reduced glutathione (GSH) and serotonin assays were performed. Results indicated that HFD fed obese mice showed severe depressive and anxiety-like behaviors. Chronic treatment with ondansetron inhibited the co-morbid depression and anxiety in obese mice by increasing sucrose consumption in sucrose preference test and reducing the immobility time in FST, increasing time and transitions of light chamber in LDT, improving head dip and crossing scores in HBT compared to HFD control mice. Ondansetron in obese mice inhibited glucose sensitivity in OGTT, improved plasma leptin and insulin sensitivity, reversed hypothalamic pituitary adrenal (HPA) axis hyperactivity by reducing the corticosterone concentration, restored brain pro-oxidant/anti-oxidant balance by inhibiting MDA and elevating GSH concentrations and facilitated serotonergic neurotransmission. In conclusion, ondansetron reversed the co-morbid depression and anxiety associated with obesity in experimental mice by attenuating the behavioral and biochemical abnormalities. PMID:26188166

  9. Brain activation predicts treatment improvement in patients with major depressive disorder.

    LENUS (Irish Health Repository)

    Samson, Andrea C

    2012-02-01

    Major depressive disorder (MDD) is associated with alterations in brain function that might be useful for therapy evaluation. The current study aimed to identify predictors for therapy improvement and to track functional brain changes during therapy. Twenty-one drug-free patients with MDD underwent functional MRI twice during performance of an emotional perception task: once before and once after 4 weeks of antidepressant treatment (mirtazapine or venlafaxine). Twelve healthy controls were investigated once with the same methods. A significant difference between groups was a relative greater activation of the right dorsolateral prefrontal cortex (dlPFC) in the patients vs. controls. Before treatment, patients responding better to pharmacological treatment showed greater activation in the dorsomedial PFC (dmPFC), posterior cingulate cortex (pCC) and superior frontal gyrus (SFG) when viewing of negative emotional pictures was compared with the resting condition. Activations in the caudate nucleus and insula contrasted for emotional compared to neutral stimuli were also associated with successful treatment. Responders had also significantly higher levels of activation, compared to non-responders, in a range of other brain regions. Brain activation related to treatment success might be related to altered self-referential processes and a differential response to external emotional stimuli, suggesting differences in the processing of emotionally salient stimuli between those who are likely to respond to pharmacological treatment and those who will not. The present investigation suggests the pCC, dmPFC, SFG, caudate nucleus and insula may have a key role as a biological marker for treatment response and predictor for therapeutic success.

  10. IL-1β and BDNF are associated with improvement in hypersomnia but not insomnia following exercise in major depressive disorder

    OpenAIRE

    Rethorst, C D; Greer, T L; Toups, M S P; Bernstein, I; Carmody, T. J.; Trivedi, M H

    2015-01-01

    Given the role of sleep in the development and treatment of major depressive disorder (MDD), it is becoming increasingly clear that elucidation of the biological mechanisms underlying sleep disturbances in MDD is crucial to improve treatment outcomes. Sleep disturbances are varied and can present as insomnia and/or hypersomnia. Though research has examined the biological underpinnings of insomnia in MDD, little is known about the role of biomarkers in hypersomnia associated with MDD. This pap...

  11. Use of antipsychotics in the treatment of depressive disorders

    Institute of Scientific and Technical Information of China (English)

    Ping WANG; Tianmei SI

    2013-01-01

    There is a long history of using antipsychotic medications in the treatment of depressive disorders. Atypical antipsychotics, which have fewer side effects than traditional antipsychotics, have been used as monotherapy or adjunctively with antidepressants to treat depressive disorders with or without psychotic symptoms. The antidepressant effect of atypical antipsychotics involves regulation of monoamine, glutamate, gamma-aminobutyric acid (GABA), cortisol, and neurotrophic factors. To date, the United States Food and Drug Administration (USFDA) has approved aripiprazole and quetiapine slow-release tablets as adjunctive treatment for depressive disorders, and the combination of olanzapine and fluoxetine for the treatment of treatment-resistant depression. When using atypical antipsychotics in the treatment of depressed patients, clinicians need to monitor patients for the emergence of adverse effects including extrapyramidal symptoms (EPS), weight gain, and hyperglycemia.

  12. Difficulties in post-stroke gait improvement caused by post-stroke depression

    Institute of Scientific and Technical Information of China (English)

    Stanislaw Kijowski

    2014-01-01

    Background Depression is a common problem impeding post-stroke rehabilitation.Up to 70% of patients show depression symptoms during the first twelve months after stroke onset.However,the depression and its effect on functional recovery can be difficult to diagnose.The purpose of this study was to use gait analysis as a tool to compare the recovery after stroke in patients with and without depression and to assess the impact of the initiation time of rehabilitation after stroke onset.Methods One hundred and forty five consecutive patients after first ever stroke admitted for designed rehabilitation program within 2 to 31 months after stroke onset participated.All patients received 4 weeks treatment program included comprehensive rehabilitation consisted of multipurpose activities 5 days a week.These included individual and group exercises,physiotherapy,occupational therapy and gait training.Gait analysis with Kistler force plates was employed to assess gait pattern symmetry before and after the treatment.Gait symmetry was evaluated based on seven gait parameters.Regaining of gait pattern symmetry was assumed as a measure of rehabilitation outcome.Results After rehabilitation program gait symmetry w()ined in patients without depression.Gait asymmetry remained unchanged in patients diagnosed with depression.No major differences in outcome from rehabilitation were noted in regards to the initiation time of rehabilitation after the stroke onset.Conclusions Depression limits gait recovery after stroke.The time of initiation of rehabilitation after stroke onset does not limit the motor recovery after rehabilitation program.

  13. Increased Mesohippocampal Dopaminergic Activity and Improved Depression-Like Behaviors in Maternally Separated Rats Following Repeated Fasting/Refeeding Cycles

    Directory of Open Access Journals (Sweden)

    Jeong Won Jahng

    2012-01-01

    Full Text Available We have previously reported that rats that experienced 3 h of daily maternal separation during the first 2 weeks of birth (MS showed binge-like eating behaviors with increased activity of the hypothalamic-pituitary-adrenal axis when they were subjected to fasting/refeeding cycles repeatedly. In this study, we have examined the psychoemotional behaviors of MS rats on the fasting/refeeding cycles, together with their brain dopamine levels. Fasting/refeeding cycles normalized the ambulatory activity of MS rats, which was decreased by MS experience. Depression-like behaviors, but not anxiety, by MS experience were improved after fasting/refeeding cycles. Fasting/refeeding cycles did not significantly affect the behavioral scores of nonhandled (NH control rats. Fasting/refeeding cycles increased dopamine levels not only in the hippocampus but also in the midbrain dopaminergic neurons in MS rats, but not in NH controls. Results demonstrate that fasting/refeeding cycles increase the mesohippocampal dopaminergic activity and improve depression-like behaviors in rats that experienced MS. Together with our previous paper, it is suggested that increased dopamine neurotransmission in the hippocampus may be implicated in the underlying mechanisms by which the fasting/refeeding cycles induce binge-like eating and improve depression-like behaviors in MS rats.

  14. Improving physical quality of life with group physical activity in the adjunctive treatment of major depressive disorder

    Directory of Open Access Journals (Sweden)

    Mannu Francesca

    2008-01-01

    Full Text Available Abstract Background The aim of the study was to compare the change in quality of life over 32 weeks in depressed women assuming antidepressant drug with (experimental group or without (control group physical exercise from a study which results on objective dimension of outcome were already published. Methods Trial with randomized naturalistic control. Patients selected from the clinical activity registries of a Psychiatric University Unit. Inclusion criteria: female, between 40 and 60 years, diagnosis of Major Depressive Disorders (MMD, DSM-IV TR resistant to ongoing treatment. Exclusion criteria: diagnosis of psychotic disorders; any contraindications to physical activity. 30 patients (71.4% of the eligible participated to the study. Cases: 10 randomized patients undergoing pharmacological treatment plus physical activity. Controls: 20 patients undergoing only pharmacological therapy. Quality of life was measured by means of WHOQOL-Bref. Results The patients that made physical activity had their WHOQOL-Bref physical score improved from T0 to T8, the differences was statistically significant. In the control group WHOQOL-Bref physical remains the same and, consequentially, the difference between T0 and T8 do not reach any statistical significance. The perceived quality of life in the other domains did not change during the treatment in both groups. Thus no other differences were found between and within groups. Discussion and Conclusion The data presented in the previous paper found that physical activity seems a good adjunctive treatment in the long term management of patients with MDD. These new data indicated that physical activity may also improve the perceived physical quality of life. The dimensions related with social functioning, environment and psychical well being seem do not improved, unexpectedly, during the trial. Two objective dimension not strictly related to the depressive symptoms improved: social functioning and Clinical Global

  15. Fish oil improves anxiety-like, depressive-like and cognitive behaviors in olfactory bulbectomised rats.

    Science.gov (United States)

    Pudell, Claudia; Vicente, Bianca A; Delattre, Ana M; Carabelli, Bruno; Mori, Marco A; Suchecki, Deborah; Machado, Ricardo B; Zanata, Sílvio M; Visentainer, Jesuí V; de Oliveira Santos Junior, Oscar; Lima, Marcelo M S; Ferraz, Anete C

    2014-01-01

    Depression is increasingly present in the population, and its pathophysiology and treatment have been investigated with several animal models, including olfactory bulbectomy (Obx). Fish oil (FO) supplementation during the prenatal and postnatal periods decreases depression-like and anxiety-like behaviors. The present study evaluated the effect of FO supplementation on Obx-induced depressive-like behavior and cognitive impairment. Female rats received supplementation with FO during habituation, mating, gestation, and lactation, and their pups were subjected to Obx in adulthood; after the recovery period, the adult offspring were subjected to behavioral tests, and the hippocampal levels of brain-derived neurotrophic factor (BDNF), serotonin (5-HT) and the metabolite 5-hydroxyindoleacetic (5-HIAA) were determined. Obx led to increased anxiety-like and depressive-like behaviors, and impairment in the object location task. All behavioral changes were reversed by FO supplementation. Obx caused reductions in the levels of hippocampal BDNF and 5-HT, whereas FO supplementation restored these levels to normal values. In control rats, FO increased the hippocampal level of 5-HT and reduced that of 5-HIAA, indicating low 5-HT metabolism in this brain region. The present results indicate that FO supplementation during critical periods of brain development attenuated anxiety-like and depressive-like behaviors and cognitive dysfunction induced by Obx. These results may be explained by increased levels of hippocampal BDNF and 5-HT, two major regulators of neuronal survival and long-term plasticity in this brain structure. PMID:24191918

  16. Depression among Alumni of Foster Care: Decreasing Rates through Improvement of Experiences in Care

    Science.gov (United States)

    White, Catherine Roller; O'Brien, Kirk; Pecora, Peter J.; English, Diana; Williams, Jason R.; Phillips, Chereese M.

    2009-01-01

    The Northwest Foster Care Alumni Study examined the relation between experiences in foster care and depression among young adults who spent at least a year in foster care as adolescents. Results indicate that preparation for leaving foster care, nurturing supports from the foster family, school stability, access to tutoring, access to therapeutic…

  17. Comparison between the AA/EPA ratio in depressed and non depressed elderly females: omega-3 fatty acid supplementation correlates with improved symptoms but does not change immunological parameters

    Directory of Open Access Journals (Sweden)

    Rizzo Angela

    2012-10-01

    Full Text Available Abstract Background Depression is one of the most frequently missed diagnoses in elderly people, with obvious negative effects on quality of life. Various studies have shown that long chain omega-3 polyunsaturated fatty acids (n-3 PUFA may be useful in its management. Our objective was to evaluate whether a supplement containing n-3 PUFA improves depressive symptoms in depressed elderly patients, and whether the blood fatty acid pattern is correlated with these changes. Methods The severity of depressive symptoms according to the Geriatric Depression Scale (GDS, blood fatty acid composition and erythrocyte phospholipids were analyzed in 46 depressed females aged 66-95y, diagnosed with depression according to DSMIV, within the context of a randomized, double-blind, placebo-controlled trial. 22 depressed females were included in the intervention group (2.5 g/day of n-3 PUFA for 8 weeks, and 24 in the placebo group. We also measured immunological parameters (CD2, CD3, CD4, CD8, CD16, CD19 and cytokines (IL-5, IL-15. Results The mean GDS score and AA/EPA ratio, in whole blood and RBC membrane phospholipids, were significantly lower after 2 months supplementation with n-3 PUFA. A significant correlation between the amelioration of GDS and the AA/EPA ratio with some immunological parameters, such as CD2, CD19, CD4, CD16 and the ratio CD4/CD8, was also found. Nevertheless, omega-3 supplementation did not significantly improve the studied immunological functions. Conclusions n-3 PUFA supplementation ameliorates symptoms in elderly depression. The n-3 PUFA status may be monitored by means of the determination of whole blood AA/EPA ratio.

  18. Are chronic low back pain outcomes improved with co-management of concurrent depression?

    Directory of Open Access Journals (Sweden)

    Pollard Henry

    2005-06-01

    Full Text Available Abstract Objective To discuss the role of depression in chronic lower back pain and comment on appropriate methods of screening and co-management. Data Sources The current scientific literature was investigated using the online web databases CINAHL, Medline/PUBMED, Proquest, Meditext and from manual library searches. Data Extraction Databases were searched from 1980 to the present (2005. Articles were searched with the key words "depression" and "low back pain". Over three hundred articles were sourced and articles were then selected on their relevance to the chronic spinal pain states that present to manual therapy practitioners. Data synthesis Pain is a subjective awareness of peripheral nociceptive stimulation, projected from the thalamus to the cerebral cortex with each individual's pain experience being mediated by his or her psychological state. Thus a psychological component will often be associated with any painful experience. A number of studies suggest (among other things that the incidence of depression predicts chronicity in lower back pain syndromes but that chronic lower back pain does not have the reciprocal action to predict depression. Conclusion The aetiology of chronic pain is multifactorial. There is sufficient evidence in the literature to demonstrate a requirement to draw treatment options from many sources in order to achieve a favourable pain relief outcome. The treatment should be multimodal, including mental and emotional support, counseling and herbal advice. While a strong correlation between depression and chronic low back pain can be demonstrated, an apparent paucity of literature that specifically addresses the patient response to chiropractic treatment and concurrent psychotherapy identifies the need for prospective studies of this nature to be undertaken. It is likely that multimodal/multidisciplinary treatment approaches should be encouraged to deal with these chronic lower back pain syndromes.

  19. Clinical Usefulness of Aripiprazole and Lamotrigine in Schizoaffective Presentation of Tuberous Sclerosis

    Science.gov (United States)

    Lee, Seung-Yup; Min, Jung-Ah; Lee, In Goo; Kim, Jung Jin

    2016-01-01

    Tuberous sclerosis is not as rare as once thought and has high psychiatric comorbidities. However, bipolar or psychotic features associated with tuberous sclerosis have been rarely reported. This report first presents a tuberous sclerosis patient, resembling a schizoaffective disorder of bipolar type. A patient with known tuberous sclerosis displayed mood fluctuation and psychotic features. Her symptoms did not remit along with several psychiatric medications. After hospitalization, the patient responded well with lamotrigine and aripiprazole without exacerbation. As demonstrated in this case, tuberous sclerosis may also encompass bipolar affective or psychotic features. We would like to point out the necessity to consider bipolarity in evaluating and treating tuberous sclerosis. PMID:27489387

  20. Repeated administration of aripiprazole produces a sensitization effect in the suppression of avoidance responding and phencyclidine-induced hyperlocomotion and increases D2 receptor-mediated behavioral function

    Science.gov (United States)

    Gao, Jun; Qin, Rongyin; Li, Ming

    2016-01-01

    The present study investigated how repeated administration of aripiprazole (a novel antipsychotic drug) alters its behavioral effects in two behavioral tests of antipsychotic activity and whether this alteration is correlated with an increase in dopamine D2 receptor function. Male adult Sprague-Dawley rats were first repeatedly tested with aripiprazole (3, 10 and 30 mg/kg, subcutaneously (sc)) or vehicle in a conditioned avoidance response (CAR) test or a phencyclidine (PCP) (3.20 mg/kg, sc)-induced hyperlocomotion test daily for five consecutive days. After 2–3 days of drug-free retraining or resting, all rats were then challenged with aripiprazole (1.5 or 3.0 mg/kg, sc). Repeated administration of aripiprazole progressively increased its inhibition of avoidance responding and PCP-induced hyperlocomotion. More importantly, rats previously treated with aripiprazole showed significantly lower avoidance response and lower PCP-induced hyperlocomotion than those previously treated with vehicle in the challenge tests. An increased sensitivity to quinpirole (a selective D2/3 agonist) in prior aripiprazole-treated rats was also found in the quinpirole-induced hyperlocomotion test, suggesting an enhanced D2/3-mediated function. These findings suggest that aripiprazole, despite its distinct receptor mechanisms of action, induces a sensitization effect similar to those induced by other antipsychotic drugs and this effect may be partially mediated by brain plasticity involving D2/3 receptor systems. PMID:25586399

  1. Trends in depression and antidepressant prescribing in children and adolescents: a cohort study in The Health Improvement Network (THIN.

    Directory of Open Access Journals (Sweden)

    Linda P M M Wijlaars

    Full Text Available BACKGROUND: In 2003, the Committee on Safety of Medicines (CSM advised against treatment with selective serotonin reuptake inhibitors (SSRIs other than fluoxetine in children, due to a possible increased risk of suicidal behaviour. This study examined the effects of this safety warning on general practitioners' depression diagnosing and prescription behaviour in children. METHODS AND FINDINGS: We identified a cohort of 1,502,753 children (6 m in The Health Improvement Network (THIN UK primary care database. Trends in incidence of depression diagnoses, symptoms and antidepressant prescribing were examined 1995-2009, accounting for deprivation, age and gender. We used segmented regression analysis to assess changes in prescription rates. Overall, 45,723 (3% children had ≥ 1 depression-related entry in their clinical records. SSRIs were prescribed to 16,925 (1% of children. SSRI prescription rates decreased from 3.2 (95%CI:3.0,3.3 per 1,000 person-years at risk (PYAR in 2002 to 1.7 (95%CI:1.7,1.8 per 1,000 PYAR in 2005, but have since risen to 2.7 (95%CI:2.6,2.8 per 1,000 PYAR in 2009. Prescription rates for CSM-contraindicated SSRIs citalopram, sertraline and especially paroxetine dropped dramatically after 2002, while rates for fluoxetine and amitriptyline remained stable. After 2005 rates for all antidepressants, except paroxetine and imipramine, started to rise again. Rates for depression diagnoses dropped from 3.0 (95%CI:2.8,3.1 per 1,000 PYAR in 2002 to 2.0 (95%CI:1.9,2.1 per 1,000 PYAR in 2005 and have been stable since. Recording of symptoms saw a steady increase from 1.0 (95%CI:0.8,1.2 per 1,000 PYAR in 1995 to 4.7 (95%CI:4.5,4.8 per 1,000 PYAR in 2009. CONCLUSIONS: The rates of depression diagnoses and SSRI prescriptions showed a significant drop around the time of the CSM advice, which was not present in the recording of symptoms. This could indicate caution on the part of GPs in making depression diagnoses and prescribing

  2. Unique Effects of Acute Aripiprazole Treatment on the Dopamine D2 Receptor Downstream cAMP-PKA and Akt-GSK3β Signalling Pathways in Rats

    Science.gov (United States)

    Pan, Bo; Chen, Jiezhong; Lian, Jiamei; Huang, Xu-Feng; Deng, Chao

    2015-01-01

    Aripiprazole is a wide-used antipsychotic drug with therapeutic effects on both positive and negative symptoms of schizophrenia, and reduced side-effects. Although aripiprazole was developed as a dopamine D2 receptor (D2R) partial agonist, all other D2R partial agonists that aimed to mimic aripiprazole failed to exert therapeutic effects in clinic. The present in vivo study aimed to investigate the effects of aripiprazole on the D2R downstream cAMP-PKA and Akt-GSK3β signalling pathways in comparison with a D2R antagonist – haloperidol and a D2R partial agonist – bifeprunox. Rats were injected once with aripiprazole (0.75mg/kg, i.p.), bifeprunox (0.8mg/kg, i.p.), haloperidol (0.1mg/kg, i.p.) or vehicle. Five brain regions – the prefrontal cortex (PFC), nucleus accumbens (NAc), caudate putamen (CPu), ventral tegmental area (VTA) and substantia nigra (SN) were collected. The protein levels of PKA, Akt and GSK3β were measured by Western Blotting; the cAMP levels were examined by ELISA tests. The results showed that aripiprazole presented similar acute effects on PKA expression to haloperidol, but not bifeprunox, in the CPU and VTA. Additionally, aripiprazole was able to increase the phosphorylation of GSK3β in the PFC, NAc, CPu and SN, respectively, which cannot be achieved by bifeprunox and haloperidol. These results suggested that acute treatment of aripiprazole had differential effects on the cAMP-PKA and Akt-GSK3β signalling pathways from haloperidol and bifeprunox in these brain areas. This study further indicated that, by comparison with bifeprunox, the unique pharmacological profile of aripiprazole may be attributed to the relatively lower intrinsic activity at D2R. PMID:26162083

  3. Induction of cytokine synthesis and fever suppresses REM sleep and improves mood in patients with major depression.

    Science.gov (United States)

    Bauer, J; Hohagen, F; Gimmel, E; Bruns, F; Lis, S; Krieger, S; Ambach, W; Guthmann, A; Grunze, H; Fritsch-Montero, R

    1995-11-01

    Beneficial effects of inflammatory events on certain psychiatric disorders, including depression, were reported sporadically by ancient Greek physicians, but have been described also in our times by a few psychiatrists during the past decades. During febrile inflammatory events, mediators of the immune system such as interleukin-1 can be detected in the brain and may act on their respective receptors which have also been demonstrated in the brain. Since cytokines such as interleukin-1 have been shown in animal studies to exert sedative behavioral effects, to be somnogenic, and to induce slow-wave sleep (SWS), we performed a pilot study to evaluate scientifically the anecdotically reported beneficial effects of inflammatory states on depressive disorders. Mood and sleep parameters were monitored in seven drug-free, severely depressed patients before, during, and after the administration of a single dose of endotoxin. All patients responded with a short pulse of increased synthesis of the cytokines tumor necrosis factor, interleukin-1, and interleukin-6 and elevated body temperature for several hours. During the night following endotoxin administration, rapid eye movement (REM) sleep was significantly suppressed, while changes in slow wave sleep were not significant. During the next day, all patients were in a significantly improved mood; however a rebound of REM sleep was observed in the second night after endotoxin administration and mood worsened again during the next days, indicating an only transient beneficial effect of the treatment. PMID:8573663

  4. Evaluation of the causes of legume yield depression syndrome usingan improved diagnostic tool

    OpenAIRE

    Fuchs, Jacques G.; Thürig, Barbara; Brandhuber, Robert; Bruns, Christian; Maria R. Finckh; Fließbach, Andreas; Mäder, Paul; Schmidt, Harald; Vogt-Kaute, Werner; Wilbois, Klaus-Peter; Tamm, Lucius

    2014-01-01

    The aim of the study was to establish a diagnostic tool to narrow down the causes for pea yield depressions. A differential two-level diagnostic test system was established under controlled conditions usingpeas (Pisum sativum L.) as test plants. Soils from 22 organically managed sites with unexplained moderate to high pea yield losses were tested in level 1 diagnostics (y-irradiation to eliminate potentiallyharmful organisms, nutrient additions to compensate for potential nutrient deficiencie...

  5. Evaluation of the causes of legume yield depression syndrome using an improved diagnostic tool

    OpenAIRE

    Fuchs, Jacques G.; Thürig, Barbara; Brandhuber, Robert; Bruns, Christian; Maria R. Finckh; Fließbach, Andreas; Mäder, Paul; Schmidt, Harald; Vogt-Kaute, Werner; Wilbois, Klaus-Peter; Lucius, Tamm

    2014-01-01

    The aim of the study was to establish a diagnostic tool to narrow down the causes for pea yield depressions. A differential two-level diagnostic test system was established under controlled conditions usingpeas (Pisum sativum L.) as test plants. Soils from 22 organically managed sites with unexplained moderate to high pea yield losses were tested in level 1 diagnostics (y-irradiation to eliminate potentiallyharmful organisms, nutrient additions to compensate for potential nutrient deficiencie...

  6. A pilot study of folic acid supplementation for improving homocysteine levels, cognitive and depressive status in eating disorders

    Directory of Open Access Journals (Sweden)

    Viviana Loria-Kohen

    2013-06-01

    Full Text Available Background & aims: Several authors have reported low folate intake in patients with eating disorders (ED. This vitamin plays an essential role in synthesis reactions for neurotransmitters and structural elements of neurons, and therefore its deficiency has been associated with the presence of different disorders linked to mental function. The aim of this study was to determine the effect of folic acid supplementation on homocysteine levels and the cognitive and depressive status of a group of patients with eating disorders with low folate intake. Subjects/methods: The study was designed as a randomised, prospective clinical trial, which included 24 participants assigned to two treatment groups for six months: supplemented group (SG (10 mg/day of folic acid [ACFOL®] and a placebo group (PG. Both groups maintained their medical, dietary and psychological treatment. At baseline and end of the intervention, anthropometric, dietary and biochemical parameters (plasma homocysteine [Hcy], serum and red blood cell folate were recorded. Cognitive and depressive status questionnaires were administered (Stroop Test, Trail Making Test and Beck Depression Inventory. Results: Twenty-two patients completed the study (SG: 12, PG: 10, mean age: 24.2 ± 8.8 years, BMI 18, ± 3.5 kg/m². The SG significantly increased their serum and red blood cell folate levels and lowered Hcy levels (9.4 ± 2.4 µmol/l vs. 7.5 ± 1.7 µmol/l, P < 0.01. The SG also significantly improved most of their test scores for cognitive and depressive status. The PG showed no significant changes in any of the evaluated variables. Conclusions: The results show that folic acid supplementation may be used as another tool within the comprehensive and multidisciplinary treatment applied to patients with ED.

  7. A Placebo-Controlled, Fixed-Dose Study of Aripiprazole in Children and Adolescents with Irritability Associated with Autistic Disorder

    Science.gov (United States)

    Marcus, Ronald N.; Owen, Randall; Kamen, Lisa; Manos, George; McQuade, Robert D.; Carson, William H.; Aman, Michael G.

    2009-01-01

    Objective: To evaluate the short-term efficacy and safety of aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Method: Two hundred eighteen children and adolescents (aged 6-17 years) with a diagnosis of autistic disorder, and with behaviors such as tantrums, aggression, self-injurious behavior, or a…

  8. Clinical efficacy comparison of escitalopram treatment combined with aripiprazole on obsessive compulsive disorder%艾司西酞普兰联合阿立哌唑治疗强迫症患者的疗效观察

    Institute of Scientific and Technical Information of China (English)

    姜涛

    2011-01-01

    Objective; To investigate the effectiveness and safety of escitalopram with or without aripi-prazole in the treatment of obsessive-compulsive disorder. Method;60 patients with obsessive compulsive disorder were randomly assigned to receive escitalopram with or without aripiprazole. Effectiveness and adverse effect were assessed by Yale-Brown obsessive compulsive scale (Y-BOCS) and treatment emergent symptom scale ( TESS) , respectively. Results; Patients both received escitalopram and escitalopram with aripiprazole showed significant improvement by Y-BOCS scores after treatment,while the combination group showed a better outcome. There was no significant difference in TESS evaluation between the two groups. Conclusion; Escitalopram could effectively treat obsessive-compulsive disorder, while escitalopram combined with aripiprazole is more effective.%目的:探讨艾司西酞普兰与阿立哌唑联合治疗强迫症的疗效及不良反应.方法:对60例强迫症患者随机分为单用艾司西酞普兰组(单用组)及艾司西酞普兰与阿立哌唑联合用药组(合用组)治疗强迫症患者各30例进行开放、随机、对照研究,通过耶鲁布朗强迫量表(Y-BOCS)评定疗效,治疗中出现的症状量表(TESS)评定不良反应. 结果:艾司西酞普兰治疗后显著改善强迫症状,艾司西酞普兰联合阿立哌唑也能显著改善强迫症状,后者改善效果更好;两组不良反应轻微.结论:艾司西酞普兰联合阿立哌唑较单用艾司西酞普兰的抗强迫效果更好.

  9. Perinatal use of aripiprazole: plasma levels, placental transfer, and child outcome in 3 new cases.

    Science.gov (United States)

    Windhager, Elmar; Kim, Sung-Wan; Saria, Alois; Zauner, Katharina; Amminger, Paul G; Klier, Claudia M

    2014-10-01

    The use of new agents of second-generation antipsychotics in childbearing women is increasing and poses an unknown risk to the fetus; thus, information of pregnancy and child outcome are urgently needed. We reviewed the literature of 12 patients, 3 of them were exposed during the first trimester, and added 3 new cases of peripartum use of aripiprazole. No teratogenesis was observed despite all 3 women having received the substance during part or full first trimester. All 3 pregnancies were uncomplicated with spontaneous birth. Dosage had to be changed during the course of gestation from 2.5 to 15 mg and plasma levels (PL) were below recommended levels, although all 3 women remained in stable remission throughout pregnancy and postpartum period.The extent of placental transfer of aripiprazole (mean ratio of 56.2%) is comparable with that of other second-generation antipsychotics.Our observations have clinical implications: antipsychotic PLs show large-scale decreases, which may require dose adjustments during pregnancy. Pregnant women may require lower PLs. In our cases, a PL of one third of the previous effective PL was effective and safe. Repeated therapeutic drug monitoring during late gestation based on individual, previous effective PLs seems to be a feasible way for safe and effective antipsychotic therapy in unplanned pregnancy. PMID:24949701

  10. Randomised controlled trial of tailored interventions to improve the management of anxiety and depressive disorders in primary care

    Directory of Open Access Journals (Sweden)

    Terluin Berend

    2011-07-01

    Full Text Available Abstract Background Anxiety and depressive disorders are highly prevalent disorders and are mostly treated in primary care. The management of these disorders by general practitioners is not always consistent with prevailing guidelines because of a variety of factors. Designing implementation strategies tailored to prospectively identified barriers could lead to more guideline-recommended care. Although tailoring of implementation strategies is promoted in practice, little is known about the effect on improving the quality of care for the early recognition, diagnosis, and stepped care treatment allocation in patients with anxiety or depressive disorders in general practice. This study examines whether the tailored strategy supplemented with training and feedback is more effective than providing training and feedback alone. Methods In this cluster randomised controlled trial, a total of 22 general practices will be assigned to one of two conditions: (1 training, feedback, and tailored interventions and (2 training and feedback. The primary outcome measure is the proportion of patients who have been recognised to have anxiety and/or depressive disorder. The secondary outcome measures in patients are severity of anxiety and depressive symptoms, level of functioning, expectation towards and experience with care, quality of life, and economic costs. Measures are taken after the start of the intervention at baseline and at three- and six-month follow-ups. Secondary outcome measures in general practitioners are adherence to guideline-recommended care in care that has been delivered, the proportion of antidepressant prescriptions, and number of referrals to specialised mental healthcare facilities. Data will be gathered from the electronic medical patient records from the patients included in the study. In a process evaluation, the identification of barriers to change and the relations between prospectively identified barriers and improvement

  11. Implementing collaborative care for depression treatment in primary care: A cluster randomized evaluation of a quality improvement practice redesign

    Directory of Open Access Journals (Sweden)

    Lee Martin

    2011-10-01

    Full Text Available Abstract Background Meta-analyses show collaborative care models (CCMs with nurse care management are effective for improving primary care for depression. This study aimed to develop CCM approaches that could be sustained and spread within Veterans Affairs (VA. Evidence-based quality improvement (EBQI uses QI approaches within a research/clinical partnership to redesign care. The study used EBQI methods for CCM redesign, tested the effectiveness of the locally adapted model as implemented, and assessed the contextual factors shaping intervention effectiveness. Methods The study intervention is EBQI as applied to CCM implementation. The study uses a cluster randomized design as a formative evaluation tool to test and improve the effectiveness of the redesign process, with seven intervention and three non-intervention VA primary care practices in five different states. The primary study outcome is patient antidepressant use. The context evaluation is descriptive and uses subgroup analysis. The primary context evaluation measure is naturalistic primary care clinician (PCC predilection to adopt CCM. For the randomized evaluation, trained telephone research interviewers enrolled consecutive primary care patients with major depression in the evaluation, referred enrolled patients in intervention practices to the implemented CCM, and re-surveyed at seven months. Results Interviewers enrolled 288 CCM site and 258 non-CCM site patients. Enrolled intervention site patients were more likely to receive appropriate antidepressant care (66% versus 43%, p = 0.01, but showed no significant difference in symptom improvement compared to usual care. In terms of context, only 40% of enrolled patients received complete care management per protocol. PCC predilection to adopt CCM had substantial effects on patient participation, with patients belonging to early adopter clinicians completing adequate care manager follow-up significantly more often than patients of

  12. A randomized,controlled study of lithium carbonate monotheraPy or combined ariPiPrazole theraPy in Patients with biPolar disorder tyPe I manic ePisode%碳酸锂单用与合并阿立哌唑治疗双相障碍I型躁狂发作患者的随机对照研究

    Institute of Scientific and Technical Information of China (English)

    宋振华; 粟幼嵩; 王勇; 黄佳; 季曹珺; 吴彦; 王祖承

    2014-01-01

    目的:探讨碳酸锂单用及合并阿立哌唑治疗双相障碍 I 型躁狂发作患者的疗效和安全性。方法:86例门诊双相障碍 I 型躁狂发作患者被随机分为联合组(碳酸锂+阿立哌唑治疗)和单药组(碳酸锂单药治疗),疗程8周。分别在治疗前、治疗2、4、8周进行杨氏躁狂量表(YMRS)和汉密顿抑郁量表(HAMD)-17项评定,采用治疗中出现的症状量表( TESS)评定不良反应。结果:治疗前两组YMRS 评分差异无统计学意义;治疗2、4、8周后联合组 YMRS 减分值明显高于对照组(P ﹤0.05或 P ﹤0.01);治疗前后两组 HAMD 均﹤7分;两组 TESS 评分差异无统计学意义。结论:碳酸锂联合阿立哌唑治疗双相障碍 I 型躁狂发作较单用碳酸锂起效快,症状改善更明显,且未见不良反应明显增加。%To investigate the clinical efficacy and safety of lithium carbonate monotherapy or combined aripiprazole therapy in patients with bipolar disorder type I manic episode. Method:Eighty-six out-patients with bipolar disorder type I manic episode were randomly divided into combining therapy group( trea-ted with lithium carbonate + aripiprazole)and monotherapy guoup(treated with lithium carbonate only),the course was 8 weeks. The patients were assessed by Young′s manic scale(YMRS)and Hamilton depression scale items(HAMD)-17 before treatment and 2,4,8 weeks after treatment. The adverse reaction was evaluated by treatment emergent symptoms scale(TESS). Results:Before treatment,the score of YMRS between the two groups was not significantly different. At 2,4,8 weeks after treatment the subtraction scores of YMRS in the combining therapy group were more obvious than the monotherapy guoup(P ﹤ 0. 05 or P ﹤ 0. 01). The scores of HAMD at each time point in the both groups were ﹤ 7. The score of TESS between the two groups was not signifi-cantly different. Conclusion:Compared lithium carbonate monotherapy

  13. Postpartum depression

    Science.gov (United States)

    Depression - postpartum; Postnatal depression; Postpartum psychological reactions ... term complications are the same as in major depression . Untreated postpartum depression may put you at risk of harming ...

  14. Comparison of the Efficacy of Cognitive Behavior Therapy and Mindfulness-based Therapy in Improving Cognitive Emotion Regulation in Major Depressive Disorder

    OpenAIRE

    H Bagherinia; Yamini, M.; L javadielmi; T nooradi

    2015-01-01

    Background & aim: Major depression disorder is one of the common mental disorders that the way of cognitive emotional regulation influences in development or reducing symptoms of this disorder. Since cognitive emotional regulation plays an important role in coping with life problems, this disorder causes emotional disturbances such as major depression. The aim of this study was to compare the efficacy of cognitive behavior therapy and mindfulness-based therapy to improve cognitive emotion reg...

  15. Efficacy of levomilnacipran extended-release in improving functional impairment associated with major depressive disorder: pooled analyses of five double-blind, placebo-controlled trials

    OpenAIRE

    Sambunaris, Angelo; Gommoll, Carl; Chen, ChangZheng; Greenberg, William M

    2014-01-01

    Major depressive disorder (MDD) is characterized by increased rates of impaired function and disability. During antidepressant treatment, functional improvement often lags behind symptomatic resolution, and residual impairment is associated with an increased risk for relapse. When evaluating MDD treatments, it is important to assess not only depressive symptoms but also functional outcomes. In this post-hoc analysis, data from five studies were pooled to examine the effect of levomilnacipran ...

  16. Effects of acute and chronic aripiprazole treatment on choice between cocaine self-administration and food under a concurrent schedule of reinforcement in rats

    DEFF Research Database (Denmark)

    Thomsen, Morgane; Fink-Jensen, Anders; Woldbye, David;

    2008-01-01

    the hypothesis that aripiprazole, both as acute and as chronic treatment, would preferentially decrease cocaine self-administration while sparing behavior maintained by a natural reinforcer, resulting in a shift in the allocation of behavior from cocaine-taking towards the alternative reinforcer. MATERIALS...... performance in the choice procedure was assessed daily. RESULTS: An intermediate dose of aripiprazole decreased cocaine self-administration and shifted the cocaine choice curve to the right as an acute treatment. However, as a chronic treatment, aripiprazole failed to decrease cocaine self-administration...... or cocaine choice, despite a dose-dependent decrease in overall response rates and food-maintained behavior. CONCLUSIONS: Our results confirm and extend earlier findings and indicate that acute administration of aripiprazole can decrease cocaine self-administration. However, based on the present data...

  17. Exercise improves physical and psychological quality of life in people with depression: A meta-analysis including the evaluation of control group response.

    Science.gov (United States)

    Schuch, Felipe B; Vancampfort, Davy; Rosenbaum, Simon; Richards, Justin; Ward, Philip B; Stubbs, Brendon

    2016-07-30

    Exercise has established efficacy as an antidepressant in people with depression. However, few meta-analyses have assessed the effects of exercise across different domains of Quality of Life (QoL) in people with depression. Furthermore, there has been no previous meta-analysis of control group response in relation to QoL in exercise trials for depression. Randomized Clinical Trials(RCTs) were initially identified from a Cochrane review, and those including QoL assessments were included in the analysis. Search of major electronic databases were conducted to identify RCTs that compared the exercise effects on QoL versus control condition in people with depression. A random effects meta-analysis was employed to evaluate the Standardized Mean Difference (SMD). Six RCTs were included. Exercise significantly improved physical and psychological domains and overall QoL. Effects on social relationship and environment domains were not significant. No significant control group response was found for any domain or overall QoL. Exercise can be considered as a therapeutic strategy to improve physical and psychological domains and overall QoL of people with depression, with no effect evident across the social and environmental domains. The lack of improvement among control groups reinforces the role of exercise as a treatment for depression with benefits to QoL. PMID:27155287

  18. Role of aripiprazole in treatment-resistant schizophrenia

    OpenAIRE

    Mossaheb N; Kaufmann RM

    2012-01-01

    Nilufar Mossaheb,1 Rainer M Kaufmann21Department of Child and Adolescent Psychiatry, 2Department of Psychiatry and Psychotherapy, Medical University, Vienna, AustriaAbstract: About one third of patients with schizophrenia respond unsatisfactorily to antipsychotic treatment and are termed “treatment-resistant”. Clozapine is still the gold standard in these cases. However, 40%–70% of patients do not improve sufficiently on clozapine either. In the search for more e...

  19. Repeated administration of aripiprazole produces a sensitization effect in the suppression of avoidance responding and phencyclidine-induced hyperlocomotion and increases D2 receptor-mediated behavioral function

    OpenAIRE

    Gao, Jun; Qin, Rongyin; LI Ming

    2015-01-01

    The present study investigated how repeated administration of aripiprazole (a novel antipsychotic drug) alters its behavioral effects in two behavioral tests of antipsychotic activity and whether this alteration is correlated with an increase in dopamine D2 receptor function. Male adult Sprague-Dawley rats were first repeatedly tested with aripiprazole (3, 10 and 30 mg/kg, subcutaneously (sc)) or vehicle in a conditioned avoidance response (CAR) test or a phencyclidine (PCP) (3.20 mg/kg, sc)-...

  20. Improving the Management of Late-Life Depression in Primary Care: Barriers and Facilitators

    Directory of Open Access Journals (Sweden)

    Tamara Sussman

    2011-01-01

    Full Text Available The objectives of this study were to elicit Canadian health professionals' views on the barriers to identifying and treating late-life depression in primary care settings and on the solutions felt to be most important and feasible to implement. A consensus development process was used to generate, rank, and discuss solutions. Twenty-three health professionals participated in the consensus process. Results were analysed using quantitative and qualitative methods. Participants generated 12 solutions. One solution, developing mechanisms to increase family physicians' awareness of resources, was highly ranked for importance and feasibility by most participants. Another solution, providing family physicians with direct mental health support, was highly ranked as important but not as feasible by most participants. Deliberations emphasized the importance of case specific, as needed support based on the principles of shared care. The results suggest that practitioners highly value collaborative care but question the feasibility of implementing these principles in current Canadian primary care contexts.

  1. Sleep deprivation in depression

    Directory of Open Access Journals (Sweden)

    Doongaji D

    1979-01-01

    Full Text Available Ten patients diagnosed as suffering from depressive illness were treated with 2 consecutive nights of sleep deprivation. Sleep deprivation was effective in both types of depression viz. endoge-nous and reactive. The improvement was greater and seemed to last longer in endogenous depression as compared to reactive depression at the time of evaluation, 7 days after completion of sleep deprivation. Depressed mood, suicidal tendencies and retard-ation seemed to show the greatest improvement while insight and gastro-intestinal and somatic symptoms, improved the least.

  2. Depression - resources

    Science.gov (United States)

    Resources - depression ... Depression is a medical condition. If you think you may be depressed, see a health care provider. ... following organizations are good sources of information on depression : American Psychological Association -- www.apa.org/topics/depress/ ...

  3. Safety and efficacy of aripiprazole for the treatment of pediatric Tourette syndrome and other chronic tic disorders

    Directory of Open Access Journals (Sweden)

    Cox JH

    2016-06-01

    Full Text Available Joanna H Cox,1 Stefano Seri,2,3 Andrea E Cavanna,2,4,5 1Heart of England NHS Foundation Trust, 2School of Life and Health Sciences, Aston Brain Centre, Aston University, 3Children’s Epilepsy Surgery Programme, The Birmingham Children’s Hospital NHS Foundation Trust, 4Department of Neuropsychiatry, Birmingham and Solihull Mental Health NHS Foundation Trust, Birmingham, 5Sobell Department of Motor Neuroscience and Movement Disorders, Institute of Neurology and UCL, London, UK Abstract: Tourette syndrome is a childhood-onset chronic tic disorder characterized by multiple motor and vocal tics and often accompanied by specific behavioral symptoms ranging from obsessionality to impulsivity. A considerable proportion of patients report significant impairment in health-related quality of life caused by the severity of their tics and behavioral symptoms and require medical intervention. The most commonly used medications are antidopaminergic agents, which have been consistently shown to be effective for tic control, but are also associated with poor tolerability because of their adverse effects. The newer antipsychotic medication aripiprazole is characterized by a unique mechanism of action (D2 partial agonism, and over the last decade has increasingly been used for the treatment of tics. We conducted a systematic literature review to assess the available evidence on the efficacy and safety of aripiprazole in pediatric patients with Tourette syndrome and other chronic tic disorders (age range: 4–18 years. Our search identified two randomized controlled trials (involving 60 and 61 participants and ten open-label studies (involving between six and 81 participants. The majority of these studies used two validated clinician-rated instruments (Yale Global Tic Severity Scale and Clinical Global Impression scale as primary outcome measures. The combined results from randomized controlled trials and open-label studies showed that aripiprazole is an

  4. Examining the Impact of Patient-Reported Hope for Improvement and Patient Satisfaction with Clinician/Treatment on the Outcome of Major Depressive Disorder Treatment

    Science.gov (United States)

    Vilhauer, Jennice; Kwock, Richard; Wu, Fan; Gohar, Sherif; Collison, Katherine; Thomas, Shannon Nicole; Naghdechi, Lancer; Elashoff, David

    2016-01-01

    Aims This analysis aims at examining if patient-reported variables such as hope for improvement and patient satisfaction with clinician/treatment could influence the outcome major depressive disorder (MDD) treatment, namely depression remission, in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial. Study Design Retrospective cohort study. Place and Duration of Study The STAR*D study was conducted at 18 primary care and 23 psychiatric care settings in the United States from 2001–2007 and was funded by the National Institute of Mental health (NIMH). The analysis contained in this manuscript was conceptualized at the Cedars-Sinai Department of Psychiatry and Behavioral Neurosciences and performed at the UCLA School of Public Health. Methodology Using data from STAR*D, the current study used logistic regression and survival analyses to examine the relationship between depressive symptoms remission and two sets of self-reported factors: Hope for improvement and, Patient satisfaction with treatment/clinician. Results First, more than 90% of STAR*D patients reported having high hope for improvement (agree or strongly agree) and more than 66% endorsed high satisfaction with clinicians and more than 50% expressed high satisfaction with treatments (very or mostly satisfied). Second, hope for improvement was predictive of depression remission (p<0.05). Third, satisfaction with clinician/treatment, did not predict remission. Conclusion This study shows the impact that patients’ subjective hope for improvement can have on predicting depression remission in contrast to satisfaction with clinician/treatment. Future studies should prospectively incorporate patients’ subjective attitudes regarding hope for improvement and satisfaction with clinicians and treatments as mediators and moderators of MDD treatment success. PMID:27294164

  5. Improvement in Depressive Symptoms Is Associated with Reduced Oxidative Damage and Inflammatory Response in Type 2 Diabetic Patients with Subsyndromal Depression: The Results of a Randomized Controlled Trial Comparing Psychoeducation, Physical Exercise, and Enhanced Treatment as Usual

    Directory of Open Access Journals (Sweden)

    Marijana Vučić Lovrenčić

    2015-01-01

    Full Text Available Aims. To examine one-year changes in oxidative damage and inflammation level in type 2 diabetic patients undergoing behavioral treatment for subsyndromal depression. Materials and Methods. A randomized controlled comparison of psychoeducation (A, physical exercise (B, and enhanced treatment as usual (C was performed in 209 eligible subjects in a tertiary diabetes care setting. Depressive symptoms (primary outcome and selected biomarkers of oxidative damage and inflammation (secondary outcomes were assessed at baseline and six- and twelve-month follow-up. Results. Out of the 74, 67, and 68 patients randomised into groups A, B, and C, respectively, 201 completed the interventions, and 179 were analysed. Participants in all three groups equally improved in depressive symptoms from baseline to one-year follow-up (repeated measures ANOVA; F=12.51, p<0.0001, η2=0.07. Urinary 8-oxo-deoxyguanosine (u-8-oxodG decreased (F=10.66, p<0.0001, η2=0.06, as did sialic acid and leukocytes (F=84.57, η2=0.32 and F=12.61, η2=0.07, resp.; p<0.0001, while uric acid increased (F=12.53, p<0.0001, η2=0.07 in all subjects during one year. Improvement of depressive symptoms at 6 months significantly predicted one-year reduction in u-8-oxodG (β=0.15, p=0.044. Conclusion. Simple behavioral interventions are capable not only of alleviating depressive symptoms, but also of reducing the intensity of damaging oxidative/inflammatory processes in type 2 diabetic patients with subsyndromal depression. This trial is registered with ISRCTN05673017.

  6. The HDAC inhibitor SAHA improves depressive-like behavior of CRTC1-deficient mice: possible relevance for treatment-resistant depression

    KAUST Repository

    Meylan, Elsa M.

    2016-03-09

    Major depression is a highly complex disabling psychiatric disorder affecting millions of people worldwide. Despite the availability of several classes of antidepressants, a substantial percentage of patients are unresponsive to these medications. A better understanding of the neurobiology of depression and the mechanisms underlying antidepressant response is thus critically needed. We previously reported that mice lacking CREB-regulated transcription coactivator 1 (CRTC1) exhibit a depressive-like phenotype and a blunted antidepressant response to the selective serotonin reuptake inhibitor fluoxetine. In this study, we similarly show that Crtc1‒/‒ mice are resistant to the antidepressant effect of chronic desipramine in a behavioral despair paradigm. Supporting the blunted response to this tricyclic antidepressant, we found that desipramine does not significantly increase the expression of Bdnf and Nr4a1-3 in the hippocampus and prefrontal cortex of Crtc1‒/‒ mice. Epigenetic regulation of neuroplasticity gene expression has been associated with depression and antidepressant response, and histone deacetylase (HDAC) inhibitors have been shown to have antidepressant-like properties. Here, we show that unlike conventional antidepressants, chronic systemic administration of the HDAC inhibitor SAHA partially rescues the depressive-like behavior of Crtc1‒/‒ mice. This behavioral effect is accompanied by an increased expression of Bdnf, but not Nr4a1-3, in the prefrontal cortex of these mice, suggesting that this epigenetic intervention restores the expression of a subset of genes by acting downstream of CRTC1. These findings suggest that CRTC1 alterations may be associated with treatment-resistant depression, and support the interesting possibility that targeting HDACs may be a useful therapeutic strategy in antidepressant development.

  7. The HDAC inhibitor SAHA improves depressive-like behavior of CRTC1-deficient mice: Possible relevance for treatment-resistant depression.

    Science.gov (United States)

    Meylan, Elsa M; Halfon, Olivier; Magistretti, Pierre J; Cardinaux, Jean-René

    2016-08-01

    Major depression is a highly complex disabling psychiatric disorder affecting millions of people worldwide. Despite the availability of several classes of antidepressants, a substantial percentage of patients are unresponsive to these medications. A better understanding of the neurobiology of depression and the mechanisms underlying antidepressant response is thus critically needed. We previously reported that mice lacking CREB-regulated transcription coactivator 1 (CRTC1) exhibit a depressive-like phenotype and a blunted antidepressant response to the selective serotonin reuptake inhibitor fluoxetine. In this study, we similarly show that Crtc1(-/-) mice are resistant to the antidepressant effect of chronic desipramine in a behavioral despair paradigm. Supporting the blunted response to this tricyclic antidepressant, we found that desipramine does not significantly increase the expression of Bdnf and Nr4a1-3 in the hippocampus and prefrontal cortex of Crtc1(-/-) mice. Epigenetic regulation of neuroplasticity gene expression has been associated with depression and antidepressant response, and histone deacetylase (HDAC) inhibitors have been shown to have antidepressant-like properties. Here, we show that unlike conventional antidepressants, chronic systemic administration of the HDAC inhibitor SAHA partially rescues the depressive-like behavior of Crtc1(-/-) mice. This behavioral effect is accompanied by an increased expression of Bdnf, but not Nr4a1-3, in the prefrontal cortex of these mice, suggesting that this epigenetic intervention restores the expression of a subset of genes by acting downstream of CRTC1. These findings suggest that CRTC1 alterations may be associated with treatment-resistant depression, and support the interesting possibility that targeting HDACs may be a useful therapeutic strategy in antidepressant development. PMID:26970016

  8. Heart disease and depression

    Science.gov (United States)

    Heart disease and depression often go hand-in-hand. You are are more likely to feel sad or depressed after a heart attack ... heart disease. The good news is that treating depression may help improve both your mental and physical ...

  9. E fficacy of Aripiprazole and Risperidone on Memory Function in Patients with Schizophrenia%阿立哌唑和利培酮对首发精神分裂症患者记忆功能的影响

    Institute of Scientific and Technical Information of China (English)

    胡茂荣; 姜淑珍; 占海燕; 胡斌; 鲍成; 余斌; 周朝雄; 吴慧玲

    2013-01-01

    Objective To explore the efficacy of aripiprazole and risperidone on memory function in patients with schizophrenia. Methods 112 first-episode patients with schizophrenia were random-ized to aripiprazole group(n=56) and risperidone group(n=56). All subjects were assessed with the Wechsler Memory Scale-ⅢSpatial Span Task(WMS-Ⅲ SST), the Hopkins Verbal Learning Test-Re-vised (HVLT-R) and The Brief Visuospatial Memory Test-Revised (BVMT-R).Results Both groups showed no statistical significance in WMS-Ⅲ SST, HVLT-R and BVMT-R scores in the baseline (P>0.05).The performances after 12 weeks of treatment in the both groups was higher than those in the baseline in all tests(P0.05).Aripiprazole group was increased significantly compared with before treatment after treatment WMS-Ⅲ SST score (P<0.05), and after treatment there was a statistical significance between the two groups (P<0.05).Conclusion Memory impairments in the patients with first-episode schizophrenia was im-proved by aripiprazole and risperidone, and effect of aripiprazole on certain memory functions was better than those of risperidone.%目的:探讨阿立哌唑和利培酮对首发精神分裂症患者记忆功能的影响。方法112例首发精神分裂症患者随机分成阿立哌唑组和利培酮组,每组56例。在治疗前和治疗12周末采用韦氏记忆量表-第三版的空间广度测验(WMS-Ⅲ SST)、霍普金斯词汇学习测验-修订版(HVLT-R)、简单视觉空间记忆测验-修订版(BVMT-R)分别对工作记忆、言语记忆和视觉记忆领域进行评定。结果在治疗前,两组的WMS-Ⅲ SST HVLT-R 和BVMT-R得分比较均无统计学意义(P>0.05)。在治疗12周后,两组的HVLT-R 和BVMT-R得分较治疗前比较均有统计学意义(P<0.05)而治疗后两组间比较无统计学意义(P>0.05);阿立哌唑组在治疗后的WMS-Ⅲ SST得分较治疗前显著增加(P<0.05),且治疗后两组间比较有统计学意义(P<0.05

  10. Aripiprazole Increases the PKA Signalling and Expression of the GABAA Receptor and CREB1 in the Nucleus Accumbens of Rats.

    Science.gov (United States)

    Pan, Bo; Lian, Jiamei; Huang, Xu-Feng; Deng, Chao

    2016-05-01

    The GABAA receptor is implicated in the pathophysiology of schizophrenia and regulated by PKA signalling. Current antipsychotics bind with D2-like receptors, but not the GABAA receptor. The cAMP-responsive element-binding protein 1 (CREB1) is also associated with PKA signalling and may be related to the positive symptoms of schizophrenia. This study investigated the effects of antipsychotics in modulating D2-mediated PKA signalling and its downstream GABAA receptors and CREB1. Rats were treated orally with aripiprazole (0.75 mg/kg, ter in die (t.i.d.)), bifeprunox (0.8 mg/kg, t.i.d.), haloperidol (0.1 mg/kg, t.i.d.) or vehicle for 1 week. The levels of PKA-Cα and p-PKA in the prefrontal cortex (PFC), nucleus accumbens (NAc) and caudate putamen (CPu) were detected by Western blots. The mRNA levels of Gabrb1, Gabrb2, Gabrb3 and Creb1, and their protein expression were measured by qRT-PCR and Western blots, respectively. Aripiprazole elevated the levels of p-PKA and the ratio of p-PKA/PKA in the NAc, but not the PFC and CPu. Correlated with this elevated PKA signalling, aripiprazole elevated the mRNA and protein expression of the GABAA (β-1) receptor and CREB1 in the NAc. While haloperidol elevated the levels of p-PKA and the ratio of p-PKA/PKA in both NAc and CPu, it only tended to increase the expression of the GABAA (β-1) receptor and CREB1 in the NAc, but not the CPu. Bifeprunox had no effects on PKA signalling in these brain regions. These results suggest that aripiprazole has selective effects on upregulating the GABAA (β-1) receptor and CREB1 in the NAc, probably via activating PKA signalling. PMID:26894264

  11. Enhancement of encapsulation efficiency of nanoemulsion-containing aripiprazole for the treatment of schizophrenia using mixture experimental design

    Directory of Open Access Journals (Sweden)

    Fard Masoumi HR

    2015-10-01

    Full Text Available Hamid Reza Fard Masoumi, Mahiran Basri, Wan Sarah Samiun, Zahra Izadiyan, Chaw Jiang Lim Nanodelivery Group, Department of Chemistry, Faculty of Science, Universiti Putra Malaysia, Serdang, Selangor, Malaysia Abstract: Aripiprazole is considered as a third-generation antipsychotic drug with excellent therapeutic efficacy in controlling schizophrenia symptoms and was the first atypical anti­psychotic agent to be approved by the US Food and Drug Administration. Formulation of nanoemulsion-containing aripiprazole was carried out using high shear and high pressure homo­genizers. Mixture experimental design was selected to optimize the composition of nanoemulsion. A very small droplet size of emulsion can provide an effective encapsulation for delivery system in the body. The effects of palm kernel oil ester (3–6 wt%, lecithin (2–3 wt%, Tween 80 (0.5–1 wt%, glycerol (1.5–3 wt%, and water (87–93 wt% on the droplet size of aripiprazole nanoemulsions were investigated. The mathematical model showed that the optimum formulation for preparation of aripiprazole nanoemulsion having the desirable criteria was 3.00% of palm kernel oil ester, 2.00% of lecithin, 1.00% of Tween 80, 2.25% of glycerol, and 91.75% of water. Under optimum formulation, the corresponding predicted response value for droplet size was 64.24 nm, which showed an excellent agreement with the actual value (62.23 nm with residual standard error <3.2%. Keywords: schizoaffective disorder, antipsychotic drug, bipolar I disorder, D-optimal mixture design, optimization formulation

  12. Aripiprazole Injection

    Science.gov (United States)

    ... pressure, seizures, difficulty swallowing, a high level of fats (cholesterol and triglycerides) in your blood, or a medical condition that may affect you receiving an injection in your arm or buttocks. Tell your doctor ...

  13. Fluvoxamine for aripiprazole-associated akathisia in patients with schizophrenia: a potential role of sigma-1 receptors

    Directory of Open Access Journals (Sweden)

    Hashimoto Kenji

    2010-03-01

    Full Text Available Abstract Background Second-generation antipsychotic drugs have been reported to cause fewer incidences of extrapyramidal side effects (EPSs than typical antipsychotic drugs, but adverse events such as akathisia have been observed even with atypical antipsychotic drugs. Although understanding of the pathophysiology of akathisia remains limited, it seems that a complex interplay of several neurotransmitter systems might play a role in its pathophysiology. The endoplasmic reticulum protein sigma-1 receptors are shown to regulate a number of neurotransmitter systems in the brain. Methods We report on two cases in which monotherapy of the selective serotonin reuptake inhibitor and sigma-1 receptor agonist fluvoxamine was effective in ameliorating the akathisia of patients with schizophrenia treated with the antipsychotic drug aripiprazole. Results The global score on the Barnes Akathisia Scale in the two patients with schizophrenia treated with aripiprazole decreased after fluvoxamine monotherapy. Conclusion Doctors may wish to consider fluvoxamine as an alternative approach in treating akathisia associated with antipsychotic drugs such as aripiprazole.

  14. Comparison of the Efficacy of Cognitive Behavior Therapy and Mindfulness-based Therapy in Improving Cognitive Emotion Regulation in Major Depressive Disorder

    Directory of Open Access Journals (Sweden)

    H Bagherinia

    2015-06-01

    Conclusion: The cognitive behavioral and based on mindfulness treatment were effective in cognitive emotional regulation improvement, since treatment of based on mindfulness puts emphasis on current feelings and avoidance of self-judgment, and can also be more effective than cognitive behavioral method in using adaptive strategies of cognitive emotional regulation by patients with major depression

  15. Sleep Management, Breastfeeding & Postpartum Depression

    OpenAIRE

    Katherine Stone

    2013-01-01

    There are research that indicates that mothers with PPD who do not get enough sleep are at greater risk for more severe depression. The authors conclude that clinicians must address measures to improve sleep quality in depressed mothers in order to decrease the severity of depressive symptoms. Furthermore, researchers must develop interventions which facilitate better sleep quality in women with postpartum depression.

  16. Improving Self-Help E-Therapy for Depression and Anxiety Among Sexual Minorities: An Analysis of Focus Groups With Lesbians and Gay Men

    OpenAIRE

    Rozbroj, Tomas; Lyons, Anthony; Pitts, Marian; Mitchell, Anne; Christensen, Helen

    2015-01-01

    Background E-therapies for depression and anxiety rarely account for lesbian and gay users. This is despite lesbians and gay men being at heightened risk of mood disorders and likely to benefit from having access to tailored self-help resources. Objective We sought to determine how e-therapies for depression and anxiety could be improved to address the therapeutic needs of lesbians and gay men. Methods We conducted eight focus groups with lesbians and gay men aged 18 years and older. Focus gr...

  17. Improvement in quality of life in depressed patients following verum acupuncture or electroacupuncture plus paroxetine A randomized controlled study of 157 cases

    Institute of Scientific and Technical Information of China (English)

    Shenghui Ma; Zhangjin Zhang; Shanshan Qu; Yong Huang; Junqi Chen; Renyong Lin; Chongqi Wang; Ganlong Li; Canghuan Zhao; Shenchang Guo

    2012-01-01

    Depressed patients with scores of 17 or more on the 17 items of the Hamilton Depression Rating Scale were treated with the antidepressant drug paroxetine. They also underwent verum acupuncture or electroacupuncture at Baihui (GV20) and Yintang (GV29). The World Health Organization Quality of Life Scale Brief Version showed a significant increase in the total scores of patients who underwent verum acupuncture and electroacupuncture for 6 weeks compared with those who were given paroxetine only; significantly increased physical domain and social relationship scores in verum acupuncture patients compared with paroxetine only; and significantly elevated psychological domain scores with electroacupuncture compared with paroxetine only. These results indicate that both verum acupuncture and electroacupuncture can improve quality of life in depressed patients undergoing paroxetine treatment.

  18. The Role of Religious Psychotherapy with Independent Ruqyah in Reducing Depression and Improved Spiritual Quality of Life of Cancer Patients at Hospital of Hasanuddin University Makassar 2016

    Directory of Open Access Journals (Sweden)

    M. Fais Satrianegara

    2016-05-01

    Full Text Available This study aims to reveal the spiritual quality of life in cancer patients who receive spiritual support to the intervention of religious psychotherapy approaches as well as the efforts made to achieve a better life quality. The research method using pre-experimental one group pre and post test design with 10 respondent who were taken by purposive sampling technique. This study measured which measure depression score by using the instrument of BDI (Beck Depression Inventory and FACIT Sp.12 (The Functional Assessment of Chronic Illness Therapy Spiritual before and after the independent ruqyah and implement devotions sunnah in cancer patient who undergoing radiotherapy treatment in Hospital of Hasanuddin University, Makassar. Analysis of the data was analyzed using t-test. The results showed that there is a significant difference between levels of depression before and after the intervention (P <0.005. Cancer patients undergoing radiotherapy treatment and apply a independently ruqyah therapy consistently for 30 days can reduce levels of depression and improve the spiritual quality of life is better than before. The use of independent ruqyah can be considered as a palliative nursing interventions in the hospital for depression and in the framework of efforts in achieving the life quality of cancer patients.

  19. Identification and quantification of the antipsychotics risperidone, aripiprazole, pipamperone and their major metabolites in plasma using ultra-high performance liquid chromatography-mass spectrometry.

    Science.gov (United States)

    Wijma, Rixt A; van der Nagel, Bart C H; Dierckx, Bram; Dieleman, Gwen C; Touw, Daan J; van Gelder, Teun; Koch, Birgit C P

    2016-06-01

    The antipsychotics risperidone, aripiprazole and pipamperone are frequently prescribed for the treatment in children with autism. The aim of this study was to validate an ultra-high performance liquid chromatography-mass spectrometry method for the quantification of these antipsychotics in plasma. An ultra-high performance liquid chromatography-mass spectrometry assay was developed for the determination of the drugs and metabolites. Gradient elution was performed on a reversed-phase column with a mobile phase consisting of ammonium acetate, formic acid in methanol or in Milli-Q ultrapure water at a flow rate of 0.5 mL/min. The method was validated according to the US Food and Drug Administration guidelines. The analytes were found to be stable enough after reconstitution and injection of only 5 μL improved the accuracy and precision in combination with the internal standard. Calibration curves of all five analytes were linear. All analytes were stable for at least 72 h in the autosampler and the high quality control of 9-OH-risperidone was stable for 48 h. The method allows quantification of all analytes. The advantage of this method is the combination of a minimal injection volume, a short run-time, an easy sample preparation method and the ability to quantify all analytes in one run. Copyright © 2015 John Wiley & Sons, Ltd. PMID:26447610

  20. Community-oriented family-based intervention superior to standard treatment in improving depression, hopelessness and functioning among adolescents with any psychosis-risk symptoms.

    Science.gov (United States)

    Granö, Niklas; Karjalainen, Marjaana; Ranta, Klaus; Lindgren, Maija; Roine, Mikko; Therman, Sebastian

    2016-03-30

    The aim of the present study was to compare change in functioning, affective symptoms and level of psychosis-risk symptoms in symptomatic adolescents who were treated either in an early intervention programme based on a need-adapted Family- and Community-orientated integrative Treatment Model (FCTM) or in standard adolescent psychiatric treatment (Treatment As Usual, TAU). 28 pairs were matched by length of follow-up, gender, age, and baseline functioning. At one year after the start of treatment, the matched groups were compared on change in functioning (GAF-M), five psychosis-risk dimensions of the Structured Interview for Psychosis-Risk Syndromes (SIPS), and self-reported anxiety, depression, and hopelessness symptoms (BAI, BDI-II, BHS). FCTM was more effective in improving functioning (20% vs. 6% improvement on GAF-M), as well as self-reported depression (53% vs. 14% improvement on BDI-II) and hopelessness (41% vs. 3% improvement on BHS). However, for psychosis-risk symptoms and anxiety symptoms, effectiveness differences between treatment models did not reach statistical significance. To conclude, in the present study, we found greater improvement in functioning and self-reported depression and hopelessness among adolescents who received a need-adapted Family- and Community-orientated integrative Treatment than among those who were treated in standard adolescent psychiatry. PMID:26921045

  1. Qigong Exercise Alleviates Fatigue, Anxiety, and Depressive Symptoms, Improves Sleep Quality, and Shortens Sleep Latency in Persons with Chronic Fatigue Syndrome-Like Illness

    Directory of Open Access Journals (Sweden)

    Jessie S. M. Chan

    2014-01-01

    Full Text Available Objectives. To evaluate the effectiveness of Baduanjin Qigong exercise on sleep, fatigue, anxiety, and depressive symptoms in chronic fatigue syndrome- (CFS- like illness and to determine the dose-response relationship. Methods. One hundred fifty participants with CFS-like illness (mean age = 39.0, SD = 7.9 were randomly assigned to Qigong and waitlist. Sixteen 1.5-hour Qigong lessons were arranged over 9 consecutive weeks. Pittsburgh Sleep Quality Index (PSQI, Chalder Fatigue Scale (ChFS, and Hospital Anxiety and Depression Scale (HADS were assessed at baseline, immediate posttreatment, and 3-month posttreatment. The amount of Qigong self-practice was assessed by self-report. Results. Repeated measures analyses of covariance showed a marginally nonsignificant (P= 0.064 group by time interaction in the PSQI total score, but it was significant for the “subjective sleep quality” and “sleep latency” items, favoring Qigong exercise. Improvement in “subjective sleep quality” was maintained at 3-month posttreatment. Significant group by time interaction was also detected for the ChFS and HADS anxiety and depression scores. The number of Qigong lessons attended and the amount of Qigong self-practice were significantly associated with sleep, fatigue, anxiety, and depressive symptom improvement. Conclusion. Baduanjin Qigong was an efficacious and acceptable treatment for sleep disturbance in CFS-like illness. This trial is registered with Hong Kong Clinical Trial Register: HKCTR-1380.

  2. Qigong exercise alleviates fatigue, anxiety, and depressive symptoms, improves sleep quality, and shortens sleep latency in persons with chronic fatigue syndrome-like illness.

    Science.gov (United States)

    Chan, Jessie S M; Ho, Rainbow T H; Chung, Ka-Fai; Wang, Chong-Wen; Yao, Tzy-Jyun; Ng, Siu-Man; Chan, Cecilia L W

    2014-01-01

    Objectives. To evaluate the effectiveness of Baduanjin Qigong exercise on sleep, fatigue, anxiety, and depressive symptoms in chronic fatigue syndrome- (CFS-) like illness and to determine the dose-response relationship. Methods. One hundred fifty participants with CFS-like illness (mean age = 39.0, SD = 7.9) were randomly assigned to Qigong and waitlist. Sixteen 1.5-hour Qigong lessons were arranged over 9 consecutive weeks. Pittsburgh Sleep Quality Index (PSQI), Chalder Fatigue Scale (ChFS), and Hospital Anxiety and Depression Scale (HADS) were assessed at baseline, immediate posttreatment, and 3-month posttreatment. The amount of Qigong self-practice was assessed by self-report. Results. Repeated measures analyses of covariance showed a marginally nonsignificant (P = 0.064) group by time interaction in the PSQI total score, but it was significant for the "subjective sleep quality" and "sleep latency" items, favoring Qigong exercise. Improvement in "subjective sleep quality" was maintained at 3-month posttreatment. Significant group by time interaction was also detected for the ChFS and HADS anxiety and depression scores. The number of Qigong lessons attended and the amount of Qigong self-practice were significantly associated with sleep, fatigue, anxiety, and depressive symptom improvement. Conclusion. Baduanjin Qigong was an efficacious and acceptable treatment for sleep disturbance in CFS-like illness. This trial is registered with Hong Kong Clinical Trial Register: HKCTR-1380. PMID:25610473

  3. Effectiveness of a Combined Dance and Relaxation Intervention on Reducing Anxiety and Depression and Improving Quality of Life among the Cognitively Impaired Elderly

    Directory of Open Access Journals (Sweden)

    Dina Adam

    2016-02-01

    Full Text Available Objectives: Cognitive impairment is a common problem among the elderly and is believed to be a precursor to dementia. This study aimed to explore the effectiveness of a combined dance and relaxation intervention as compared to relaxation alone in reducing anxiety and depression levels and improving quality of life (QOL and cognitive function among the cognitively impaired elderly. Methods: This quasi-experimental study was conducted between May and December 2013 in Peninsular Malaysia. Subjects from four government residential homes for older adults aged ≥60 years with mild to moderate cognitive function as assessed by the Mini-Mental State Examination were included in the study. Subjects were divided into an intervention group and a control group; the former participated in a combined poco-poco dance and relaxation intervention whilst the latter participated in relaxation exercises only. Both groups participated in two sessions per week for six weeks. Anxiety and depression were self-assessed using the Hospital Anxiety and Depression Scale and QOL was self-assessed using the Quality of Life in Alzheimer’s Disease questionnaire. Results: A total of 84 elderly subjects were included in the study; 44 were in the intervention group and 40 were in the control group. When compared to control subjects, those in the intervention group showed significantly decreased anxiety (P <0.001 and depression (P <0.001 levels as well as improved QOL (P <0.001 and cognitive impairment (P <0.001. Conclusion: Dance as a form of participationbased physical exercise was found to reduce anxiety and depression levels and improve QOL and cognitive function among the studied sample of cognitively impaired elderly subjects in Malaysia.

  4. Aripiprazole loaded poly(caprolactone) nanoparticles: Optimization and in vivo pharmacokinetics.

    Science.gov (United States)

    Sawant, Krutika; Pandey, Abhijeet; Patel, Sneha

    2016-09-01

    In the present investigation, a Quality by Design strategy was applied for formulation and optimization of aripiprazole (APZ) loaded PCL nanoparticles (APNPs) using nanoprecipitation method keeping entrapment efficiency (%EE) and particle size (PS) as critical quality attributes. Establishment of design space was done followed by analysis of its robustness and sensitivity. Characterization of optimized APNPs was done using DSC, FT-IR, PXRD and TEM studies and was evaluated for drug release, hemocompatibility and nasal toxicity. PS, zeta potential and %EE of optimized APNPs were found to be 199.2±5.65nm, -21.4±4.6mV and 69.2±2.34% respectively. In vitro release study showed 90±2.69% drug release after 8h. Nasal toxicity study indicated safety of developed formulation for intranasal administration. APNPs administered via intranasal route facilitated the brain distribution of APZ incorporated with the AUC0→8 in rat brain approximately 2 times higher than that of APNPs administered via intravenous route. Increase in Cmax was observed which might help in dose reduction along with reduction in dose related side effects. The results of the study indicate that intranasally administered APZ loaded PCL NPs can potentially transport APZ via nose to brain and can serve as a non-invasive alternative for the delivery of APZ to brain. PMID:27207059

  5. Improving Adherence and Clinical Outcomes in Self-Guided Internet Treatment for Anxiety and Depression: Randomised Controlled Trial

    OpenAIRE

    Titov, Nickolai; Dear, Blake F.; Johnston, Luke; Lorian, Carolyn; Zou, Judy; Wootton, Bethany; Spence, Jay; McEvoy, Peter M.; Rapee, Ronald M

    2013-01-01

    Background Depression and anxiety are common, disabling and chronic. Self-guided internet-delivered treatments are popular, but few people complete them. New strategies are required to realise their potential. Aims To evaluate the effect of automated emails on the effectiveness, safety, and acceptability of a new automated transdiagnostic self-guided internet-delivered treatment, the Wellbeing Course, for people with depression and anxiety. Method A randomised controlled trial was conducted t...

  6. Establishing key components of yoga interventions for reducing depression and anxiety, and improving well-being: a Delphi method study

    OpenAIRE

    de Manincor, Michael; Bensoussan, Alan; Smith, Caroline; Fahey, Paul; Bourchier, Suzanne

    2015-01-01

    Background Previous research suggests benefits of yoga in reducing depression and anxiety. However, common concerns in reviews of the research include lack of detail, rationale and consistency of approach of interventions used. Issues related to heterogeneity include amount, types and delivery of yoga interventions. This study aims to document consensus-based recommendations for consistency of yoga interventions for reducing depression and anxiety. Methods The Delphi method was used to establ...

  7. Innovation in health economic modelling of service improvements for longer-term depression: demonstration in a local health community

    OpenAIRE

    Tosh, J.; Kearns, B; Brennan, A.(School of Physics, University of Melbourne, Victoria, Australia); Parry, G; Ricketts, T.; Saxon, D; Kilgarriff-Foster, A.; Thake, A; Chambers, E.; Hutten, R.

    2013-01-01

    Background The purpose of the analysis was to develop a health economic model to estimate the costs and health benefits of alternative National Health Service (NHS) service configurations for people with longer-term depression. Method Modelling methods were used to develop a conceptual and health economic model of the current configuration of services in Sheffield, England for people with longer-term depression. Data and assumptions were synthesised to estimate cost per Quality Ad...

  8. Improving responses to depression and related disorders: evaluation of a innovative, general, mental health care workers training program

    Directory of Open Access Journals (Sweden)

    Graham Annette L

    2010-09-01

    Full Text Available Abstract Background Australian General Practitioners have been beneficiaries of extensive training in mental health care delivery over the last few years but less so other workers who support those with mental illness. Training is needed as it is widely recognised that the most effective interventions to prevent and treat mental disorders are often not readily available. The Mental Health Aptitudes into Practice (MAP training package is a broad, innovative, interdisciplinary, general mental health training aimed at improving responses to individuals with depression and related disorders. The modular structure of this training program meant that such training could be targeted at those with varied backgrounds. Two hundred and seventy one days of free MAP training was delivered across Victoria in 2004/2005. The evaluation reported here assessed whether changes occurred in the trainees' confidence, mental health literacy, attitudes towards effective treatments, mental health knowledge and skills and community mental health ideology following training. Methods These elements were assessed using pen and paper tests prior, immediately following, 6 months after and then 12 months after the training. Trainees' confidence, mental health literacy and social distance were measured using scales that have been used in evaluations of Mental Health First Aid Training. Community mental health ideology was measured using a sub-scale of the Community Attitudes to the Mentally Ill (CAMI scale. The trainees' knowledge and skills were accessed using instrumentation specifically designed for this evaluation. Results Following training, participants had more confidence in their ability to work with those who have mental health issues and less desire for social distance from them. Participants' knowledge and skills in relation to the treatment of mental disorders increased. These changes were observed immediately after training. The limited existing evidence suggests

  9. Computer-delivered and web-based interventions to improve depression, anxiety, and psychological well-being of university students: a systematic review and meta-analysis

    OpenAIRE

    Davies, E. Bethan; Morriss, Richard K; Glazebrook, Cris

    2015-01-01

    Background: Depression and anxiety are common mental health difficulties experienced by university students and can impair academic and social functioning. Students are limited in seeking help from professionals. As university students are highly connected to digital technologies, Web-based and computer-delivered interventions could be used to improve students’ mental health. The effectiveness of these intervention types requires investigation to identify whether these are viable prevention s...

  10. Computer-Delivered and Web-Based Interventions to Improve Depression, Anxiety, and Psychological Well-Being of University Students: A Systematic Review and Meta-Analysis

    OpenAIRE

    Davies, E. Bethan; Morriss, Richard; Glazebrook, Cris

    2014-01-01

    Background Depression and anxiety are common mental health difficulties experienced by university students and can impair academic and social functioning. Students are limited in seeking help from professionals. As university students are highly connected to digital technologies, Web-based and computer-delivered interventions could be used to improve students’ mental health. The effectiveness of these intervention types requires investigation to identify whether these are viable prevention st...

  11. A collaborative approach to identifying effective incentives for mental health clinicians to improve depression care in a large managed behavioral healthcare organization

    OpenAIRE

    Meredith, Lisa S; Branstrom, Robert B.; Fikes, Ruth; Azocar, Francisca; Ettner, Susan L.

    2011-01-01

    This descriptive study used stakeholder input to prioritize evidence-based strategies for improving depression care and to select incentives for mental health clinicians to adopt those strategies, and to conduct a feasibility test of an incentive-based program in a managed behavioral healthcare organization (MBHO). In two rounds of interviews and a stakeholder meeting, MBHO administrators and clinicians selected increasing combination treatment (antidepressant plus psychotherapy) rates as the...

  12. 5-(4-hydroxy-3-dimethoxybenzylidene)-rhodanine (RD-1)-improved mitochondrial function prevents anxiety- and depressive-like states induced by chronic corticosterone injections in mice.

    Science.gov (United States)

    Yang, Nan; Ren, Zhili; Zheng, Ji; Feng, Lu; Li, Dongmei; Gao, Kai; Zhang, Lianfeng; Liu, Yanyong; Zuo, Pingping

    2016-06-01

    Most current pharmacologic antidepressant treatments target monoaminergic systems confronts some problems such as low rate of remission and high risk for relapse indicating new therapeutic strategy is urgently need. Evidences showed that impairments in mitochondrial function were associated with the pathogenesis of mood disorders and improvement in its function may be a novel therapeutic choice. In the present study, effects of 5-(4-hydroxy-3-dimethoxybenzylidene)-2-thioxo-4-thiazolidinone (RD-1) were investigated in mice model of depression/anxiety induced by corticosterone (20 mg/kg) subcutaneously repeated injections in 5-week male BALB/c mice. Our results showed that five weeks of corticosterone administration induced anxiety/depressive-like behavioral changes, including decreased central activities in open field test, increased the immobility time in forced swimming test and the latency in the novelty-suppressed feeding test, as well as reduced bodyweight. Results showed that oral administration with RD-1 at the doses of 25, 50, and 100 mg/kg for five weeks significantly improved the anxiety/depressive-like behavioral changes induced by corticosterone. In glucose metabolism analysis by photon emission computed tomography/-computed tomography (PET/CT) imaging, corticosterone significantly deactivated the prefrontal cortex (PFC), temporal lobe and hippocampus. RD-1 treatment obviously improved the energy metabolism in the involved brain regions. In primary cultured hippocampal neuron, corticosterone reduced speed of anterograde transport, yet speed of retrograde transport was increased. Furthermore, RD-1 enhanced the mitochondrial anterograde transport to supply energy for the neurotransmitter release. In conclusion, RD-1 prevents anxiety/depressive-like behavior of mice induced by corticosterone repeated injections with novel mechanism of improvement in the mitochondrial function. PMID:26926430

  13. Depression, diet and exercise.

    Science.gov (United States)

    Jacka, Felice N; Berk, Michael

    2013-09-16

    Unhealthy lifestyle behaviour is driving an increase in the burden of chronic non-communicable diseases worldwide. Recent evidence suggests that poor diet and a lack of exercise contribute to the genesis and course of depression. While studies examining dietary improvement as a treatment strategy in depression are lacking, epidemiological evidence clearly points to diet quality being of importance to the risk of depression. Exercise has been shown to be an effective treatment strategy for depression, but this is not reflected in treatment guidelines, and increased physical activity is not routinely encouraged when managing depression in clinical practice. Recommendations regarding dietary improvement, increases in physical activity and smoking cessation should be routinely given to patients with depression. Specialised and detailed advice may not be necessary. Recommendations should focus on following national guidelines for healthy eating and physical activity. PMID:25370279

  14. Salivary and serum biomarkers for the study of side effects of aripiprazole coprescribed with mirtazapine in rats

    OpenAIRE

    Bogdan, Maria; SILOSI, Isabela; SURLIN, PETRA; Tica, Andrei Adrian; Tica, Oana Sorina; Balseanu, Tudor-Adrian; Rauten, Anne-Marie; Camen, Adrian

    2015-01-01

    The aim of this study was to investigate whether the co-administration of aripiprazole and mirtazapine could determine weight gain and lipid metabolism disorders in Wistar rats, compared to the same side effects produced by mirtazapine alone, and the risk of hepatotoxicity due to the combination of the two substances. Tumor necrosis factor alpha (TNF-α), liver fatty acid binding protein (L-FABP/FABP1) and repulsive guidance molecule C/hemojuvelin (RGM-C/HJV) levels were determined in serum an...

  15. Efficacy of levomilnacipran extended-release in improving functional impairment associated with major depressive disorder: pooled analyses of five double-blind, placebo-controlled trials.

    Science.gov (United States)

    Sambunaris, Angelo; Gommoll, Carl; Chen, Changzheng; Greenberg, William M

    2014-07-01

    Major depressive disorder (MDD) is characterized by increased rates of impaired function and disability. During antidepressant treatment, functional improvement often lags behind symptomatic resolution, and residual impairment is associated with an increased risk for relapse. When evaluating MDD treatments, it is important to assess not only depressive symptoms but also functional outcomes. In this post-hoc analysis, data from five studies were pooled to examine the effect of levomilnacipran extended-release (ER) versus placebo on functional impairment as measured using the Sheehan Disability Scale. The mean change in the Sheehan Disability Scale total score was significantly greater for levomilnacipran ER versus placebo in the overall pooled population, for both sexes, and across all ages. Statistically significantly higher rates of functional response, functional remission, combined (functional and symptomatic) response, and combined remission were achieved with levomilnacipran ER compared with placebo in the pooled population, as well as in the male, female, younger, and middle-aged population subgroups. The levomilnacipran ER group also showed significantly improved functional outcomes versus placebo regardless of baseline depression severity. Similarly, functional impairment was significantly improved and higher functional and combined response and remission rates were achieved with levomilnacipran ER compared with placebo regardless of the baseline level of functional impairment. PMID:24667487

  16. A cluster randomized trial of standard quality improvement versus patient-centered interventions to enhance depression care for African Americans in the primary care setting: study protocol NCT00243425

    Directory of Open Access Journals (Sweden)

    Ghods Bri K

    2010-02-01

    Full Text Available Abstract Background Several studies document disparities in access to care and quality of care for depression for African Americans. Research suggests that patient attitudes and clinician communication behaviors may contribute to these disparities. Evidence links patient-centered care to improvements in mental health outcomes; therefore, quality improvement interventions that enhance this dimension of care are promising strategies to improve treatment and outcomes of depression among African Americans. This paper describes the design of the BRIDGE (Blacks Receiving Interventions for Depression and Gaining Empowerment Study. The goal of the study is to compare the effectiveness of two interventions for African-American patients with depression--a standard quality improvement program and a patient-centered quality improvement program. The main hypothesis is that patients in the patient-centered group will have a greater reduction in their depression symptoms, higher rates of depression remission, and greater improvements in mental health functioning at six, twelve, and eighteen months than patients in the standard group. The study also examines patient ratings of care and receipt of guideline-concordant treatment for depression. Methods/Design A total of 36 primary care clinicians and 132 of their African-American patients with major depressive disorder were recruited into a cluster randomized trial. The study uses intent-to-treat analyses to compare the effectiveness of standard quality improvement interventions (academic detailing about depression guidelines for clinicians and disease-oriented care management for their patients and patient-centered quality improvement interventions (communication skills training to enhance participatory decision-making for clinicians and care management focused on explanatory models, socio-cultural barriers, and treatment preferences for their patients for improving outcomes over 12 months of follow

  17. Sub-chronic dietary tryptophan depletion--an animal model of depression with improved face and good construct validity.

    Science.gov (United States)

    Franklin, M; Bermudez, I; Murck, H; Singewald, N; Gaburro, S

    2012-02-01

    Sub-chronic tryptophan depletion (SCTD) is proposed as an animal model for depression. Aims were to test the hypothesis and optimise the time of SCTD-induced depression-related behaviour and associated biochemical changes. Sprague Dawley rats were treated with a low tryptophan (TRP) containing diet for 0, 7 or 14 days. Peripheral and central neurochemical markers were measured. SCTD-induced depression-related behaviour was assessed by the forced swim test (FST). Model sensitivity to antidepressants was tested by concomitant treatment with paroxetine. SCTD-induced significant reductions in weight gain and measures of peripheral and central TRP. Corticosterone, aldosterone and kynurenine (K), increased whilst kynurenic acid (KA), an NMDA antagonist decreased. 5-HT(2) receptor binding Bmax was enhanced but was reversed by paroxetine. Corticosterone and aldosterone were significantly negatively-correlated to weight gain. SCTD increased floating time and reduced swimming time in the FST but were reversed by paroxetine. Aldosterone was increased at 7 and 14 days, whereas other changes maximised at 14 days. Aldosterone may be an early marker or causal link for depression development. Increased corticosterone and brain tissue 5-HT-receptor density may be correlates of depressive behaviour. Consequential increases in NMDA signalling through increased K/KA ratios suggest the model may be useful for testing novel antidepressants. PMID:22074993

  18. Depression (PDQ)

    Science.gov (United States)

    ... others. Family members also have a risk of depression. Anxiety and depression are also common in family members ... cancer . A small number of children may have: Depression . Anxiety . Trouble sleeping. Problems getting along with family or ...

  19. Caregiver Depression

    Science.gov (United States)

    ... will not sell or share your name. Caregiver Depression Tweet Bookmark this page | Email | Print Many caregivers ... depression See your doctor Treatment Coping Symptoms of depression Caregiving is hard — and can lead to feelings ...

  20. Efficacy and safety of aripiprazole in treating negative symptoms of schizophrenia%阿立哌唑与利培酮治疗精神分裂症阴性症状的疗效和安全性观察

    Institute of Scientific and Technical Information of China (English)

    贾天成

    2014-01-01

    incidence of adverse effect in experimental group was less than that in the control group(P <0.05).Conclusion Both aripiprazole and risperidone can improve the negative symptoms of schizophrenia with the similar efficacy;however,aripi-prazole is adept in treating the symptoms of affection and cognition,compared with the advantage of risperidone in treating the symptoms of af-fection and behavior.Aripiprazole is generally safer than risperidone.

  1. Effects of an Internet-based cognitive behavioral therapy (iCBT program in Manga format on improving subthreshold depressive symptoms among healthy workers: a randomized controlled trial.

    Directory of Open Access Journals (Sweden)

    Kotaro Imamura

    Full Text Available OBJECTIVE: The purpose of this study was to develop a new Internet-based computerized cognitive behavior therapy (iCBT program in Manga format, the Japanese cartoon, for workers and to examine the effects of the iCBT program on improving subthreshold depression using a randomized controlled trial (RCT design among workers employed in private companies in Japan. METHOD: All workers in a company (n = 290 and all workers in three departments (n = 1,500 at the headquarters of another large company were recruited by an invitation e-mail. Participants who fulfilled the inclusion criteria were randomly allocated to intervention or control groups (N = 381 for each group. A six-week, six-lesson iCBT program using Manga (Japanese comic story was developed. The program included several CBT skills: self-monitoring, cognitive restructuring, assertiveness, problem solving, and relaxation. The intervention group studied the iCBT program at a frequency of one lesson per week. Depression (Beck Depression Inventory II; BDI-II was assessed as a primary outcome at baseline, and three- and six-month follow-ups for both intervention and control groups were performed. RESULTS: The iCBT program showed a significant intervention effect on BDI-II (t = -1.99, p<0.05 with small effect sizes (Cohen's d: -0.16, 95% Confidence Interval: -0.32 to 0.00, at six-month follow-up. CONCLUSIONS: The present study first demonstrated that a computerized cognitive behavior therapy delivered via the Internet was effective in improving depression in the general working population. It seems critical to improve program involvement of participants in order to enhance the effect size of an iCBT program. TRIAL REGISTRATION: UMIN Clinical Trials Registry UMIN000006210.

  2. The effect of resveratrol on pharmacokinetics of aripiprazole in vivo and in vitro.

    Science.gov (United States)

    Zhan, Yun-Yun; Liang, Bing-Qing; Li, Xiang-Yu; Gu, Er-Min; Dai, Da-Peng; Cai, Jian-Ping; Hu, Guo-Xin

    2016-05-01

    1. The objective of this study were to investigate the effect of orally administered resveratrol on the pharmacokinetics of aripiprazole (APZ) in rat, and the inhibitory effects of resveratrol on APZ dehydrogenation activity in liver microsomes and human cytochrome P450 3A4 and 2D6. 2. Twenty-five healthy male Sprague-Dawley rats were randomly divided into five groups: A (control group), B (multiple dose of 200 mg/kg resveratrol), C (multiple dose of 100 mg/kg resveratrol), D (a single dose of 200 mg/kg resveratrol) and E (a single dose of 100 mg/kg resveratrol). A single dose of 3 mg/kg APZ administered orally 30 min after administration of resveratrol. In addition, CYP2D6*1, CYP3A4*1, human and rat liver microsomes were performed to determine the effect of resveratrol on the metabolism of APZ in vitro. 3. The multiple dose of 200 or 100 mg/kg resveratrol significantly increased the AUC and Cmax of APZ. The resveratrol also obviously decreased the CL, but without any significant difference on t1/2 in vivo. On the other hand, resveratrol showed inhibitory effect on CYP3A4*1, CYP2D6*1, human and rat microsomes, the IC50 of resveratrol was 6.771, 87.87, 45.11 and 35.59 μmol l(-1), respectively. 4. Those results indicated more attention should be paid when APZ was administrated combined with resveratrol. PMID:26391142

  3. Effectiveness of preventive family intervention in improving cognitive attributions among children of depressed parents: a randomized study.

    Science.gov (United States)

    Punamäki, Raija-Leena; Paavonen, Juulia; Toikka, Sini; Solantaus, Tytti

    2013-08-01

    Our randomized trial examined the effectiveness of preventive interventions in increasing positive cognitive attributions and reducing negative cognitive attributions in children of depressed parents. In addition, it tested the role of attribution changes in mediating the intervention effects on children's depressive and emotional symptoms. The participants were 109 Finnish families with at least one parent in treatment for affective disorder, for a total of 145 children, 8-16 years of age. Families were randomized into two groups: the "family talk intervention" (FTI, a whole-family approach enhancing communication and child resilience, Beardslee et al., 1997) group, and an active control, the "let's talk about the children" (LTC, a parent-only psycho-educational approach, Solantaus, Paavonen, Toikka, & Punamäki, 2010) group. Children reported their cognitive attributions (CASQ-R, Children's Attributional Style Questionnaire-Revised (Thompson, Kaslow, Weiss, & Nolen-Hoeksema, 1998)), depressive (CDI/BDI, Child Depression Inventory (Kovacs, 1981)/Beck Depression Inventory (Beck, Steer, & Garbin, 1988)) and emotional (SDQ, Strengths and Difficulties Questionnaire (Goodman, 1997)) symptoms, and mothers reported their children's emotional symptoms (SDQ at baseline (T1) and 10-month (T2) and 18-month (T3)) follow-ups. Contrary to our hypothesis, no beneficial attribution changes were found in the FTI group across the follow-ups. Instead, positive cognitive appraisals increased in the LTC group, especially from T2 to T3. The increase of positive attribution further served as a mediator for changes in children's emotional and depressive symptoms. The findings suggest that a short preventive intervention can enhance beneficial cognitive processes in high-risk families in routine adult psychiatric care. PMID:23978323

  4. On 'polypharmacy' and multi-target agents, complementary strategies for improving the treatment of depression: a comparative appraisal.

    Science.gov (United States)

    Millan, Mark J

    2014-07-01

    Major depression is a heterogeneous disorder, both in terms of symptoms, ranging from anhedonia to cognitive impairment, and in terms of pathogenesis, with many interacting genetic, epigenetic, developmental and environmental causes. Accordingly, it seems unlikely that depressive states could be fully controlled by a drug possessing one discrete mechanism of action and, in the wake of disappointing results with several classes of highly selective agent, multi-modal treatment concepts are attracting attention. As concerns pharmacotherapy, there are essentially two core strategies. First, multi-target antidepressants that act via two or more complementary mechanisms and, second, polypharmacy, which refers to co-administration of two distinct drugs, usually in separate pills. Both multi-target agents and polypharmacy ideally couple a therapeutically unexploited action to a clinically established mechanism in order to enhance efficacy, moderate side-effects, accelerate onset of action and treat a broader range of symptoms. The melatonin MT1/MT2 agonist and 5-HT(2C) antagonist, agomelatine, which is effective in the short- and long-term treatment of depression, exemplifies the former approach, while evidence-based polypharmacy is illustrated by the adjunctive use of second-generation antipsychotics with serotonin reuptake inhibitors for treatment of resistant depression. Histone acetylation and methylation, ghrelin signalling, inflammatory modulators, metabotropic glutamate-7 receptors and trace amine-associated-1 receptors comprise attractive substrates for new multi-target and polypharmaceutical strategies. The present article outlines the rationale underpinning multi-modal approaches for treating depression, and critically compares and contrasts the pros and cons of established and potentially novel multi-target vs. polypharmaceutical treatments. On balance, the former appear the most promising for the elaboration, development and clinical implementation of

  5. Managing depression in adults

    OpenAIRE

    Sanati, Abdi; Young, Stephanie

    2009-01-01

    Depression is one of the leading causes of disability worldwide. The majority of patients suffering from depressive disorder are diagnosed and managed in primary care. Optimal management reduces the risk of relapse and improves the quality of life. The main treatment modalities are antidepressants and psychological therapies. Lifestyle changes, exercise and psychoeducation also play an important role in management.

  6. Medication adherence and utilization in patients with schizophrenia or bipolar disorder receiving aripiprazole, quetiapine, or ziprasidone at hospital discharge: A retrospective cohort study

    OpenAIRE

    Berger Ariel; Edelsberg John; Sanders Kafi N; Alvir Jose Ma J; Mychaskiw Marko A; Oster Gerry

    2012-01-01

    Abstract Background Schizophrenia and bipolar disorder are chronic debilitating disorders that are often treated with second-generation antipsychotic agents, such as aripiprazole, quetiapine, and ziprasidone. While patients who are hospitalized for schizophrenia and bipolar disorder often receive these agents at discharge, comparatively little information exists on subsequent patterns of pharmacotherapy. Methods Using a database linking hospital admission records to health insurance claims, w...

  7. Improvement in Personal Meaning Mediates the Effects of a Life Review Intervention on Depressive Symptoms in a Randomized Controlled Trial

    Science.gov (United States)

    Westerhof, Gerben J.; Bohlmeijer, Ernst T.; van Beljouw, Ilse M. J.; Pot, Anne Margriet

    2010-01-01

    Purpose: The purpose of the study was to assess the impact of a life review intervention on personal meaning in life and the mediating effect of personal meaning on depressive symptoms as the primary outcome of this form of indicated prevention. Design and Methods: A multicenter randomized controlled trial was conducted with one group of older…

  8. Aripiprazole for the management of schizophrenia in the Japanese population: a systematic review and meta-analysis of randomized controlled trials

    Directory of Open Access Journals (Sweden)

    Kishi T

    2015-02-01

    Full Text Available Taro Kishi, Yuki Matsuda, Shinji Matsunaga, Nakao Iwata Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Aichi, Japan Background: We conducted a systematic review and meta-analysis of randomized controlled trials comparing aripiprazole with pooled antipsychotics in Japanese patients with schizophrenia. Methods: We performed a literature search of data published in PubMed®, the Cochrane Library database, the Japan Medical Abstracts Society, and PsycINFO® up to January 5, 2014. The odds ratio (OR, number-needed-to-harm (NNH, and standardized mean difference (SMD based on a random effects model were calculated. Results: We identified five relevant studies (seven comparisons, n=684; one comparison each for haloperidol [n=243], mosapramine [n=238], olanzapine [n=39], quetiapine [n=42], perospirone [n=100], and two comparisons for risperidone [n=66]. There were no significant differences in the Positive and Negative Syndrome Scale (PANSS total, negative, and general scores (SMD=0.10, SMD=-0.09, SMD=0.10, respectively; discontinuation rate associated with all causes (OR=1.35; or side effects (OR=1.03 between aripiprazole and the pooled antipsychotics. Aripiprazole was inferior to the pooled antipsychotics in PANSS positive subscale scores (SMD=0.17 and discontinuation because of inefficacy (OR=2.21, NNH=11. However, aripiprazole had fewer side effects compared with the pooled antipsychotics (OR=0.21, NNH=20 for one or more side effects, including fatigue (OR=0.22, NNH=8, hyperprolactinemia (OR=0.00, NNH=1, extrapyramidal symptoms (OR=0.46, NNH=6, and weight gain (OR=0.36, NNH=7. Moreover, aripiprazole was associated with lower total cholesterol (SMD=-0.20 and triglyceride (SMD=-0.17 levels and body weight (SMD=-0.20 compared with the pooled antipsychotics. Conclusion: Although the discontinuation rate associated with inefficacy was higher with aripiprazole than with the pooled antipsychotics, aripiprazole was associated

  9. Understanding Depression

    OpenAIRE

    McNair, F. E.

    1981-01-01

    To understand the effects of depression on a patient's life, the physician must be aware how depression manifests itself. Somatic tension, strategies to relieve discomfort and social withdrawal must be recognized as symptoms of depression. An awareness of life situations which can give rise to these symptoms, as well as the effect of the physician's own reactions to the patient's depression, are helpful.

  10. Pharmacological treatment of depression in women with breast cancer

    DEFF Research Database (Denmark)

    Toftegård Andersen, Lærke; Voigt Hansen, Melissa; Rosenberg, Jacob;

    2013-01-01

    escitalopram and the norepinephrine reuptake inhibitor, reboxetine, significantly improved depression and QOL compared with baseline values. In conclusion, depression is a clinical problem in patients with breast cancer. Pharmacological treatment with antidepressants may improve depression and QOL. However...

  11. Rapid improvement of depressive symptoms in suicide attempters following treatment with milnacipran and tricyclic antidepressants – a case series

    OpenAIRE

    Kirino E; Gitoh M

    2011-01-01

    Eiji Kirino, Masao GitohDepartment of Psychiatry, Juntendo University, School of Medicine, Shizuoka, JapanAbstract: Suicide is a serious social problem in many countries, including Japan. The majority of people who commit suicide suffer from depression. Suicide attempt patients suffering from serious physical injuries are initially treated in hospital emergency departments. The present post hoc analysis examined data from patients admitted to an emergency hospital for treatment of physical in...

  12. Screening for Depression

    Science.gov (United States)

    ... improve the lives of people who have mood disorders. The Power of Peers DBSA envisions wellness for people who live with depression and bipolar disorder. Because DBSA was created for and is led ...

  13. 围产期认知干预在改善产后抑郁中的应用%Application of perinatal cognitive intervention in postpartum depression improvement

    Institute of Scientific and Technical Information of China (English)

    李馨; 谭惠兴; 林小凤; 胡敏

    2016-01-01

    Objective:To discuss on clinical application effects of perinatal cognitive intervention in postpartum depression improvement. Methods:Selected 100 pregnant women who would deliver in our hospital,and randomly divided them into observation group and control group. The control group women re-ceived conventional nursing,while observation group women received perinatal cognitive intervention. Compared postpartum depression conditions between both groups. Results:The occurrence rate of postpartum depression in observation group was lower than that in control group(P ﹤ 0. 05). Conclusion:Peri-natal cognitive intervention for pregnant women can effectively reduce occurrence rate of postpartum depression and plays a positive role in helping lying -in women to recuperate,so it is worth clinical popularization and application.%目的:探讨围产期认知干预在改善产后抑郁中的临床应用效果。方法:选择在我院住院分娩的孕产妇100例,将其随机等分为观察组和对照组,对照组予以常规护理,观察组行围产期认知干预。比较两组产妇产后抑郁发生情况。结果:观察组产妇产后抑郁发生率低于对照组(P ﹤0.05)。结论:针对孕产妇实施围产期认知干预,可以有效降低其产后抑郁发生率,对产妇恢复健康具有积极意义,值得临床推广应用。

  14. Effects of an Internet-Based Cognitive Behavioral Therapy (iCBT) Program in Manga Format on Improving Subthreshold Depressive Symptoms among Healthy Workers: A Randomized Controlled Trial

    OpenAIRE

    Imamura, Kotaro; Kawakami, Norito; Furukawa, Toshi A; Matsuyama, Yutaka; Shimazu, Akihito; Umanodan, Rino; Kawakami, Sonoko; Kasai, Kiyoto

    2014-01-01

    Objective The purpose of this study was to develop a new Internet-based computerized cognitive behavior therapy (iCBT) program in Manga format, the Japanese cartoon, for workers and to examine the effects of the iCBT program on improving subthreshold depression using a randomized controlled trial (RCT) design among workers employed in private companies in Japan. Method All workers in a company (n = 290) and all workers in three departments (n = 1,500) at the headquarters of another large comp...

  15. Atypical Depression

    Directory of Open Access Journals (Sweden)

    Erhan Ertekin

    2013-09-01

    Full Text Available Atypical depression is defined as a specifier of major depressive disorder. Columbia criteria for atypical depression are commonly used to make a diagnosis. Female sex, onset at early age, chronic course, and higher rate of comorbidity (especially anxiety disorder and bipolar disorder is noteworthy in atypical depression. Although, the atypical depression seems to support the familial genetic transition, there is not any specific study supporting these data. In the treatment of atypical depression, monoamine oxidase inhibitors are reported to be more effective than tricyclic antidepressants. In recent studies, selective serotonin reuptake inhibitors have also proven to be efficient.

  16. Hippocampal neurogenesis and dendritic plasticity support running-improved spatial learning and depression-like behaviour in stressed rats.

    Directory of Open Access Journals (Sweden)

    Suk-Yu Yau

    Full Text Available Exercise promotes hippocampal neurogenesis and dendritic plasticity while stress shows the opposite effects, suggesting a possible mechanism for exercise to counteract stress. Changes in hippocampal neurogenesis and dendritic modification occur simultaneously in rats with stress or exercise; however, it is unclear whether neurogenesis or dendritic remodeling has a greater impact on mediating the effect of exercise on stress since they have been separately examined. Here we examined hippocampal cell proliferation in runners treated with different doses (low: 30 mg/kg; moderate: 40 mg/kg; high: 50 mg/kg of corticosterone (CORT for 14 days. Water maze task and forced swim tests were applied to assess hippocampal-dependent learning and depression-like behaviour respectively the day after the treatment. Repeated CORT treatment resulted in a graded increase in depression-like behaviour and impaired spatial learning that is associated with decreased hippocampal cell proliferation and BDNF levels. Running reversed these effects in rats treated with low or moderate, but not high doses of CORT. Using 40 mg/kg CORT-treated rats, we further studied the role of neurogenesis and dendritic remodeling in mediating the effects of exercise on stress. Co-labelling with BrdU (thymidine analog /doublecortin (immature neuronal marker showed that running increased neuronal differentiation in vehicle- and CORT-treated rats. Running also increased dendritic length and spine density in CA3 pyramidal neurons in 40 mg/kg CORT-treated rats. Ablation of neurogenesis with Ara-c infusion diminished the effect of running on restoring spatial learning and decreasing depression-like behaviour in 40 mg/kg CORT-treated animals in spite of dendritic and spine enhancement. but not normal runners with enhanced dendritic length. The results indicate that both restored hippocampal neurogenesis and dendritic remodelling within the hippocampus are essential for running to counteract

  17. Tualang honey improves memory performance and decreases depressive-like behavior in rats exposed to loud noise stress

    Directory of Open Access Journals (Sweden)

    Khairunnuur Fairuz Azman

    2015-01-01

    Full Text Available Recent evidence has exhibited dietary influence on the manifestation of different types of behavior induced by stressor tasks. The present study examined the effects of Tualang honey supplement administered with the goal of preventing or attenuating the occurrence of stress-related behaviors in male rats subjected to noise stress. Forty-eight adult male rats were randomly divided into the following four groups: i nonstressed with vehicle, ii nonstressed with Tualang honey, iii stressed with vehicle, and iv stressed with honey. The supplement was given once daily via oral gavage at 0.2 g/kg body weight. Two types of behavioral tests were performed, namely, the novel object recognition test to evaluate working memory and the forced swimming test to evaluate depressive-like behavior. Data were analyzed by a two-way analysis of variance (ANOVA using IBM SPSS 18.0. It was observed that the rats subjected to noise stress expressed higher levels of depressive-like behavior and lower memory functions compared to the unexposed control rats. In addition, our results indicated that the supplementation regimen successfully counteracted the effects of noise stress. The forced swimming test indicated that climbing and swimming times were significantly increased and immobility times significantly decreased in honey-supplemented rats, thereby demonstrating an antidepressant-like effect. Furthermore, cognitive function was shown to be intensely affected by noise stress, but the effects were counteracted by the honey supplement. These findings suggest that subchronic exposure to noise stress induces depressive-like behavior and reduces cognitive functions, and that these effects can be attenuated by Tualang honey supplementation. This warrants further studies to examine the role of Tulang honey in mediating such effects.

  18. Agmatine, by Improving Neuroplasticity Markers and Inducing Nrf2, Prevents Corticosterone-Induced Depressive-Like Behavior in Mice.

    Science.gov (United States)

    Freitas, Andiara E; Egea, Javier; Buendia, Izaskun; Gómez-Rangel, Vanessa; Parada, Esther; Navarro, Elisa; Casas, Ana Isabel; Wojnicz, Aneta; Ortiz, José Avendaño; Cuadrado, Antonio; Ruiz-Nuño, Ana; Rodrigues, Ana Lúcia S; Lopez, Manuela G

    2016-07-01

    Agmatine, an endogenous neuromodulator, is a potential candidate to constitute an adjuvant/monotherapy for the management of depression. A recent study by our group demonstrated that agmatine induces Nrf2 and protects against corticosterone effects in a hippocampal neuronal cell line. The present study is an extension of this previous study by assessing the antidepressant-like effect of agmatine in an animal model of depression induced by corticosterone in mice. Swiss mice were treated simultaneously with agmatine or imipramine at a dose of 0.1 mg/kg/day (p.o.) and corticosterone for 21 days and the daily administrations of experimental drugs were given immediately prior to corticosterone (20 mg/kg/day, p.o.) administrations. Wild-type C57BL/6 mice (Nrf2 (+/+)) and Nrf2 KO (Nrf2 (-/-)) were treated during 21 days with agmatine (0.1 mg/kg/day, p.o.) or vehicle. Twenty-four hours after the last treatments, the behavioral tests and biochemical assays were performed. Agmatine treatment for 21 days was able to abolish the corticosterone-induced depressive-like behavior and the alterations in the immunocontent of mature BDNF and synaptotagmin I, and in the serotonin and glutamate levels. Agmatine also abolished the corticosterone-induced changes in the morphology of astrocytes and microglia in CA1 region of hippocampus. In addition, agmatine treatment in control mice increased noradrenaline, serotonin, and dopamine levels, CREB phosphorylation, mature BDNF and synaptotagmin I immunocontents, and reduced pro-BDNF immunocontent in the hippocampus. Agmatine's ability to produce an antidepressant-like effect was abolished in Nrf2 (-/-) mice. The present results reinforce the participation of Nrf2 in the antidepressant-like effect produced by agmatine and expand literature data concerning its mechanisms of action. PMID:25966970

  19. Does Interpersonal Psychotherapy improve clinical care for adolescents with depression attending a rural child and adolescent mental health service? Study protocol for a cluster randomised feasibility trial

    Directory of Open Access Journals (Sweden)

    Villanueva Elmer V

    2007-10-01

    Full Text Available Abstract Background Depression amongst adolescents is a costly societal problem. Little research documents the effectiveness of public mental health services in mapping this problem. Further, it is not clear whether usual care in such services can be improved via clinician training in a relevant evidence based intervention. One such intervention, found to be effective and easily learned amongst novice clinicians, is Interpersonal Psychotherapy (IPT. The study described in the current paper has two main objectives. First, it aims to investigate the impact on clinical care of implementing Interpersonal Psychotherapy for Adolescents for the treatment of adolescent depression within a rural mental health service compared with Treatment as Usual (TAU. The second objective is to record the process and challenges (i.e. feasibility, acceptability, sustainability associated with implementing and evaluating an evidence-based intervention within a community service. This paper outlines the study rationale and design for this community based research trial. Methods/design The study involves a cluster randomisation trial to be conducted within a Child and Adolescent Mental Health Service in rural Australia. All clinicians in the service will be invited to participate. Participating clinicians will be randomised via block design at each of four sites to (a training and delivery of IPT, or (b TAU. The primary measure of impact on care will be a clinically significant change in depressive symptomatology, with secondary outcomes involving treatment satisfaction and changes in other symptomatology. Participating adolescents with significant depressive symptomatology, aged 12 to 18 years, will complete assessment measures at Weeks 0, 12 and 24 of treatment. They will also complete a depression inventory once a month during that period. This study aims to recruit 60 adolescent participants and their parent/guardian/s. A power analysis is not indicated as an intra

  20. Depression In Primary Care Part 2: Management

    OpenAIRE

    2007-01-01

    The management of depression in the primary care setting should ideally take a biological, psychological, and sociological approach. Antidepressants are the most commonly used biological agents in the treatment of depression. Psychological therapies and psychosocial interventions improve the outcome of treatment when combined with pharmacotherapy. Clinical depression is treatable and thus efforts should be made to alleviate the suffering of patients with depression.

  1. Depression following myocardial infarction

    DEFF Research Database (Denmark)

    Larsen, Karen Kjær

    2013-01-01

    Myocardial infarction (MI) is a severe life event that is accompanied by an increased risk of depression. Mounting evidence suggests that post-MI depression is associated with adverse outcomes, but the underlying mechanisms of this association remain unclear, and no previous studies have examined...... whether the mental burden of MI is so heavy that it increases the risk of suicide. Although post-MI depression is common and burdensome, the condition remains under-recognised and under-treated. The development of new strategies to improve the quality of care for people with post-MI depression requires...... thorough understanding of the mechanisms that influence the prognosis as well as knowledge of the present care provided. The purpose of this PhD thesis is accordingly subdivided into four specific aims: 1. To estimate the prevalence of depression in people with MI after three months, and to estimate the...

  2. Postpartum Depression

    Science.gov (United States)

    ... and do not need treatment. The symptoms of postpartum depression last longer and are more severe. You may ... get treatment right away, often in the hospital. Postpartum depression can begin anytime within the first year after ...

  3. Depression - overview

    Science.gov (United States)

    Depression may be described as feeling sad, blue, unhappy, miserable, or down in the dumps. Most of ... one time or another for short periods. Clinical depression is a mood disorder in which feelings of ...

  4. Postpartum Depression

    Science.gov (United States)

    ... do not need treatment. The symptoms of postpartum depression last longer and are more severe. You may ... treatment right away, often in the hospital. Postpartum depression can begin anytime within the first year after ...

  5. Nutritional Aspects of Depression

    Directory of Open Access Journals (Sweden)

    Undine E. Lang

    2015-09-01

    Full Text Available Several nutrition, food and dietary compounds have been suggested to be involved in the onset and maintenance of depressive disorders and in the severity of depressive symptoms. Nutritional compounds might modulate depression associated biomarkers and parallel the development of depression, obesity and diabetes. In this context, recent studies revealed new mediators of both energy homeostasis and mood changes (i.e. IGF-1, NPY, BDNF, ghrelin, leptin, CCK, GLP-1, AGE, glucose metabolism and microbiota acting in gut brain circuits. In this context several healthy foods such as olive oil, fish, fruits, vegetables, nuts, legumes, poultry, dairy and unprocessed meat have been inversely associated with depression risk and even have been postulated to improve depressive symptoms. In contrast, unhealthy western dietary patterns including the consumption of sweetened beverage, refined food, fried food, processed meat, refined grain, and high fat diary, biscuits, snacking and pastries have been shown to be associated with an increased risk of depression in longitudinal studies. However, it is always difficult to conclude a real prospective causal relationship from these mostly retrospective studies as depressed individuals might also change their eating habits secondarily to their depression. Additionally specific selected nutritional compounds, e.g. calcium, chromium, folate, PUFAs, vitamin D, B12, zinc, magnesium and D-serine have been postulated to be used as ad-on strategies in antidepressant treatment. In this context, dietary and lifestyle interventions may be a desirable, effective, pragmatical and non-stigmatizing prevention and treatment strategy for depression. At last, several medications (pioglitazone, metformin, exenatide, atorvastatin, gram-negative antibiotics, which have traditionally been used to treat metabolic disorders showed a certain potential to treat depression in first randomized controlled clinical trials.

  6. Chronic exercise improves repeated restraint stress-induced anxiety and depression through 5HT1A receptor and cAMP signaling in hippocampus

    OpenAIRE

    Kim, Mun Hee; Leem, Yea Hyun

    2014-01-01

    [Purpose] Mood disorders such as anxiety and depression are prevalent psychiatric illness, but the role of 5HT1A in the anti-depressive effects of exercise has been rarely known yet. We investigated whether long-term exercise affected a depressive-like behavior and a hippocampal 5HT1A receptor-mediated cAMP/PKA/CREB signaling in depression mice model. [Methods] To induce depressive behaviors, mice were subjected to 14 consecutive days of restraint stress (2 hours/day). Depression-like behavio...

  7. Shifts Toward Morningness During Behavioral Sleep Interventions Are Associated With Improvements in Depression, Positive Affect, and Sleep Quality.

    Science.gov (United States)

    Hasler, Brant P; Buysse, Daniel J; Germain, Anne

    2016-01-01

    Morningness-eveningness (M-E) is typically considered to be a trait-like construct. However, M-E could plausibly shift in concert with changes in circadian or homeostatic processes. We examined M-E changes across three studies employing behavioral or pharmacological sleep treatments. Baseline and posttreatment M-E scores were strongly correlated across all three samples. M-E showed small but systematic changes toward morningness in sleep-disturbed military veterans receiving behavioral interventions. No systematic M-E changes were observed in the two pharmacological studies (sleep-disturbed military veterans and adults with primary insomnia, respectively). In the behavioral study, M-E changes correlated with changes in depression, positive affect, and sleep quality. M-E changes also correlated with changes in positive affect in the adult insomnia group. M-E appears to exhibit state-like aspects in addition to trait-like aspects. PMID:26549156

  8. Quetiapine versus aripiprazole in children and adolescents with psychosis--protocol for the randomised, blinded clinical Tolerability and Efficacy of Antipsychotics (TEA) trial

    DEFF Research Database (Denmark)

    Pagsberg, Anne Katrine; Jeppesen, Pia; Klauber, Dea Gowers;

    2014-01-01

    BACKGROUND: The evidence for choices between antipsychotics for children and adolescents with schizophrenia and other psychotic disorders is limited. The main objective of the Tolerability and Efficacy of Antipsychotics (TEA) trial is to compare the benefits and harms of quetiapine versus...... aripiprazole in children and adolescents with psychosis in order to inform rational, effective and safe treatment selections. METHODS/DESIGN: The TEA trial is a Danish investigator-initiated, independently funded, multi-centre, randomised, blinded clinical trial. Based on sample size estimation, 112 patients...... aged 12-17 years with psychosis, antipsychotic-naïve or treated for a limited period are, 1:1 randomised to a 12- week, double-blind intervention with quetiapine versus aripiprazole. Effects on psychopathology, cognition, health-related quality of life, and adverse events are assessed 2, 4, and 12...

  9. Behandlingsresistent depression kan behandles

    DEFF Research Database (Denmark)

    Vinberg, Maj; Levinsen, Mette Frandsen; Kessing, Lars Vedel

    2011-01-01

    Depression is considered resistant when two treatment attempts with antidepressants from different classes fail to produce significant clinical improvement. In cases of treatment-resistant depression, it is recommended to reevaluate the diagnosis, clarify comorbidity, substance abuse and lack...... of compliance. Regarding treatment, evidence is sparse, but switching to a different antidepressant, and combination or augmentation with another agent, admission and treatment with ECT are the options. The choice of treatment must be based on the characteristics of the depression, the severity of treatment...

  10. Using ASL Method for Monitoring of Brain Perfusion Changes in a Rat Model of Schizophrenia and After Chronic Administration of Aripiprazole

    Czech Academy of Sciences Publication Activity Database

    Dražanová, Eva; Grossová, Lucie; Pistovčáková, J.; Khainar, A.; Demlová, R.; Kašpárek, T.; Starčuk jr., Zenon

    Bratislava: Institute of Measurement Science, SAS, 2015, s. 81-84. ISBN 978-80-969672-9-2. [International Conference on Measurement /10./. Smolenice (SK), 25.05.2015-28.05.2015] R&D Projects: GA MŠk(CZ) LO1212; GA MŠk ED0017/01/01 Institutional support: RVO:68081731 Keywords : ASL * schizophrenia * poly I:C animal model * rats * aripiprazole Subject RIV: BH - Optics, Masers, Lasers

  11. Cognitive and psychomotor effects of adjunctive aripiprazole or paliperidone in patients of schizophrenia receiving olanzapine: a double blind placebo controlled clinical study

    OpenAIRE

    Mayur M. Mayabhate; Vandana A. Badar; Praveer Waradkar; Abhishek Somani

    2014-01-01

    Background: Emergence of atypical antipsychotics has revolutionized the treatment of schizophrenia by exploiting dual actions on serotonin as well as dopaminergic receptors. Still, monotherapy with these agents is insufficient to control cognitive and psychomotor as well as positive and negative symptoms. Hence combination therapy with antipsychotics is common in clinical practice. Objective of current study is to compare the effects of addition of aripiprazole or paliperidone on cognition an...

  12. Effects of Dopamine D2 Receptor Partial Agonist Antipsychotic Aripiprazole on Dopamine Synthesis in Human Brain Measured by PET with L-[β-11C]DOPA

    OpenAIRE

    Ito, Hiroshi; Takano, Harumasa; Arakawa, Ryosuke; Takahashi, Hidehiko; Kodaka, Fumitoshi; Takahata, Keisuke; Nogami, Tsuyoshi; Suzuki, Masayuki; Suhara, Tetsuya

    2012-01-01

    Dopamine D2 receptor partial agonist antipsychotic drugs can modulate dopaminergic neurotransmission as functional agonists or functional antagonists. The effects of antipsychotics on presynaptic dopaminergic functions, such as dopamine synthesis capacity, might also be related to their therapeutic efficacy. Positron emission tomography (PET) was used to examine the effects of the partial agonist antipsychotic drug aripiprazole on presynaptic dopamine synthesis in relation to dopamine D2 rece...

  13. Placebo for depression: we need to improve the quality of scientific information but also reject too simplistic approaches or ideological nihilism.

    Science.gov (United States)

    Cipriani, Andrea; Geddes, John R

    2014-01-01

    The placebo response plays a major role in psychiatry, particularly in depression. A new network meta-analysis investigates whether the effects of placebo vary in studies comparing fluoxetine and venlafaxine, two widely prescribed antidepressants. Even though data from this article indicate that the effects of placebos do not differ, publication bias cannot be ruled out. The authors use their finding to criticise the paradigm of evidence-based medicine, questioning whether there is anything certain in psychiatry and, more precisely, in the field of antidepressant treatment for major depression. This study stimulates the debate about validity of scientific knowledge in medicine and highlights the importance of considering things from a different perspective. However, the authors' view should be considered with caution. As clinicians, we make decisions every day, integrating individual clinical expertise and patients' preferences and values with the best, up-to-date research data. The quality of scientific information must be improved, but we still think that valid conclusions to help clinical practice can be drawn from a critical and cautious use of the best available, if flawed, evidence. PMID:24962638

  14. Tailored lighting intervention improves measures of sleep, depression, and agitation in persons with Alzheimer’s disease and related dementia living in long-term care facilities

    Directory of Open Access Journals (Sweden)

    Figueiro MG

    2014-09-01

    Full Text Available Mariana G Figueiro,1 Barbara A Plitnick,1 Anna Lok,1 Geoffrey E Jones,1 Patricia Higgins,2,3 Thomas R Hornick,3,4 Mark S Rea1 1Lighting Research Center, Rensselaer Polytechnic Institute, Troy, NY, USA; 2School of Nursing, 3School of Medicine, Case Western Reserve University, 4Geriatric Research Education and Clinical Center, Louis Stokes Cleveland Veterans Affairs Medical Center, Cleveland, OH, USABackground: Light therapy has shown great promise as a nonpharmacological method to improve symptoms associated with Alzheimer’s disease and related dementias (ADRD, with preliminary studies demonstrating that appropriately timed light exposure can improve nighttime sleep efficiency, reduce nocturnal wandering, and alleviate evening agitation. Since the human circadian system is maximally sensitive to short-wavelength (blue light, lower, more targeted lighting interventions for therapeutic purposes, can be used. Methods: The present study investigated the effectiveness of a tailored lighting intervention for individuals with ADRD living in nursing homes. Low-level “bluish-white” lighting designed to deliver high circadian stimulation during the daytime was installed in 14 nursing home resident rooms for a period of 4 weeks. Light–dark and rest–activity patterns were collected using a Daysimeter. Sleep time and sleep efficiency measures were obtained using the rest–activity data. Measures of sleep quality, depression, and agitation were collected using standardized questionnaires, at baseline, at the end of the 4-week lighting intervention, and 4 weeks after the lighting intervention was removed. Results: The lighting intervention significantly (P<0.05 decreased global sleep scores from the Pittsburgh Sleep Quality Index, and increased total sleep time and sleep efficiency. The lighting intervention also increased phasor magnitude, a measure of the 24-hour resonance between light–dark and rest–activity patterns, suggesting an increase

  15. Treatment of depressed mothers of depressed children: pilot study of feasibility.

    Science.gov (United States)

    Verdeli, Helen; Ferro, Tova; Wickramaratne, Priya; Greenwald, Steven; Blanco, Carlos; Weissman, Myrna M

    2004-01-01

    Numerous studies have shown that depression is highly familial and impairing and that a history of depression in a parent is the strongest risk factor for depression in a child. Many of the parents in these studies have never received sustained treatment despite histories of recurrent depression. None of the studies have examined the effects of maternal symptom remission on offspring symptom or functioning. We sought to determine the feasibility of treating depressed mothers who brought an offspring for the treatment of depression and to examine the relationship between improved maternal depression and symptomatic improvement and social functioning in their offspring. Nine mothers bringing their offspring for treatment of depression, and who were evaluated and found to be currently depressed, completed a 12-week open trial of interpersonal psychotherapy. Mothers and their depressed offspring were assessed by independent evaluators at weeks 0, 6, and 12 for depressive symptomatology and social functioning. Although the rates of depression were high among the mothers, few eligible mothers agreed to participate. Of the 12 who entered treatment, 9 (75%) completed it. Mothers and offspring improved with regard to depressive symptomatology and global functioning over the course of the trial. Improvement in maternal depression was significantly associated with improvement in offspring functioning but not symptom reduction. Improvement of maternal depression may be associated with improved outcomes in depressed offspring. However, it is difficult to engage depressed mothers in treatment for themselves if they come to the clinic to bring their child for treatment of depression. It may be more feasible to study the effect of improved maternal depression on offspring by sampling depressed mothers coming for their own treatment and then assessing their children over the course of maternal treatment. PMID:14978786

  16. Potential long-term effects of a mind-body intervention for women with major depressive disorder: Sustained mental health improvements with a pilot yoga intervention

    OpenAIRE

    Kinser, Patricia Anne; Elswick, R. K.; Kornstein, Susan

    2014-01-01

    Despite pharmacologic and psychotherapeutic advances over the past decades, many individuals with major depressive disorder (MDD) experience recurrent depressive episodes and persistent depressive symptoms despite treatment with the usual care. Yoga is a mind-body therapeutic modality which has received attention in both the lay and research literature as a possible adjunctive therapy for depression. Although promising, recent findings about the positive mental health effects of yoga are limi...

  17. Real Stories of Depression

    Medline Plus

    Full Text Available ... Depression Publications About Men and Depression Getting Help Real Stories of Depression Bill Maruyama , Lawyer Jimmy Brown , ... in Men Signs & Symptoms Depression Treatment Getting Help Real Stories of Depression Publications About Men and Depression ...

  18. Clinical Observation on Fluvoxamine and Aripiprazole as Adjunctive Therapy in the Treatment of Obsessive-compulsive Disorders%阿立哌唑辅助氟伏沙明治疗强迫障碍的临床观察

    Institute of Scientific and Technical Information of China (English)

    魏宏强; 康瑞; 李爱玲; 赵秀娟

    2013-01-01

    Objective:To explore the efficacy and safety of fluvoxamine and aripiprazole as adjunctive therapy in the treatment of obsessive-compulsive disorders patients.Method:Total 54 obsessive-compulsive disorders patients were randomly divided into two groups:Fluvoxamine(250-300 mg/d)auxiliaried by aripiprazole(2.5-10 mg/d)group(study group)and fluvoxamine(250-300 mg/d)group(contral group),27 for each. Each group had a 8-week treatment.The efficacy were assessed and analyzed by Yale-Brown Obsessive Compulsive Scale(Y-BOCS) at baseline and at week 2,4,6 and 8. The side effects were assessed by Treatment Emergent Syptom Scale(TESS)during the treatment. Result:Study group and contral group had 1,2 case being off respectively. The obsession and compulsion scores of study group had all statistical difference at baseline and week 2,4 ,6,8 each other(P0.05). At week 4,in both groups,the compulsion scores had statistical difference(P0.05). Conclusion:Fluvoxamine and aripiprazole as adjunctive therapy can effectively continue to improve the compulsive symptoms in the treatment of obsessive-compulsive disorders patients,the rate of side effects is similar to that of simple fluvoxamine therapy.%  目的:探讨阿立哌唑辅助氟伏沙明治疗强迫障碍的临床疗效及安全性.方法:将54例强迫障碍患者随机分为两组(各27例):阿立哌唑(2.5~10 mg/d)辅助氟伏沙明(250~300 mg/d)组(研究组)、氟伏沙明(250~300 mg/d)组(对照组),治疗观察期均为8周.两组患者于基线及治疗2、4、6、8周末分别评定Yale-Brown强迫量表(Y-BOCS),并采用副反应量表(TESS)评定治疗期间的不良反应.结果:研究组、对照组分别脱落1例、2例.研究组的强迫思维和强迫行为评分在基线及2、4、6、8周末时点间比较差异均有统计学意义(P0.05);4周末时,两组间的强迫行为评分比较差异有统计学意义(P0.05).结论:阿立哌唑辅助氟伏沙明可有效、持续地改善强迫障

  19. The Vascular Depression Hypothesis: Mechanisms Linking Vascular Disease with Depression

    OpenAIRE

    Taylor, Warren D.; Aizenstein, Howard J.; Alexopoulos, George S.

    2013-01-01

    The ‘Vascular Depression’ hypothesis posits that cerebrovascular disease may predispose, precipitate, or perpetuate some geriatric depressive syndromes. This hypothesis stimulated much research that has improved our understanding of the complex relationships between late-life depression (LLD), vascular risk factors, and cognition. Succinctly, there are well-established relationships between late-life depression, vascular risk factors, and cerebral hyperintensities, the radiological hallmark o...

  20. Aripiprazole in the Treatment of Refractory Mood Disorders: A Case Series

    OpenAIRE

    Muneer, Ather

    2014-01-01

    Major depressive disorder and bipolar disorders are among the commonest neuropsychiatric conditions, affecting persons of both sexes which belong to all age groups. Comorbidity is the rule rather than the exception; anxiety spectrum disorders, somatoform disorders, eating disorders and substance use disorders frequently co-exist with mood disorders. Catatonia is a serious complication of the latter and every patient with a severe affective exacerbation should be assessed for the presence of c...

  1. Diurnal variation of depressive symptoms

    OpenAIRE

    Wirz-Justice, Anna

    2008-01-01

    Diurnal variation of depressive symptoms appears to be part of the core of depression. Yet longitudinal investigation of an individual's pattern regularity, relation to clinical state, and clinical improvement reveals little homogeneity. Morning lows, afternoon slump, evening worsening - all can occur during a single depressive episode. Mood variability, or the propensity to produce mood swings, appears to be the characteristic that most predicts capacity to respond to treatment. Laboratory s...

  2. Adjunctive Triple Chronotherapy (Combined Total Sleep Deprivation, Sleep Phase Advance, and Bright Light Therapy) Rapidly Improves Mood and Suicidality in Suicidal Depressed Inpatients: An Open Label Pilot Study

    OpenAIRE

    Sahlem, Gregory L.; Kalivas, Benjamin; Fox, James B.; Lamb, Kayla; Roper, Amanda; Williams, Emily N.; Williams, Nolan R.; Korte, Jeffrey E.; Zuschlag, Zachary D.; El Sabbagh, Salim; Guille, Constance; Barth, Kelly S.; Uhde, Thomas W.; George, Mark S.; Short, E. Baron

    2014-01-01

    Previous studies have demonstrated that combined total sleep deprivation (Wake therapy), sleep phase advance, and bright light therapy (Triple Chronotherapy) produce a rapid and sustained antidepressant effect in acutely depressed individuals. To date no studies have explored the impact of the intervention on unipolar depressed individuals with acute concurrent suicidality. Participants were suicidal inpatients (N=10, Mean age=44±16.4SD, 6F) with unipolar depression. In addition to standard o...

  3. Real Stories of Depression

    Science.gov (United States)

    ... Men and Depression Getting Help Real Stories of Depression Bill Maruyama , Lawyer Jimmy Brown , Firefighter Melvin Martin , ... Sierra , Trauma and Recovery Specialist Share Men and Depression Depression in Men Signs & Symptoms Depression Treatment Getting ...

  4. Real Stories of Depression

    Medline Plus

    Full Text Available ... Men and Depression Getting Help Real Stories of Depression Bill Maruyama , Lawyer Jimmy Brown , Firefighter Melvin Martin , ... Sierra , Trauma and Recovery Specialist Share Men and Depression Depression in Men Signs & Symptoms Depression Treatment Getting ...

  5. Nonsomatic treatment of depression.

    Science.gov (United States)

    Sherrill, Joel T; Kovacs, Maria

    2002-07-01

    There is solid evidence that active and goal-oriented cognitive-behavioral or relationship-focused therapies are generally superior to more generic therapies or to no treatment for clinically diagnosed and for undiagnosed but symptomatic youths. Between 50% to 87% of diagnosed youths who received a targeted treatment had recovered from their depressive episodes, in comparison to 21% to 75% of those who received some other generic therapy and 5% to 48% of wait-listed youths. The cognitive behavioral and relationship-oriented interventions that were tested tended to be even more successful in reducing depressive symptoms in school-based samples, possibly because the participants in the school-based studies may have been less disturbed than the clinically diagnosed cases. Although the targeted treatments generally yielded better results than the comparison conditions, the targeted interventions seem to be similarly successful in ameliorating depression. Determining which psychosocial therapy works best for a given depressed youngster remains problematic. As noted in recent reviews [30,46,47], little attention has been devoted to which interventions, or parts of an intervention, are likely to be effective with children with various characteristics. This issue acquires added importance because in some diagnosed samples half or more of the treated participants were still in a depressive episode at the end of the trial. Likewise, in intervention studies involving symptomatic, school-based youngsters, not all children improved, and gains were not uniform across domains of functioning (e.g., severity of depression, self-esteem, global functioning). Possibly, for some of the nonresponders, the participant's characteristics and relevant problems and the target interventions were mismatched. For example, a depressed youth with a long history of highly dysfunctional relationships may not respond optimally to a therapy focusing on negative cognitions; alternatively

  6. Postnatal depression.

    OpenAIRE

    Craig, Michael; Howard, Louise Michele

    1991-01-01

    The differentiation between postnatal depression and other types of depression is often unclear, but there are treatment issues in nursing mothers that do not apply in other situations. Overall, the prevalence of depression in postpartum women is the same as the prevalence in women generally, at about 12–13%.Suicide is a major cause of maternal mortality in resource-rich countries, but rates are lower in women postpartum than in women who have not had a baby.Most episodes resolve spontaneo...

  7. 提高综合医院焦虑障碍与抑郁障碍的识别率%General Hospital to improve the recognition rate of anxiety disorders and depression disorder

    Institute of Scientific and Technical Information of China (English)

    苏文英; 陈芸; 赵新宇; 杨欣

    2014-01-01

    目的:通过对南充综合医院门诊病人的抑郁障碍和焦虑障碍的发生率及共病现象研究,提高焦虑障碍与抑郁障碍的识别率。方法:随机抽取1000例门诊患者进行焦虑自评量表(SAS)和抑郁自评量表(SDS)的问卷调查,通过数据统计分析,阳性筛查焦虑障碍和抑郁障碍的患病情况。结果:门诊中有8.56%的患者存在焦虑障碍,6.03%的患者存在抑郁障碍,2.96%的患者存在焦虑障碍与抑郁障碍共病现象。女性焦虑障碍患病率大于男性患病率,女性抑郁障碍患病率大于男性患病率。结论:综合医院提高焦虑障碍与抑郁障碍的识别率的过程中应注意性别的影响,加强综合门诊对焦虑障碍及抑郁障碍的识别率。%Through Nanchong depression and anxiety disorders in general hospitals and outpatient incidence of comorbidity research, improving the recognition rate of anxiety disorders and depression. Methods: 1000 cases were randomly selected outpatients Self-Rating Anxiety Scale (SAS) and Self-rating Depression Scale (SDS) questionnaire, through statistical analysis, positive screening for anxiety disorders and depressive disorders prevalence. Results: The patient had 8.56% of patients with anxiety disorders, 6.03% of patients with major depressive disorder, anxiety disorders and depressive disorders exist Comorbidity 2.96%of patients. Women prevalence of anxiety disorders than men prevalence of women than men prevalence of depressive disorder prevalence. Conclusion: General Hospital to improve the recognition rate of anxiety disorders and depressive disorders in the process should pay attention to the impact of gender, strengthen the comprehensive clinic for anxiety disorders and depression recognition rate.

  8. Minocycline Improves the Depressive Behaviors of Vascular Depression Mice and Influences the Neurotransmitters Content in Hippocampus via Restraining Neuroinlfammation%Minocycline对血管性抑郁小鼠抑郁行为及神经递质的作用

    Institute of Scientific and Technical Information of China (English)

    李海龙; 刘敏; 张海; 郑惠文; 周凯歌; 王云霞; 毕晓莹

    2014-01-01

    divided into experimental group (n=10), control group (n=10) and sham group (n=10). Minocycline (30 mg/kg, i.p.) and same dose of saline were administrated immediately after the surgery and subsequently the consecutive 6 days in experimental group and control group respectively. Mice in sham group were conducted the same surgery expect occluding carotid artery, then administered the same dose of saline as the control group. After the administration, tail suspension test and open-ifeld test were used to assess depression behaviors of mice on the post operation day (POD) 8 and 9 respectively, and Morris water maze was used to assess cognitive function on the POD 10. On POD 11, mice were deeply anesthetized and euthanized and transcardially perfused with phosphate buffered saline (PBS). Expressions of tumor necrosis factor α (TNF-α), interleukin-1β (IL-1β) and interleukin-6 (IL-6) in hippocampus were measured by enzyme-linked immunosorbent assay (ELISA) kit. Contents of 5-hydroxytryptamine (5-HT), norepinephrine (NE) and dopamine (DA) were measured by high performance liquid chromatography (HPLC). Results Among the three groups, the immobility time was signiifcantly different ([174.75±11.37]s vs [194.32±14.32]s vs [169.62±19.27]s, F=6.59, P=0.005), and the immobility time of experimental group and sham group was shorter than control group significantly. The times of exploring holes, prolonged time and distance of movement were signiifcantly different (F=6.17, P=0.008;F=11.55, P Conclusion Minocycline can restrain the expression of inflammatory cytokines in vascular depression mice, and inhibited inflammation may improve their depression behaviors, but no improvement found in the cognitive impairment. Among those relevant neurotransmitters, the content of DA changes most signiifcantly.

  9. Diagnosis, phenomenology and treatment of poststroke depression

    Directory of Open Access Journals (Sweden)

    Starkstein Sergio E

    2002-01-01

    Full Text Available Diagnosing depression in stroke patients is a challenge in neuropsychiatry since depression symptoms may overlap neurological deficit signs. The best approach is to assess the presence of depressive symptoms using semi-structured or structured psychiatric interviews, such as the Present State Exam, the Structured Clinical Interview for DSM-IV or the Schedules for Clinical Assessment in Neuropsychiatry. The diagnosis of a depressive syndrome should be made according to standardized diagnostic criteria for mood disorders due to neurological disease such as in the DSM-IV or ICD-10. Depression rating scales such as the Hamilton Depression Scale and the Center for Epidemiologic Scales for Depression may be used to rate the depression severity and monitor the progression of antidepressant treatment. Most studies have reported the effectiveness of pharmacological treatment in patients with post-stroke depression, and there is preliminary evidence that the degree of impairment in activities of daily living (ADL may improve as well.

  10. The detection and treatment of depression in the physically ill

    OpenAIRE

    Goldberg, David

    2010-01-01

    Depression and chronic physical illness are in reciprocal relationship with one another: not only do many chronic illnesses cause higher rates of depression, but depression has been shown to antedate some chronic physical illnesses. Depression associated with physical illness is less well detected than depression occurring on its own, and various ways of improving both the detection and treatment of depression accompanying physical illness are described. This paper is in fou...

  11. Postpartum Depression

    DEFF Research Database (Denmark)

    Smith-Nielsen, Johanne

    Background: In three academic articles, this PhD thesis investigates maternal postpartum depression (PPD) as a risk factor for the infant-mother attachment and infant development. Previous studies have been contradictory with respect to the question of whether PPD can have long term effects on...... offspring. This may be due to not differing between when PPD is only occurring in the postpartum period and when effects are also due to ongoing or recurrent depression. However, it may also be due to viewing maternal depression as a unitary construct, and not considering underlying maternal psychological...... difficulties which may moderate potential adverse effects. The present thesis investigates two potential maternal moderators of risk:. Comorbid personality disorder and adult attachment insecurity. Moreover, the question of early environmental effects of PPD versus effects of later or ongoing depression is...

  12. Teen Depression

    Science.gov (United States)

    ... a real, treatable brain illness, or health problem. Depression can be caused by big transitions in life, stress, or changes in your body’s chemicals that affect your thoughts and moods. Even ...

  13. Major depression

    Science.gov (United States)

    ... period of time. It also changes how your body works. ... prescription. It may help some people with mild depression. But it can change the way other medicines work in your body, including antidepressants. Talk to your provider before trying ...

  14. Postpartum Depression

    DEFF Research Database (Denmark)

    Smith-Nielsen, Johanne

    Background: In three academic articles, this PhD thesis investigates maternal postpartum depression (PPD) as a risk factor for the infant-mother attachment and infant development. Previous studies have been contradictory with respect to the question of whether PPD can have long term effects on...... offspring. This may be due to not differing between when PPD is only occurring in the postpartum period and when effects are also due to ongoing or recurrent depression. However, it may also be due to viewing maternal depression as a unitary construct, and not considering underlying maternal psychological...... months with the Bayley Scales of Infant and Toddler Development, third edition. Additionally, at 13 months infant-mother attachment security was assessed using Strange Situation Procedure. Results: We found that even in a well-functioned sample, symptoms of depression in the postpartum period was...

  15. Medication adherence and utilization in patients with schizophrenia or bipolar disorder receiving aripiprazole, quetiapine, or ziprasidone at hospital discharge: A retrospective cohort study

    Directory of Open Access Journals (Sweden)

    Berger Ariel

    2012-08-01

    Full Text Available Abstract Background Schizophrenia and bipolar disorder are chronic debilitating disorders that are often treated with second-generation antipsychotic agents, such as aripiprazole, quetiapine, and ziprasidone. While patients who are hospitalized for schizophrenia and bipolar disorder often receive these agents at discharge, comparatively little information exists on subsequent patterns of pharmacotherapy. Methods Using a database linking hospital admission records to health insurance claims, we identified all patients hospitalized for schizophrenia (ICD-9-CM diagnosis code 295.XX or bipolar disorder (296.0, 296.1, 296.4-296.89 between January 1, 2001 and September 30, 2008 who received aripiprazole, quetiapine, or ziprasidone at discharge. Patients not continuously enrolled for 6 months before and after hospitalization (“pre-admission” and “follow-up”, respectively were excluded. We examined patterns of use of these agents during follow-up, including adherence with treatment (using medication possession ratios [MPRs] and cumulative medication gaps [CMGs] and therapy switching. Analyses were undertaken separately for patients with schizophrenia and bipolar disorder, respectively. Results We identified a total of 43 patients with schizophrenia, and 84 patients with bipolar disorder. During the 6-month period following hospitalization, patients with schizophrenia received an average of 101 therapy-days with the second-generation antipsychotic agent prescribed at discharge; for patients with bipolar disorder, the corresponding value was 68 therapy-days. Mean MPR at 6 months was 55.1% for schizophrenia patients, and 37.3% for those with bipolar disorder; approximately one-quarter of patients switched to another agent over this period. Conclusions Medication compliance is poor in patients with schizophrenia or bipolar disorder who initiate treatment with aripiprazole, quetiapine, or ziprasidone at hospital discharge.

  16. PROGNOSIS OF DEPRESSION

    OpenAIRE

    Sachdev, S.; Nandi, D. N.; Mukherjee, S. P.

    1983-01-01

    SUMMARY Relationship of different symptoms, personal history, some measures of Rorschach, neuroticism, ego strength score with prognosis of depression was studied. Out of 60 items studied in 60 cases, eleven were found to have statistically significant association with improvement. Multiple regression of percentage of improvement on 23 items (12 from personal and family history and 13 measurable items of Rorschach) was determined. To check the ability of this multiple regression to expl. in d...

  17. Optimal management of perimenopausal depression

    Directory of Open Access Journals (Sweden)

    Barbara L Parry

    2010-06-01

    Full Text Available Barbara L ParryDepartment of Psychiatry, University of California, San Diego, USAAbstract: Only recently has the perimenopause become recognized as a time when women are at risk for new onset and recurrence of major depression. Untreated depression at this time not only exacerbates the course of a depressive illness, but also puts women at increased risk for sleep disorders, cardiovascular disease, diabetes, and osteoporosis. Although antidepressant medication is the mainstay of treatment, adjunctive therapy, especially with estrogen replacement, may be indicated in refractory cases, and may speed the onset of antidepressant action. Many, but not all, studies, report that progesterone antagonizes the beneficial effects of estrogen. Although some antidepressants improve vasomotor symptoms, in general they are not as effective as estrogen alone for relieving these symptoms. Estrogen alone, however, does not generally result in remission of major depression in most (but not all studies, but may provide benefit to some women with less severe symptoms if administered in therapeutic ranges. The selective serotonin reuptake inhibitors (SSRIs in addition to estrogen are usually more beneficial in improving mood than SSRIs or estrogen treatment alone for major depression, whereas the selective norepinephrine and serotonin reuptake inhibitors do not require the addition of estrogen to exert their antidepressant effects in menopausal depression. In addition to attention to general health, hormonal status, and antidepressant treatment, the optimal management of perimenopausal depression also requires attention to the individual woman’s psychosocial and spiritual well being.Keywords: menopause, depression, management

  18. Pragmatic randomised controlled trial of an exercise programme to improve wellbeing outcomes in women with depression: findings from the qualitative component

    OpenAIRE

    Khalil, Elizabeth; Callaghan, Patrick; Carter, Tim; Morres, Ioannis

    2012-01-01

    This paper reports the qualitative component from a pragmatic randomized controlled trial (PRCT), the quantitative component is reported in Callaghan, Khalil, Morres and Carter (2011). Exercise may be effective in treating depression, but trials testing its effect in depressed women are rare. Our previous research found that standard exercise programmes, prescribed by General Practitioners and based on national guidelines of intensity levels thought to produce health benefits, are not suitabl...

  19. Antenatal depression and hematocrit levels as predictors of postpartum depression and anxiety symptoms.

    Science.gov (United States)

    Roomruangwong, Chutima; Kanchanatawan, Buranee; Sirivichayakul, Sunee; Maes, Michael

    2016-04-30

    The aim of this study is to delineate the risk factors of antenatal depression and its consequences, including postnatal depression, and to examine whether the hematocrit (Hct) is associated with maternal depression. The Edinburgh Postnatal Depression Scale (EPDS), Spielberger's State Anxiety Inventory (STAI), Kennerley and Gath Maternity Blues Assessment Scale (KGB), Beck Depression Inventory (BDI) and Hamilton Depression Rating Scale (HAMD) were assessed at the end of term (T1) and 2-3 days (T2) and 4-6 weeks (T3) after delivery in 126 women with and without antenatal depression. The Hct was measured at T1. Antenatal depression was significantly predicted by lifetime depression and premenstrual syndrome and less education. Antenatal depression was not associated with obstetric or neonatal outcomes. Antenatal depression symptoms strongly predict depression and anxiety symptoms at T2 and T3. The EPDS, KGB, STAI and BDI, but not the HAMD, scores, were significantly lower at T3 than before. The incidence of depression significantly decreased from T1 (23.8%) to T2 (7.8%) and T3 (5.3%). T1 Hct values significantly predicted the T3 postnatal EPDS, STAI, KGB and BDI scores. Delivery significantly improves depression and anxiety symptoms. Increased Hct in the third trimester is a biomarker of postpartum depression and anxiety symptoms. PMID:27086235

  20. Treating comorbid anxiety and depression: Psychosocial and pharmacological approaches.

    Science.gov (United States)

    Coplan, Jeremy D; Aaronson, Cindy J; Panthangi, Venkatesh; Kim, Younsuk

    2015-12-22

    pain syndromes. Aripiprazole, quetiapine, risperidone and other novel atypical agents may be effective as augmentations. For treatment-resistant patients, we recommend a "stacking approach" not dissimilar from treatment of hypertension In conclusion, we delineate a comprehensive approach comprising integration of various psychosocial approaches and incremental pharmacological interventions entailing bridging strategies, augmentation therapies and ultimately stacking approaches towards effectively treating comorbid anxiety and depression. PMID:26740928

  1. Older Adults and Depression

    Science.gov (United States)

    ... Older Adults and Depression Share Older Adults and Depression Download PDF Download ePub Download Mobi Order a ... If so, you may have depression. What is depression? Everyone feels down or sad sometimes, but these ...

  2. Caregiving and Depression

    Science.gov (United States)

    ... FCA - A A + A You are here Home Depression and Caregiving Order this publication Printer-friendly version ... a more serious depression over time. Symptoms of Depression People experience depression in different ways. Some may ...

  3. Postpartum Depression Facts

    Science.gov (United States)

    ... for herself or her family. What is postpartum depression? Postpartum depression is a mood disorder that can affect ... for themselves or for others. What causes postpartum depression? Postpartum depression does not have a single cause, but ...

  4. Mono- and combination drug therapies in hospitalized patients with bipolar depression. Data from the European drug surveillance program AMSP

    Directory of Open Access Journals (Sweden)

    Haeberle Anne

    2012-09-01

    Full Text Available Abstract Background For the pharmacological treatment of bipolar depression several guidelines exist. It is largely unknown, to what extent the prescriptions in daily clinical routine correspond to these evidence based recommendations and which combinations of psychotropic drugs are frequently used. Methods The prescriptions of psychotropic drugs were investigated of all in-patients with bipolar depression (n = 2246; time period 1994–2009 from hospitals participating in the drug surveillance program AMSP. For the drug use in 2010, 221 cases were analysed additionally. Results From 1994 to 2009, 85% of all patients received more than one class of psychotropic substances: 74% received antidepressants in combination therapy, 55% antipsychotics, 48% anticonvulsants and 33% lithium. When given in combination, lithium is the most often prescribed substance for bipolar depression (33%, followed by valproic acid (23%, mirtazapine and venlafaxine (16% each, quetiapine (15%, lamotrigine (14% and olanzapine (13%. Both, lithium and valproic acid are often combined with selective serotonin reuptake inhibitors (SSRI, but also with mirtazapine und venlafaxine. Combinations of more than one antidepressant occur quite often, whereby combinations with bupropion, paroxetine, fluoxetine or fluvoxamine are very rare. In 2010, quetiapine (alone and combined was the most frequently prescribed drug (39%; aripiprazole was administered in 10%. Conclusion Combinations of antidepressants (SSRI, mirtazapine, venlafaxine with mood stabilizers (lithium, valproic acid, lamotrigine and / or atypical antipsychotics (quetiapine, olanzapine are common. Of most of those combinations the efficacy has not been studied. The use of aripiprazole and the concomitant use of two or three antidepressants contrast the guidelines.

  5. Getting out of Depression: Teens' Self-Help Interventions to Relieve Depressive Symptoms

    Science.gov (United States)

    Wisdom, Jennifer P.; Barker, Ellen C.

    2006-01-01

    Most depressed adolescents do not access medical care for symptoms, yet many improve without professional intervention. While several self-help interventions have empirical support, teens' non-directed efforts to reduce symptoms are not documented. We reviewed 14 depressed adolescents' reports of attempts to reduce depressive symptoms. Results…

  6. The research on the clinical effect of cognitive therapy in improving pregnancy depression%认知疗法在改善妊娠期抑郁症状的临床效果研究

    Institute of Scientific and Technical Information of China (English)

    向琴

    2012-01-01

    目的:探讨认知疗法对妊娠期女性抑郁症状的改善效果.方法:选取2009年3月~2010年3月在该院产科门诊建卡进行围产期产检的有抑郁症状的孕妇120例,作为研究对象,将所有孕妇随机分为观察组和对照组,对照组孕妇实施常规护理,观察组孕妇在常规护理的基础上予以认知疗法,比较两组孕妇经治疗后抑郁症状改善情况及后续分娩的剖宫产率、产程时间、疼痛发生率及疼痛级别、产后抑郁症发生率结果,综合评价认知疗法对妊娠期并发抑郁症孕妇的治疗效果.结果:两组孕妇经过治疗后,抑郁评分均较治疗前改善,但观察组孕妇的抑郁评分指数改善效果明显优于对照组孕妇.对照组患者分娩期的剖宫产率、产程时间、疼痛发生率及疼痛级别、产后抑郁症的发生率均明显高于观察组患者,P值均<0.05,均有统计学意义.结论:认知疗法对围产期妇女抑郁症状改善及提高分娩过程质量具有重要意义,值得临床推广应用.%Objective: To investigate the effect of cognitive therapy in improving pregnancy depression. Methods; 120 pregnant women with depressive symptoms from March 2009 to March 2010 in our hospital were selected as the research object. All pregnant women were randomly divided into control group and observation group. The pregnant women in the control group were taken routine care. The pregnant women in the observation group were taken cognitive therapy on the basis of routine care. The improving situation for depression and follow - up rate of cesarean section delivery, labor time, the incidence of pain and pain level, the results of the incidence of postpartum depression for pregnant women after treatment were compared. The effect of cognitive therapy in improving symptoms of depression during pregnancy was evaluated. Results; After treatment the scores of depression in the two groups were improved. But the improved effect in the

  7. Study on Psychological Nursing Improvement Cognitive Function of Depression Patients%心理护理改善抑郁症患者认知功能的对照研究

    Institute of Scientific and Technical Information of China (English)

    刘倩

    2014-01-01

    Objective:To evaluate the effect of psychological nursing in improving cognitive function in patients with depression.Method:Collected the clinical data of 80 patients with depression in our hospital,all the cases were randomly divided into two groups,the observation group(40 cases) was given oral fluoxetine,on the basis of the conventional nursing given psychological care.The control group(40 cases) just taken the foundation treatment and conventional nursing.The depression severity was assessed with Hamilton depression scale(HAMD),Wisconsin card sorting test(WCST) and the attachment test(TMT) before and after treatment.Result:HAMD grade,the WCST and TMT test times of all the cases after treatment were significant improved than before(P<0.05);After psychological nursing,the cognitive function of depression patients in observation group were significantly better than the control group(P<0.05).Conclusion:The psychological nursing can improve the cognitive function in depression,and conducive to the recovery.%目的:评价心理护理改善抑郁症患者认知功能的效果。方法:收集笔者所在医院临床心理科80例住院抑郁症患者临床资料,采用随机数字表法分为两组,观察组(40例)口服氟西汀,在常规护理基础上增加心理护理;对照组40例,仅给予基础治疗,采用常规护理。治疗前后分别进行汉密尔顿抑郁量表(HAMD)评定、威斯康星卡片分类测验(WCST)和连线测验(TMT)。结果:干预后两组HAMD评分、WCST测验、TMT测验得分较干预前均有所改善(P<0.05);观察组心理护理后对患者的认知功能改善作用显著优于对照组(P<0.05)。结论:心理护理对抑郁症患者认知功能的改善有积极作用,并有利于病情的康复。

  8. 喹硫平利培酮阿立哌唑对精神分裂症患者认知功能的影响%The effect of quetiapine,risperidone and aripiprazole on cog-nitive function of schizophrenia patients

    Institute of Scientific and Technical Information of China (English)

    鞠康; 陈思路; 谢茹韵; 高炬; 孙祝平; 季卫东

    2015-01-01

    目的:探讨喹硫平、利培酮和阿立哌唑对精神分裂症患者临床疗效及认知功能的影响。方法将154例精神分裂症患者分为3组,分别口服喹硫平(65例)、利培酮(47例)和阿立哌唑(42例)治疗,观察24周。采用阳性与阴性症状量表评定临床疗效,重复性成套神经心理状态测验评定认知功能。结果治疗24周末3组阳性与阴性症状量表评分均有显著改善,但喹硫平组改善阳性症状显著优于利培酮组和阿立哌唑组(P<0.05);3组重复性成套神经心理状态测验的9个因子分比较差异有显著性( P<0.05或0.01),阿立哌唑组对8个因子分的改善优于其他2组。不同性别、文化程度患者的认知功能改善有显著性差异(P<0.05)。合并躯体疾病患者认知功能的改善显著差于单纯精神分裂症患者(P<0.05)。结论喹硫平、利培酮和阿立哌唑均能显著改善精神分裂症患者的各种精神症状及认知功能;合并躯体疾病的患者认知功能改善差于单纯精神分裂症患者,性别、文化程度是影响认知功能改变的重要因素。%Objective To explore the efficacy of quetiapine ,risperidone and aripiprazole in schizophrenia patients and their effects on cognitive functions .Methods A total of 154 schizophrenics were assigned to three groups taking orally quetiapine (n=65) ,risperidone (n=47) or aripiprazole (n=42) for 24 weeks . Efficacies were assessed with the Positive and Negative Syndrome Scale (PANSS) and cognitive functions with the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) .Results In the 24th week the PANSS scores of 3 groups improved more significantly ,so did that in quetiapine than risperi‐done and aripiprazole group (P<0 .05);there were significant differences in 9 factor scores of the RBANS among 3 groups (P<0 .05 or 0 .01) ,8 factor scores improved more significantly in

  9. The Complex Role of Sleep in Adolescent Depression

    OpenAIRE

    Clarke, Greg; Harvey, Allison G.

    2012-01-01

    Psychological and pharmacological treatments for youth depression yield post-acute response and remission rates that are modest at best. Improving these outcomes is an important long-term goal. To that end, in this paper, the authors examine the possibility that a youth CBT insomnia intervention may be employed as an adjunct to traditional depression-focused treatment with the aim of improving depression outcomes. This “indirect route” to improving youth depression treatment outcomes is based...

  10. Cognitive improvement after treatment of depressive symptoms in the acute phase of stroke Melhora cognitiva com tratamento antidepressivo na fase aguda do acidente vascular cerebral

    Directory of Open Access Journals (Sweden)

    Samuel Simis

    2006-06-01

    Full Text Available The outcome of antidepressant treatment for depressive symptoms and cognitive impairment at the acute phase of stroke is controversial. We investigated 93 patients, treating with citalopram 36 with severe depressive symptoms (HAM-D: Hamilton Depression Rating Scale >18, whilst 19 patients with mild depressive symptoms, and 38 non-depressed patients, remained untreated. At baseline (two weeks after stroke, patients with severe depressive symptoms had lower scores in total Dementia Rating Scale (DRS and in the attention and memory DRS subscales, than the non-depressed patients (pOs resultados do tratamento com antidepressivo para os sintomas depressivos e comprometimento cognitivo da fase aguda do acidente vascular cerebral não estão estabelecidos. Investigamos 93 pacientes, 36 com sintomas depressivos graves (HAM-D: Escala de Depressão de Hamilton >18 foram tratados com citalopram, enquanto 19 pacientes com sintomas depressivos leves e 38 não-deprimidos não foram tratados. Ao início do tratamento (duas semanas depois do icto, pacientes com sintomas depressivos graves tinham escores mais baixos na Escala de Avaliação de Demência (DRS total e nas subescalas de atenção e de memória da DRS do que os pacientes não-deprimidos (p<0,001. Ao fim de três meses de acompanhamento essas diferenças tinham desaparecido, mas pacientes que inicialmente tinham sintomas depressivos leves passaram a ter escores mais altos no HAM-D do que os não-deprimidos (p=0,015, e escores mais baixos nas subescalas de atenção e memória da DRS (p<0,01 do que os pacientes tratados com citalopram. O tratamento associou-se a melhora de humor, memória e atenção, e demonstra que é necessário um estudo controlado com placebo para o tratamento de sintomas depressivos leves.

  11. 31-Year-Old Female Shows Marked Improvement in Depression, Agitation, and Panic Attacks after Genetic Testing Was Used to Inform Treatment

    Directory of Open Access Journals (Sweden)

    Scott Lawrence

    2014-01-01

    Full Text Available This case describes a 31-year-old female Caucasian patient with complaints of ongoing depression, agitation, and severe panic attacks. The patient was untreated until a recent unsuccessful trial of citalopram followed by venlafaxine which produced a partial response. Genetic testing was performed to assist in treatment decisions and revealed the patient to be heterozygous for polymorphisms in 5HT2C, ANK3, and MTHFR and homozygous for a polymorphism in SLC6A4 and the low activity (Met/Met COMT allele. In response to genetic results and clinical presentation, venlafaxine was maintained and lamotrigine was added leading to remission of agitation and depression.

  12. [Postpartum depression].

    Science.gov (United States)

    Guo, S F

    1993-09-01

    A retrospective study was carried out in Beijing, China, in 1992. Edinburgh postnatal depression scale was used to inquire the mothers at 6-12 month after delivery. A total of 550 women were investigated by mailing. 425 women replied. The positive rate of PPD in our study was 17.9%. Women who had had a history of mood disorder before pregnancy had a higher risk of PPD. Social and psychological factors such as lacking support from the women's relatives, the poor marital relationship and the bad living condition shown to be significantly associated with postnatal depression. PPD can seriously affected the physical and mental health and well-being of women, her child's early education causing delayed development and her family causing a great deal of suffering, personal distress and marital troubles even causing divorce and suicide. Thus it is important to identify the high risk women and give treatment as early as possible. PMID:8313745

  13. Aqueous Solubility of Piperazine and 2-Amino-2-methyl-1-propanol plus Their Mixtures Using an Improved Freezing-Point Depression Method

    DEFF Research Database (Denmark)

    Fosbøl, Philip Loldrup; Neerup, Randi; Waseem Arshad, Muhammad; Tecle, Zacarias; Thomsen, Kaj

    2011-01-01

    In this work the solid–liquid equilibrium (SLE) and freezing-point depression (FPD) in the electrolytic binary aqueous systems piperazine (PZ, CAS No. 110-85-0) and aqueous 2-amino-2-methyl-1-propanol (AMP, CAS No. 124-68-5) were measured. The FPD and solubility were also determined in the ternar...

  14. Adjunctive triple chronotherapy (combined total sleep deprivation, sleep phase advance, and bright light therapy) rapidly improves mood and suicidality in suicidal depressed inpatients: an open label pilot study.

    Science.gov (United States)

    Sahlem, Gregory L; Kalivas, Benjamin; Fox, James B; Lamb, Kayla; Roper, Amanda; Williams, Emily N; Williams, Nolan R; Korte, Jeffrey E; Zuschlag, Zachary D; El Sabbagh, Salim; Guille, Constance; Barth, Kelly S; Uhde, Thomas W; George, Mark S; Short, E Baron

    2014-12-01

    Previous studies have demonstrated that combined total sleep deprivation (Wake therapy), sleep phase advance, and bright light therapy (Triple Chronotherapy) produce a rapid and sustained antidepressant effect in acutely depressed individuals. To date no studies have explored the impact of the intervention on unipolar depressed individuals with acute concurrent suicidality. Participants were suicidal inpatients (N = 10, Mean age = 44 ± 16.4 SD, 6F) with unipolar depression. In addition to standard of care, they received open label Triple Chronotherapy. Participants underwent one night of total sleep deprivation (33-36 h), followed by a three-night sleep phase advance along with four 30-min sessions of bright light therapy (10,000 lux) each morning. Primary outcome measures included the 17 item Hamilton depression scale (HAM17), and the Columbia Suicide Severity Rating Scale (CSSRS), which were recorded at baseline prior to total sleep deprivation, and at protocol completion on day five. Both HAM17, and CSSRS scores were greatly reduced at the conclusion of the protocol. HAM17 scores dropped from a mean of 24.7 ± 4.2 SD at baseline to a mean of 9.4 ± 7.3 SD on day five (p = .002) with six of the ten individuals meeting criteria for remission. CSSRS scores dropped from a mean of 19.5 ± 8.5 SD at baseline to a mean of 7.2 ± 5.5 SD on day five (p = .01). The results of this small pilot trial demonstrate that adjunctive Triple Chronotherapy is feasible and tolerable in acutely suicidal and depressed inpatients. Limitations include a small number of participants, an open label design, and the lack of a comparison group. Randomized controlled studies are needed. PMID:25231629

  15. Depression screening and patient outcomes in pregnancy or postpartum : A systematic review

    NARCIS (Netherlands)

    Thombs, Brett D.; Arthurs, Erin; Coronado-Montoya, Stephanie; Roseman, Michelle; Delisle, Vanessa C.; Leavens, Allison; Levis, Brooke; Azoulay, Laurent; Smith, Cheri; Ciofani, Luisa; Coyne, James C.; Feeley, Nancy; Gilbody, Simon; Schinazi, Joy; Stewart, Donna E.; Zelkowitz, Phyllis

    2014-01-01

    Objective: Clinical practice guidelines disagree on whether health care professionals should screen women for depression during pregnancy or postpartum. The objective of this systematic review was to determine whether depression screening improves depression outcomes among women during pregnancy or

  16. Rosa damascena oil improves SSRI-induced sexual dysfunction in male patients suffering from major depressive disorders: results from a double-blind, randomized, and placebo-controlled clinical trial

    Directory of Open Access Journals (Sweden)

    Farnia V

    2015-03-01

    Full Text Available Vahid Farnia,1 Mehdi Shirzadifar,2 Jalal Shakeri,1 Mansour Rezaei,3 Hafez Bajoghli,4,5 Edith Holsboer-Trachsler,6 Serge Brand6,7 1Substance Abuse Prevention Research Center, Psychiatry Department, Kermanshah University of Medical Sciences, Kermanshah, Iran; 2Student Research Center, Psychiatry Department, Kermanshah University of Medical Sciences, Kermanshah, Iran; 3Department of Statistics and Epidemiology, Kermanshah University of Medical Sciences, Kermanshah, Iran; 4Iranian National Center for Addiction Studies, Iranian Institute for Reduction of High-Risk Behaviors, Tehran University of Medical Sciences, Tehran, Iran; 5ASEAN Institute for Health Development, Mahidol University, Nakhon Pathom, Thailand; 6Psychiatric Clinics of the Center for Affective, Stress and Sleep Disorders, Psychiatric Hospital of the University of Basel, Basel, Switzerland; 7Sport Science Section, Department of Sport, Exercise and Health, University of Basel, Basel, Switzerland Background: A substantial disadvantage of psychopharmacological treatment of major depressive disorder (MDD with selective serotonin-reuptake inhibitors (SSRIs is the impact on sexual dysfunction. The aim of the present study was to investigate whether the oil of Rosa damascena can have a positive influence on SSRI-induced sexual dysfunction (SSRI-I SD of male patients who are suffering from MDD and are being treated with SSRIs.Method: In a double-blind, randomized, and placebo-controlled clinical trial, a total of 60 male patients treated with an SSRI and suffering from MDD (mean age =32 years and SSRI-I SD were randomly assigned to take either verum (R. damascena oil or a placebo. Patients completed self-ratings of depression and sexual function at baseline, at 4 weeks later, and at the end of the study, 8 weeks after it started.Results: Over time, sexual dysfunction improved more in the verum group than in the control group. Improvements were observed in the verum group from week 4 to week

  17. Correlation research of delighted thinking on improving negative emotion of depression patients%愉悦思维对改善抑郁症患者负性情绪的相关性研究

    Institute of Scientific and Technical Information of China (English)

    杜荣荣; 刘文琴; 林彩霞; 潘志芳; 张景明

    2010-01-01

    Objective To investigate the effect of delighted thinking on improving negative emotion of depression patients. Methods 100 depression patients were randomly divided into the observation group and the control group with 50 in each according to admission sequence. Both groups was executed antidepressionant drugs treatment and routine psychiatric care simultaneously. The observation group was given delighted thinking training on the basis of above treatment. The emotional recovery of two groups was observed. Results There was significant difference on facial expression, communication and limbs language after executing delighted thinking training in the observation group. And there was significant difference on scores of Hamilton depression rating scale (HAMD) at discharge. Scores of Nurses' Observation Scale during early, middle and late stage of delighted thinking training greatly improved compared with those before training. Conclusions Delighted thinking contributes to throw off negative thinking pattern of self-denial, stimulate positive passion threshold, improve depressed mood and raise treatment effect for depression patients.%目的 探讨愉悦思维对改善抑郁症患者负性情绪的作用.方法 将100例抑郁症患者按入院先后顺序随机分为观察组和对照组各50例.2组患者同时实施抗抑郁药物治疗及精神科常规护理.观察组在此基础上进行愉悦思维训练.观察2组患者情绪的恢复情况.结果 观察组患者面部表情、语言交流、肢体语言在实施诱导愉悦思维后有显著改善;2组患者在出院时汉密尔顿抑郁量表评分比较差异显著.观察组患者在愉悦思维训练的早、中、晚期护士观察量表评分较训练前均有显著提高.结论 愉悦思维有助于患者摆脱自我否定的负性思维模式,刺激患者的正性情感阈值,改善抑郁心境,提高治疗效果.

  18. Antagonism of the adenosine A2A receptor attenuates akathisia-like behavior induced with MP-10 or aripiprazole in a novel non-human primate model.

    Science.gov (United States)

    Bleickardt, Carina J; Kazdoba, Tatiana M; Jones, Nicholas T; Hunter, John C; Hodgson, Robert A

    2014-03-01

    Akathisia is a subset of the larger antipsychotic side effect profile known as extrapyramidal syndrome (EPS). It is associated with antipsychotic treatment and is characterized as a feeling of inner restlessness that results in a compulsion to move. There are currently no primate models available to assess drug-induced akathisia; the present research was designed to address this shortcoming. We developed a novel rating scale based on both the Barnes Akathisia Rating Scale (BARS) and the Hillside Akathisia Scale (HAS) to measure the objective, observable incidence of antipsychotic-induced akathisia-like behavior in Cebus apella non-human primates (NHPs). To induce akathisia, we administered the atypical antipsychotic aripiprazole (1 mg/kg) or the selective phosphodiesterase 10A (PDE10A) inhibitor MP-10 (1-3 mg/kg). Treatment with both compounds produced significantly greater akathisia scores on the rating scale than vehicle treatment. Characteristic behaviors observed included vocalizations, stereotypies, teeth grinding, restless limb movements, and hyperlocomotion. Adenosine A2A receptor antagonists have previously been shown to be effective in blocking antipsychotic-induced EPS in primates. The selective A2A receptor antagonist, SCH 412348 (10-30 mg/kg), effectively reduced or reversed akathisia-like behavior induced by both aripiprazole and MP-10. This work represents the first NHP measurement scale of akathisia and demonstrates that NHPs are responsive to akathisia-inducing agents. As such, it provides a useful tool for the preclinical assessment of putative antipsychotics. In addition, these results provide further evidence of the utility of A2A receptor antagonists for the treatment of antipsychotic-induced movement disorders. PMID:24211858

  19. Rationale and design of an independent randomised controlled trial evaluating the effectiveness of aripiprazole or haloperidol in combination with clozapine for treatment-resistant schizophrenia

    Directory of Open Access Journals (Sweden)

    Piantato Ennio

    2009-05-01

    Full Text Available Abstract Background One third to two thirds of people with schizophrenia have persistent psychotic symptoms despite clozapine treatment. Under real-world circumstances, the need to provide effective therapeutic interventions to patients who do not have an optimal response to clozapine has been cited as the most common reason for simultaneously prescribing a second antipsychotic drug in combination treatment strategies. In a clinical area where the pressing need of providing therapeutic answers has progressively increased the occurrence of antipsychotic polypharmacy, despite the lack of robust evidence of its efficacy, we sought to implement a pre-planned protocol where two alternative therapeutic answers are systematically provided and evaluated within the context of a pragmatic, multicentre, independent randomised study. Methods/Design The principal clinical question to be answered by the present project is the relative efficacy and tolerability of combination treatment with clozapine plus aripiprazole compared with combination treatment with clozapine plus haloperidol in patients with an incomplete response to treatment with clozapine over an appropriate period of time. This project is a prospective, multicentre, randomized, parallel-group, superiority trial that follow patients over a period of 12 months. Withdrawal from allocated treatment within 3 months is the primary outcome. Discussion The implementation of the protocol presented here shows that it is possible to create a network of community psychiatric services that accept the idea of using their everyday clinical practice to produce randomised knowledge. The employed pragmatic attitude allowed to randomly allocate more than 100 individuals, which means that this study is the largest antipsychotic combination trial conducted so far in Western countries. We expect that the current project, by generating evidence on whether it is clinically useful to combine clozapine with aripiprazole

  20. Diagnosis of depression among adolescents

    DEFF Research Database (Denmark)

    Haavet, Ole Rikard; Christensen, Kaj Aage Sparle; Sirpal, Manjit;

    2007-01-01

    BACKGROUND: The objective of the study is to improve general practitioners' diagnoses of adolescent depression. Major depression is ranked fourth in the worldwide disability impact. METHOD: Validation of 1) three key questions, 2) SCL-dep6, 3) SCL-10, 4) 9 other SCL questions and 5) WHO-5 in a...... number of GPs will be recruited from both countries and at least 162 adolescents will be enrolled in the study from the patient lists of the GPs in each country, giving a total of at least 323 adolescent participants. DISCUSSION: The proportion of adolescents suffering from depressive disorders also...... seems to be increasing worldwide. Early interventions are known to reduce this illness. The earlier depression can be identified in adolescents, the greater the advantage. Therefore, we hope to find a suitable questionnaire that could be recommended for GPs....

  1. Psychosocial Interventions in Depressive Disorders

    Directory of Open Access Journals (Sweden)

    Ceyda Basogul

    2015-03-01

    Full Text Available In the last ten years, improvements in effective psychosocial interventions in the prevention and treatment of depression are remarkable. The World Health Organization stated that major depression affects children, adults and the elderly and is the leading cause of approximately 12% of all disabilities around the World. Medical expenses, loss of workforce, suicide risk, the risk of relapse or recurrence are taken into account, depression is an issue that needs to be handled with utmost care for health care workers especially psychiatric nurses. The purpose of this literature review is to examine psychosocial interventions and effectiveness of these interventions for depressive disorders shows a gradual increase in prevalence in worlwide. [Psikiyatride Guncel Yaklasimlar - Current Approaches in Psychiatry 2015; 7(1: 1-15

  2. Chronotherapeutic treatments for depression in youth.

    Science.gov (United States)

    Gest, Stephanie; Holtmann, Martin; Bogen, Sarah; Schulz, Carina; Pniewski, Benjamin; Legenbauer, Tanja

    2016-02-01

    Chronotherapeutics such as wake therapy and bright light therapy are well-established methods in treating adults with depressive disorders and are additionally beneficent for sleep regulation. Few studies concerning chronotherapeutics in juvenile depression exist, though the established treatments are insufficient and sleep disorders often co-occur. In this study, we investigate the impact of two types of chronotherapeutics on depressive symptoms and sleep behavior in a juvenile setting. Juvenile inpatients (n = 62) with moderate to severe depressive symptoms took part in either a combined setting consisting of one night wake therapy followed by 2 weeks bright light therapy or in a setting of bright light therapy alone. Depressive symptoms, general psychopathology, clinical impression and sleep behavior were measured before (T1), directly after (T2) and 2 weeks after intervention (T3). Depressive symptoms decreased while sleep quality increased in both groups. The bright light therapy alone group showed further improvement at T3 in regards to depressive symptoms. Correlation analyses indicated significant negative correlations between sleep quality and awaking after restorative sleep with the depressive symptoms. However, only awaking after restorative sleep had a predictive impact on treatment outcome. The present study provides first evidence for a positive impact of chronotherapeutic interventions on treatment outcome in depressed juvenile inpatients. Bright light therapy seems to stabilize and further enhance reduction of depressive symptoms during follow-up, whereas one night wake therapy does not have an additional long-lasting impact on depressive symptoms and sleep parameters. PMID:25982568

  3. Qigong Exercise Alleviates Fatigue, Anxiety, and Depressive Symptoms, Improves Sleep Quality, and Shortens Sleep Latency in Persons with Chronic Fatigue Syndrome-Like Illness

    OpenAIRE

    2014-01-01

    Objectives. To evaluate the effectiveness of Baduanjin Qigong exercise on sleep, fatigue, anxiety, and depressive symptoms in chronic fatigue syndrome- (CFS-) like illness and to determine the dose-response relationship. Methods. One hundred fifty participants with CFS-like illness (mean age = 39.0, SD = 7.9) were randomly assigned to Qigong and waitlist. Sixteen 1.5-hour Qigong lessons were arranged over 9 consecutive weeks. Pittsburgh Sleep Quality Index (PSQI), Chalder Fatigue Scale (ChFS)...

  4. Qigong Exercise Alleviates Fatigue, Anxiety, and Depressive Symptoms, Improves Sleep Quality, and Shortens Sleep Latency in Persons with Chronic Fatigue Syndrome-Like Illness

    OpenAIRE

    Jessie S. M. Chan; Ho, Rainbow T. H.; Chung, Ka-Fai; Wang, Chong-Wen; Yao, Tzy-Jyun; Ng, Siu-man; Chan, Cecilia L. W.

    2014-01-01

    Objectives:. To evaluate the effectiveness of Baduanjin Qigong exercise on sleep, fatigue, anxiety, and depressive symptoms in chronic fatigue syndrome- (CFS-) like illness and to determine the dose-response relationship. Methods:. One hundred fifty participants with CFS-like illness (mean age = 39.0, SD = 7.9) were randomly assigned to Qigong and waitlist. Sixteen 1.5-hour Qigong lessons were arranged over 9 consecutive weeks. Pittsburgh Sleep Quality Index (PSQI), Chalder Fatigue Scale (ChF...

  5. Screening for depression in older medical inpatients.

    OpenAIRE

    Cullum, Sarah; Tucker, Sue; Todd, Chris; Brayne, Carol

    2006-01-01

    BACKGROUND: Older people with depression make greater use of healthcare services, but the detection of the disorder is poor. The National Service Framework for Older People recommended screening for depression in acute healthcare settings to improve health outcomes of older people. Previous studies, mainly outside the UK, report widely differing rates for depression that do not usefully inform UK practice. Thus the aim of this study is to estimate, in a large representative sample of older me...

  6. Depression after Stroke

    Science.gov (United States)

    ... Library CARING FOR SOMEONE WITH EMOTIONAL & BEHAVIORAL NEEDS Depression After Stroke After a stroke, your loved one ... available! Almost half of all stroke survivors have depression. Depression is a normal response to the losses ...

  7. CHLOROQUINE—RELATED DEPRESSION

    OpenAIRE

    Das, E. Mohan; Mohan, D.

    1981-01-01

    SUMMARY Drugs are known to induce depressive states. Chloroquine, an antimalarial, in therapeutic doses administered for malaria therapy, may produce symptoms rather indistinguishable from endogenous depression. The possible mechanisms of production of depression related to chloroquine use are hypothesised.

  8. Depression and Multiple Sclerosis

    Science.gov (United States)

    Depression - National Multiple Sclerosis Society Skip to navigation Skip to content Menu Navigation National Multiple Sclerosis Society ... Twitter Email Home Symptoms & Diagnosis MS Symptoms Depression Depression Share Smaller Text Larger Text Print In this ...

  9. Men and Depression

    Science.gov (United States)

    ... in crisis? For more information Share Men and Depression Download PDF Download ePub Order a free hardcopy ... If so, you may have depression. What is depression? Everyone feels sad or irritable sometimes, or has ...

  10. Depression in Women

    Science.gov (United States)

    ... or someone I know is in crisis? Share Depression in Women Download PDF Download ePub Order a ... If so, you may have depression. What is depression? Everyone sometimes feels sad, but these feelings usually ...

  11. Various forms of depression

    OpenAIRE

    BENAZZI, FRANCO

    2006-01-01

    The current subtyping of depression is based on the Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Text Revision (DSM-IV-TR) categorical division of bipolar and depressive disorders. Current evidence, however, supports a dimensional approach to depression, as a continuum/spectrum of overlapping disorders, ranging from bipolar I depression to major depressive disorder. Types of depression which have recently been the focus of most research will be reviewed ; bipolar II depressi...

  12. Not all partial dopamine D2 receptor agonists are the same in treating schizophrenia. Exploring the effects of bifeprunox and aripiprazole using a computer model of a primate striatal dopaminergic synapse

    Directory of Open Access Journals (Sweden)

    Athan Spiros

    2010-09-01

    Full Text Available Athan Spiros1, Robert Carr1, Hugo Geerts1,21In Silico Biosciences, Berwyn, PA, USA; 2School of Medicine, University of Pennsylvania, PA, USAAbstract: Species differences in physiology and unique active human metabolites contribute to the limited predictive value of preclinical rodent models for many central nervous system (CNS drugs. In order to explore possible drivers for this translational disconnect, we developed a computer model of a dopaminergic synapse that simulates the competition among three agents and their binding to pre- and postsynaptic receptors, based on the affinities for their targets and their actual concentrations. The model includes presynaptic autoreceptor effects on neurotransmitter release and modulation by presynaptic firing frequency and is calibrated with actual experimental data on free dopamine levels in the striatum of the rodent and the primate. Using this model, we simulated the postsynaptic dopamine D2 receptor activation levels of bifeprunox and aripiprazole, two relatively similar dopamine D2 receptor agonists. The results indicate a substantial difference in dose–response for the two compounds when applying primate calibration parameters as opposed to rodent calibration parameters. In addition, when introducing the major human and rodent metabolites of aripiprazole with their specific pharmacological activities, the model predicts that while bifeprunox would result in a higher postsynaptic D2 receptor antagonism in the rodent, aripiprazole would result in a higher D2 receptor antagonism in the primate model. Furthermore, only the highest dose of aripiprazole, but not bifeprunox, reaches postsynaptic functional D2 receptor antagonism similar to 4 mg haloperidol in the primate model. The model further identifies a limited optimal window of functionality for dopamine D2 receptor partial agonists. These results suggest that computer modeling of key CNS processes, using well-validated calibration paradigms, can

  13. 音乐疗法改善女性恶性肿瘤患者焦虑及抑郁心理的效果%Effects of Music Therapy in Improving Anxiety and Depression for Female Malignant Tumor Patients

    Institute of Scientific and Technical Information of China (English)

    李小妹; 周凯娜

    2011-01-01

    Objective To explore the effect of music therapy in improving anxiety and depression for patients with breast or cervical cancer. Methods Totally 240 patients with breast cancer or cervical cancer were recruited and randomly allocated to the intervention group(n = 120) and control group(n = 120). State-trait anxiety inventory(STAI) and self-rating depression scale(SDS) were used as data collection instruments. Based on the routine nursing care,patients of the intervention group accepted music therapy( music listening) , twice a day (one is in the early morning and the other is in the evening) ,30min per session from the first day before surgery to the third month after surgery; whereas the control group patients only received the routine nursing care. The scores of STAI and SDS were compared on the day before surgery, and the 30 d,60 d,90 d after surgery respectively. Results The scores of anxiety and depression at 30 d, 60 d,90 d after surgery showed a downward trend over time in both groups. The scores of anxiety and depression in the intervention group were significantly lower than those in the control group. Linear mixed model analysis of repeated measurements showed significant differences on anxiety and depression score at different intervals(P<0. 01) as well as an interaction effect between the two groups(P<0. 01). Conclusion Music therapy can improve the negative psychological state of anxiety and depression for patients with breast cancer or cervical cancer, and have satisfied measure time and group effects and long-term therapeutic effects.%目的 探讨音乐疗法改善乳腺癌及宫颈癌患者焦虑及抑郁心理的作用.方法 将240例乳腺癌及宫颈癌患者采用随机数字表法分为干预组和对照组各120例,干预组患者于术后第1天起在常规护理基础上接受音乐疗法(聆听法),每日2次(晨起和晚睡前),每次30 min,持续至术后3个月;对照组接受常规护理.比较两组患者术前1d和术后30、60

  14. Depression in Cancer Patients

    Directory of Open Access Journals (Sweden)

    Beyhan Bag

    2014-06-01

    Full Text Available It is not enough to consider treatment and care depression in the oncology that is the most common psychiatric illness in cancer patient affects of cancer treatment and the patient`s quality of life negatively, which is determined through researches in the field. With development of psycho-oncology it has been demonstrated to establish an important link between the cancer patient`s treatment as well as psycho-social support for the patient and psychiatric treatment and care for the if it is needed. With this connection between them it has been proposed to use of bio-psycho-social-model in cancer patient to improve their care. To achieve this goal, it is expected from medical personnel to realize patients psychosocial need und if he/she has a psychiatric disorders or syndromes. For the medical personnel that work in oncology services, it is inevitable to organize in order to raise the awareness of depression in the cancer patients. In the present study, it is focused on raising the awareness of depression in cancer patient for the medical personnel. [Psikiyatride Guncel Yaklasimlar - Current Approaches in Psychiatry 2014; 6(2.000: 186-198

  15. 31-Year-Old Female Shows Marked Improvement in Depression, Agitation, and Panic Attacks after Genetic Testing Was Used to Inform Treatment

    OpenAIRE

    Scott Lawrence

    2014-01-01

    This case describes a 31-year-old female Caucasian patient with complaints of ongoing depression, agitation, and severe panic attacks. The patient was untreated until a recent unsuccessful trial of citalopram followed by venlafaxine which produced a partial response. Genetic testing was performed to assist in treatment decisions and revealed the patient to be heterozygous for polymorphisms in 5HT2C, ANK3, and MTHFR and homozygous for a polymorphism in SLC6A4 and the low activity (Met/Met) COM...

  16. The effect of empathy nursing on improvement of depressive emotion and life function in depressive patients%共情护理对抑郁症患者抑郁情绪及生活功能的改善作用

    Institute of Scientific and Technical Information of China (English)

    马洪霞; 陈圣霞; 李遵清; 李织若

    2012-01-01

    Objective To explore the effect of empathy nursing on depressive emotion and life function in depressive patients and to improve treatment and nurse effect.Method Sixties depressive inpatients treated with antidepressive drugs were randomly assigned to receive general nursing and health education ( experimental group 31 ) and empathy nursing (control group 29).Hamilton Depression Scale (HAMD),Nurses'observation scale for inpatient evaluation (NOSIE) and the hospital nursing work satisfaction questionnaire were used before and after intervention to evaluate the clinical and nursing effects of two groups.Results After interventions,the total score of HAMD was ( 16.7 ± 3.2) in experimental group and (20.2 ± 3.6) in control group,with significant difference between two groups.The social ability factor of score of NOSIE was (9.78 ± 2.13 ) in experimental group and ( 13.32 ± 3.22) in control group,and the scores of 3 other factors of NOSIE in experimental group was obviously lower than that in control group.The score ( 121.37 ± 11.25 ) of nursing work satisfaction in experimental group was obviously higher than that( 113.26 ± 9.72) in control group ( t =2.98).Conclusions Empathy nursing can improve depressive emotion and life function of patients with depression,and improve nursing work satisfaction.%目的 探讨共情护理对抑郁症患者的抑郁情绪及生活功能的改善作用,为抑郁症患者的治疗及护理提供客观依据.方法 60例住院抑郁症患者分为研究组(31例)和对照组(29例),研究组实施共情护理,对照组实施普通护理,干预时间为4周,干预前后,采用汉密顿抑郁量表(HAMD)、住院患者护理观察量表(NOSIE)、医院护理工作满意度调查表评定两组临床及护理效果.结果 干预后,研究组和对照组HAMD总分分别为(16.7±3.2)分、(20.2±3.6)分,差异具有显著性.干预后,研究组和对照组NOS-IE中社会能力因子分分别为(9.78±2.13)分、(13.32±3.22)分,差异

  17. A control study of SVSRT plus aripiprazole in the treatment of manic episode of bipolar disorder%丙戊酸钠缓释片联合阿立哌唑治疗双相障碍躁狂发作对照研究

    Institute of Scientific and Technical Information of China (English)

    李菲; 谭柏坚; 郭彦杨

    2016-01-01

    plus aripiprazole in the treatment of manic episode of bipolar disorder has an evident effect and could effectively improve patients ’ quality of life and sleep quality .

  18. [Behavioral Activation for Depression: Theory and Practice].

    Science.gov (United States)

    Nakao, Tomohiro

    2015-01-01

    Behavioral activation (BA) has recently attracted marked attention. While cognitive therapy focuses on the cognitive distortion of patients with depression and asks them to change their behaviors as the process of altering the cognitive distortion, BA pays attention to behavior to avoid an unpleasant situation or social situation as a key symptom that leads to persistence of the depression. Avoidance behaviors are often seen during every process of depression, from onset to recurrence. Avoidance behaviors, a decrease in pleasant phenomena, or increase in unpleasant phenomena, result in reinforcing a depressive mood. If patients can set appropriate behavioral targets and achieve them, the beneficial behaviors will be further promoted with positive feed-back. The behavioral change, as-a consequence, will result in improvement of the mood, cognition, and depression itself. In this manuscript, the author presents two clinical cases, in which BA assisted the patients in recovering from their depression. The first case was a male in his thirties who repeatedly took sick leave from his work because of maladjustment, which resulted in persistent depression. The second case was a female in her thirties who suffered from OCD and then became maladjusted to her place of work, depressive, and emotionally unstable. In both cases, avoidant behaviors caused their conditions to persist. Appropriate activities formed by BA improved their moods, and their self-efficacies were gradually regained. It was suggested that BA is markedly effective, especially in patients whose avoidant behaviors mainly cause the persistence of their depressive symptoms. PMID:26514042

  19. The therapeutic or prophylactic effect of exogenous melatonin against depression and depressive symptoms

    DEFF Research Database (Denmark)

    Voigt Hansen, Melissa; Danielsen, A K; Hageman, I;

    2014-01-01

    Circadian- and sleep disturbances may be central for understanding the pathophysiology and treatment of depression. The effect of melatonin on depression/depressive symptoms has been investigated previously. This systematic review assesses the current evidence of a therapeutic- and prophylactic...... effect of melatonin in adult patients against depression or depressive symptoms. A search was performed in The Cochrane Library, PubMed, EMBASE and PsycINFO for published trials on November 14th 2013. Inclusion criteria were English language, RCTs or crossover trials. Our outcome was measurement of...... meta-analyses. Melatonin doses varied from 0.5-6 mg daily and the length of follow-up varied from 2 weeks to 3.5 years. Three studies were done on patients without depression at inclusion, two studies in patients with depression and five studies included a mixture. Six studies showed an improvement in...

  20. Depression and Smoking

    Science.gov (United States)

    ... Someone Quit Stress & Mood Stress & Mood Smoking & Mood Stress Depression Anger Weight Management Weight Management Smoking and Weight ... Lifestyle Healthier Lifestyle Physical Fitness Food & Nutrition Sleep, Stress & Relaxation ... » Tools » Depression Basics » Depression and Smoking Depression and Smoking Why ...

  1. Tablet-Based Education to Reduce Depression-Related Stigma

    Science.gov (United States)

    Lu, Catherine; Winkelman, Megan; Wong, Shane Shucheng

    2016-01-01

    Objectives: This study investigated the efficacy of a tablet-based multimedia education application, the Project Not Alone Depression Module, in improving depression literacy and reducing depression stigma among a community-based mental health clinic population. Methods: A total of 93 participants completed either a tablet-based multimedia…

  2. Depression after Delivery: Risk Factors, Diagnostic and Therapeutic Considerations

    OpenAIRE

    Debra A. Scrandis; Sheikh, Tehmina M.; Robina Niazi; Tonelli, Leonardo H.; Teodor T. Postolache

    2007-01-01

    Postpartum mood disorders can negatively affect women, their offspring, and their families when left untreated. The identification and treatment of postpartum depression remains problematic since health care providers may often not differentiate postpartum blues from depression onset. Recent studies found potentially new risk factors, etiologies, and treatments; thus, possibly improving the untreated postpartum depression rates. This integrated review examined several postpartum psychiatric d...

  3. Group prevention of depression and anxiety symptoms.

    Science.gov (United States)

    Seligman, Martin E P; Schulman, Peter; Tryon, Alyssa M

    2007-06-01

    To prevent depression and anxiety, we delivered a brief, classroom-based cognitive-behavioral workshop along with ongoing Web-based materials and e-mail coaching to college students at risk for depression. At risk was defined as having mild to moderate depressive symptoms on a self-report measure of depression. Two hundred forty students were randomized into either an eight-week workshop that met in groups of 10, once per week for 2 h or into an assessment-only control group. We plan to track participants for 3 years after the workshop and here we report the 6 month preventive effects on depression and anxiety. The workshop group had significantly fewer depressive symptoms and anxiety symptoms than the control group, but there was no significant difference between the conditions on depression or anxiety episodes at 6 month follow up. The workshop group had significantly better well being than the control group, and the workshop group had significantly greater improvement in optimistic explanatory style than the control group. Improved explanatory style was a significant mediator of the prevention effects from pre- to post-workshop for depressive and anxiety symptoms, as well as for improved well being. PMID:17074301

  4. Therapieresistente Depression

    Directory of Open Access Journals (Sweden)

    Holsboer-Trachsler E

    2006-01-01

    Full Text Available In der Behandlung einer Depression wird ein Nichtansprechen auf zwei adäquate Antidepressivatherapien während je 6–8 Wochen als Therapieresistenz bezeichnet. Da häufig zu geringe Dosierungen oder eine zu kurze Behandlungsdauer die Ursache für ein Nichtansprechen sind, sollte in einem ersten Schritt die medikamentöse Therapie hinsichtlich Dauer und Dosierung, eventuell unter Einbezug von Plasmaspiegelbestimmungen, überprüft und optimiert werden. Als pharmakologische Maßnahmen werden zunächst ein Wechsel des Antidepressivums und danach eine Kombination von verschiedenen Antidepressiva mit unterschiedlichem biochemischem Wirkungsansatz empfohlen. Zeigen beide nicht den gewünschten Erfolg, so sollte zusätzlich zur bestehenden Antidepressivabehandlung eine Augmentationstherapie, primär mit Lithium und/oder dem Schilddrüsenhormon T3, durchgeführt werden. Ein neuer, vielversprechender Behandlungsansatz ist eine Augmentationstherapie mit atypischen Neuroleptika. Als akut wirkende nichtpharmakologische Zusatzmaßnahme hat sich der partielle Schlafentzug bewährt. Weitere nichtpharmakologische Strategien umfassen Psychotherapie, Elektrokrampftherapie und Vagusnervstimulationsbehandlung.

  5. Depression severity, diet quality, and physical activity in women with obesity and depression

    OpenAIRE

    Appelhans, Bradley M.; Whited, Matthew C.; Schneider, Kristin L.; Ma, Yunsheng; Oleski, Jessica L.; Merriam, Philip A.; Waring, Molly E.; Olendzki, Barbara C.; Mann, Devin M.; OCKENE, IRA S.; Pagoto, Sherry L.

    2012-01-01

    Major depressive disorder (MDD) is prevalent in clinical weight loss settings and predicts poor weight loss outcomes. It is unknown whether the severity of depressive symptoms among those with MDD is associated with diet quality or physical activity levels. This knowledge is important for improving weight loss treatment for these patients. It was hypothesized that more severe depression is associated with poorer diet quality and lower physical activity levels among individuals with obesity an...

  6. Well-Being and the Risk of Depression under Stress

    OpenAIRE

    Faren Grant; Constance Guille; Srijan Sen

    2013-01-01

    Improving our ability to accurately predict individual risk for depression would have profound public health benefits. While there has been growing interest in understanding the relation between measures of positive emotion, such as well-being, and depression, it is not clear whether low well-being is an independent predictor of short term depression risk. We assessed whether low well-being is a risk factor for depressive symptoms. Medical internship is a well-established period of stress whe...

  7. Coping with Unexpected Events: Depression and Trauma

    Science.gov (United States)

    ... improve the lives of people who have mood disorders. The Power of Peers DBSA envisions wellness for people who live with depression and bipolar disorder. Because DBSA was created for and is led ...

  8. Severe water intoxication and secondary depressive syndrome in relation to delusional infestation.

    Science.gov (United States)

    Lai, Jianbo; Lu, Qiaoqiao; Xu, Yi; Hu, Shaohua

    2016-01-01

    This study presents a case of severe water intoxication in a female patient with delusional infestation. Self-induced excessive water ingestion is a rare medical condition, which has not been reported in patients with delusional infestation yet. The patient in this case study was a 60-year-old Chinese woman, who was admitted to our hospital because of a feeling of skin infestation. She suffered from loss of consciousness and generalized tonic-clonic seizure after drinking 12 L of water during bowel cleansing before colonoscopy. Sufficient laboratory and imaging examinations were performed to exclude other possible causes of severe hyponatremia, such as hypothyroidism, diabetes insipidus, and syndrome of inappropriate antidiuretic hormone. Besides, the cystic lesion in the posterior pituitary revealed by cranial magnetic resonance imaging was not accountable for her delusional symptoms as well as excessive drinking behavior. Her delusional symptoms were in complete remission with a combination of risperidone and aripiprazole. However, nearly 3 months after discharge, this patient suffered from depressed mood and was diagnosed with depressive syndrome, and even attempted suicide. This case highlights the possibility of self-induced water intoxication in patients with delusional infestation, inevitably adding to the complexity of the disease, and indicates the necessity of precautions for secondary psychotic or mood problems after symptomatological remission. PMID:27013878

  9. Screening for Depression In Hospitalized Pediatric Patients

    Directory of Open Access Journals (Sweden)

    Mohammad-Reza ESMAEELI

    2013-12-01

    Full Text Available Abstract How to Cite This Article: Esmaeeli M, Erfani Sayar R, Saghebi A, Elmi Saghi, Rahmani Sh, Elmi S, Rabbani Javadi A. Screening for Depression in Hospitalized Pediatric Patients. Iran J Child Neurol. 2014 Winter; 8(1:47-51. Objective In chronically ill children who are hospitalized, many mood changes occur. For example, in children with cancer or renal failure, prolonged hospitalization and chemotherapy can lead to depression. With the improved survival of childhood malignancies, the effect of treatment on child’s psychosocial well-being becomes increasingly relevant. In this study, we examined the prevalence of depression in hospitalized children with chronic and acute conditions in Dr Sheikh Pediatrics Hospital in Mashhad. Materials & Methods After receiving the approval from the Ethics Committee of Mashhad University of Medical Sciences, we did this cross-sectional descriptive study, from April to June 2012 in Dr Sheikh Pediatric Hospital in Mashhad. Ninety children, aged between 8 to 16 years, were screened for depression. The sampling method was census. Children with a history of depressive or other mental disorders were excluded. Three groups of children (children with chronic renal disease, malignancy, and acute disease were evaluated for depression using standard Children Depression Inventory Questionnaire (CDI. Two specifically trained nurses with the supervision of a psychiatrist filled out the questionnaires at patients’ bedside. Depression scores were then analyzed by SPSS software. Results Of 90 children, 43(47.7% were male and 47(52.2% were female. The Children’s mean age was 11±2.3 years, and the mean length of hospitalization was 8±5.3 days. Depression was detected in various degrees in 63% of patients (N=57, and 36.6% of children (N=32 had no symptoms of depression. Severe depression was not seen in any of the patients with acute illness. More than half of patients with cancer and chronic kidney disease had

  10. Pharmacist interventions in depressed patients

    OpenAIRE

    Rubio Valera, Maria

    2012-01-01

    1) Objectives: - To systematically evaluate the effectiveness of pharmacist care compared with usual care (UC) on improving adherence to antidepressants in depressed outpatients. - To evaluate the effectiveness and cost‐effectiveness of a community pharmacist intervention (CPI) compared to UC in the improvement of adherence to antidepressants and patient wellbeing in a primary care population initiating treatment with antidepressants. 2) Methods: A systematic review and meta‐a...

  11. Evaluation of depressive symptoms in older caregivers

    Directory of Open Access Journals (Sweden)

    Bruna Moretti Luchesi

    2015-04-01

    Full Text Available Background The number of older caregivers is getting bigger and it is important to know if they experience depressive symptoms because there can be consequences for both caregiver and care recipient. Objective To analyze the recent publications related to the assessment of depressive symptoms in elderly caregivers. Methods Lilacs and PubMed databases were reviewed associating the descriptors “caregivers” AND “aged” AND “depression”. Inclusion criteria were texts including primary data in Portuguese, Spanish or English, published between 2009-2013, also data which evaluated elderly caregivers (≥ 60 and depression or depressive symptoms. There were found n = 1129 texts and after applying the inclusion criteria n = 17 were selected and analyzed. Results Geriatric Depressive Scale (-30 and -15 items and Center for Epidemiologic Studies Depression scale were the most used scales to evaluate depressive symptoms in older caregivers. Caregivers were in the most of the cases female and cared for a family member with dementia. The majority of the texts that compared older caregivers to older non-caregivers found that caregivers had more depressive symptoms. Discussion Early identification of depressive symptoms can help professionals to minimize damage in caregivers and in care recipient and to plan interventions focusing on improving quality of life of this specific caregiver group.

  12. Inflammatory and Epigenetic Pathways for Perinatal Depression.

    Science.gov (United States)

    Garfield, Lindsey; Mathews, Herbert L; Janusek, Linda Witek

    2016-05-01

    Depression during the perinatal period is common and can have adverse consequences for women and their children. Yet, the biobehavioral mechanisms underlying perinatal depression are not known. Adverse early life experiences increase the risk for adult depression. One potential mechanism by which this increased risk occurs is epigenetic embedding of inflammatory pathways. The purpose of this article is to propose a conceptual model that explicates the linkage between early life adversity and the risk for maternal depression. The model posits that early life adversity embeds a proinflammatory epigenetic signature (altered DNA methylation) that predisposes vulnerable women to depression during pregnancy and the postpartum period. As proposed, women with a history of early life adversity are more likely to exhibit higher levels of proinflammatory cytokines and lower levels of oxytocin in response to the demands of pregnancy and new motherhood, both of which are associated with the risk for perinatal depression. The model is designed to guide investigations into the biobehavioral basis for perinatal depression, with emphasis upon the impact of early life adversity. Testing this model will provide a better understanding of maternal depressive risk and improve identification of vulnerable women who would benefit from targeted interventions that can reduce the impact of perinatal depression on maternal-infant health. PMID:26574573

  13. Depression among type 2 diabetic patients

    Directory of Open Access Journals (Sweden)

    Taghreed Mohamed El-Shafie ,Entesar Omar A. El-Saghier and Iman ,Kamal Ramadan

    2011-07-01

    Full Text Available Background & Objectives: Diabetes and depression are highly prevalent conditions and have significant impact on health outcomes. The combination of depression with type 2 diabetes is a public health problem. Therefore, we aimed to assess some socio-demographic characteristics of type 2 diabetes and to investigate the relationship between type 2 diabetes and depression among patients aged from 40 to 60 years old. Methods: 125 patients diagnosed with type 2 diabetes attending diabetes clinics in the Al-Zahraa hospital were invited to participate in this cross-sectional study. Patients were interviewed using structured questionnaires to gather data on socio-demographics, clinical, self care compliance, medication usage, and diabetes complications. The MADRS was administered as a screening tool for depression level evaluation. Binary logistic regression model was used to examine association between predictor variables and risk of depression among diagnosed type 2 diabetes at 95% C.I. and P < 0.05. Results: One hundred and twenty five participants completed the interview. More than half of participants were females (58.4% and the mean age was 48 (sd = 5.9, 47.2% hypertensive, and 59.2% on insulin. More than two third (74.4% of patients were depressed; (24.8% mild, 37.6% moderate and 12% severely depressed. Almost four out of five patients (88.8% had diabetes complications, Depression was strongly associated with neuropathy, age, retinopathy, sex and cardiac complications. However, the likelihood of depression was not associated with nephropathy, hypertension and sexual dysfunction. Conclusion: The current study demonstrates a strong correlation between depression and diabetes particularly complications. In particular, patients who are depressed tended to have poorer self-care, more severe physical symptoms and were less likely to adhere to prescribed care regimens. These findings raise the possibility that improving the mental health as part of a

  14. Seismic Velocity Structure and Improved Seismic Image of the Southern Depression of the Tainan Basin from Pre-Stack Depth Migration

    Directory of Open Access Journals (Sweden)

    Qunshu Tang and Chan Zheng

    2010-01-01

    Full Text Available In this paper, a velocity model of the Southern Depression of the Tainan Basin is obtained along with its migrated image from an iterative pre-stack depth migration approach. The Cenozoic strata are uniformly layered with velocities varying from ~1.8 to ~3.6 km s-1. However, the general velocity is slightly lower in the NW segment than the SE. Both fractures and burial depth might be the controls of their seismic velocities. There is an unconformable contact between the Cenozoic and underlying Mesozoic strata with an abrupt velocity jump from ~3.2 to ~4.3 km s-1. The Mesozoic strata are recognized with acoustically distinct reflection patterns (chaotic, deformed and discontinuous and complex internal structures (uplift, folds and faults. Their interval velocities range from ~4.3 to ~4.7 km s-1 within a depth from ~3.5 down to ~12.5 km, and the maximum depositional thickness reaches up to 6.5 km. Multiple tectonic events such as collision, subsidence and uplift might be responsible for the complexity of the Mesozoic strata.

  15. Improving Treatment Engagement for Returning Operation Enduring Freedom and Operation Iraqi Freedom Veterans With Posttraumatic Stress Disorder, Depression, and Suicidal Ideation.

    Science.gov (United States)

    Gallegos, Autumn M; Streltzov, Nicholas A; Stecker, Tracy

    2016-05-01

    Posttraumatic stress disorder (PTSD) is associated with increased risk of suicidal ideation among veterans of Operation Enduring Freedom and Operation Iraqi Freedom. This report examined the effectiveness of a brief phone-based cognitive-behavioral intervention on treatment seeking among suicidal and nonsuicidal Operation Enduring Freedom and Operation Iraqi Freedom veterans who screened positive for PTSD. Participants were randomized to the intervention or control conditions. We found that suicidal participants, regardless of condition, were twice as likely to attend treatment as nonsuicidal participants. Participants assigned to the control condition who did not indicate suicidality at baseline were less likely to attend treatment at both the 1- and 6-month follow-up interviews. Qualitative findings of the suicidal participants indicated PTSD and depressive symptoms, low social support, and infrequent positive coping mechanisms. Our finding indicates the effectiveness of an intervention to motivate veterans with PTSD to initiate and remain in treatment. The intervention might be particularly useful prior to experiencing a psychological crisis. PMID:26894313

  16. Exploring the feasibility of a community-based strength training program for older people with depressive symptoms and its impact on depressive symptoms

    OpenAIRE

    Davidson Sandra; Hill Keith; Sims Jane; Gunn Jane; Huang Nancy

    2006-01-01

    Abstract Background Depression is a disabling, prevalent condition. Physical activity programs may assist depression management in older people, ameliorate co-morbid conditions and reduce the need for antidepressants. The UPLIFT pilot study assessed the feasibility of older depressed people attending a community-based progressive resistance training (PRT) program. The study also aimed to determine whether PRT improves depressive status in older depressed patients. Methods A randomised control...

  17. Mechanisms Underlying Neurocognitive Dysfunctions in Recurrent Major Depression

    Science.gov (United States)

    Gałecki, Piotr; Talarowska, Monika; Anderson, George; Berk, Michael; Maes, Michael

    2015-01-01

    Recent work shows that depression is intimately associated with changes in cognitive functioning, including memory, attention, verbal fluency, and other aspects of higher-order cognitive processing. Changes in cognitive functioning are more likely to occur when depressive episodes are recurrent and to abate to some degree during periods of remission. However, with accumulating frequency and duration of depressive episodes, cognitive deficits can become enduring, being evident even when mood improves. Such changes in cognitive functioning give depression links to mild cognitive impairment and thereby with neurodegenerative conditions, including Alzheimer’s disease, Parkinson’s disease, schizophrenia, and multiple sclerosis. Depression may then be conceptualized on a dimension of depression – mild cognitive impairment – dementia. The biological underpinnings of depression have substantial overlaps with those of neurodegenerative conditions, including reduced neurogenesis, increased apoptosis, reactive oxygen species, tryptophan catabolites, autoimmunity, and immune-inflammatory processes, as well as decreased antioxidant defenses. These evolving changes over the course of depressive episodes drive the association of depression with neurodegenerative conditions. As such, the changes in cognitive functioning in depression have important consequences for the treatment of depression and in reconceptualizing the role of depression in wider neuroprogressive conditions. Here we review the data on changes in cognitive functioning in recurrent major depression and their association with other central conditions. PMID:26017336

  18. Dementia: Depression and Alzheimer's Disease

    Science.gov (United States)

    MENU Return to Web version Dementia | Depression and Alzheimer’s Disease What is depression? When doctors talk about depression, they mean the medical illness called major depression. Someone who has ...

  19. Depression Disturbs Germany

    Institute of Scientific and Technical Information of China (English)

    2011-01-01

    The suicide of Robert Enke,the goalkeeper of the Germany national football team who had battled depression for years,stunned the country and cast depression into the national spotlight as a disturbing disease.

  20. Adjustments and Depression

    Medline Plus

    Full Text Available ... a number of topics, including depression with a self-test to help identify the signs of depression. ... Get involved Become a peer mentor Advocate for change Fundraise with Team Reeve Champions Committee Volunteering About ...

  1. Depression and College Students

    Science.gov (United States)

    ... other mental health issues? Reference Share Depression and College Students Download PDF Download ePub Order a free hardcopy Answers to college students’ frequently asked questions about depression Feeling moody, sad, ...

  2. Adjustments and Depression

    Medline Plus

    Full Text Available ... of your life. Depression can cause physical and psychological symptoms. It can worsen pain, make sleep difficult, ... affecting about 1 in 5 people. There are treatments available to ease the symptoms of depression using ...

  3. Depression and cardiovascular disease.

    Science.gov (United States)

    Bradley, Steven M; Rumsfeld, John S

    2015-10-01

    There is a wealth of evidence linking depression to increased risk for cardiovascular disease (CVD) and worse outcomes among patients with known CVD. In addition, there are safe and effective treatments for depression. Despite this, depression remains under-recognized and undertreated in patients at risk for or living with CVD. In this review, we first summarize the evidence linking depression to increased risk of CVD and worse patient outcomes. We then review the mechanisms by which depression may contribute to cardiovascular risk and poor cardiovascular outcomes. We then summarize prior studies of depression treatment on cardiovascular outcomes. Finally, we offer guidance in the identification and management of depression among CVD populations. Given that 1 in 4 CVD patients has concurrent depression, application of these best-practices will assist providers in achieving optimal outcomes for their CVD patients. PMID:25850976

  4. Adjustments and Depression

    Medline Plus

    Full Text Available ... depression and adjustment to my SCI? How do I deal with depression and adjustment to my SCI? ☷ ▾ ... following an SCI? What are the secondary conditions? I have no health insurance, what are my options? ...

  5. Depression in Older Adults

    Science.gov (United States)

    ... Student - College Concerns Stressed or Depressed? Know the Difference Boost Your School Performance by Taking Care of You Top Ten Freshman Year Issues Alcohol, Substance Abuse and Depression Winter Break Survival Tips for College ...

  6. Depression: Working It Out

    Science.gov (United States)

    ... page please turn Javascript on. Feature: Depression Working It Out Past Issues / Fall 2009 Table of Contents ... of this technique. Especially when combined with medications, it can help relieve depression. Research shows that it ...

  7. Depression - stopping your medicines

    Science.gov (United States)

    ... prescription medicines you may take to help with depression, anxiety, or pain. Like any medicine, there are ... at risk for: Returning symptoms, such as severe depression Increased risk of suicide (for some people) Withdrawal ...

  8. Depression - stopping your medicines

    Science.gov (United States)

    ... this page: //medlineplus.gov/ency/patientinstructions/000570.htm Depression - stopping your medicines To use the sharing features ... prescription medicines you may take to help with depression, anxiety, or pain. Like any medicine, there are ...

  9. Depression and Pregnancy

    Science.gov (United States)

    ... best live chat Live Help Fact Sheets Share Depression and Pregnancy Thursday, 20 March 2014 In every ... risk. This sheet talks about whether exposure to depression may increase the risk for birth defects over ...

  10. Heart disease and depression

    Science.gov (United States)

    ... gov/ency/patientinstructions/000790.htm Heart disease and depression To use the sharing features on this page, ... a heart attack or heart surgery Signs of Depression It is pretty common to feel down or ...

  11. Learning about depression

    Science.gov (United States)

    ... medlineplus.gov/ency/patientinstructions/000325.htm Learning about depression To use the sharing features on this page, ... trigger or reason. What Are the Signs of Depression? You may notice some or all of the ...

  12. Depression and Suicide Risk

    Science.gov (United States)

    Depression and Suicide Risk (2014) Definition: A mood disorder that causes a persistent feeling of sadness and ... i Prevalence: 1. Ranges of lifetime risk for depression: from 6.7% overall to 40% in men, ...

  13. Depression in the Workplace

    Science.gov (United States)

    ... Balance 5 Myths About Mental Illness Support an Employee Workplace Bullying & Violence Signs of a Healthy Workplace Complementary Medicine ... depression can be successfully treated. With early recognition, intervention, and support, most employees can overcome clinical depression and pick up where ...

  14. Adjustments and Depression

    Medline Plus

    Full Text Available ... to my SCI? How do I deal with depression and adjustment to my SCI? ☷ ▾ Page contents The ... the moment you are injured. Understanding adjustment and depression Adjustment to paralysis is a process of changing ...

  15. Postpartum Depression Action Plan

    Science.gov (United States)

    MENU Return to Web version Postpartum Depression | Postpartum Depression Action Plan Patient __________________________ Physician/NP/PA __________________ Clinic ____________________________ Phone Number ____________________ Choose one area and add other areas as you begin to feel ...

  16. Recognizing teen depression

    Science.gov (United States)

    ... page: //medlineplus.gov/ency/patientinstructions/000648.htm Recognizing teen depression To use the sharing features on this ... teen's life. Be Aware of the Risk for Teen Depression Your teen is more at risk for ...

  17. Depression in adolescence

    OpenAIRE

    Thapar, Anita; Collishaw, Stephan; Pine, Daniel S.; Thapar, Ajay K

    2012-01-01

    Unipolar depressive disorder in adolescence is common worldwide but often unrecognised. The incidence, notably in girls, rises sharply after puberty and, by the end of adolescence, the 1 year prevalence rate exceeds 4%. The burden is highest in low-income and middle-income countries. Depression is associated with sub stantial present and future morbidity, and heightens suicide risk. The strongest risk factors for depression in adolescents are a family history of depression and exposure to psy...

  18. DEPRESSION IN CEREBROVASCULAR DISEASES

    OpenAIRE

    Voskresenskaya, Tatyana

    2009-01-01

    The paper discusses the topical problem of depression in cerebrovascular diseases. It shows its possible causes, mechanisms of occurrence, clinical picture and negative impact on the course of cerebrovascular disease and recovery of neurological functions. There is a bilateral association between stroke and depression: on the one hand, stroke is a risk factor for the development of depression and, on the other, depression is a both direct and indirect risk factor for the development of stroke...

  19. DEPRESSION IN CEREBROVASCULAR DISEASES

    OpenAIRE

    Tat'yana Gratsievna Voznesenskaya; Tatyana Gratsievna Voskresenskaya

    2009-01-01

    The paper discusses the topical problem of depression in cerebrovascular diseases. It shows its possible causes, mechanisms of occurrence, clinical picture and negative impact on the course of cerebrovascular disease and recovery of neurological functions. There is a bilateral association between stroke and depression: on the one hand, stroke is a risk factor for the development of depression and, on the other, depression is a both direct and indirect risk factor for the development of str...

  20. Method of treating depression

    Science.gov (United States)

    Henn, Fritz

    2013-04-09

    Methods for treatment of depression-related mood disorders in mammals, particularly humans are disclosed. The methods of the invention include administration of compounds capable of enhancing glutamate transporter activity in the brain of mammals suffering from depression. ATP-sensitive K.sup.+ channel openers and .beta.-lactam antibiotics are used to enhance glutamate transport and to treat depression-related mood disorders and depressive symptoms.

  1. Depression bei Koronarer Herzerkrankung

    OpenAIRE

    Rieckmann, Nina

    2013-01-01

    Depression is a common comorbid condition in patients with coronary heart disease (CHD) which causes substantial burden of disease. Furthermore, depression negatively impacts the medical prognosis of CHD patients. After an acute coronary syndrome (acute myocardial infarction or unstable angina), patients with a major depressive episode as well as patients with subthreshold depression symptoms are at increased risk for re-hospitalization for a major adverse cardiac event and mortality. This in...

  2. Method of treating depression

    Science.gov (United States)

    Henn, Fritz

    2012-01-24

    Methods for treatment of depression-related mood disorders in mammals, particularly humans are disclosed. The methods of the invention include administration of compounds capable of enhancing glutamate transporter activity in the brain of mammals suffering from depression. ATP-sensitive K.sup.+ channel openers and .beta.-lactam antibiotics are used to enhance glutamate transport and to treat depression-related mood disorders and depressive symptoms.

  3. Depression Training in an Assisted Living Facility: A Pilot Study.

    Science.gov (United States)

    Beuscher, Linda; Dietrich, Mary

    2016-05-01

    Depression in older adults residing in assisted living facilities (ALFs) is often not recognized. ALF staff who work with residents on a daily basis are the most likely individuals to recognize residents' depressive symptoms. The purpose of the current pilot study was to determine feasibility of a 4-week training program for 15 direct care staff to recognize any depression symptoms of 32 residents. Although training significantly improved knowledge, it did not improve staff recognition of residents with positive depressive symptoms. Staff reported the training provided them a better understanding about depression and rated the training as very helpful to be able to recognize depression symptoms. Staff requested more information on ways to respond to someone who is depressed. Additional training should emphasize staff-resident communication skills for staff. Challenges included resident attrition and dwindling staff participation. Strategies to address these challenges are presented. [Journal of Psychosocial Nursing and Mental Health Services, 54(5), 25-31.]. PMID:26848806

  4. A clinical comparative study in first-onset schizophrenia patients treated with Aripiprazole and Quetiapine%阿立哌唑与喹硫平治疗首发精神分裂症的临床对照研究

    Institute of Scientific and Technical Information of China (English)

    刘娜

    2012-01-01

    Objective To study the clinical effects of Aripiprazole and Quetiapine in the treatment of first -onset schizophrenia. Methods 63 adult patients who were diagnosed as schizophreniain accordance with the CCMD-3 diagnosis standard were recruited in this study. All the cases were randomized into two groups and were treated with Aripiprazole and Quetiapine for 8 weeks. The positive and negative syndrome scale (PANSS) and treatment emergent side effect scale (TESS) were used to evaluate efficacy and adverse effects respectively. Results The significant efficacy rates of Aripiprazole was 93.55%, Quetiapine was 90.63%, there was no significant difference (P > 0.05). Before and after treatment between Aripiprazole group and Quetiapine group, the PANSS score had no significant difference (P > 0.05). The level of LEP and TG was elevated which were treated by Aripiprazole, the difference was statistically significant (P < 0.05). The level of LEP, PRL, BG and TG was elevated which were treated by Quetiapine, the difference was statistically significant (P < 0.05). Conclusion The curative effect of first-onset schizophrenia between Aripiprazole and Quetiapine is quite, but the adverse reactions are different, the former is better than the latter.%目的 探讨阿立哌唑与喹硫平治疗首发精神分裂症的临床疗效.方法 63例首发精神分裂症患者,符合CCMD-3精神分裂症诊断标准,随机分成两组,分别使用阿立哌唑和喹硫平治疗,疗程共8周.采用阳性和阴性症状量表(PANSS)和不良反应症状量表(TESS)进行副反应评定.结果 阿立哌唑组总有效率为93.55%,喹硫平组总有效率为90.63%,差异无统计学意义(P>0.05).阿立哌唑组和喹硫平组两组患者治疗前后PANSS量表评分,差异无统计学意义(P>0.05);阿立哌唑组治疗前后相比,瘦素和三酰甘油水平升高,差异有统计学意义(P<0.05),喹硫平组治疗前后瘦素、催乳素、血糖和三酰甘油水平升

  5. Understanding Depression (For Parents)

    Science.gov (United States)

    ... Story" 5 Things to Know About Zika & Pregnancy Depression KidsHealth > For Parents > Depression Print A A A ... to Help en español Comprender la depresión About Depression It's normal for kids to feel sad, down, ...

  6. Measuring psychotic depression

    DEFF Research Database (Denmark)

    Østergaard, Søren Dinesen; Meyers, B S; Flint, A J;

    Psychotic depression (PD) is a highly debilitating condition, which needs intensive monitoring. However, there is no established rating scale for evaluating the severity of PD. The aim of this analysis was to assess the psychometric properties of established depression rating scales and a number of...... new composite rating scales, covering both depressive and psychotic symptoms, in relation to PD....

  7. Help With Depression

    Science.gov (United States)

    ... five to 10 percent of black men have depression. Several factors can contribute to college-aged black men becoming depressed, such as the ... Groups National Institute on Mental Health What is Depression? Clinical Trials Physician Review ... Students Patients & Families About APA Newsroom News Releases Psychiatric ...

  8. Lifestyle and Depression among Hong Kong Nurses

    Directory of Open Access Journals (Sweden)

    Teris Cheung

    2016-01-01

    Full Text Available Recent longitudinal data suggest a close association between depression and lifestyle. Little work to date has estimated the prevalence of depression in the nursing workforce in China, nor considered what lifestyle factors might be correlated with it—a gap filled by the present study. The study’s web-based cross-sectional survey solicited data from qualified nurses aged between 21 and 65 registered with the Hong Kong Nursing Council. The Depression, Anxiety and Stress Scale 21 was used to measure 850 nurses for depression, anxiety and symptoms of stress; a generalized linear regression model examined associations between lifestyle factors and depression. Mean depression symptom scores show a downward linear trend for male and female participants. Gender and age, however, did not emerge as significant predictors of depression. Three lifestyles factors (sleep, entertainment and hobbies showed a significant association with depression. Nurses should make therapeutic lifestyle changes to improve their work-life balance and safeguard their functioning at work and personal well-being.

  9. Interpersonal psychotherapy (IPT) in major depressive disorder.

    Science.gov (United States)

    Brakemeier, Eva-Lotta; Frase, Lukas

    2012-11-01

    In this article, we will introduce interpersonal psychotherapy as an effective short-term treatment strategy in major depression. In IPT, a reciprocal relationship between interpersonal problems and depressive symptoms is regarded as important in the onset and as a maintaining factor of depressive disorders. Therefore, interpersonal problems are the main therapeutic targets of this approach. Four interpersonal problem areas are defined, which include interpersonal role disputes, role transitions, complicated bereavement, and interpersonal deficits. Patients are helped to break the interactions between depressive symptoms and their individual interpersonal difficulties. The goals are to achieve a reduction in depressive symptoms and an improvement in interpersonal functioning through improved communication, expression of affect, and proactive engagement with the current interpersonal network. The efficacy of this focused and structured psychotherapy in the treatment of acute unipolar major depressive disorder is summarized. This article outlines the background of interpersonal psychotherapy, the process of therapy, efficacy, and the expansion of the evidence base to different subgroups of depressed patients. PMID:22955493

  10. [Symptomatic and concurrent depressions].

    Science.gov (United States)

    Terra, J L

    1999-04-01

    The symptomatic and concurrent depressions description need to resort to comorbidity and symptomatic co-occurrence concepts. Patients with depressive symptoms or in a major depressive episode may also be suffering from another nonmood psychiatric disorders as alcoholism, anxiety or eating disorders. Many general medical conditions which are link with depression are illustrated with the examples of cancer, coronary artery disease, endocrinologic diseases, dementia, stroke and chronic fatigue syndrome. When depression and another psychiatric or medical conditions occur together, it is important to provide to the practitioner guidelines for the decision to treat one of the two disorders. This paper contains an example of decisional algorithm. PMID:10337217

  11. Effects of a Multi-Component Behavioral Intervention (MCI) for Insomnia on Depressive and Insomnia Symptoms in Individuals with High and Low Depression

    OpenAIRE

    Johnson, Kirsten; Sidani, Souraya; Epstein, Dana R.

    2015-01-01

    Insomnia and depression are prevalent and co-occurring conditions that are associated with significant impairment of life. Previous research indicates that cognitive-behavioral interventions for insomnia (CBT-I) can improve both insomnia and depressive symptoms. The aim of this study was to determine whether a multi-component behavioral intervention (MCI) improved both insomnia and depressive symptoms in persons presenting with insomnia and high levels of depression. The sample consisted of 3...

  12. Always Consider the Possibility of Opioid Induced Respiratory Depression in Patients Presenting with Hypercapnic Respiratory Failure Who Fail to Improve as Expected with Appropriate Therapy

    OpenAIRE

    Martin Steynor; Andrew MacDuff

    2015-01-01

    Hypercapnic respiratory failure is a frequently encountered medical emergency. Two common causes are acute exacerbations of chronic obstructive pulmonary disease (COPD) and as a side effect of opioids. The two causes may coexist leading to diagnostic confusion and consequent delay in optimal management. We report a case of what was initially thought to be an exacerbation of COPD. The patient failed to improve with treatment as expected which led to the empirical administration of naloxone res...

  13. Noradrenergic symptom cluster in depression

    Directory of Open Access Journals (Sweden)

    Montgomery S

    2011-05-01

    Full Text Available Stuart Montgomery1, Mike Briley21Imperial College School of Medicine, London, UK; 2NeuroBiz Consulting and Communication, Castres, FranceDepression is characterized by a wide range of diverse symptoms, the severity of which can be quantified by various depression rating scales, such as the Montgomery Asberg Depression Rating Scale. Analyses of the individual items of this scale in patients treated with the selective serotonin reuptake inhibitors (SSRIs have shown that not all items respond equally or with the same time of onset of improvement (Table 1.1,2 The items which respond less well or more slowly with SSRIs include lassitude, loss of energy, retardation of thoughts or actions, as well as concentration difficulties and loss of alertness. The loss of interest or pleasure that depressed patients experience (anhedonia also responds poorly to SSRIs, and patients often complain of emotional indifference or blunting. Certain sleep difficulties are sometimes worsened by SSRIs. Appetite loss can be aggravated by certain SSRIs, an effect which can be made worse by nausea at the beginning of treatment.

  14. Collaborative Depression Care Among Latino Patients in Diabetes Disease Management, Los Angeles, 2011–2013

    OpenAIRE

    Wu, Brian; Jin, Haomiao; Vidyanti, Irene; Lee, Pey-Jiuan; Ell, Kathleen; Wu, Shinyi

    2014-01-01

    Introduction The prevalence of comorbid diabetes and depression is high, especially in low-income Hispanic or Latino patients. The complex mix of factors in safety-net care systems impedes the adoption of evidence-based collaborative depression care and results in persistent disparities in depression outcomes. The Diabetes–Depression Care-Management Adoption Trial examined whether the collaborative depression care model is an effective approach in safety-net clinics to improve clinical care o...

  15. Progress of Researcheson Mechanisms of Acupuncture Underlying Improvement of Depression in the Past Five Years%针刺治疗抑郁症作用机制近5年研究进展

    Institute of Scientific and Technical Information of China (English)

    户丽; 梁佳; 金树英; 韩焱晶; 卢峻; 图娅

    2013-01-01

    Depression is a state of low mood and aversion to activity that has a negative effect on the patient's thoughts,behavior,feelings,and physical well-being.In the past five years,a significant progress has been made in understanding the mechanism of acupuncture therapy for improving depression.In the present paper,the authors summarize mechanisms of acupuncture for depression from 1) upregulating levels of monoamine neurotransmitters,gamma-aminobutyric acid,5-HT1A receptor binding,and hypothalamic neuropeptide Y,β-endorphine,and μ-receptor expression,and down-regulating hippocampal glutamate content,etc.; 2) upregulating expression of hippocampal brain-derived neurotrophic factor protein and mRNA and its receptor TrkB,and activating adenyl eyclase-cAMP-PKA-CREB signaling pathway; 3) increasing hi ppocampal growth-associated protein 43 level and suppressing hippocampal c-Jun N-terminal kinase activation and cellular apoptosis; 4) upregulating expression of glial fibrillary acidic protein (activating glia cells) ; 5) regulating activities of hypothalamus-pituitary-adrenal axis and hypothalamus-pituitary-sex gland axis; 6) down-regulating serum IL-1β,IL-6,and tumor necrosis factor-α levels.Moreover,the authors also put forward some suggestions about the further research on the mechanisms of acupuncture intervention for depression in the future.%近5年来,针刺治疗抑郁症的作用机制研究取得了显著进展,笔者对此进行了综述,主要包括以下几方面:(1)针刺上调海马内单胺类神经递质、γ-氨基丁酸含量和5-羟色胺1A受体结合位点,及下丘脑神经肽Y、β-内啡肽、μ受体的表达,降低海马谷氨酸含量;(2)针刺上调海马脑源性神经营养因子蛋白及基因和相关受体的表达,激活腺苷酸环化酶-环磷酸腺苷(cAMP)-蛋白激酶A-cAMP反应元件结合蛋白信号通路;(3)针刺增加海马生长相关蛋白-43水平,并抑制c-J un氨基末端激酶活性和细胞凋亡;(4)针刺

  16. Always Consider the Possibility of Opioid Induced Respiratory Depression in Patients Presenting with Hypercapnic Respiratory Failure Who Fail to Improve as Expected with Appropriate Therapy

    Science.gov (United States)

    Steynor, Martin; MacDuff, Andrew

    2015-01-01

    Hypercapnic respiratory failure is a frequently encountered medical emergency. Two common causes are acute exacerbations of chronic obstructive pulmonary disease (COPD) and as a side effect of opioids. The two causes may coexist leading to diagnostic confusion and consequent delay in optimal management. We report a case of what was initially thought to be an exacerbation of COPD. The patient failed to improve with treatment as expected which led to the empirical administration of naloxone resulting in a dramatic reversal of her respiratory failure. The patient was subsequently discovered to be taking regular dihydrocodeine for chronic back pain. PMID:25893118

  17. Always Consider the Possibility of Opioid Induced Respiratory Depression in Patients Presenting with Hypercapnic Respiratory Failure Who Fail to Improve as Expected with Appropriate Therapy

    Directory of Open Access Journals (Sweden)

    Martin Steynor

    2015-01-01

    Full Text Available Hypercapnic respiratory failure is a frequently encountered medical emergency. Two common causes are acute exacerbations of chronic obstructive pulmonary disease (COPD and as a side effect of opioids. The two causes may coexist leading to diagnostic confusion and consequent delay in optimal management. We report a case of what was initially thought to be an exacerbation of COPD. The patient failed to improve with treatment as expected which led to the empirical administration of naloxone resulting in a dramatic reversal of her respiratory failure. The patient was subsequently discovered to be taking regular dihydrocodeine for chronic back pain.

  18. 换用阿立哌唑对精神分裂症患者代谢的影响%Metabolic effects in treating schizophrenia patients after switching to aripiprazole

    Institute of Scientific and Technical Information of China (English)

    程群; 朱怀轩

    2012-01-01

    目的:探讨换用阿立哌唑治疗后精神分裂症患者各项代谢指标的改善情况. 方法:选择43例换用阿立哌唑治疗的精神分裂症患者,分别在换药前和换药12周对患者的血糖、血脂和体质量等代谢指标进行检测. 结果:换用阿立哌唑12周,患者的体质量(t=3.38,P<0.01)和体质量指数(t=3.07,P<0.01)显著改善,空腹血糖(t=2.96,P<0.01)、2h血糖(=2.58,P<0.01)、糖化血红蛋白(t=3.50,P<0.01)、空腹胰岛素(t=19.71,P<0.01)、和稳态模型评估的胰岛素抵抗系数(t=2.70,P<0.05)均较治疗前显著降低,总胆固醇(t=2.78,P<0.01)、三酰甘油(t=4.38,P<0.01)和低密度脂蛋白(=2.81,P<0.01)亦有显著降低,代谢综合征的患病率(x2=19.07,P<0.01)显著降低. 结论:换用阿立哌唑治疗对精神分裂症患者的代谢有显著改善作用.%Objective: To evaluate extensively the metabolic improvements of switching to aripirzazole in the treatment of schizophrenia. Method :43 patients who had successfully switched to aripirazole with a schizophrenia diagnosis went through an extensive metabolic evaluation, including blood glucose, blood lipids and body weight test at baseline and at 12 weeks post switch. Results: There was significant decreases in body weight(t=3. 38, P< 0.01), body mass index(t =3. 07,P <0. 01) .fasting glucose(t =2. 96,P <0. 01) .glucose at 2 h(t = 2. 58,P<0. 01) .glycated hemoglobin(t = 3. 50, P < 0.01) .fasting insulin(t = 19. 71,P< 0.01),insulin resistance index(t =2. 70,P<0.05) .total cholesterol (t =2. 78,P <0.01), triglycerides (t = 4. 38,P<0.01) and low-density lipoprotein (t =2. 81 ,P<0.01) levels. There was also a significant reduction in the prevalence of metabolic syndrome(χ 2 = 19.07,P <0.01). Conclusion: Switching to aripiprazole can significantly improve metabolic abnormalities in treating schizophrenia.

  19. Depressive symptoms and early retirement intentions among Danish eldercare workers

    DEFF Research Database (Denmark)

    Nexo, Mette Andersen; Borg, Vilhelm; Sejbaek, Camilla Sandal;

    2015-01-01

    Danish eldercare sector. Depressive symptoms were measured by the Major Depression Inventory and the impact of different levels of depressive symptoms (severe, moderately severe, moderate, mild and none) and changes in depressive symptoms (worsened, improved, unaffected) on early retirement intentions...... were analysed with multinomial logistic regression. RESULTS: In the cross-sectional analysis all levels of depressive symptoms were significantly associated with retirement intentions before the age of 62 years. Similar associations were found prospectively. Depressive symptoms and worsened depressive...... symptoms in the two year period from baseline to follow-up were also significantly associated with early retirement intentions before age 62. The prospective associations lost statistical significance when controlling for early retirement intentions at baseline. CONCLUSIONS: The whole spectrum of...

  20. Sphingolipids in Major Depression

    Directory of Open Access Journals (Sweden)

    Peter L. Jernigan

    2015-12-01

    Full Text Available Major depression is one of the most common and severe diseases affecting the world's population. However, the pathogenesis of the disease remains inadequately defined. Previously, a lack of monoaminergic neurotransmitters was the focus of pathophysiological concepts; however, recent concepts focus on a alteration of neurogenesis in the hippocampus. This concept suggests that neurogenesis is decreased in major depression with a rarefication of neuronal networks and a lack of new, immature neurons in the hippocampus, events that may result in the clinical symptoms of major depression. However, molecular targets involved in the pathogenesis of major depression and, in particular, a reduction of neurogenesis, are largely unknown. We have recently discovered that an inhibition of the acid sphingomyelinase/ceramide system mediates the effects of tri- and tetracyclic antidepressants. Moreover, an accumulation of ceramide in the hippocampus results in depression-like symptoms. This suggests the acid sphingomyelinase/ceramide system is very important in the pathogenesis of major depression.

  1. Measuring psychotic depression

    DEFF Research Database (Denmark)

    Østergaard, Søren Dinesen; Meyers, B S; Flint, A J; Mulsant, B H; Whyte, E M; Ulbricht, C M; Bech, P; Rothschild, A J

    2014-01-01

    OBJECTIVE: Psychotic depression (PD) is a highly debilitating condition, which needs intensive monitoring. However, there is no established rating scale for evaluating the severity of PD. The aim of this analysis was to assess the psychometric properties of established depression rating scales and...... a number of new composite rating scales, covering both depressive and psychotic symptoms, in relation to PD. METHOD: The psychometric properties of the rating scales were evaluated based on data from the Study of Pharmacotherapy of Psychotic Depression. RESULTS: A rating scale consisting of the 6...... Hamilton Depression Scale failed to meet criteria for unidimensionality. CONCLUSION: Our results suggest that the HAMD-BPRS11 is a more valid measure than pure depression scales for evaluating the severity of PD....

  2. What is depression?

    DEFF Research Database (Denmark)

    Sofie Davidsen, Annette; Fosgerau, Christina Fogtmann

    2014-01-01

    depression is insufficient and a collaborative care (CC) model between general practice and psychiatry has been proposed to overcome this. However, for successful implementation, a CC model demands shared agreement about the concept of depression and the diagnostic process in the two sectors. We aimed to......The diagnosis of depression is defined by psychiatrists, and guidelines for treatment of patients with depression are created in psychiatry. However, most patients with depression are treated exclusively in general practice. Psychiatrists point out that general practitioners' (GPs') treatment of...... explore how depression is understood by GPs and clinical psychiatrists. We carried out qualitative in-depth interviews with 11 psychiatrists and 12 GPs. Analysis was made by Interpretative Phenomenological Analysis. We found that the two groups of physicians differed considerably in their views on the...

  3. Standardization of depression measurement

    DEFF Research Database (Denmark)

    Wahl, Inka; Löwe, Bernd; Bjørner, Jakob;

    2014-01-01

    OBJECTIVES: To provide a standardized metric for the assessment of depression severity to enable comparability among results of established depression measures. STUDY DESIGN AND SETTING: A common metric for 11 depression questionnaires was developed applying item response theory (IRT) methods. Data...... of 33,844 adults were used for secondary analysis including routine assessments of 23,817 in- and outpatients with mental and/or medical conditions (46% with depressive disorders) and a general population sample of 10,027 randomly selected participants from three representative German household...... surveys. RESULTS: A standardized metric for depression severity was defined by 143 items, and scores were normed to a general population mean of 50 (standard deviation = 10) for easy interpretability. It covers the entire range of depression severity assessed by established instruments. The metric allows...

  4. Pulsed depressed collector

    Energy Technology Data Exchange (ETDEWEB)

    Kemp, Mark A

    2015-11-03

    A high power RF device has an electron beam cavity, a modulator, and a circuit for feed-forward energy recovery from a multi-stage depressed collector to the modulator. The electron beam cavity include a cathode, an anode, and the multi-stage depressed collector, and the modulator is configured to provide pulses to the cathode. Voltages of the electrode stages of the multi-stage depressed collector are allowed to float as determined by fixed impedances seen by the electrode stages. The energy recovery circuit includes a storage capacitor that dynamically biases potentials of the electrode stages of the multi-stage depressed collector and provides recovered energy from the electrode stages of the multi-stage depressed collector to the modulator. The circuit may also include a step-down transformer, where the electrode stages of the multi-stage depressed collector are electrically connected to separate taps on the step-down transformer.

  5. Screening for Depression in Latino Immigrants: A Systematic Review of Depression Screening Instruments Translated into Spanish.

    Science.gov (United States)

    Limon, Francisco J; Lamson, Angela L; Hodgson, Jennifer; Bowler, Mark; Saeed, Sy

    2016-08-01

    The research on the diagnostic accuracy of Spanish language depression-screening instruments continues to be scarce in the US. Under-detection of depression by Primary Care Providers is approximately 50 % in the general population and this rate may be even higher for Latino immigrants for whom the depression rate tends to be higher than for non-Hispanic Whites. This systematic review shows that there is still limited evidence that guides primary care-based depression screening for Spanish speakers. The economic, social, and human costs of depression are high and complex; yet improvements in the effectiveness of treatment cannot be made available to sufferers of the disorder if they go undetected. PMID:26660481

  6. Fibromyalgia and Depression

    OpenAIRE

    Gracely, Richard H.; M. Catherine Bushnell; Marta Ceko

    2011-01-01

    Fibromyalgia and depression might represent two manifestations of affective spectrum disorder. They share similar pathophysiology and are largely targeted by the same drugs with dual action on serotoninergic and noradrenergic systems. Here, we review evidence for genetic and environmental factors that predispose, precipitate, and perpetuate fibromyalgia and depression and include laboratory findings on the role of depression in fibromyalgia. Further, we comment on several aspects of fibromyal...

  7. Physical activity & depression

    OpenAIRE

    Tsiantoula E.; Tsiadoula L.; Patsiaouras A.; Kokaridas D.

    2012-01-01

    Depression is a major public health disorder. Clinical depression is the most frequent disability in North America among other countries and by 2020 it is estimated that it will represent the second most common disability worldwide. Physical activity can be used to prevent as well as treat depression. Its characteristics and structure should be individualized to the personality and special needs of the patient as well as to the severity of the disorder. Intensity, duration and the place of pe...

  8. The Nation in Depression

    OpenAIRE

    Christina D. Romer

    1993-01-01

    This paper examines the American Great Depression and the ways in which the U.S. experience during the 1930s resembled that of other countries in some regards and fundamentally differed in other aspects. I also evaluate the evidence on the causes of the Great Depression in the United States and the sources of the eventual recovery. The picture painted of the American Great Depression is one that stresses the importance of national, rather than international, aggregate demand shocks. The exper...

  9. Stress, norepinephrine and depression.

    OpenAIRE

    Leonard, B E

    2001-01-01

    Stress is an important precipitant factor in depression, and the changes in various body systems that occur in depression are similar to those observed in response to stress. This paper discusses the interactions among the immune, endocrine and norepinephrine systems that are evident in patients with depression, as well as those affected by stress. Many of the stress-induced changes can be reversed by antidepressants, particularly norepinephrine reuptake inhibitors.

  10. DEPRESSION IN CEREBROVASCULAR DISEASES

    Directory of Open Access Journals (Sweden)

    Tat'yana Gratsievna Voznesenskaya

    2009-06-01

    both direct and indirect risk factor for the development of stroke. on the other. The vascular depression concept by G.S. Alexopoulos and its main points are discussed. The author gives her own data on the prevalence of depression in dyscirculatory encephalopathy with non-dementia cognitive disorders. She gives prove that a neurologist should diagnose and treat depression and to choose antidepressants for its treatment.

  11. Management of Bipolar Depression

    OpenAIRE

    Jae Seung Chang; Kyooseob Ha

    2011-01-01

    Patients with bipolar disorder spend more time in a depressed than manic state, even with individualized treatment. To date, bipolar depression is often misdiagnosed and ineffectively managed both for acute episodes and residual symptoms. This review attempts to summarize the current status of available treatment strategies in the treatment of bipolar depression. For acute and prophylactic treatment, a substantial body of evidence supports the antidepressive efficacy of lithium for bipolar di...

  12. Depression in Older Adults

    OpenAIRE

    Fiske, Amy; Wetherell, Julie Loebach; Gatz, Margaret

    2009-01-01

    Depression is less prevalent among older adults than among younger adults but can have serious consequences. Over half of cases represent a first onset in later life. Although suicide rates in the elderly are declining, they are still higher than in younger adults and more closely associated with depression. Depressed older adults are less likely to endorse affective symptoms and more likely to display cognitive changes, somatic symptoms, and loss of interest than are younger adults. Risk fac...

  13. The Effect of Interpersonal Psychotherapy for Depression on Insomnia Symptoms in a Cohort of Women with Sexual Abuse Histories

    OpenAIRE

    Pigeon, Wilfred R.; May, Pamela E.; Perlis, Michael L.; Ward, Erin A.; Lu, Naiji; Talbot, Nancy L.

    2009-01-01

    Insomnia frequently occurs with trauma exposure and depression, but can ameliorate with improvements in depression. Insomnia was assessed by the insomnia subscale of the Hamilton Rating Scale for Depression in 106 women with childhood sexual abuse (CSA) and major depression receiving Interpersonal Psychotherapy in an uncontrolled pilot (n = 36) and an immediately subsequent randomized controlled trial (n = 70) comparing IPT to treatment as usual. Depression improved in each study and in both ...

  14. Effects of group reminiscence on elderly depression: A meta-analysis

    Directory of Open Access Journals (Sweden)

    Dan Song

    2014-12-01

    Conclusion: Group reminiscence was associated with short-term depression relief among elderly patients with depression and effectively improved self-esteem and life satisfaction. Higher-quality large-scale randomised controlled trials are needed to confirm these findings.

  15. Going to Scale: Re-Engineering Systems for Primary Care Treatment of Depression

    OpenAIRE

    Dietrich, Allen J.; Oxman, Thomas E.; Williams, John W.; Kroenke, Kurt; Schulberg, H. Charles; Bruce, Martha; Barry, Sheila L.

    2004-01-01

    BACKGROUND Recent trials have shown improved depression outcomes with chronic care models. We report the methods of a project that assesses the sustainability and transportability of a chronic care model for depression and change strategy.

  16. Integration of Depression and Hypertension Treatment: A Pilot, Randomized Controlled Trial

    OpenAIRE

    BOGNER, HILLARY R.; de Vries, Heather F.

    2008-01-01

    PURPOSE We wanted to examine whether integrating depression treatment into care for hypertension improved adherence to antidepressant and antihypertensive medications, depression outcomes, and blood pressure control among older primary care patients.

  17. Striatal Dopamine D-2/3 Receptor Availability in Treatment Resistant Depression

    NARCIS (Netherlands)

    de Kwaasteniet, Bart P.; Pinto, Chedwa; Ruhe, Eric H. G.; van Wingen, Guido A.; Booij, Jan; Denys, Damiaan

    2014-01-01

    Several studies demonstrated improvement of depressive symptoms in treatment resistant depression (TRD) after administering dopamine agonists which suggest abnormal dopaminergic neurotransmission in TRD. However, the role of dopaminergic signaling through measurement of striatal dopamine D-2/3 recep

  18. Depression and eating disorders.

    Science.gov (United States)

    Casper, R C

    1998-01-01

    Both depressive disorders and eating disorders are multidimensional and heterogeneous disorders. This paper examines the nature of their relationship by reviewing clinical descriptive, family-genetic, treatment, and biological studies that relate to the issue. The studies confirm the prominence of depressive symptoms and depressive disorders in eating disorders. Other psychiatric syndromes which occur with less frequency, such as anxiety disorders and obsessive-compulsive disorders in anorexia nervosa, or personality disorders, anxiety disorders, and substance abuse in bulimia nervosa, also play an important role in the development and maintenance of eating disorders. Since few studies have controlled for starvation-induced physical, endocrine, or psychological changes which mimic the symptoms considered diagnostic for depression, further research will be needed. The evidence for a shared etiology is not compelling for anorexia nervosa and is at most suggestive for bulimia nervosa. Since in contemporary cases dieting-induced weight loss is the principal trigger, women with self-critical or depressive features will be disproportionately recruited into eating disorders. The model that fits the data best would accommodate a relationship between eating disorders and the full spectrum of depressive disorders from no depression to severe depression, with somewhat higher rates of depression in bulimic anorectic and bulimia nervosa patients than in restricting anorexia nervosa patients, but the model would admit a specific pathophysiology and psychopathology in each eating disorder. PMID:9809221

  19. [Sleep in depression].

    Science.gov (United States)

    Pringuey, D; Darcourt, G

    1990-11-28

    Insomnia is a cardinal symptom of depression, side by side with alterations of mood and slowing down of psychomotor activities. It bears witness to a rupture in the built-in circadian rhythm: architectural changes in sleep betray a biological desynchronization. Insomnia is also a failed attempt at finding a solution to depression. Total deprivation of sleep for one night may damp down the depressive disorders, and so does partial sleep deprivation in the second part of the night during several days. This leads to the conclusion that the waking-sleep system participates in the expression of symptoms of depression or even contributes to the genesis of the disease. PMID:2148377

  20. Cognitive impairments and depression: a critical review.

    Science.gov (United States)

    Roca, Miquel; Vives, Margalida; López-Navarro, Emilio; García-Campayo, Javier; Gili, Margalida

    2015-09-01

    Cognitive impairments are core symptoms of depressive disorders. We assess the systematic reviews and meta-analysis studies published over the last 10 years (2004-2014) that address cognitive performance of depressed patients and taking into account age; clinical and demographic features; symptom severity; number of previous episodes; clinical remission; depressive subtypes and pharmacological treatment. Twelve (12) papers were included after search in international databases. In first episode depression the cognitive domains affected were psychomotor speed, attention, visual learning and memory as well as executive functions. Depressive patients in remission phase improved their performance in attention tasks although they did not achieve similar performance levels as healthy controls. Melancholic patients seem to have a different pattern of cognitive impairment compared with non-melancholic depressive patients. Patients treated with the current antidepressants perform worse in inhibition tasks, verbal fluency, and working memory scores as well as on composite scores of visual and verbal working memory. Future research should study longitudinal outcome and clinical relevance of cognitive symptoms, determine their underlying etiopathogenesis and how they impact on clinical functioning. Specifically, it would be important to analyze the ability of the new antidepressant drugs to improve affective symptoms as well as cognitive dysfunctions. PMID:26320897

  1. Facial recognition of happiness among older adults with active and remitted major depression.

    Science.gov (United States)

    Shiroma, Paulo R; Thuras, Paul; Johns, Brian; Lim, Kelvin O

    2016-09-30

    Biased emotion processing in depression might be a trait characteristic independent of mood improvement and a vulnerable factor to develop further depressive episodes. This phenomenon of among older adults with depression has not been adequately examined. In a 2-year cross-sectional study, 59 older patients with either active or remitted major depression, or never-depressed, completed a facial emotion recognition task (FERT) to probe perceptual bias of happiness. The results showed that depressed patients, compared with never depressed subjects, had a significant lower sensitivity to identify happiness particularly at moderate intensity of facial stimuli. Patients in remission from a previous major depressive episode but with none or minimal symptoms had similar sensitivity rate to identify happy facial expressions as compared to patients with an active depressive episode. Further studies would be necessary to confirm whether recognition of happy expression reflects a persistent perceptual bias of major depression in older adults. PMID:27428081

  2. Depression in the aging: an important health problem in Mexico

    Directory of Open Access Journals (Sweden)

    Jesús RIVERA NAVARRO

    2015-12-01

    Full Text Available Depression is a disease which has an especially worrying impact on old aged people due to the increased risk factors for diseases in this age group. In Mexico there are very few studies on depression in aging. The objectives of our study are: 1 to estimate the prevalence of depressive symptoms in old aged people and; 2 to analyze the relation between depressive symptoms and different risk factors of depression. The research is a cross-sectional population study and was made in Ciudad Victoria, Tamaulipas state. 1,126 elderly were interviewed (455 male and 671 female, which constituted 5.1% of the old age population in Ciudad Victoria. Depression was measured on the Geriatric Depression Scale. The results point out: 1 the prevalence of depressive symptoms was estimated to be 29% of the interviewed subjects; 2 the factors favoring depression were the dependence on daily life activities, cognitive impairment, lack of social support, age, gender, loneliness, poverty, stressful events and subjective perception of health. Decreasing depression is not only related to improvement of health but also to the improvement of the conditions of old age life.

  3. How Should We Treat Depression in Patients with Cardiovascular Disease?

    OpenAIRE

    Kronish, Ian M.; Krupka, David J.; Davidson, Karina W.

    2012-01-01

    Among patients with cardiovascular disease (CVD), depression is highly prevalent and is associated with worse cardiovascular prognosis and lower quality of life. Treatments for depression in CVD patients produce modest, but clinically significant reductions in depressive symptoms and show promise for improving cardiovascular prognosis. While tricyclics should generally be avoided, antidepressants from multiple other classes appear to be safe in cardiac patients. A strategy of engaging patient...

  4. Depresija in bolečina: Depression and pain:

    OpenAIRE

    Kores-Plesničar, Blanka

    2010-01-01

    Depression is one of the leading causes of global disease burden. In addition, depression is frequently associated with troublesomephysical symptoms, such as fatigue, sleep disturbances and appetite changes, and also with painful physical symptoms, like back pain,headache, fibromyalgia and others. Depression and pain have a reciprocal relationship in that one heightens the severity of the other. There remains a clear room for further improvement and change in the approach to elimination of th...

  5. Effectiveness of the workshop "Adolescent depression: What can schools do?"

    OpenAIRE

    Vania eMartinez; Daniel eEspinosa; Pedro eZitko; Rigoberto eMarin; Sara eSchilling; Camila eSchwerter; Graciela eRojas

    2015-01-01

    Introduction: Adolescent depression is associated with serious consequences. School staff is in a unique position to screen and refer adolescents with depression in a timely manner, and can collaborate with healthcare teams to assist in the proper management of the disease. The objective of this paper is to describe the results of a workshop that aims to improve the knowledge of adolescent depression among school staff.Material and methods: This was a single-arm trial with a pre-post design. ...

  6. Studying depression using imaging and machine learning methods

    OpenAIRE

    Patel, Meenal J.; Alexander Khalaf; Aizenstein, Howard J.

    2015-01-01

    Depression is a complex clinical entity that can pose challenges for clinicians regarding both accurate diagnosis and effective timely treatment. These challenges have prompted the development of multiple machine learning methods to help improve the management of this disease. These methods utilize anatomical and physiological data acquired from neuroimaging to create models that can identify depressed patients vs. non-depressed patients and predict treatment outcomes. This article (1) presen...

  7. Treatment of Comorbid Obesity and Major Depressive Disorder: A Prospective Pilot Study for their Combined Treatment

    Directory of Open Access Journals (Sweden)

    Lucy F. Faulconbridge

    2011-01-01

    Full Text Available Background. Obese individuals who suffer from major depressive disorder are routinely screened out of weight loss trials. Treatments targeting obesity and depression concurrently have not been tested. Purpose. To test the short-term efficacy of a treatment that combined behavioral weight management and cognitive behavioral therapy (CBT for obese adults with depression. Methods. Twelve obese females diagnosed with major depressive disorder received weekly group behavioral weight management, combined with CBT for depression, for 16 weeks. Weight, symptoms of depression, and cardiovascular disease (CVD risk factors were measured at baseline and week 16. Results. Participants lost 11.4% of initial weight and achieved significant improvements in symptoms of depression and CVD risk factors. Conclusions. Obese individuals suffering from major depressive disorder can lose weight and achieve improvements in symptoms of depression and CVD risk factors with 16 weeks of combined treatment. A larger randomized controlled trial is needed to establish the efficacy of this treatment.

  8. Depression in patients with mastocytosis: prevalence, features and effects of masitinib therapy.

    Directory of Open Access Journals (Sweden)

    Daniela Silva Moura

    Full Text Available Depression in patients with mastocytosis is often reported but its prevalence and characteristics are not precisely described. In addition, the impact of therapies targeting mast cells proliferation, differentiation and degranulation on psychic symptoms of depression have never been investigated. Our objective was to determine the prevalence and to describe features of depression in a large cohort of mastocytosis patients (n = 288 and to investigate the therapeutic impact of the protein kinase inhibitor masitinib in depression symptoms. The description of depression was based on the analysis of a database with Hamilton scores using Principal Component Analysis (PCA. Efficacy of masitinib therapy was evaluated using non parametric Wilcoxon test for paired data within a three months period (n = 35. Our results show that patients with indolent mastocytosis present an elevated prevalence of depression (64%. Depression was moderate in 56% but severe in 8% of cases. Core symptoms (such as psychic anxiety, depressed mood, work and interests characterized depression in mastocytosis patients. Masitinib therapy was associated with significant improvement (67% of the cases of overall depression, with 75% of recovery cases. Global Quality of Life slightly improved after masitinib therapy and did not predicted depression improvement. In conclusion, depression is very frequent in mastocytosis patients and masitinib therapy is associated with the reduction its psychic experiences. We conclude that depression in mastocytosis may originate from processes related to mast cells activation. Masitinib could therefore be a useful treatment for mastocytosis patients with depression and anxiety symptoms.

  9. Depression in Children and Teens

    Science.gov (United States)

    ... Return to Web version Depression in Children and Teens Depression in Children and Teens How are the symptoms ... aafp.org/afp/20001115/2297.html) Childhood and Adolescent Depression by SK Bhatia, M.D., and SC Bhatia, ...

  10. Symptoms and Treatment of Depression

    Medline Plus

    Full Text Available ... Prevention (7 items) Treatments (11 items) Symptoms and Treatment of Depression February 1, 2010 People with depression ... why it affects some people but not others. Treatments for depression do work. One type of effective ...

  11. Helping your teen with depression

    Science.gov (United States)

    ... ency/patientinstructions/000646.htm Helping your teen with depression To use the sharing features on this page, please enable JavaScript. Your teen's depression may be treated with talk therapy, anti-depression ...

  12. Depression During and After Pregnancy

    Science.gov (United States)

    ... Depression during and after pregnancy fact sheet ePublications Depression during and after pregnancy fact sheet This information in Spanish (en español) Print this fact sheet Depression during and after pregnancy fact sheet (PDF, 260 ...

  13. St. John's Wort and Depression

    Science.gov (United States)

    ... W X Y Z St. John's Wort and Depression: In Depth Share: On This Page Introduction Key ... will help ensure coordinated and safe care. About Depression Depression is a medical condition that affects about ...

  14. Antidepressant treatment of the depressed patient with insomnia.

    Science.gov (United States)

    Thase, M E

    1999-01-01

    Sleep disturbances are an integral part of depressive disorder. As such, they are a part of all contemporary sets of diagnostic criteria for major depression and of all major symptom-based rating scales for depression. Insomnia is a particularly frequent complaint, and it is reported by more than 90% of depressed patients. Although the "kindling" or "illness transduction" model of depression remains hypothetical, there is evidence that people with recurrent depression have more pronounced abnormalities of sleep neurophysiology than those experiencing a single or initial episode. Therefore, early relief of insomnia in a depressed patient, in addition to alleviating other symptoms, may increase adherence to treatment and increase daytime performance and overall functioning, while complete relief of insomnia may improve prognosis. Stimulation of serotonin-2 (5-HT2) receptors is thought to underlie insomnia and changes in sleep architecture seen with selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors (SNRIs). This is the reason why hypnotics or low-dose trazodone are commonly coprescribed at the initiation of the treatment with either the SSRIs or SNRIs. On the other hand, antidepressant drugs with 5-HT2 blocking properties, such as mirtazapine or nefazodone, alleviate insomnia and improve sleep architecture. In depressed patients, mirtazapine produces a significant shortening of sleep-onset latency, increases a total sleep time, and leads to a marked improvement in sleep efficiency. Antidepressants with preferential 5-HT2 blocking properties are therefore a good treatment option for depressed patients with marked insomnia. PMID:10446739

  15. Memory training in depression

    NARCIS (Netherlands)

    Becker, E.S.; Vanderhasselt, M.A.; Vrijsen, J.N.

    2015-01-01

    Memory biases, that is, general memory impairments as well as specific mood-congruent memory biases, are important vulnerability factors in depression. Recently, computerized memory trainings have been developed to target these biases, reducing rumination and lightening depressive symptoms. This rev

  16. Adjustments and Depression

    Medline Plus

    Full Text Available ... on navigating depression following a spinal cord injury. University of Washington provides pamphlets on depression with spinal ... grant number 90PR3002, from the U.S. Administration for Community Living, ... Services, Washington, D.C. 20201. Grantees undertaking projects under ...

  17. Real Stories of Depression

    Medline Plus

    Full Text Available ... and Depression Background on Educational Materials Resources for Health Care Providers Public Service Announcements (PSAs) Join A Study Depression Studies for Adults Contact Us Staff Directories Privacy Notice Policies FOIA Accessibility Topic ... The National Institute of Mental Health (NIMH) is part of the National Institutes of ...

  18. Testosterone and Depression

    Directory of Open Access Journals (Sweden)

    Şükrü Kartalcı

    2010-12-01

    Full Text Available Androgens have various effects on human body and mood. Testosterone, a hormone mainly secreted from testes and adrenals, is one of the most potent androgens. Multiple studies have found that testosterone plays a role in regulating sexual activity, libido, social behaviors, aggression, cognitive functions, sleep control and well-being in men and women. Testosterone deficiency in hypogonadic or elderly men leads to neuropsychiatric problems, such as fatigue, loss of libido, irritability, insomnia and depressive mood. Testosterone replacement therapy consistently reverses these sequel in men. On the other hand, hyperandrogenic states in women are related to aggression and antisocial behavior, which might lead to depressive mood. Low testosterone levels may also result in depression among oophorectomized women. Because of such effects, a relationship between testosterone and depression has long been an issue of speculation, but yet very few studies have addressed this relation. Along with clinical studies, experimental and epidemiological studies show that testosterone is related to depression in men and women. But studies of testosterone concentrations in depression have yielded inconsistent results reporting low as well as high testosterone levels associated with depression. In this article, the physiological and psychological effects of testosterone and evidence regarding its relationship to depressive disorders and possible gender differences have been reviewed.

  19. Depression Begets Depression: Comparing the Predictive Utility of Depression and Anxiety Symptoms to Later Depression

    Science.gov (United States)

    Keenan, Kate; Feng, Xin; Hipwell, Alison; Klostermann, Susan

    2009-01-01

    Background: The high comorbidity between depressive and anxiety disorders, especially among females, has called into question the independence of these two symptom groups. It is possible that childhood anxiety typically precedes depression in girls. Comparing of the predictive utility of symptoms of anxiety with the predictive utility of symptoms…

  20. Depression and African Americans

    Science.gov (United States)

    ... is a common, yet serious, medical illness. Clinical depression is a “whole-body” illness that affects your mood, thoughts, body and behavior. Without treatment, symptoms can last for weeks, months or years. Appropriate ... Clinical depression can affect anyone: Anyone can experience ...

  1. Real Stories of Depression

    Medline Plus

    Full Text Available ... and Depression Background on Educational Materials Resources for Health Care Providers Public Service Announcements (PSAs) Join A Study Depression Studies for Adults Contact Us Staff Directories Privacy ... The National Institute of Mental Health (NIMH) is part of the National Institutes of ...

  2. Adjustments and Depression

    Medline Plus

    Full Text Available ... 7309 ☰ Living with Paralysis Get Support Get Involved Research Events Blog & Forum About Us Donate Living with Paralysis > Newly paralyzed > How do I deal with depression and adjustment to my SCI? How do I deal with depression and ...

  3. Postpartum Depression: An Overview.

    Science.gov (United States)

    Albright, Angela

    1993-01-01

    Occurring in about 12 percent of postpartum women, postpartum depression has been focus of considerable research. Variables that have been correlated with postpartum depression range from biological causes, to lack of social support, to relationship with husband, to attributional styles, to psychodynamic explanations. There is need for more…

  4. Adjustments and Depression

    Medline Plus

    Full Text Available ... Depression, however, is a serious medical disorder that affects your thoughts, feelings, physical health and behaviors as well as other aspects of your life. Depression can cause physical and psychological symptoms. It can worsen pain, make sleep difficult, cause loss of energy, take away your ...

  5. [Severe depression : psychoanalysis].

    Science.gov (United States)

    Bouvet de la Maisonneuve, O

    2009-12-01

    The indication for psychoanalysis in severe depression is not clear. And yet, demands for this type of intervention are increasing, despite the absence of any form of consensus on the subject. Freud considered depression as a failure of analytical efforts and, based on this observation, revised his theory, in particular to include the notions of narcissism and the death drive. Many analysts have been reluctant to follow his teachings on this last point and provide depressed patients with analytical-type therapies aimed at restoring narcissism. Melanie Klein pushed Freud's ideas about depression even further and brought such therapies back to the heart of analytical practice. Jacques Lacan took the debate to another level by proposing an overhaul of the principles on which analysis has been based. Today, while following certain precautionary rules, true psychoanalyses can be proposed to patients with severe depression, whether of the bipolar, recurring or even neurotic type that can reach this level of severity. PMID:20141799

  6. Depression in schizophrenia.

    Science.gov (United States)

    Becker, R E

    1988-12-01

    Depressive syndromes that occur during the course of schizophrenia are not clearly understood but have important implications for the treatment of the schizophrenic patient. In this review of the literature on depression secondary to schizophrenia, the author notes that lack of tested diagnostic criteria has led to a misunderstanding of its relatively high frequency and its association with poor outcome features such as impaired psychosocial functioning, schizophrenic relapse, and suicide. Differential diagnosis, including ruling out akinetic depression, is essential, he believes, partly because the concept of schizophrenic depression as postpsychotic is not supported by evidence. Clinical management must address such increased risk factors as relapse and suicide, but evidence indicates that secondary depression in schizophrenia does not respond to antidepressant medication. PMID:3068116

  7. Lao Depression Inventory.

    Science.gov (United States)

    Davidson-Muskin, M B; Golden, C

    1989-01-01

    There are no measurement tools that accurately measure depression among Lao refugees. The overall purpose of this research was to complete the development and validation procedures for the Lao Depression Inventory (LDI). The study consisted of 216 Ethnic Lao refugees. A clinical interview and 164 true/false questions were administered to identify specific items which could identify depression among the Ethnic Lao people. All items were administered in both English and Lao. Overall, 78 of the 164 items differentiated groups of depressed and nondepressed Lao at the .01 level. Results of validation procedures showed that a 30-item scale had an accuracy rate of 89% in identifying the presence of depression in the validation group; the hit-rate for the same items and cutoff was 92% in the cross-validation group. Potential uses of the scale are discussed. PMID:2918451

  8. Relationship dynamics around depression in gay and lesbian couples.

    Science.gov (United States)

    Thomeer, Mieke Beth; Reczek, Corinne; Umberson, Debra

    2015-12-01

    Research on intimate relationship dynamics around depression has primarily focused on heterosexual couples. This body of work shows that wives are more likely than husbands to offer support to a depressed spouse. Moreover, when wives are depressed, they are more likely than husbands to try and shield their spouse from the stress of their own depression. Yet, previous research has not examined depression and relationship dynamics in gay and lesbian couples. We analyze in-depth interviews with 26 gay and lesbian couples (N = 52 individuals) in which one or both partners reported depression. We find evidence that dominant gender scripts are both upheld and challenged within gay and lesbian couples, providing important insight into how gender operates in relation to depression within same-sex contexts. Our results indicate that most gay and lesbian partners offer support to a depressed partner, yet lesbian couples tend to follow a unique pattern in that they provide support both as the non-depressed and depressed partner. Support around depression is sometimes viewed as improving the relationship, but if the support is intensive or rejected, it is often viewed as contributing to relationship strain. Support is also sometimes withdrawn by the non-depressed partner because of caregiver exhaustion or the perception that the support is unhelpful. This study points to the importance of considering depression within gay and lesbian relational contexts, revealing new ways support sustains and strains intimate partnerships. We emphasize the usefulness of deploying couple-level approaches to better understand depression in sexual minority populations. PMID:26523788

  9. Depression and Bipolar Support Alliance

    Science.gov (United States)

    ... Series JOINT COMMISSION LAUNCHES EDUCATIONAL CAMPAIGN ON ADULT DEPRESSION Educational Brochure Provides Guidance on Recognizing and Treating Depression [PDF] DBSA 2013–2017 STRATEGIC PLAN Learn how ...

  10. Depression in dialysis patients.

    Science.gov (United States)

    King-Wing Ma, Terry; Kam-Tao Li, Philip

    2016-08-01

    Depression is the most common psychiatric illness in patients with end-stage renal disease (ESRD). The reported prevalence of depression in dialysis population varied from 22.8% (interview-based diagnosis) to 39.3% (self- or clinician-administered rating scales). Such differences were attributed to the overlapping symptoms of uraemia and depression. Systemic review and meta-analysis of observational studies showed that depression was a significant predictor of mortality in dialysis population. The optimal screening tool for depression in dialysis patients remains uncertain. The Beck Depression Inventory (BDI), Patient Health Questionnaire (PHQ) and Center for Epidemiologic Studies Depression Scale (CESD) have been validated for screening purposes. Patients who scored ≥14 using BDI should be referred to a psychiatrist for early evaluation. Structured Clinical Interview for DSM disorders (SCID) remains the gold standard for diagnosis. Non-pharmacological treatment options include cognitive behavioural therapy and exercise training programs. Although frequent haemodialysis may have beneficial effects on patients' physical and mental well-being, it cannot and should not be viewed as a treatment of depression. Selective serotonin reuptake inhibitors (SSRIs) are generally effective and safe in ESRD patients, but most studies were small, non-randomized and uncontrolled. The European Renal Best Practice (ERBP) guideline suggests a trial of SSRI for 8 to 12 weeks in dialysis patients who have moderate-major depression. The treatment effect should be re-evaluated after 12 weeks to avoid prolonging ineffective medication. This review will discuss the current understanding in the diagnosis and management of depression in dialysis patients. PMID:26860073

  11. Physical (in)activity and depression in older people

    NARCIS (Netherlands)

    Wassink-Vossen, Sanne; Collard, Rose M; Oude Voshaar, Richard C; Comijs, Hannie C; de Vocht, Hilde M; Naarding, Paul

    2014-01-01

    BACKGROUND: Knowledge about characteristics explaining low level of physical activity in late-life depression is needed to develop specific interventions aimed at improving physical health in depressed people above the age of 60. METHODS: This cross-sectional study used data from the Netherlands Stu

  12. Therapist Competence and Patient Outcome in Interpersonal Psychotherapy of Depression.

    Science.gov (United States)

    O'Malley, Stephanie S.; And Others

    1988-01-01

    Examined whether therapist's level of competence in conducting interpersonal psychotherapy of depression was associated with patient improvement. Used data from 35 depressed outpatients receiving interpersonal psychotherapy. Results showed that measures of therapist performance contributed significantly to prediction of patient-rated change and…

  13. A Treatment-control Study of Aripiprazole and Ziprasidone in Female First-onset Schizophrenia%阿立哌唑与齐拉西酮治疗女性首发精神分裂症对照研究

    Institute of Scientific and Technical Information of China (English)

    许爱琴; 尤加永; 赵长银

    2013-01-01

    Objective:To evaluate the efficacy and adverse reactions of aripiprazole and ziprasidone in female first-onset schizophrenia.Method:31 female first-onset schizophrenia patients met the CCMD-3 diagnosis of schizophrenia were randomly assigned to aripiprazole group (36 patients) and ziprasidone group (35 cases). Positive symptoms and negative syndrome scale(PANSS) and treatment Emergent Symptom Scale(TESS) were used to evaluate the efficacy and safety.Result:There was no significant difference in PANSS scores(P>0.05) before and after 2,4,8 week’treatment between two groups. The two groups had no serious adverse reactions.Conclusion:Aripiprazole and ziprasidone were effective and less adverse reactions in treatment of female first-onset schizophrenia.%目的:评价齐拉西酮与阿立哌唑治疗女性首发精神分裂症的疗效与不良反应。方法:31例符合CCMD-3精神分裂症诊断标准的女性首发患者随机分为阿立哌唑(博思清)组(36例)和齐拉西酮(思贝格)组(35例),采用阳性症状与阴性症状量表(positive symptoms and negative symptoms scale,PANSS)评定疗效,副反应量表(treatment Emergent Symptom Scale,TESS)评价药物安全性。结果:两组患者治疗前及治疗后2、4、8 PANSS评分差异无显著性(P>0.05),两组均无严重不良反应。结论:阿立哌唑和齐拉西酮治疗女性首发精神分裂症有效,且不良反应少。

  14. 阿立哌唑应用于老年精神分裂症临床治疗的疗效和安全性%The clinical therapeutic effect and safety of aripiprazole in clinical treatment of senile schizophrenia

    Institute of Scientific and Technical Information of China (English)

    王琪

    2014-01-01

    目的:探讨阿立哌唑应用于老年精神分裂症临床治疗效果及安全性,总结其治疗经验。方法:2010年1月-2013年10月收治老年精神分裂症患者40例,采用阿立哌唑治疗,平均治疗剂量(18.5±5.5)mg/d,治疗8周后采用简明精神病评定量表(BPRS)评定临床疗效,不良反应量表(TESS)评定安全性。结果:显效率70.0%,有效率87.5%,无明显锥体外系反应,不良反应轻。结论:阿立哌唑应用于老年精神分裂症患者的治疗依从性好、安全性高,可以有效缓解老年精神分裂症的精神病症状,值得临床推广应用。%Objective:To explore the clinical therapeutic effect and safety of aripiprazole in clinical treatment of senile schizophrenia,to summarize the treatment experience.Methods:40 elderly patients with schizophrenia were selected from January 2010 to October 2013.They were treated with aripiprazole.Average dose was (18.5 ± 5.5)mg/day.At 8 weeks after treatment,the clinical efficacy was assessed by the brief psychiatric rating scale(BPRS),and security was assessed by side effects scale(TESS). Results:The significant efficiency rate was 70%,and the efficiency was 87.5%.There was no obvious extrapyramidal reaction,and adverse reaction was light.Conclusion:Treatment compliance of application of aripiprazole in clinical treatment of senile schizophrenia is good,and security is high.It can effectively alleviate psychotic symptoms of senile schizophrenia,and it is worth the clinical promotion.

  15. Well-being and the risk of depression under stress.

    Directory of Open Access Journals (Sweden)

    Faren Grant

    Full Text Available Improving our ability to accurately predict individual risk for depression would have profound public health benefits. While there has been growing interest in understanding the relation between measures of positive emotion, such as well-being, and depression, it is not clear whether low well-being is an independent predictor of short term depression risk. We assessed whether low well-being is a risk factor for depressive symptoms. Medical internship is a well-established period of stress when levels of depressive symptoms increase dramatically. 1621 individuals beginning medical internship were assessed for well-being, depressive symptoms, and a set of psychological and demographic traits prior to starting internship year and again for depressive symptoms at 3 month intervals during the year. Low subjective well-being significantly predicted increased depression symptom scores during the stress of medical internship and accounted for individual level inter-variability in depression symptom trends across time. Assessing well-being may have utility in predicting future depression risk.

  16. Depression and Obstructive Sleep Apnea (OSA

    Directory of Open Access Journals (Sweden)

    O'Hara Ruth

    2005-06-01

    Full Text Available Abstract For over two decades clinical studies have been conducted which suggest the existence of a relationship between depression and Obstructive Sleep Apnea (OSA. Recently, Ohayon underscored the evidence for a link between these two disorders in the general population, showing that 800 out of 100,000 individuals had both, a breathing-related sleep disorder and a major depressive disorder, with up to 20% of the subjects presenting with one of these disorders also having the other. In some populations, depending on age, gender and other demographic and health characteristics, the prevalence of both disorders may be even higher: OSA may affect more than 50% of individuals over the age of 65, and significant depressive symptoms may be present in as many as 26% of a community-dwelling population of older adults. In clinical practice, the presence of depressive symptomatology is often considered in patients with OSA, and may be accounted for and followed-up when considering treatment approaches and response to treatment. On the other hand, sleep problems and specifically OSA are rarely assessed on a regular basis in patients with a depressive disorder. However, OSA might not only be associated with a depressive syndrome, but its presence may also be responsible for failure to respond to appropriate pharmacological treatment. Furthermore, an undiagnosed OSA might be exacerbated by adjunct treatments to antidepressant medications, such as benzodiazepines. Increased awareness of the relationship between depression and OSA might significantly improve diagnostic accuracy as well as treatment outcome for both disorders. In this review, we will summarize important findings in the current literature regarding the association between depression and OSA, and the possible mechanisms by which both disorders interact. Implications for clinical practice will be discussed.

  17. Rumination-focused cognitive behaviour therapy for residual depression: a case series.

    Science.gov (United States)

    Watkins, Ed; Scott, Jan; Wingrove, Janet; Rimes, Katharine; Bathurst, Neil; Steiner, Herbert; Kennell-Webb, Sandra; Moulds, Michelle; Malliaris, Yanni

    2007-09-01

    The treatment of chronic and recurrent depression is a priority for the development of new interventions. The maintenance of residual symptoms following acute treatment for depression is a risk factor for both chronic depression and further relapse/recurrence. This open case series provides the first data on a cognitive-behavioural treatment for residual depression that explicitly targets depressive rumination. Rumination has been identified as a key factor in the onset and maintenance of depression, which is found to remain elevated following remission from depression. Fourteen consecutively recruited participants meeting criteria for medication--refractory residual depression [Paykel, E.S., Scott, J., Teasdale, J.D., Johnson, A.L., Garland, A., Moore, R. et al., 1999. Prevention of relapse in residual depression by cognitive therapy--a controlled trial. Archives of General Psychiatry 56, 829-835] were treated individually for up to 12 weekly 60-min sessions. Treatment specifically focused on switching patients from less helpful to more helpful styles of thinking through the use of functional analysis, experiential/imagery exercises and behavioural experiments. Treatment produced significant improvements in depressive symptoms, rumination and co-morbid disorders: 71% responded (50% reduction on Hamilton Depression Rating Scale) and 50% achieved full remission. Treating depressive rumination appears to yield generalised improvement in depression and co-morbidity. This study provides preliminary evidence that rumination-focused CBT may be an efficacious treatment for medication--refractory residual depression. PMID:17367751

  18. Depression in hypertensive subjects.

    Science.gov (United States)

    Ramachandran, V; Parikh, G J; Srinivasan, V

    1983-10-01

    168 patients attending hypertension clinic were randomly selected for the study. They were thoroughly investigated using E.C.G., X-ray chest, Urine analysis, Blood sugar, Blood urea, Serum cholesterol, Serum K, Serum Na, Scrum creatinine and Uric acid level. Detailed psychiatric case history and mental examination was carried out. Beck Rating Scale was used to measure the depression. 25% of hypertensive subjects exhibited depressive features and their mean score in Beck Rating scale is 21.76. The mean score of non-depressives is 4.46. All patients were receiving methyl dopa.25 mg. twice or thrice daily with thiazide diuretic. No significant difference in the incidence of depression with the duration of medication was observed.The hypertension was classified into mild, moderate and severe depending on the diastolic pressure. Depression was more frequent in severe hypertensives but not to the statistically significant level.Further hypertensives were classified into:1. Hypertension without organ involvement2. Hypertension with LVH only3. Hypertension with additional organ involvement4. Malignant hypertensionDepression was significantly more frequent in hypertensives with complications and also hypertensives in whom the B.P. remained uncontrolled. As all the patients were on the same drug, the drug effect is common to all; hence, the higher incidence of depression in hypertensives with complications is due to the limitation and distress caused by the illness. PMID:21847301

  19. Predictors of depression stigma

    Directory of Open Access Journals (Sweden)

    Jorm Anthony F

    2008-04-01

    Full Text Available Abstract Background To investigate and compare the predictors of personal and perceived stigma associated with depression. Method Three samples were surveyed to investigate the predictors: a national sample of 1,001 Australian adults; a local community sample of 5,572 residents of the Australian Capital Territory and Queanbeyan aged 18 to 50 years; and a psychologically distressed subset (n = 487 of the latter sample. Personal and Perceived Stigma were measured using the two subscales of the Depression Stigma Scale. Potential predictors included demographic variables (age, gender, education, country of birth, remoteness of residence, psychological distress, awareness of Australia's national depression initiative beyondblue, depression literacy and level of exposure to depression. Not all predictors were used for all samples. Results Personal stigma was consistently higher among men, those with less education and those born overseas. It was also associated with greater current psychological distress, lower prior contact with depression, not having heard of a national awareness raising initiative, and lower depression literacy. These findings differed from those for perceived stigma except for psychological distress which was associated with both higher personal and higher perceived stigma. Remoteness of residence was not associated with either type of stigma. Conclusion The findings highlight the importance of treating the concepts of personal and perceived stigma separately in designing measures of stigma, in interpreting the pattern of findings in studies of the predictors of stigma, and in designing, interpreting the impact of and disseminating interventions for stigma.

  20. Emotion socialization within the family environment and adolescent depression.

    Science.gov (United States)

    Schwartz, Orli S; Sheeber, Lisa B; Dudgeon, Paul; Allen, Nicholas B

    2012-08-01

    This review evaluates research addressing the association between parent-child emotional interactions and the development and maintenance of depression in adolescence, with a focus on studies using observational research methods that assess parental responses to children and adolescents' emotional displays. We argue that parental socialization behaviors in response to different emotions expressed by youths may have distinct associations with depressive outcomes. In particular, parental behaviors that reinforce depressive behavior, reciprocate aggression, and fail to positively reinforce positive behavior have each been associated with youth depression. This review identifies a need for more observational research, including prospective, longitudinal studies, to better understand these behaviors, elucidate the directionality of influence between parental socialization behaviors and youth depression, and more clearly identify protective parental socialization behaviors. However, the use of existing findings to inform family-based interventions may improve prevention and treatment efforts directed at youth depression. PMID:22717335

  1. Do You Have Major Depression?

    Science.gov (United States)

    ... of this page please turn Javascript on. Feature: Depression Do You Have Major Depression? Past Issues / Fall 2009 Table of Contents Simple ... member may have major depression. —NIMH Types of Depression Just like other illnesses, such as heart disease, ...

  2. Comparative Study on Aripiprazole and Risperidone in the Treatment of Schizophrenia%阿立哌唑与利培酮治疗精神分裂症的对照研究

    Institute of Scientific and Technical Information of China (English)

    彭红波

    2013-01-01

    目的比较阿立哌唑和利培酮对精神分裂症的疗效,为临床用药提供参考。方法以我院2011年1月~2012年9月收治的120例精神分裂症患者为研究对象,将患者随机分为治疗组和对照组,每组60例。对照组患者应用利培酮,治疗组患者服用阿立哌唑。观察两组的治疗效果以及不良反应。结果治疗组总有效率高于对照组,但是差异不具有统计学意义( P>0.05);两组患者PANSS总分、阳性症状分、阴性症状分、一般精神病理分治疗后明显比治疗前降低(P<0.05),但是组间比较差异不具有统计学意义(P>0.05);治疗组不良反应发生率明显低于对照组(P<0.05)。结论临床对精神分裂症采用阿立哌唑和利培酮治疗效果均较显著,两种药物疗效相似;但是采用阿立哌唑治疗的不良反应发生率少,因此阿立哌唑治可作为临床的首要选择。%Objective Objective To analyze effect of aripiprazole and risperidone in the treatment of schizo-phrenia ,and provide reference for clinical medication choice .Methods 120 cases with schizophrenia from in-patient department in January 2011 to September 2012 were selected .These patients were randomly di-vided into treatment group and control group , 60 cases in each group .Control group received risperidone , and treatment group received aripiprazole .Curative effect and adverse reaction for two groups were observed and compared .Results Total effective rate for treatment group was obviously higher than control group , but there were no significant difference ( P>0 .05 ) .PANSS score , positive symptoms score , negative symp-toms score and general psychopathology score after treatment were obviously lower than the score before treatment ( P0 .05 ) .Incidence of adverse effect was obviously lower than control group ( P<0.05 ) .Conclusion herapeutic effects of aripiprazole and risperi-done in the treatment of

  3. 阿立哌唑和利培酮治疗女性精神分裂症对照研究%Aripiprazole and Risperidone in the Treatment of Female Schizophrenia

    Institute of Scientific and Technical Information of China (English)

    姜丽艳

    2014-01-01

    目的:研究女性精神分裂症患者运用阿立哌唑和利培酮治疗的临床效果。方法2012年4月~2013年4月间诊治的160例女性精神分裂症患者,将其分为两组,组1使用阿立哌唑进行治疗,组2使用利培酮进行治疗,比较两组患者的临床效果。结果通过对两组患者进行比较,组1有效率为87.5%,组2为90.0%,两组患者临床效果未见明…显差异,无统计学意义(P >0.05);但组2患者的体质量增加情况、椎体外系反应的发生率、泌乳以及月经紊乱情况均比组1高,两组患者差异显著,有统计学意义(P <0.05)。结论对于女性精神分裂症治疗上效果上阿立哌唑和利培酮基本一致,但是阿立哌唑更适合用于女性精神分裂症患者。%Objective To study the clinical effect of female schizophrenia with aripiprazole and risperidone in the treatment of patients with. Methods 160 cases of female spirit in 2012 April ~2013 April in the diagnosis and treatment of patients with schizophrenia,it is divided into two groups, group 1 were treated by aripiprazole risperidone group, 2 were treated by comparison of the clinical effects of two groups of patients. Results The two groups of patients were compared, the group has an efficiency of 1 for 87.5%, group 2 to 90%,The patients in the two groups no significant differences in clinical effect, no statistical significance (P>0.05), but the group of 2 patients with body mass increase, extrapyramidal reaction rate, lactation and menstrual disorders are 1 higher than group, the differences between the two groups were significant, with statistical significance (P<0.05). Conclusion For the treatment of female schizophrenia aripiprazole and risperidone effect on basically the same,but aripiprazole is more suitable for female patients with schizophrenia.

  4. DISABILITY AND DEPRESSION AMONG HIGH UTILIZERS OF HEALTH-CARE - A LONGITUDINAL ANALYSIS

    NARCIS (Netherlands)

    VONKORFF, M; ORMEL, J; KATON, W; LIN, EHB

    1992-01-01

    We evaluated, among depressed medical patients who are high utilizers of health care, whether improved vs unimproved depression is associated with differences in the course of functional disability. At baseline, 6 months, and 12 months, depression and disability were assessed among a sample of enrol

  5. Depression Treatment in Patients With Coronary Artery Disease: A Systematic Review

    OpenAIRE

    Ramamurthy, Gita; Trejo, Edgardo; Faraone, Stephen V.

    2013-01-01

    Objective: Depression has been linked to adverse coronary artery disease outcomes. Whether depression treatment improves or worsens coronary artery disease prognosis is unclear. This 25-year systematic review examines medical outcomes, and, secondarily, mood outcomes of depression treatment among patients with coronary artery disease.

  6. Effects of an Intensive Depression-Focused Intervention for Smoking Cessation in Pregnancy

    Science.gov (United States)

    Cinciripini, Paul M.; Blalock, Janice A.; Minnix, Jennifer A.; Robinson, Jason D.; Brown, Victoria L.; Lam, Cho; Wetter, David W.; Schreindorfer, Lisa; McCullough, James P., Jr.; Dolan-Mullen, Patricia; Stotts, Angela L.; Karam-Hage, Maher

    2010-01-01

    Objective: The objective of this study was to evaluate a depression-focused treatment for smoking cessation in pregnant women versus a time and contact health education control. We hypothesized that the depression-focused treatment would lead to improved abstinence and reduced depressive symptoms among women with high levels of depressive…

  7. Remission of Depression in Parents: Links to Healthy Functioning in Their Children

    Science.gov (United States)

    Garber, Judy; Ciesla, Jeff A.; McCauley, Elizabeth; Diamond, Guy; Schloredt, Kelly A.

    2011-01-01

    This study examined whether improvement in parents' depression was linked with changes in their children's depressive symptoms and functioning. Participants were 223 parents and children ranging in age from 7 to 17 years old (M = 12.13, SD = 2.31); 126 parents were in treatment for depression and 97 parents were nondepressed. Children were…

  8. Adjustments and Depression

    Medline Plus

    Full Text Available ... us anything ⟟ Resources in your area ☇ Fundraise with Team Reeve Need to talk to someone? We’re ... are looking for more information on how to manage depression or have a specific question, our information ...

  9. Suicide and Depression

    Science.gov (United States)

    ... Sign-Up Save. Suicide Awareness Voices of Education Suicide and Depression Q&A Why do people kill ... does not become an option. Do people attempt suicide to prove something or to get sympathy? No. ...

  10. Adjustments and Depression

    Medline Plus

    Full Text Available ... our repository of fact sheets on hundreds of topics ranging from state resources to secondary complications of ... Center (MSKTC) maintains factsheets on a number of topics, including depression with a self-test to help ...

  11. Adjustments and Depression

    Medline Plus

    Full Text Available ... feelings of helplessness and confusion is to arm yourself with information on what a spinal cord injury ... control, talking about your disability, taking care of yourself, and looking ahead. Depression, however, is a serious ...

  12. Adjustments and Depression

    Medline Plus

    Full Text Available ... University of Washington provides pamphlets on depression with spinal cord injury and potential ... do I find a rehabilitation facility? How can I locate funding for rehabilitation ...

  13. Adjustments and Depression

    Medline Plus

    Full Text Available ... adjustment and depression Adjustment to paralysis is a process of changing one's thoughts and feelings and is ... stem cell research? What is the clinical trials process? Get support Ask us anything Get a peer ...

  14. Adjustments and Depression

    Medline Plus

    Full Text Available ... behaviors as well as other aspects of your life. Depression can cause physical and psychological symptoms. It ... loss of energy, take away your enjoyment of life and make it difficult for you to take ...

  15. Adjustments and Depression

    Medline Plus

    Full Text Available ... yourself with information on what a spinal cord injury is, and what it means in terms of ... thoughts. Depression is common in the spinal cord injury population -- affecting about 1 in 5 people. There ...

  16. Adjustments and Depression

    Medline Plus

    Full Text Available ... as other aspects of your life. Depression can cause physical and psychological symptoms. It can worsen pain, make sleep difficult, cause loss of energy, take away your enjoyment of ...

  17. Recognizing teen depression

    Science.gov (United States)

    Your teen is more at risk for depression if: Mood disorders run in your family They experience a stressful life event like a death in the family, divorcing parents, bullying, a break up with a boyfriend or girlfriend, ...

  18. Persistent depressive disorder

    Science.gov (United States)

    American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders . 5th ed. Arlington, VA: American Psychiatric Publishing, 2013. Fava M, Cassano P. Mood disorders: major depressive disorder and dysthymic ...

  19. Adjustments and Depression

    Medline Plus

    Full Text Available ... grieving, taking control, talking about your disability, taking care of yourself, and looking ahead. Depression, however, is ... make it difficult for you to take good care of your health. Other symptoms include oversleeping, change ...

  20. Vision in depressive disorder

    DEFF Research Database (Denmark)

    Bubl, E.; Tebartz Van Elst, L.; Ebert, D.;

    2009-01-01

    Background. Reduced dopaminergic transmission has been implicated in the pathophysiology of major depression. Furthermore, dopaminergic neurotransmission plays an important role in the physiology of visual contrast sensitivity (CS). To test the hypothesis that altered dopaminergic neurotransmissi...

  1. Real Stories of Depression

    Medline Plus

    Full Text Available ... Health Care Providers Public Service Announcements (PSAs) Join A Study Depression Studies for Adults Contact Us Staff ... part of the National Institutes of Health (NIH), a component of the U.S. Department of Health and ...

  2. Adjustments and Depression

    Medline Plus

    Full Text Available ... helplessness and confusion is to arm yourself with information on what a spinal cord injury is, and ... Karp Resources If you are looking for more information on how to manage depression or have a ...

  3. Real Stories of Depression

    Medline Plus

    Full Text Available ... Health & Education Mental Health Information Publications Educational Resources Clinical Trials — Participants Statistics Help for Mental Illnesses Outreach Research Priorities Funding Labs at NIMH News About Us Home > Health & Education > Mental Health Information > Depression > Men ...

  4. Comparative Effectiveness of Psychotherapies for Depressed Elders.

    Science.gov (United States)

    Thompson, Larry W.; And Others

    1987-01-01

    Treated 91 elders with a major depressive disorder (MDD) using behavioral, cognitive, or brief psychodynamic psychotherapy. By the end of six weeks patients in all three treatment conditions showed improvement equally, whereas controls did not. Overall, 52 percent of the treatment sample attained remission by termination. The remainder still met…

  5. Hypothyroidism and Depression

    OpenAIRE

    Dayan, Colin M; Panicker, Vijay

    2013-01-01

    Background: A relationship between hypothyroidism and depression has been assumed for many years; however, the true nature of this association has been difficult to define with many conflicting studies. In recent years, our knowledge in this area has increased significantly with large cohort studies and genetically driven studies being published. Objectives: We reviewed the literature on thyroid function and depression to determine if this relationship has been clarified. Methods: We performe...

  6. Identifying Depression on Twitter

    OpenAIRE

    Nadeem, Moin

    2016-01-01

    Social media has recently emerged as a premier method to disseminate information online. Through these online networks, tens of millions of individuals communicate their thoughts, personal experiences, and social ideals. We therefore explore the potential of social media to predict, even prior to onset, Major Depressive Disorder (MDD) in online personas. We employ a crowdsourced method to compile a list of Twitter users who profess to being diagnosed with depression. Using up to a year of pri...

  7. Sleep deprivation and depression

    OpenAIRE

    Elsenga, Simon

    1992-01-01

    The association between depression and sleep disturbances is perhaps as old as makind. In view of the longstanding experience with this association it is amazing that only some 20 years ago, a few depressed patients attracted attention to the fact that Total Sleep Deprivation (TSD) had antidepressant effects. A large number of studies have followed these observations. The purpose of the studies presented in this thesis was to evaluate the clinical usefulness of TSD and related procedures for ...

  8. LIFE EVENTS AND DEPRESSION

    OpenAIRE

    R N Chatterjee; Mukherjee, S. P.; Nandi, D.N.

    1981-01-01

    SUMMARY The life events occurring in a 6 month period preceding onset of illness in 50 OPD primary depressives were inquired into by a Life Events Inventory and compared with those in a corresponding time period of 50 matched controls. The relation between life events and the depth of depression at initial interview was also studied. The results are analysed and the probable pitfalls discussed.

  9. Depression in Parkinson's disease

    OpenAIRE

    Marina Romanovna Nodel

    2010-01-01

    Parkinson's disease (PD) is a multisystemic neurodegenerative disease with a wide spectrum of not only motor, but also neuropsychic disorders. Depression occurs in an average of 40-50% of patients and it is one of the leading factors that decrease their quality of life. The paper gives the present views of the clinical presentation and pathogenesis of depression, and approaches to its therapy in PD.

  10. [Evidence-based therapy of depression: S3 guidelines on unipolar depression].

    Science.gov (United States)

    Härter, M; Klesse, C; Bermejo, I; Bschor, T; Gensichen, J; Harfst, T; Hautzinger, M; Kolada, C; Kopp, I; Kühner, C; Lelgemann, M; Matzat, J; Meyerrose, B; Mundt, C; Niebling, W; Ollenschläger, G; Richter, R; Schauenburg, H; Schulz, H; Weinbrenner, S; Schneider, F; Berger, M

    2010-09-01

    Unipolar depressive disorders are among the most frequent reasons for utilizing the health care system. Although efficacious treatments are available and further advances have recently been made there is still a need for improving diagnostic and therapeutic procedures. Alignment of treatment on evidence-based treatment guidelines establishes an essential mainstay. The new S3 and National Health Care guidelines on unipolar depression, the compilation of which was coordinated by the German Society of Psychiatry, Psychotherapy and Neurology (DGPPN) and which were approved by 29 scientific and professional associations, is the ambitious effort to present state of the art evidence and clinical consensus for the treatment of depression. For pharmacotherapy of depression differentiated recommendations can be given, also separate from and in addition to psychotherapy. PMID:20802992

  11. Interpersonal Psychotherapy for Postpartum Depression

    OpenAIRE

    Stuart, Scott

    2012-01-01

    Perinatal depression is prevalent and has a great impact on both mother and infant. There are empirically validated treatments for both postpartum depression and depression during pregnancy. Primary among these is interpersonal psychotherapy, which has been shown to be effective for postpartum women across the spectrum from mild to severe depression. At present, interpersonal psychotherapy is the best validated treatment for postpartum depression and should be considered first-line treatment,...

  12. The Molecular Neurobiology of Depression

    OpenAIRE

    Shelton, Richard C.

    2007-01-01

    The molecular neurobiology of depression begins with an idea: depressive disorders represent a family of related but distinct conditions. Different points of vulnerability in the brain may predispose to depressive disorders. For example, it is likely that the core pathophysiology of depression associated with early life adversity is different from non-trauma related disorders. In particular, the pathophysiology of trauma-related depression involves the hypothalamic-pituitary-adrenal (HPA) axi...

  13. Depression - The Proteus of Medicine

    OpenAIRE

    Rao, A. Venkoba

    2004-01-01

    Depression is discussed as a disease of antiquity with suitable contemporary references also. The prevalence of this disorder, which at a given time constitutes 121 millions world-wide is mentioned. Among the types of depression, comorbid depression forms an important one. Classical depression forms the visible part of the depression iceberg while somatic and other life contextual situation forms the submerged part. Somatic manifestations per se do not carry diagnostic weightage unless the co...

  14. Depression and Coronary Heart Disease

    OpenAIRE

    Davidson, Karina W

    2012-01-01

    There are exciting findings in the field of depression and coronary heart disease. Whether diagnosed or simply self-reported, depression continues to mark very high risk for a recurrent acute coronary syndrome or for death in patients with coronary heart disease. Many intriguing mechanisms have been posited to be implicated in the association between depression and heart disease, and randomized controlled trials of depression treatment are beginning to delineate the types of depression manage...

  15. How Adolescent Girls Understand and Manage Depression Within Their Peer Group: A Grounded Theory Investigation

    OpenAIRE

    Pinto-Foltz, Melissa D.; Hines-Martin, Vicki; Logsdon, M. Cynthia

    2010-01-01

    Depression is prevalent among adolescent girls, but few receive mental health treatment. Adolescent girls often forgo needed mental health treatment because they fear responses of peers about depression. Understanding the processes of how adolescent girls respond to peers with depression is an important first step to improve access to mental health treatment. This qualitative study describes the knowledge, perceptions, and behaviors of adolescent girls about depression and mental health treat...

  16. Selection of depression measures for use among Vietnamese populations in primary care settings: a scoping review

    OpenAIRE

    Murphy, Jill; Elliot M. Goldner; Goldsmith, Charles H; Oanh, Pham Thi; Zhu, William; Corbett, Kitty K; Nguyen, Vu Cong

    2015-01-01

    Depression is an important and growing contributor to the burden of disease around the world and evidence suggests the experience of depression varies cross-culturally. Efforts to improve the integration of services for depression in primary care are increasing globally, meaning that culturally valid measures that are acceptable for use in primary care settings are needed. We conducted a scoping review of 27 studies that validated or used 10 measures of depression in Vietnamese populations. W...

  17. The role of body image in prenatal and postpartum depression: a critical review of the literature

    OpenAIRE

    Silveira, Marushka L.; Ertel, Karen A.; Dole, Nancy; Chasan-Taber, Lisa

    2015-01-01

    Maternal depression increases risk of adverse perinatal outcomes, and recent evidence suggests that body image may play an important role in depression. This systematic review identifies studies of body image and perinatal depression with the goal of elucidating the complex role that body image plays in prenatal and postpartum depression, improving measurement, and informing next steps in research. We conducted a literature search of the PubMed database (1996– 2014) for English language studi...

  18. Incidence of Depression and Associated Factors in Patients With Type 2 Diabetes in Quebec, Canada

    OpenAIRE

    Lunghi, Carlotta; Moisan, Jocelyne; Grégoire, Jean-Pierre; Guénette, Line

    2016-01-01

    Abstract It has been reported that the risk of depression is higher among people with type 2 diabetes compared with a nondiabetic population. Among diabetic patients, depression has been associated with worse self-care behaviors, poor glycemic control, and an increased risk of diabetes complications. Identifying factors associated with the occurrence of depression may help physicians identify earlier diabetic patients at a high risk of developing depression, improve prevention, and accelerate...

  19. USE OF TRANYLCYPROMINE IN SEVERE RESISTANT DEPRESSION : A CASE REPORT

    OpenAIRE

    Maulik, Pallab K.; Das, Sudipto; Saxena, Shekhar

    1999-01-01

    This case report describes the improvement obtained by using tranylcypromine in a patient of severe treatment resistant depression. The adverse effects faced and steps taken to overcome them have also been discussed.

  20. Flux-depression factors for scattering and absorbing media

    International Nuclear Information System (INIS)

    The method of elementary solutions, along with Chandrasekhar's invariance principles, is used to solve a two-region problem relevant to flux-depression calculations. An improved P-L-type approximation is also discussed